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Dissertation Abstract
Michael A. Rieger
Behavior in higher eukaryotes is a complex process which integrates signals in the en-
vironment, the genetic makeup of the organism, and connectivity in the nervous system
to produce extremely diverse adaptations to the phenomenon of existence. Unraveling
the subcellular components that contribute to behavioral output is important for both un-
derstanding how behavior occurs in an unperturbed state, as well as understanding how
behavior changes when the underlying systems that generate it are altered. Of the nu-
merous molecular species that make up a cell, the regulation of messenger RNAs (mR-
NAs), the coding template of all proteins, is of key importance to the proper maintenance
and functioning of cells of the brain, and thus the synaptic signals and information inte-
gration which underlie behavior. RNA binding proteins, a class of regulatory molecules,
associate with mRNAs and facilitate their maturation from pre-spliced nascent transcripts,
their stabilization and degradation ensuring appropriate levels are maintained, as well as
their translation and subcellular compartmentalization, which ensures that proteins are
translated at the appropriate level and in the places where they are required to fulfill
their cellular functions. Our laboratory identified polymorphisms in the gene coding for
the CUGBP and ELAV-like Factor 6 (CELF6) RNA binding protein to be associated with
Autism Spectrum Disorder risk in humans. ASD is a spectrum of disorders of early neu-
xii
rodevelopment which present with lowered sociability and communication skills as well
as restricted patterns of interests. When expression of the Celf6 gene was ablated in
mice, we found that they exhibited reductions to early communication as well as altered
aspects of their exploratory behavior. In this dissertation, I explore the communication
changes in young mouse pups with loss of CELF6 protein and identify that despite being
able to produce vocalization patterns similar to their wild-type littermates, they neverthe-
less exhibit reduced response to maternal separation. Despite a history of literature on
other CELF family proteins, the functions of the CELF6 protein in the brain have not been
previously described. I provide characterization of the mRNA binding targets of CELF6 in
the brain, and show that they share common UGU-containing sequence motifs which has
been noted for other CELF proteins, and that CELF6 binding occurs primarily in the 3’ un-
translated regions (3’ UTR) of mRNA. I hypothesized that this mode of interaction would
result in regulation of mRNA degradation or translation efficiency as 3’ UTR regions are
known for providing binding sites for numerous regulators of such processes. In order
to answer this question, I cloned sequence elements from the 3’ UTRs of target mRNAs
into a massively parallel reporter assay which has enabled me to test the effect of CELF6
expression on hundreds of binding targets simultaneously. When expressed in vitro, I
found that CELF6 induced reduction to reporter library levels but exhibited few effects on
translation efficiency, and I was able to rescue effects to reporter abundance mutation of
binding motifs. Intriguingly, like CELF6, CELF3, CELF4, and CELF5 were all able to pro-
duce the same effect. CELF5 and CELF6 both showed similar, intermediate repression of
reporter library mRNAs, while CELF3 and CELF4 exerted the strongest levels of repres-
sion. The level of repression under these conditions was somewhat predicted by number
of motifs present per element, however a large amount of the variance in reporter levels
is still unexplained and a mechanism for CELF6’s action is unknown. Nevertheless, the
work I present in this dissertation shows that CELF6 and other members of its family are
xiii
key regulators of mRNA abundance levels which has direct implications to downstream
consequence in the cell. As several of CELF6 binding target mRNAs are known regulators
of neuronal signaling and synaptic function, the information I present is crucial for future
experimentation. This work well help lead us to understand how behavior is altered when
this protein is absent, along the way uncovering important mechanistic steps connecting
the molecular landscape of cells to the behavior of organisms.
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Chapter 1
The CELF6 gene and autism spectrum
disorder phenotyping in mice
Abstract
Autism spectrum disorders (ASD) are developmental disorders with preva-
lence rates estimated 1-2.5% in the United States, defined by abnormal social
behavior, restricted interests, and language delay. For the last four decades,
ASD has been recognized to have a measurable heritable component, with
that heritability stemming from some burden in common variation as well as
rare/de novo genetic variation. Several Mendelian syndromes also present
clinically with autistic features. The influence of genes believed to confer ASD
risk has therefore been widely explored in research, with gene function com-
monly investigated in laboratory model systems such as rats and mice. Al-
though rodents may not be expected to fully reproduce the features of the hu-
man condition, the biological function of risk genes in the brain can be explored
vis-à-vis their relationship to behavioral changes in the expected domains of
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sociability, repetitive behaviors, and altered communication. In particular, the
ultrasonic vocalization (USV) communication system in mice has been widely
used to evaluate models in which ASD risk genes are knocked out or mutated.
Our lab discovered an association between the RNA binding protein CELF6,
enriched for expression in serotonergic neurons, and ASD risk in human pa-
tient data. When we knocked out this gene in mice, the animals showed deficits
to neonatal pup USV among other abnormalities in behavior. This association
between the CELF6 gene and changes to USV, among others, forms the basis
for our pursued study of the CELF6 gene in this disseration work. Thus as a
prelude to our work on CELF6, this chapter is devoted to a brief review of the
history of ASD genetics research and modeling the disorder in mice, as well
as our initial observations concerning the CELF6 gene.
A Brief History of ASD Genetic Studies
Autism spectrum disorder (commonly "autism" or ASD) is a neurodevelopmental disorder
diagnosed in early childhood typified by abnormalities in the domains of social interaction,
stereotypies/restricted interests/repetitive behaviors, and language delay/communication
difficulties, and is often comorbid with other medical problems or behavioral difficulties
including epilepsy, ADHD, and intellectual disability [1]. ASD was recognized early on as a
disorder with some measurable heritable component from concordance rates in diagnosis
in monozygotic (MZ) vs. dizygotic (DZ) twins. An original twin study by Folstein and Rutter
of 11 pairs of MZ & 10 pairs of DZ twins in 1977 showed a 36% concordance rate for ASD
diagnosis in MZ twins with 0% concordance for ASD diagnosis in DZ twins, and an 82%
concordance rate for cognitive abnormalities at all in MZ twins, and 10% in DZ twins [2].
At the time, the rates of ASD were considered uncommon at 2-4 in 10,000 and twins for
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the Folstein study were selected to meet the then diagnostic criteria [3]:
• impairment in the development of social relationships (limited eye gaze, poor social
responsiveness, impaired selective bonding, failure to go to parents for comfort, lack
of empathy when older, lack of personal friendships, little group interaction);
• delayed and deviant language development (poor comprehension, limited gesture
usage, echolalia, pronomial reversal, limited social use of language, repetitive utter-
ances, flat or staccato speech, restricted play);
• stereotyped, repetitive/ritualistic play or interests (abnormal attachment to objects,
resistance to change, rituals, repetitive behavior, unusual preoccupations, restricted
interest patterns).
Diagnosis was carefully conducted to be as "blinded" as possible - randomizing the case
histories when presented to the diagnoser so pairs were not diagnosed together, and sep-
arate diagnoses of cognitive impairment (e.g. IQ tests, verbal IQ) also performed. Almost
20 years later, a meta-analysis of two twin studies from the United Kingdom included 25
MZ twin pairs & 20 DZ twin pairs [4] found a 60% concordance rate in MZ twins vs. 0% DZ
twins, and 92% of MZ twins were generally concordant more broadly for other cognitive
and social impairments vs. 10% of DZ twins. Since the original Folstein and Rutter study
in 1977, twin studies have attempted to control for obstetric hazards and other medical
conditions, but of course these cannot be completely discounted. However the consensus
at the time was that ASD was the result of multiple loci acting epistatically.
By the year 2000, a number of de novo chromosomal abnormalities such as deletions,
translocations, and inversions, had been associated with ASD as well as other cognitive
disorders in siblings [5]. A number of candidate genes were investigated, such as the
GABAA receptor cluster on chromosome 15, which was also implicated in epilepsy [6, 7].
Additionally, elevated peripheral serotonin levels in some autistic patients [8, 9] relative
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to controls led to the investigation of genes in the serotonergic system. A particular fo-
cus was an association of a polymorphism in the promoter for the serotonin transporter
gene 5-HTT/SLC6A4/SERT with some contradiction in the literature as to whether the
short variant was associated with ASD [10], or the long variant [11] of the same polymor-
phism. Other potential candidate genes emerging at this time included genes involved in
syndromes with Mendelian inheritance patterns which presented clinical with autistic phe-
notypes, such as the neurofibromatosis type 1 (NF1) gene [12], the Rett syndrome gene
MECP2[13], and the tuberous sclerosis genes TSC1 and TSC2 [14]. Some early reports
at this time began to document the prevalence of ASD diagosis & Fragile X syndrome
(FMR1) [15, 16].
Also around this time, linkage studies were undertaken to identify ASD susceptibility
genes in multiplex families (families with near relatives also sharing this diagnosis) such
as the study by the International Molecular Genetic Study of Autism Consortium in 1998
[17] in 87 affected sibling pairs with significant linkage on chromosome 7q and 16p, geno-
typing several hundred markers across the genome. Another study by the Paris ASD
Research International Sibpair Study of about 300 microsatellite markers in 51 families,
found nominally significant (p<0.05) linkage on chromosomes 2,4,5,6,7,10,15,16,18,19, &
X, including the 7q and 16p previously associated loci [18]. However, these studies were
performed in the pre-genomic sequence and pre-Next Generation Sequencing era. They
were thus limited in their ability to precisely identify loci of interest, and retrospectively are
considered somewhat underpowered.
By the early 21st century, prevalence rates for ASD had increased due to changes in
awareness, and diagnostic testing/standardization. Initially the rate was estimated as 1
to 6 per 1000 people [19] but current estimates are an order of magnitude higher, near
2.5% in the United States[20] with similar estimates globally [21]. By 2008, a number of
genome wide association studies (GWAS) were being performed on patients part of the
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Autism Genetic Resource Exchange (AGRE) [22]. By 2010, three GWAS results were
published on AGRE data [23–25] using unrelated unaffected individual samples as con-
trols. Few variants reached genome wide significance leading to the hypothesis that com-
mon variants may contribute to ASD as a convergence of a number of genetic aberrations
of small effect size. Alternatively, this could be explained by common variation having a
limited role and that a large proportion of heritability could be explained by rare single
nucleotide (SNV) or copy number variants (CNV) of moderate to large effect [26]. Indeed,
by 2012, five key publications undertook exome sequencing of autistic probands and un-
affected siblings, and these reports highlighted the effect of rare and de novo variation on
the disorder[27–31].
The evolving picture of ASD genetics is one of clear influence of heritability, but hetero-
geneous genetic effects, with some contribution of common variants of small effect size,
as well as an increased burden of rare and de novo variants of larger effect size. In order
to determine the actionable approach to be taken in research, investigators often turn to
model organisms to better understand the biological function of genes, variants of which
exhibit risk in the human population. Model organisms such as mice have sequenced
genomes, a molecular toolkit for experimentation, and a complex central nervous system
to probe effects of ASD risk genes on the brain. ASD model organism research has fo-
cused on mice, looking at disruptions to behavior and physiological function in the central
nervous system. Although an "autistic mouse" is a difficult construct to define, the biolog-
ical function of specific genes can be explored, with the ability to then make generalizable
hypotheses about their function in ASD in humans.
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Overview of Behavioral Phenotyping in Mouse Models of
ASD
Mouse models of ASD fall into two broad classes: (a) spontaneous models where a
particular inbred strain or strains of laboratory mouse show phenotypes which mimic some
apsects of human ASD, and (b) environmental or genetic models where experimenters
have specifically engineered a manipulation in an inbred strain of mouse which is already
implicated in human ASD risk, and then set about characterizing its behavior. The most
well known classes of the spontaneous models are the BALB/c and BTBR strains which
show reduced sociability in several assays, repetitive behaviors such as repetitive self-
grooming, as well as altered ultrasonic vocalizations compared to other strains such as
the common C57BL6 strain [32–35]. While these strains have proven to be exemplars
in characterization of certain behavioral deficits, it is hard to isolate the effect of specific
genes in comparison to control animals since control animals (e.g. C57BL6) will come
from a different genetic background entirely. Furthermore, the identity of certain genes
which may be causal to observed traits in these strains may not necessarily share identity
with those contributing to ASD risk in humans. Therefore, the approach of our laboratory,
as well as others, has been to manipulate specific ASD risk genes and determine their
correlation to behavioral changes with respect to littermate control animals that lack these
manipulations.
Regardless of the way the model is constructed, investigators then turn to determining
whether the behavioral domains overlapping the core abnormalities in ASD are altered in
model animals. Recently our group has reviewed behavioral paradigms used to pheno-
type mouse models of ASD [36]. To briefly summarize, as ASD is defined by deficits to
the domains of sociability, restricted or repetitive interests, and communication, laboratory
experiments focus on these activities in animals. Mice are pro-social animals, and social
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assays in mice include full contact assays between conspecifics where different behaviors
are measured such as fraction of assay time spent sniffing or engaging in other aspects
of social investigation such as displays of aggression, locomotor play, allogrooming, and
time spent in close proximity [37, 38]. The laboratory of Jacqueline Crawley developed a
highly utilized three-chambered social approach assay which is ammenable to automated
scoring, and in which a mouse is able to choose between spending time with a novel
conspecfic or a familiar conspecific, or time spent investigation a conspecific or an object
[39]. Repetitive behaviors are associated with several mouse models of ASD risk genes,
such as repetitive grooming to the point of causing self-abrasions in Shank3-deficient
mice [40] . In addition to repetitive grooming, repetitive digging and nestlet shredding in
the homecage can also be quantified [41, 42]. Mice exhibit natural preferences for novel
experiences, so resistance to change behavior can be assessed by quantifying the lack
of preference in certain exploratory behaviors even in the presence of novel stimuli. One
such assay is the T-maze, in which a reward presented in one of the arms of the maze is
moved between arms in subsequent sessions, and the tendency of the mice to perserver-
ate in exploring an arm even in the presence of a rewarding stimulus in an alternate arm
is quantified, as well as the overall amount of spontaneous alternation between arms[43].
Additionally, mice naturally poke their noses in holes to engage in olfactory exploration of
their environment, and mazes with multiple holes, charged with rewarded olfactory stim-
uli, can also be used to quantify how mice perseverate in their exploration of some holes
versus others, even in the presence of changing stimuli [44, 45]. Again, although a truly
"autistic mouse" is not an easily definable construct, laboratory mice have a repertoire of
social and locomotor behaviors which can be exploited to determine whether changes to
behavior occur after manipulation of ASD risk genes.
In addition to abnormal sociability and restricted interests, the modeling of commu-
nication abnormalities has been afforded a large amount of attention in model systems.
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Human language development does not exist in mice and cannot be explored. However,
vocal communication behavior is conserved across mammalian taxa, most commonly as
the rudimentary communication between infants and their caregivers [46]. As other mam-
mals, including humans, neonatal mice vocalize when separated from their parent. This
behavior is a simple form of communication which is hypothesized to have evolved to facil-
itate reunion with an infant’s caretaker in species such as mammals and birds which show
extend periods of parental care [47]. This behavior in mice is "ultrasonic" (higher than the
range of human hearing, > 20 kHz) and is correlated to search and retrieval behavior on
the part of the parent [48]. In addition to neonatal vocalization behavior, mice also exhibit
this ultrasonic vocalization (USV) in playful encounters as juvenile mice and during non-
aggressive social exploration in adult mice [49]. In adult mice vocalization has primarily
been studied in the context of male & female mating encounters [50, 51] which can be
elicited with female urine or an anesthetized female. In fully awake male and female in-
teractions, it was long thought that only the male is vocalizing, however it has since been
learned that females are also vocalizing during these encounters [52]. In all these cases,
vocalization appears to serve as a social attractant, facilitating interaction [49]. Because
of the correlation of USV to other interactive behaviors in mice such as caregiving during
infancy and social investigation later in life, deficits to this behavior may be important indi-
cators of poor development of the social communication apparatus in mice, and thus USV
is often assayed in mouse models of ASD [45, 53–57]. In addition to these groups, our
group discovered variants in the RNA-binding protein gene CELF6 associated with ASD
risk. This gene was identified in a study of genes showing enriched expression in sero-
tonergic neurons, and knockout of this gene in mice resulted in pronounced reductions to
neonatal USV [45]. This finding forms the motivation for this thesis work, and thus in a
final overview section, I will provide some of the background to our studies on the CELF6
gene and our initial findings in the USV behavioral system.
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Celf6 and its association to ASD and USV
In 2013, our group published a report in which we profiled serotonergic neurons using
Translating Ribosome Affinity Purification (TRAP), which was work that began at The
Rockefeller University under the laboratory of Nathaniel Heintz and continued at Wash-
ington University in St. Louis [45]. The serotonergic system, as described above, had
previously been implicated in the etiology of ASD. As a candidate system approach, our
group used TRAP, a method for profiling genes enriched for expression in a specific cell
types [58], to determined previously unidentified transcripts with enriched expression in
these cells, with the goal being to then determine whether these enriched genes showed
association with risk of ASD diagnosis. Thus unlike a full GWAS endeavor, to conserve
statistical power, this approach narrows the search space by first choosing a high priority
candidate cell type, profiling its enriched transcripts, and determining whether the human
homologues of these transcripts show evidence of assocation, rather than testing across
the entire genome. TRAP requires the exogenous expression of an epitope-tagged ri-
bosomal protein (RPL10a), and in our work this was performed using EGFP-RPL10a
expressed under the control of the promoter for the serotonin transporter gene Slc6a4
in transgenic mice. This approach generated a candidate list of 174 genes showing en-
riched expression in serotonergic neurons, 147 of which had clear human homologues,
and were distributed across 136 noncontiguous regions in the genome.
These 136 regions were tested for association of single nucleotide polymorphisms to
ASD diagnosis in data from the AGRE, with two SNPs achieving significance after mul-
tiple testing correction across the narrowed genomic search space of these 136 regions
relevant to the serotonergic sytem. One of these variants is located in the 5’ untranslated
region (5UTR) of the CELF6 gene near an alternative transcriptional start site. CELF6 is
part of the CUGBP and ELAV-like Family (CELF) of RNA binding proteins, which I have
reviewed more extensively in Chapter 4. Aside CELF1 (CUGBP1) (associated with my-
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otonic muscular dystrophy [59]), these proteins are on the whole poorly studied, however
they may act as regulators of alternative splicing [60, 61]and well as mRNA stability and
translation regulation [62, 63]. In addition to the common variant assocaition, we also
identified a rare inherited premature stop codon in this gene in one autistic patient and no
deleterious mutations in controls.
Due to these findings, we generated a knockout mouse with global loss of Celf6 gene
expression, in order to characterize behavioral changes that may be relevant to ASD,
and to further explore the physiological and molecular consequences of loss of CELF6
protein. In characterizing Celf6-null (Celf6−/−) mice, we found that Celf6−/− mice showed
almost 2 fold reduction to neonatal USV calls when assayed at post-natal day 8 compared
to wild type littermates and we have since validated these findings in several replication
cohorts of animals. In adult animals, Celf6−/− showed normal perfomance on general
locomotor activity tasks. Although they performed similarly to wild type littermates in the
three-chambered social approach task described above, in an exploratory holeboard as-
say (used to test resistance to change) we found their exploratory behavior was not poten-
tiated by exposure to an attracting stimulus (chocolate chips, later replicated as well with
sweetened condensed milk). This exposure in wild type animals enhanced overall nose-
poking over baseline throughout the apparatus, which may indicate some exploratory and
novelty seeking behavior in Celf6−/−animals, particularly after potentiation by a rewarding
stimulus, was blunted.
Aside the behavioral findings, we also found that Celf6−/− mice showed decreased
levels of serotonin, dopamine, and norepinephrine in the brain as assayed by mass spec-
trometry. Indeed, in addition to the serotonergic system, we went on to determine that
the Celf6 gene shows enhanced expression in all of these neurotransmitter systems in
the brain, and not only the serotonergic system [64]. We initially hypothesized that the
behavioral changes we observed would be associated with actions of the CELF6 protein
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in one or more of these systems. Additionally, aside a single publication on alternative
splicing promoted by CELF6 protein in vitro [61], the overall molecular function of CELF6
has not been characterized. Thus, I set forth to:
• determine whether loss of CELF6 to key regions in the brain (neuromodulatory neu-
rotransmitter systems) could phenocopy behavioral changes observed in the global
knockout animal, thereby further implicating specific cell types in the mechanism of
CELF6’s relationship to behavior
• identify the mRNA binding targets of CELF6 in the brain and begin to assess how it
may regulate them.
Using the advanced molecular toolkit available for mice, including Cre-Lox recombina-
tion [65], as well as other advances such as cross-linking immunoprecipitation and next-
generation sequencing [66], we began to (a) assess the USV behavior of animals condi-
tionally lacking CELF6 in specific cell populations, as well as (b) further understand how
CELF6 may act in the brain to regulate downstream mRNA molecules.
Summary and Dissertation Overview
In summary, we began our studies of the CELF6 gene by identifying its association to
ASD risk, and investigating how it may be associated with ASD-related phenotyping in
mice. We determined that certain domains of behavior, namely early communication and
exploratory behavior, were altered in Celf6-null animals. Chapters 2 and 3, making up
Part 1 of this dissertation, examine USV data in Celf6 knockout animals. In Chapter
2, I present previously unpublished data regarding USV in Celf6 knockout mice as neo-
natal pups, as well as neonatal USV in mice lacking Celf6 expression in serotonergic and
dopaminergic neurons. In Chapter 3, I present my work, as published in the journal Fron-
tiers in Behavioral Neuroscience, consisting of a meta-analytic study of the development
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of neonatal pup USV. This study shows that as pups this behavior is relatively unpre-
dictable from animal to animal, but that as animals age, each animal demonstrates more
characteristic individual behavior in certain aspects of USV production.
Part 2 of this dissertation is concerned with my initial work characterizing the molecu-
lar function of the CELF6 protein. In Chapter 4, I review the known work on the function
of CELF RNA binding proteins and I review how RNA binding protein-RNA interactions
are characterized. In Chapter 5, I present my original work identifying CELF6 binding
targets and my initial experiments to assay CELF6 function in how it regulates these tar-
gets using a powerful massively parallel approach. It is my hope that the research I have
presented here lays an important foundation in the study of this protein, which is likely
a key regulator of mRNAs in the brain. Thus far, my work has represented parallel lines
of inquiry: correlations of protein presence or absence to changes in behavior, and in-
vestigations of molecular function. While it is not yet possible for me to propose a direct
mechanism by which the molecular function of Celf6 leads to changes in behavioral out-
come, future research on this protein in our group and others will certainly shed important
light on how this gene and its downstream regulatory pathways ultimately influence the
larger phenotype of behavior.
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Chapter 2
Characterization of deficit to ultrasonic
vocalization in Celf6 knockout mice
Abstract
We used Translating Ribosome Affinity Purification to identify genes whose
expression is enriched in serotonergic neurons. The genomic loci containing
these genes were assayed for associated to ASD diagnosis in case and con-
trol samples from the AGRE. A common variant in CELF6 was find associated
with ASD in the 5’ untranslated region, as well as a premature stop codon ob-
served in one autistic patient and no controls. Because of this association, we
made a knockout mouse with global loss of CELF6 expression and subjected
it to ASD behavioral phenotyping. Celf6−/− mice showed >2-fold reduction to
neonatal ultrasonic vocalizations compared to wild-type animals. Additionally,
I assessed the temporal and spectral nature of the ultrasonic calls of Celf6−/−
mice. I found that the same reduction to total numbers of calls was also ob-
served in total numbers of bouts. Differences in intercall pause times were not
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detected, nor interbout intervals, nor call duration compared to wild-type litter-
mates. Celf6−/− and Celf6+/+ mice showed similar usage of the frequence
spectrum and also showed similar proportions of calls containing jumps in
pitch. Because CELF6 is enriched for expression in neuromodulatory neuro-
transmitter populations, I sought to determine whether cell-type specific knock-
out in dopaminergic (DA) or serotonergic (5HT) neurons was sufficient to result
in the same effect in vocalization as the global null mouse. I used a Cre-Lox re-
combination strategy to spatially restrict CELF6 loss to DA or 5HT neurons and
confirmed loss of protein expression with immunofluorescent staining. Upon
assay for vocalization in pups, however, mice will loss of CELF6 in DA or 5HT
neurons did not reproduce the findings of the global null, but showed similar
vocalization levels to CELF6+ littermates. Taken together, Celf6−/− animals
show reductions to vocalization but do not show gross changes to temporal
structure or usage of the frequency spectrum. Future work on this protein will
be needed to determine the population or populations which may be mediating
reductions to vocalization in Celf6−/− mice.
Introduction
As described in the preceding section, in order to narrow the search space for ASD-
associated polymorphisms, we used a candidate cell type approach by profiling targeted
a targeted cell type of interest. Cell types already implicated in ASD include the GABAer-
gic system [1, 2] as well as the serotonergic system [3, 4]. By profiling the serotonergic
system [5], we identified 174 transcripts showing enriched expression in these cells com-
pared to the rest of the brain, using Translating Ribosome Affinity Purification. When
testing these genomic loci for polymorphisms associated with ASD, we identified associ-
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ations in the CELF6 gene. We proceeded to make a knockout model of this gene and
assess whether there were notable changes to behavior in an battery of behavioral tests
related to ASD.
The CELF6 gene codes for a protein which is a member of the CUGBP- and ELAV-
Like Factor family of proteins containing 6 members CELF1-6. These proteins interact
with RNA via RNA Recognition Motif (RRM) binding domains. Family members exhibit
diverse regulatory capacities: regulating alternative splicing, mRNA degradation, and
mRNA translation [6]. I discuss previous research on this family of proteins in greater
detail in Chapter 4 of this dissertation. To our knowledge, our group’s report on CELF6
in 2013 [5] is one of few studies linking a CELF protein to some change in behavior, in
addition to CELF4 which has been shown to be associated with disruption of synaptic
function and seizures [7, 8]. I found that Celf6−/− mice showed reductions to neonatal
ultrasonic vocalization (USV) [5].
USV is emitted by mice throughout the lifetime under different social contexts: as pups
when separated from their caregiver[9], as juvenile mice during playful encounters [10],
and as adults in both same sex and mating associated encounters [11]. Therefore, be-
cause USV is part of the normal repertoire of mouse social behavior, and as it is readily
ammenable to automated analysis pipelines [12, 13], it has thus become a standard phe-
notyping protocol across labs studying disruptions in ASD phenotyping. In this chapter, I
present previously unpublished data characterizing the neonatal vocalization of Celf6−/−
mice. I found that although the overall rate of calling of these mice was reduced com-
pared to wild-type littermates, there were not overt changes to the temporal and spectral
structure of these calls. Additionally, because I aimed to characterize the cell populations
which may be responsible for the deficit observed in knockout animals, I used a Cre-
Lox recombination strategy to remove Celf6−/− expression from serotonergic (5HT) and
dopaminergic (DA) neurons. I found that deletion in either population was insufficient to
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recapitulate the reduction to USV observed in the global null animal. Taken together, the
Celf6−/− phenotype is largely in the overall volume of response to maternal separation
which is reduced in the knockout. Beyond this reduction in behavior, these animals are
capable of emitting the same kinds of sounds as their wild-type littermates. We have so
far been unable to identify a single cell type which can be more narrowly correlated to this
change in behavior and future work will be needed to identify which cell subpopulation(s)
or circuit(s) are responsible.
Results
Celf6−/−mice show reductions to overall rate of ultrasonic calling when
separated from their mothers.
Ultrasonic vocalization emission is not a continuous phenomenon but rather is emit-
ted in bouts of calling separated by longer pauses. An example trace demonstrating this
structure is shown in Figure 1A. Empirically, a lower bound for the minimum pause be-
tween bouts can be established by inspecting the histogram of all pause times, which
which I use here as 300 msec. Calls vary in duration on the order of 20-100 msec, with
pauses between these calls within bouts between 100-200 msec.
Total numbers of calls were reduced 2.4 fold in Celf6−/− animals compared to wild-type
animals (p<0.002) and 2.8-fold reduced (p<0.02) compared to Celf6+/− animals (Figure
1B). When calls were segmented into bouts, we found a ≈2-fold reduction in Celf6−/− an-
imals compared to wild-type (1.97-fold, p<0.03) and Celf6+/− animals (2.1-fold, p<0.008)
(Figure 1C). In either case (total calls or total numbers of bouts) we did not detect differ-
ences between wild-type and heterozygote animals, indicating that this phenotype did not
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Figure 1: Celf6 knockout mice show reductions to overall rate of ultrasonic calling when separated
from their mothers.
(A) Example spectrogram showing a recording of neonatal pup USV on post-natal day 8. In lower pane, a
single bout of USV is zoomed it to show the scale of individual calls. (B) Total numbers of calls per 3
minute recording in Celf6 wild-type (N=23), heterozygote (+/-, N=41) and knockout (-/-,N=21) animals.
Data points are shown with means ± standard error. (C) Total numbers of calling bouts (minimum interbout
gap length of 0.3 msec). Statistical testing is shown as ANOVA testing for main effect of genotype, with
post hoc pairwise comparisons performed using t-tests with Bonferroni adjustment for multiple testing.
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appear sensitive to Celf6 gene dosage.
Although overall calling rate and number of bouts per recording are necessarily cor-
related features of vocalization, it might be possible that lowered numbers of total calls
were still separated into an equal number of bouts per recording. This would be the case,
for example, if the average pause length between calls were lengthened such that each
bout were composed of fewer calls. A lack of correlation between call rate and bout rate
then would indicate some change to temporal structure. Because segmentation of calls
into bouts depends on the temporal structure of the calls and the intervals between them,
I next set about analyze temporal features of vocalization, in addition to spectral features
of calls produced by Celf6−/− .
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Celf6−/− knockout mice show similar temporal and spectral features
of vocalization to wild-type mice
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Figure 2: Spectral and temporal properties of ultrasonic calls are unperturbed in Celf6 knockout
mice.
As in Figure 1, all data are shown color-coded according to group: green: Celf6+/+ (N=23), blue:
Celf6+/−(N=41), red: Celf−/−(N=21). (A) Pauses between calls within bouts ("intrabout", < 0.3 msec), (B)
Gaps between bouts ("interbout"), (C) Call duration. For features of USV measured in (A)-(C), data point
represent the average across all calls per animal. All animals showed at least 10 calls per recording. (D)
Frequency spectrum. Power summed over all calls was computed as FFT amplitude2 and normalized to
the sum across the spectrum. Spectra are shown as means ± standard error. (E) Area under each peak in
(D) was summed and compared across groups. Because one sum is simply the exact complement of the
other sum, statistical testing was only performed for the low peak data (40-70kHz). (F) Example call
showing a jump in pitch. (G) In order to classify pitch jumps as either upward or downward, the
two-dimensional histogram of all frequency transitions <t,t+1> was computed. "u" and "d" clusters were
manually defined using ROI tools in MATLAB. (H) Calls were classified as containing at least one u-type
jump, at least one d-type jump, both, or none. (I) The proportion of calls containing at least one u-type
jump or one d-type jump is shown per animal. In cases (A-C) and (E), main effects of genotype were
determined using one-way ANOVA. In (I) main effects of genotype, and genotype x call type interaction
were computed using repeated measures ANOVA.
Temporal and spectral features of vocalization describe the repertoire of sounds that
animals are able to produce in addition to acting as proxy measurements for the phys-
ical functioning of structures necessary in the vocalization apparatus. For example, in
collaborative work with the laboratory of Paul Gray, I have found that pause time within
bouts of vocalization is associated to the function of hind brain motor neurons controlling
rhythmic breathing [14]. The relationship of intercall pause intervals and the duration of
subsequent calls is also related to the respiratory apparatus of other species, e.g. the
muscular output of the airsacs of zebra finches [15]. Additionally, the temporal nature
of vocalization is related to its role in communication, as the duration of calls must exist
within certain parameters to effectively elicit maternal search and retrieval behavior [16].
To determine whether these aspects of USV in Celf6 −/− mice was altered, I looked at
pauses and duration times of calls and these data are shown in Figure 2. Pauses were
separated into short pauses between calls of bouts of behavior ("intrabout pauses", 2A)
and longer gaps between bouts ("interbout pauses", 2B). Pauses and duration times (Fig-
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ure 2C) were averaged across all calls per animal, with all animals considered producing
at least 10 calls per recording. No significant effects of genotype were detected across
all features. Intrabout calls were on average 144 msec, with interbout gap times at about
6 seconds. Intrabout pauses exhibited a tight distribution (2A), while interbout pauses
ranged to tens of seconds.
The neurons responsible for controlling the spectral content of vocalization are not
known, however it has been shown that mice are able to discriminate between calls of dif-
ferent spectral subtypes [17], and populations in the auditory cortex and inferior colliculus
respond to USVs of different frequency composition[18–20]. In the periphery, laryngeal
muscle contraction is most proximally involved with the ability to produce sounds of differ-
ing frequency, as high frequency requires maintenance of a narrow aperture. Mice with
transections to the laryngeal nerve cannot vocalize as well as mice with intact control
over this musculature [21]. Thus producing ultrasound, as measured in the frequency
spectrum, may act as a proxy for normal laryngeal function. In order to examine whether
Celf6 −/− produced vocalizations spectrally similar to their wild-type and heterozygote lit-
termates, I estimated usage of the spectrum across each recording by computer power
per frequency across all calls (Figure 2D). Average traces largely overlapped and I was
able to identify two main bands, between 40-70 kHz and 70-120 kHz. I quantified these
bands as an area under the curve for all groups (Figure 2E) but did not detect significant
differences (Figure 2E).
USV stereotypically presents with a number of calls containing instantaneous jumps in
pitch (Example in Figure 2F, where I define pitch as frequency containing maximum power
over time) and this has been used directly to classify calls [12, 22] as well as forming part
of the criteria for other classification schemes[23]. I used the method of [12] by quantifying
pairwise pitch estimates at time t and t+1 across all recordings (Figure 2G). Most pitch
transitions are between the same values of frequency and exist along a diagonal, but
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clear clusters of larger transitions upward and downward in pitch were definable. These
were then used to classify calls as containing upward (u) or downward (d) changes in
pitch, both directions, or no jumps. The fraction of calls per animal containing u or d-type
changes is shown in (Figure 2H). Across all four classes, I did not detect any significant
changes to calls containing pitch jumps of different kinds. Taken together, these results
imply that the primary change in Celf6 −/− mice is reduction to the overall amount of
response to maternal separation, measured as total calls or total bouts of vocalization,
but that otherwise these animals are capable of producing the same kinds of calls as their
wild-type and heterozygote littermates.
Mice with CELF6 loss in 5HT and DA neurons fail to show reductions
to USV
Our group first identified CELF6 as exhibiting enriched expression in serotonergic neu-
rons, but with follow up immunohistochemical work, members of our group found that it
was enriched in several other populations including populations of the hypothalamus, the
5HT, DA, and noradrenergic (NE) monoaminergic neurotransmitter populations, as well
as a subpopulation of neurons in the lateral habenula (likely Substance P+ cells), with
weaker expression elsewhere[24]. Known markers for these populations ca be used to
drive expression of Cre recombinase for Cre-Lox mediated excision [25] in specific cell
types. Thus we used this approach with a Celf6loxP/loxP mouse which has loxP sites
flanking a constitutive exon [5].
5HT neurons can be reliably marked by specific genes, such as those in the serotonin
biosynthesis pathway (e.g., Tph2, Ddc) or the serotonin transporter (Slc6a4). However,
genes such as Slc6a4 are not unique to serotonergic neurons during early post-natal
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Figure 3: Mice with CELF6 loss in 5HT and DA neurons fail to show reductions to USV.
(A) Conditional loss of CELF6 in Celf6loxP/loxP ; FEV-Cre+ animals. 40X confocal images are shown from
40 µm slices of Celf6loxP/loxP ; FEV-Cre- or FEV-Cre+ animals stained with anti-CELF6 (red) and
anti-TPH2 (green) antibodies in the dorsal raphe (DR) nucleus. (B) Post-natal USV measured from
FEV-Cre- (24) and FEV-Cre+ (20) Celf6loxP/loxP animals. (C) Conditional loss of CELF6 in Celf6loxP/loxP ;
DAT-Cre+ animals. 20X confocal images are shown from 40 µm slices of Celf6loxP/loxP ; DAT-Cre- or
DAT-Cre+ stained with anti-CELF6 (red) or anti-TH (green) antibodies in the substantia nigra pars
compacta (SNPc) and the ventral tegmental area (VTA). (D) Staining in locus coeruleus (LC) as in (C)
where no conditional loss observed. (E) Post-natal USV measured from DAT-Cre- (32) and DAT-Cre+ (25)
Celf6loxP/loxP animals. Staining experiments in (A),(C),(D) are representative of 3 animals per group
(Cre+ or Cre-). No significant changes to calls produced in 3 minutes were detected in (C),(E).
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development when we are measuring USV but are observed elsewhere[26]. The FEV
(also Pet1, ePet) transcription factor specifies the development of the raphe nuclei of the
hindbrain during the late embryonic stage and maintains expression after birth [27]. Thus
I employed transgenic mice expressing Cre recombinase under the control of the FEV
promoter to drive Celf6 knockout in 5HT neurons. Conditional loss of Celf6 in raphe
neurons was confirmed by immunofluorscent staining on 40 µm sectioned brain tissue
with anti-Celf6 and anti-Tph2 antibodies followed by confocoal fluorescent microscopy.
These results are shown in Figure 3A.
I recorded USV from Cre- and Cre+ Celf6loxP/loxP pups at post-natal day 8. I did not
detect an effect of genotype (Figure 3B, p = 0.9237) and USV call rate in both genotypes
was comparable (Celf6loxP/loxP ; FEV-Cre+ 42 calls/3minutes, Celf6loxP/loxP ;Cre- 53). It
is worth noting that these population estimates are nearly 3-fold lower than the wild-type
controls for the global knockout animal (average calls/3minutes = 182), which is likely
due to intercross with the background of the FEV-Cre animals. Thus, despite our origi-
nal description of CELF6 as demonstrating enriched expression in serotonergic neurons,
conditional knockout in serotonergic neurons alone is insufficient to recapitulate the USV
phenotype observed in the global null.
I next looked to DA neurons and used DAT-Cre transgenic animals, expressing Cre
recombinase under the control of the dopamine transporter gene promoter (DAT ) to drive
recombination in dopaminergic neurons [28]. Confirmation of conditional knockout using
immunofluorescent staining with anti-CELF6 and anti-Th (marking DA neurons) antibod-
ies is shown in Figure 3C. Loss of CELF6 is shown for both DA neurons of the substantia
nigra pars compacta (SNPc, upper panels) and the ventral tegmental area (VTA, lower
panels) for Cre- and Cre+ animals demonstrating loss of CELF6 expression in these cells.
Th, or tyrosine hydroxylase, is the first enzyme in the biosynthesis pathways for both DA
and NE, and Celf6 is expressed in both DA (e.g., VTA, SNPc, and smaller populations
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of the hypothalamus) and NE neurons (in the locus coeruleus (LC)). Thus in Figure 3D
using the same anti-Th stain to mark the noradrenergic population of the LC in the dorsal
hindbrain, we show that loss of CELF6 mediated by DAT-Cre recombination is specific to
the DA neurons and that the LC retains CELF6 expression.
After measuring USV in these animals I again did not detect an effect of genotype
(p ≈1) with comparable estimates for calls/3minutes in both Celf6loxP/loxP ;DAT-Cre+ (115
calls/3minutes) and Celf6loxP/loxP ;Cre- animals (116 calls/3minutes) indicating that both
genotypes behaved similarly. We also measured USV in these animals on additional post
natal days (5 & 9) and did not find significant differences on any days (See Chapter 3,
Supplemental Figure S1). The negative data from this study were used as part of the
meta-analytic study on variability in USV across early development in the following chap-
ter. Taken together, we were unable to isolate the USV phenotype observed in Celf6−/−
to either 5HT or DA neurons.
Discussion
The ultrasonic vocalization of neonatal mouse pups has become a standard task in behav-
ioral characterization of mouse models of ASD and other neurodevelopmental disorders
[9]. Our group’s publication in 2013 of reductions to vocalization in Celf6−/− mice is ex-
panded here to include my analysis of other aspects of USV in these mice. USV is a data
rich behavior, containing information on how the animal makes use of the frequency spec-
trum, how the temporal sequences of calls are composed, and how much behavior overall
is elicited by the stimulus (e.g., maternal separation). We have shown that Celf6−/− mice
have reduced levels vocalization produced in response to maternal separation. Because
emission of USV is correlated to maternal search and retrieval behavior [29], deficits to
USV may impact the communication between pups and their mothers leading to altered
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levels of maternal care. We have not explicitly tested this in Celf6−/− mice, however it
will be interesting to see whether pups producing less vocalization in this model indeed
receive less attention from their caregivers. In addition to USV, throughout the post-natal
period, we routinely test mice for other developmental milestones such as development
of the righting reflex [30] as well as pinna detachment of the ears, eye opening, and
weight gain. We have not found any differences during the post-natal period, suggest-
ing that other than the deficit to USV, Celf6−/− are developing similarly to their wild-type
littermates.
My strategy to localize the USV behavior of Celf6−/− mice has been to use Cre-Lox
recombination to mediate cell-type specific knockout. This has not yet yielded further
narrowing of the phenotype to a specific population of cells. Current research in our
group is employing multiple strategies to remove CELF6 across all the monoaminergic
populations of cells simultaneously. When I began my knockout studies, the full extent
of CELF6 protein expression was not yet known. Given a more current understanding
of where in the brain CELF6 is expressed, an alternate strategy may be to use Cre-Lox
to remove CELF6 from whole regions of the developing brain, such as the diencephalon
or the hindbrain . Such strategies may help better define the subregions of the brain
responsible for driving the phenotype in Celf6 knockout mice.
Methods
Animals
All protocols involving animals were approved by the Animal Studies Committee of Wash-
ington University in St. Louis. Original cohort published in Dougherty et al. 2013 study
was generated by breeding Celf6+/− X Celf6+/− crosses. For conditional knockout stud-
ies, Celf6loxP/loxP animals were first crossed to either FEV-Cre (Jackons Laboratory Strain
33
B6.Cg-Tg (Fev-cre)1Esd/J) or DAT-Cre (Jackson Laboratory strain B6.SJL -Slc6a3tm1.1(cre)
Bkmn/J) animals to generate Celf6loxP/loxP to generate Celf6loxP/loxP ; Cre+ and Cre- litter-
mates. Cages were maintained by our facility on a 12 hr : 12 hr light:dark schedule with
food and water supplied ad libidum. Animals were genotyped from toe clip tissue lysed
by incubation at 50oC in Tail Lysis Buffer ( 0.5 M Tris-HCl pH 8.8, 0.25 M EDTA, 0.5%
Tween-20 ) containing 4 µL/mL 600 U/mL Proteinase K enzyme (EZ BioResearch) for
1 hour to overnight, followed by heat denaturation at 99oC for 10 minutes. Crude lysate
containing DNA was genotyped using Quickload Taq Mastermix (New England Biolabs)
with the following cycling conditions: 94oC 1 min, (94oC 30 s, 60 oC 30 s, 68oC 30 sec) x
30 cycles, 68oC 5 minutes, 10ohold. Celf6−/− animals were genotyped with:
• B6_J_geno_3U: 5’-CCCTGCCACCTAGCTCTTCAGGTT-3’,
• BRUNOL KO 3’: 5’ ATGGCTGAGCTCTTTCTTGAGAAGTAC-3’
primers. The wild-type allele is detected as a 415 bp PCR product and the knockout as a
188 bp product. Celf6loxP/loxP ; Cre+ animals were genotyped using: B6_J_geno_3U and
BRUNOL KO 3’ primers above which yield a 500 bp product for the flanked-by-loxP allele.
Cre recombinase was genotyped using:
• Cre-F: 5’-CCGGTCGATGCAACGAGTGATGAGGTTC-3’ and
• Cre-R 5’-GCCAGATTACGTATATCCTGGCAGCG-3’
primers yielding a 450 bp product and using primers amplifying Actb as an internal control
for PCR failure.
USV recording
USVs were recorded on post-natal day 8 or 7 (DAT-Cre cohort) using a CM16 microphone
and RECORDER software (Avisoft Bioacoustics). Full description of USV recording pro-
tocol is provided in Chapter 3 - Methods. Mice in original global Celf6−/− cohort and
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crosses to FEV-Cre were measured on post-natal day 8. Mice in crosses to DAT-Cre
were measured on post-natal day 7 and not post-natal day 8 due to changing procedures
in our laboratory, where we have standardized USV measurements across multiple time
points in development. The USV deficit in Celf6−/− mice has been confirmed as well for
post-natal day 7 (Maloney et al., manuscript in preparation).
USV processing
Acquired USV recordings were processed using a custom pipeline in MATLAB based
on code authored by Timothy Holy[12]. Description of this pipeline is given in Chapter
3 - Methods and a tutorial in its usage is given in Appendix I - Using the MATLAB
VocalizationFunctions Package.
Immunofluorescent staining
Mice on post-natal day 21 were euthanized by CO2 according to protocols approved by
the Animal Studies Committee of Washington University in St. Louis and in accordance
with NIH guidelines. Mice were subjected to transcardial perfusion with 1X PBS for 5 min-
utes, followed by 4% paraformaldehyde in 1X PBS for 7 minutes. After perfusion, brains
were dissected and post-fixed in 4% paraformaldehyde overnight, followed by progressive
sucrose protection in 5% sucrose/1X PBS for 1 hour, 15% sucrose/1X PBS overnight,
and 30% sucrose/1XPBS overnight. Brains were frozen in Neg-50 medium (Thermo)
and sectioned on a Leica cryostat as 40 µm floating sections in 1X PBS. Free floating
sections were blocked in 0.25% Triton-X 100/1X PBS (PBST) supplemented with 10%
donkey serum (Jackson Immunoresearch), and then incubated overnight in PBST/10%
donkey serum containing 1:1000 diluted mouse anti-Th (Millipore MAB318) or anti-Tph2
(Thermo) antibodies and 1:250 diluted custom rabbit anti-CELF6 antibody (#176, as de-
scribed in [5]) overnight at room temperature. Sections were washed 3x10 minutes in
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PBST, and then incubated for 1.5 hours at room temperature in PBST/10% donkey serum
containing secondary antibodies. 5HT conditional knockout used 1:500 Alexa Fluor 488 f
anti-Rabbit secondary for CELF6 staining and Alexa Fluor 546 anti-Mouse secondaries for
anti-Tph2 costain. We subsequently observed better resolution of CELF6 staining using
more spectrally distantly fluorophores. For DA conditional knockout we used 1:500 Alexa
Fluor anti 647 (far red) anti-Rabbit antibody to mark CELF6 staining and 1:500 Alexa Fluor
488 anti-Mouse for anti-Th costain (Thermo). After incubation with secondary antibodies,
slices were washed 3x10minutes in PBST and then incubated for 10 minutes with 1XPBS,
1:30,000 DAPI, followed by 3x10 minute washes in PBS. Slices were mounted to slides
and coverslips were applied using ProLong Gold antifade mounting medium (Thermo).
Sections were imaged with a Perkin Elmer UltraView Vox spinning-disk confocal on a
Zeiss Axiovert. Monochromatic images were adjusted for background signal in MATLAB
and colored images were prepared as RGB TIFF format storing CELF6 signal in the red,
and Th/Tph2 signal in green, and DAPI in blue.
Statistical Analysis
Main effects of genotype across USV features described were assessed using univariate
linear models and analysis of variance (ANOVA) in MATLAB. Pairwise post hoc compar-
isons were performed with simple Student’s t-test and adjusted for multiple comparisons
by Bonferroni correction. Main effect of genotype and interaction of genotype with sub-
class of USVs containing upward and downward jumps in pitch were assessed by re-
peated measures ANOVA in MATLAB.
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Chapter 3
Analysis of within subjects variability
across Celf6 conditional knockout
studies: pups exhibit inconsistent,
state-like patterns of call production
Adapted from original work in:
Rieger, M.A. and Dougherty, J.D., 2016. Analysis of within subjects vari-
ability in mouse ultrasonic vocalization: Pups exhibit inconsistent, state-like
patterns of call production. Frontiers in behavioral neuroscience, 10, p.182.
Abstract
Mice produce ultrasonic vocalizations (USV) in multiple communicative con-
texts, including adult social interaction (e.g., male to female courtship), as well
as pup calls when separated from the dam. Assessment of pup USV has been
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widely applied in models of social and communicative disorders, dozens of
which have shown alterations to this conserved behavior. However, features
such as call production rate can vary substantially even within experimental
groups and it is unclear to what extent aspects of USV represent stable trait-
like influences or are vulnerable to an animal’s state. To address this ques-
tion, we have employed a mixed modeling approach to describe consistency
in USV features across time, leveraging multiple large cohorts recorded from
two strains, and across ages/times. We find that most features of pup USV
show consistent patterns within a recording session, but inconsistent patterns
across postnatal development. This supports the conclusion that pup USV
is most strongly influenced by “state”-like variables. In contrast, adult USV
call rate and call duration show higher consistency across sessions and may
reflect a stable “trait”. However, spectral features of adult song such as the
presence of pitch jumps do not show this level of consistency, suggesting that
pitch modulation is more susceptible to factors affecting the animal’s state at
the time of recording. Overall, the utility of this work is threefold. First, as
variability necessarily affects the sensitivity of the assay to detect experimen-
tal perturbation, we hope the information provided here will be used to help
researchers plan sufficiently powered experiments, as well as prioritize spe-
cific ages to study USV behavior and to decide which features to consider
most strongly in analysis. Second, via the mouseTube platform, we have pro-
vided these hundreds of recordings and associated data to serve as a shared
resource for other researchers interested in either benchmark data for these
strains or in developing algorithms for studying features of mouse song. Finally,
we hope that this work informs both interpretation of USV studies in models of
developmental disorder, and helps to further research into understanding the
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neural processes that contribute to the production and predictability of USV
behavior.
Introduction
The ultrasonic vocalizations (USV) of young mouse pups in response to maternal isola-
tion has been studied for over five decades [1–6]. The ability of isolation to elicit pup USV
begins within days of birth and shows a peak in early postnatal development followed by
a steady decline until two weeks of age [5]. These vocalizations function as a simple
form of communication as they stimulate search and retrieval behavior from dams [2, 7,
8]. Because pup USV is easily elicited in the laboratory [6], and amenable to automated
analysis [9, 10], it has been assessed routinely as an anxiety- and communication-related
phenotype in models of neurodevelopmental disorder [11, 12]. A number of knockout
mouse lines for ASD spectrum disorder [13–15], as well as for speech and language dis-
order risk genes [16] and stuttering [17], show changes to pup USV. These include either
changes in the rate of USV production, or other spectral or temporal features of vocaliza-
tion. Although this behavior is not human language, pup USV is a robust milestone of early
postnatal development, and isolation-induced infant vocalization is a conserved behavior
across mammals [3, 18–21]. Thus, understanding the neurobiological mechanisms medi-
ating deficits of pup USV in disease models may help elucidate some conserved biology
underlying these disorders of neurodevelopment.
Though production of USV is typically a robust behavior across a litter of animals, in-
dividual mouse pups show substantial variability, ranging from 0 to several hundred calls
in a typical recording of wildtype C57BL/6J animals during the first week of life. Although
most studies of USV in neurodevelopmental disorder models focus on mean differences
between experimental and control groups, it is not often reported how variable this be-
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havior is between and within subjects. While two mice of an inbred line are assumed
to possess identical genetic backgrounds, this does not preclude a large degree of in-
dividual difference in behavioral expression [22–24]. The relative degree of inter- and
intra-individual variation provides an estimate of the consistency or predictability of USV.
The utility of estimation of the consistency of behavior and modeling intra-individual varia-
tion has been recognized in human clinical studies [25], human psychology [26, 27], and
ecology, but such variability is not typically reported in studies of mouse USV, though it
has been explored in the vocalizations of other species [28, 29]. In human personality
theory, it has been useful to consider the differences between “trait” versus “state” influ-
ences on behavior: a state is a transient condition that influences behavior (e.g., feeling
fear when seeing a snake), while a “trait” is a more stable aspect of personality that has a
durable influence on behavior across time and situations (e.g., being a generally anxious
person) [30, 31]. Borrowing these terms, individual-level behavioral expression patterns
in USV might be due to any number of uncontrolled covariates that could mediate either
state-like or trait-like differences in behavior. These include differences in intra-uterine
environments and maternal health during pregnancy [32–34] or maternal experience and
quality of care (feeding, licking, etc.) [35], which might have stable, trait-like impacts. Ad-
ditionally, extrinsic factors such as degree of handling during the assay and temperature
of the assay chamber [6], maternal behavior just prior to the assay, or physiological vari-
ables (hunger/satiety, heart rate, breathing, etc.) may have a more immediate impact.
Only a subset of these external factors can be reasonably measured during the course of
an experiment. For example, typical USV protocols call for controlling temperature using
an incubator or a heating pad before recording, as well as minimizing handling [6]. How-
ever, even if all such factors could be controlled, some aspects of USV may yet exhibit
stochasticity. Such “randomness” in behavior is demonstrable even in simpler organisms.
In C. elegans, although the average response of worms is to move towards an attractive
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olfactory stimulus, individual worms deviate from the expected pattern. In this organism,
this has been shown to be controlled by neural states, where specific neurons control
apparent randomization of the output behavior [36]. In mice, integration of enviromental
covariates and intrinsic neuronal states may differ between time points and individuals,
generating a variable amount of produced USV.
Furthermore, USV is a data-rich behavioral response with numerous features in the
spectral and temporal domains of audio. In particular, some features of USV may be highly
consistent within an animal relative to the population across days, showing a strong “trait”-
like influence on variability. Other features may be more consistent within a recording ses-
sion, but display high levels of intra-individual variability across days, perhaps reflecting
an individual mouse’s acute “state” on a given day. Finally some features may yet re-
main unpredictable even within a recording session. These degrees of consistency within
and between individuals may reflect differential susceptibilities among features of USV to
genetic, environmental, and intrinsic neuronal factors, leading some behaviors to show
more stable “trait”-like influences (high consistency across days) while others might show
patterns of variation more consistent with “state”-like responses (low consistency across
days). Importantly, prior studies of features of pup USV have not considered the con-
sistency of individuals, and determining whether a feature is more state- or trait-like may
alter both interpretation of findings in disease models and the search for neurobiological
mediators of pup USV.
Thus, to address the concept of consistency in USV behavior, we have used mixed
modeling statistical approaches. Linear mixed models (LMMs) have proven a powerful
way to estimate behavioral consistency patterns by partitioning random variance terms
which describe the degree of inter- and intra-individual variability. In this study, we have
employed the mixed model intra-class correlation (ICC) coefficient ([25], also referred
to as “repeatability” [37, 38]) in order to understand consistency in features of USV
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across three independent discovery cohorts, totaling 285 subjects, and across two strains:
FVB/Ant & C57BL/6J (“Pooled Cohort Study”, PCS). We analyzed call rate (calls per
minute), spectral, and temporal features of USV across three time points during post-
natal development after controlling for effects of animal strain, age, and relative size.
We also analyzed these features binned within recording session at each postnatal time
point in order to understand consistency within a session. In order to validate our find-
ings, we recorded additional litters of each strain at high temporal density (postnatal days
3-14, “Time Course Study”, TCS) as a replication study and to further probe the tempo-
ral dynamics of consistency. We found that despite clear group-level changes (due to
age or strain) in both discovery and replication cohorts, features nevertheless varied in
consistency across development, with some features, such as call rate, being largely un-
predictable from day to day for a given animal. Within session however, we found that
most features of USV exhibited significantly higher consistency on any given postnatal
day. Furthermore, some features that showed low consistency over postnatal days, such
as USV call rate, demonstrated a narrow window of high consistency near the peak of
USV behavior. Early postnatal development is a highly dynamic time period for pups. To
explore whether features of USV exhibit more stable behavior across measurements after
animals have fully developed, we additionally looked at consistency in features of USV
exhibited during adult male-female encounters. In contrast to pup USV, some features of
adult USV showed dramatically higher consistency across test days, including the rate of
ultrasonic calling and average call duration. Remaining features, such as the fraction of
calls containing instantaneous jumps in pitch, did not show increased consistency. Thus
while the amount of USV produced by an animal may acquire trait-like stability later in
life, other features remain dependent on the state of the animal, environmental context,
or other influences.
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Results
Assessment of consistency of USV features across early postnatal
development
In order to examine consistency, we have employed the intra-class correlation coefficient
defined from the LMM. For a LMM of a response y (e.g., a feature of USV such as call
duration), modeling fixed effects and a random intercept, we have a model of the form:
y(i) = X(i)∗β + α(i) + ε(i)
where y(i)is the i th measurement, X(i) is the i th row of the design matrix of fixed effect
covariates X, β is the vector of fitted coefficients (e.g. slopes or contrasts between group
means), α(i) is the i th random intercept (a function of subject identity), and (i) is the i th
error. Both α and  are assumed to be normally distributed random variables, which have
means of 0 and variances described by σ2α and σ2ε , and these variance terms are fitted as
part of the likelihood-based modeling procedure. The intraclass correlation coefficient is
defined as:
ICC = σ
2
α
σ2α + σ2ε
and ranges between 0 and 1. Figure 1 illustrates how the ICC measures the degree of
consistency between subject measurements. If the response variable y is adjusted for its
expected value based on fixed effects as y-E(y), where E(y) = X ∗ β (e.g., a group mean),
the resulting data will be centered around 0. In the simplest scenario, the random intercept
will represent the average of subject values after accounting for E(y). If measurements
are consistent, then respective individuals will vary tightly around this intercept (Figure
1A) after adjustment. If this is the case, very little variance between subjects will remain
after adjusting for these intercepts, σ2α  σ2ε , and the ICC will approach 1.0. However,
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if individuals vary inconsistently, then their intercepts after adjusting will be close to 0.
In other words, it will be difficult to predict where, with respect to the group estimate,
an individual will be encountered from measurement to measurement (Figure 1B) and
the fitted intercepts will do little to account for the remaining variance. In this scenario,
σ2α  σ2ε and the ICC will approach 0. Although the fitted values of σ2α and σ2ε derived from
the mixed model are point estimates, using a bootstrap approach, we are able to assign
confidence intervals to these values, and thus the value of the ICC.
Figure 1: The Intra-Class Correlation (ICC) defined from a linear mixed model (LMM) reflects
the level of behavioral consistency of individual animals across multiple measurements.
The ICC (upper right) is defined as σ2α/
(
σ2α + σ2ε
)
, using mixed model random variance terms, and represents consistency of
behavior across multiple measurements, where σ2α is the random effect variance term and σ2ε is the error variance term from the
LMM (fitting a random intercept only, as a function of animal identity). (A) Hypothetical scenario showing how the ICC reflects a
consistent pattern. Left Panel: a response variable (e.g., rate of ultrasonic calls per minute) is measured for the same six
animals(color coded x’s) across conditions and time points. Middle Panel: After adjusting for expected values E(y) (e.g., group means
or regression predictions for variables such as age or strain), random intercepts reflect an average expectation for a particular
animal’s position in the distribution of residuals. If measurements are consistent, the variance of these intercepts (σ2α) reflects most of
the remaining variance in the data. Right Panel: After adjusting for intercepts α, residuals are squeezed towards zero. Thus σ2α  σ2ε
and the ICC approaches 1.0. (B) Hypothetical scenario showing inconsistent measurements. After adjusting for time point or
condition (Left Panel), residuals (Middle Panel) vary inconsistently from measurement to measurement for a given animal, and
average values across measurements (random intercepts) are close to zero, and σ2α is small and reflects little of the remaining
variance in the data. After adjusting for random intercepts, the residuals are mostly unchanged (Right Panel). Thus σ2ε  σ2α and the
ICC approaches 0. Thus, the ICC is a metric which summarizes consistency of patterns of behavior across measurements. The ICC
is a point estimate, but using a bootstrap procedure we are able to assign confidence intervals to the ICC.
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Using the ICC, we sought to explore consistency across some of the most commonly
estimated features of USV in the time and frequency domains (Figure 2). In addition to
the call production rate, we also looked at the fraction of calls with pitch jumps (≥ 10
kHz), as well as the duration, median pitch, and peak power. Because animals differ in
the number of calls they produce, duration, pitch, and power estimates were computed as
either an average over all calls for each recording, or the variability over all calls expressed
as the coefficient of variation (standard deviation/mean). These features were selected
based upon their salience in previous studies of USV. Pup calls are distinguishable from
adult USV [39] and pitch and duration of these calls elicit maternal neuronal response and
search behavior [40–42]. Using these call features as our dependent variables, the ICC
represents a summary statistic describing how consistently an individual’s place in the
population varies across measurements from time point to time point. It helps to address,
for example, whether an animal producing the longest or loudest calls on day 5 is also
producing the longest or loudest calls on day 7, relative to the rest of the population.
Thus, we first analyzed a discovery cohort (PCS) gleaned from 3 datasets, 2 from
C57BL/6J animals and 1 from FVB/Ant animals. In our statistical model, we controlled
for effects of: strain (genetic effects and shared environment), age (postnatal day), and
relative animal size (weight normalized by strain and postnatal day). We also considered
other factors such as sex and litter size, however exploratory preliminary analysis did not
determine statistically significant effects for these factors and they were excluded from
the model [not shown]. Descriptive statistics for call features between groups and across
days in the PCS are shown in Supplemental Table 1.
Examining the consistency of these eight features, we found that each generally showed
low consistency across days for a given animal (Figure 3). Specifically, the most widely
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Figure 2: USV features under investigation include commonly measured features from the
time and frequency domain.
Example image shows two pup isolation-induced ultrasonic calls. (A) Waveform: the time domain data for the noise- and
frequency-filtered calls. A root mean squared (RMS) amplitude envelope is determined for each calls, and the peak power from this
envelope (power = amplitude2) is determined and reported as dB ref 1.0. The average of this measurement is determined over all
calls, per recording, as well as the variability in this measurement, reported as the standard deviation divided by the mean (coefficient
of variation). (B) Spectogram: the frequency domain data for the noise- and frequency-filtered calls. The presence of a pitch jump is
determined by an instantaneous change in the frequency of maximum power ≥ 10 kHz, and the fraction of all calls containing at least
1 such jump was computed. The median value of the pitch (kHz) as well as the duration (msec) were determined, and both the
average over all calls by recording as well as the coefficients of variation (sd/mean) representing the variability in these
measurements over all calls, were computed.
assessed variable in studies of pup USV, call rate (Figure 3A), showed an ICC of 0.20 (c.i.
[0.12,0.27]) indicating low consistency over postnatal days, and Studentized residuals z
show rank correlations of 0.26 (Day 5 vs. Day 7) and 0.24 (Day 7 vs. Day 9) which are
within the range of the ICC interval. In contrast, average call duration (Figure 3B) showed
a marginally higher ICC at 0.40 (c.i. [0.32, 0.48]) and residuals showed rank correlations
of 0.48 and 0.40 for Days 5/7 and Days 7/9 respectively. However, aside from call duration
and median pitch (Figure 3E), most features showed low consistencies with ICC values
and rank correlations less than 0.3.
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Figure 3: Lack of Strong consistency across pup USV features in Pooled Cohort Study
(PCS)
. Each panel shows: (left) the value of the ICC with its boostrapped 95% confidence interval, the data, with bee plots of individual
animals, and trend lines, color-coded by cohort (blue: Cohort 1 (C57BL/6JBL/6J, N=133), cyan: Cohort 2 (C57BL/6JBL/6J, N=105),
red: Cohort 3 (FVB/AntJ/AntJ N=47), showing expected values from the LMM (fixed effects only, w=0 (average weight)) ±
bootstrapped 95% confidence intervals on regression estimates (right) Studentized residuals (z) after adjusting for fixed effects
plotting day 5 vs. day 7, and day 7 vs. day 9, and their respective Spearman rank correlation coefficients. The ICC is a summary
statistic for each USV feature’s consistency, but note that Spearman rank correlation coefficients are typically within or near the range
of the respective ICC’s confidence bounds. (A) Call Rate (calls-min−1). LMM was fitted on log
(
counts+1
minutes
)
(abbreviated “log” on
y-axis) with data (left panel) shown alongside linear scale values for ease of interpretation. LMMs can tolerate missing data points,
and not all animals have data on all three time points due to pup death. Residual plots and associated correlation coefficients were
only computed for animals with data on all three time points: N= (1) 119, (2) 101, (3) 47. (B) Call Duration (averaged over all calls,
milliseconds). (C) Pitch Jumps (fraction of all calls). (D) Peak Power (averaged over all calls , dB ref. 1.0). (E) Median Pitch
(averaged over all calls, kHz). (F) Variability in Pitch. (G) Variability in Duration. (H) Variability in Peak Power (F-H: (coefficient
of variation (σ/µ) over all calls). Other than call rate (A), other features of USV (B-H) were only computed for animals possessing at
least 10 calls (Day 5: N=(1) 114, (2) 90, (3) 47 | Day 7: N=(1) 122, (2) 99, (3) 47 | Day 9 N= (1) 116, (2) 98, (3) 46). LMMs fitted in R
using lme4 with models in Wilkinson notation as: feature ~cohort*w*(d+d(2) + (1|id) where cohort is categorical, w is a z-score of the
animals weight by cohort & day reflecting its relative size, and d is postnatal day centered around day 7, fitting both linear and
quadratic terms, and (1|id) is a random intercept for each animal. Residual plots for (B)-(H) had at least 10 calls and data for all time
points, N = (1) 98, (2) 80, (3) 46. Highest ICC was observed for call duration with ICC = 0.400 [0.320,0.477], with rank correlations of
0.475 on day 7 vs. day 5, and 0.396 on day 9 vs. day 7, and median pitch ICC = 0.432 [0.355, 0.507], with correlations of 0.446 on
day 7 vs. day 5 and 0.417 on day 5 vs. day 9. Most features of USV have values off ICC near 0.3 or 0.2 indicating overall low levels of
day-to-day consistency. Gray dotted lines show correlation of 1.0 for comparison.
To replicate these findings and improve the temporal resolution of these data, we
recorded animals from two litters each of C57BL/6J and FVB/Ant every day between
postnatal days 3-14 (TCS). Descriptive statistics for this group of animals is shown in
Supplemental Table 2. Since most FVB/Ant animals did not call beyond postnatal day 10,
only 3-10 are considered for USV features other than call rate. These data are shown in
Figure 4. Features of USV in the TCS largely recapitulated the overall low consistency
exhibited by animals in the PCS. Pairwise, day-by-day, rank correlations of residuals are
shown as heatmaps. ICC is an aggregate measure across all time points. Although on
the whole call rate shows low consistency, inspecting the heat maps (Figure 4A), one can
observe an increase in pairwise correlation near the peak of vocalization behavior (just
before postnatal day 5 for FVB/Ant (Spearman’s rank correlation rs days 4 & 3 = 0.54,
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days 5 & 4 = 0.63) and just after postnatal day 7 (Spearman’s rank correlation rs days
8 & 7 = 0.58, days 9 & 8 = 0.75) for C57BL/6J). Thus call rate appears to show a trend
towards increased stability at specific times. Interestingly, the pattern of correlation over
time is different across other features of USV. Strong correlation of the median pitch (Fig-
ure 4E) for C57BL/6J appears to be restricted to an early time window (days 3-4), which
degrades later in development, while FVB/Ant shows this stronger correlation for a wider
time window (days 3-7). Both strains show similar increased consistency in peak power
later in development (after postnatal day 7). Thus features of USV, while on the whole
inconsistent across developmental time, show windows of stability which depend on the
feature and the strain.
The values of ICC are tabulated for the PCS and TCS in Table 1. The point estimates
of ICC for each USV feature between the PCS and TCS are replicable (Pearson’s R=0.77,
p=0.025, note largely overlapping confidence intervals for most variables), although some
features such as median pitch did not replicate well as indicated by poorly overlapping
confidence intervals. Considering results from both datasets, after predicting an animal’s
response using fixed effects, where in the distribution the animal will lie above or below this
estimate is not strongly consistent from day to day. However, although overall consistency
is low for features of USV, the actual estimates of the ICC values are reproducible across
studies, describing a seemingly robust property of these features. This is remarkable,
considering that the PCS and TCS differ markedly in terms of their size, composition, and
number of time points.
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Figure 4: Lack of strong consistency across pup USV features in Time Course Study (TCS)
.Univariate linear mixed models (LMMs), ICC values, and residuals, and associated correlation coefficients were computed for data
from 2 litters each of C57BL/6JBL/6J (N = 8,5) and FVB/AntJ/AntJ (N=8,5) as in Figure 2, measured each day postnatally between
days 3-14. Each panel shows: (left) value of the ICC, data, with expected values (w=0, average weight) and 95% confidence intervals
above beeplots and trendlines as in Figure 2, (right) pairwise day-by-day Spearman correlation of Studentized residuals after
adjusting for fixed effects, as in Figure 2, displayed as heat maps (range: blue rs=-1.0, red rs=1.0). (A) Call rate. Data were
transformed as log
(
counts+1
minutes
)
(abbreviated “log” on y-axis) as in Figure 3, with linear scale values shown for ease of interpretation.
Note that modeling day as both linear and quadratic terms allows for prediction of the characteristic rise and fall in call rate observed
through the first two weeks of life. Overall ICC is low and within range of PCS (ICC = 0.175 [0.041, 0.272]), however heatmaps reveal
a density of stronger correlation near the respective peak for each strain. Beyond day 10, most FVB/AntJ animals did not exhibit >10
calls per sonogram, so graphs in B-H, and all correlation heat maps only show data between days 3-10. (B) Call Duration. (C) Pitch
Jumps. (D) Peak Power. (E) Median Pitch. (F) Variability in Pitch. (G) Variability in Duration. (H) Variability in Peak Power.
Heatmaps showing residual Spearman cross-correlation for (B)-(H) had at least 10 calls and data for all time points, N = 9
(C57BL/6JBL/6J), 13 (FVB/AntJ/AntJ). As in the PCS (Figure 2), call duration (B) shows the highest ICC 0.542 [ 0.317, 0.663 ] with
higher levels of correlation day to day across all days. Median pitch did not reproduce the result in Figure 2 when all days were taken
into account though slightly overlaps the confidence interval: ICC = 0.261 [0.085, 0.380]. Note both strains show an inflection in their
correlations for fraction of calls with pitch jumps near day 5-6 for FVB/AntJ and day 4-5 for C57BL/6J which may indicate that
something around this time is important for the development of this kind of call.
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Table 1: Values of the ICC and Confidence Intervals Computed in the PCS TCS.
PCS TCS
Feature Estimate Lower 95%o Upper 95%o Estimate Lower 95%o Upper 95%o
log call rate 0.199 0.121 0.276 0.175 0.041 0.272
duration 0.400 0.320 0.477 0.542 0.317 0.663
calls with pitch jumps 0.268 0.186 0.349 0.300 0.112 0.424
median pitch 0.432 0.355 0.507 0.261 0.085 0.380
peak power 0.291 0.210 0.372 0.206 0.050 0.317
variability in duration 0.179 0.099 0.261 0.087 0 0.168
variability in pitch 0.135 0.056 0.216 0.112 0 0.201
variability in peak power 0.182 0.099 0.263 0.138 0.009 0.234
o 95% confidence intervals computed from paramateric bootstrap (N = 1x105) on linear mixed model parameters (see Methods).
Consistency of USV features within recording sessions
The relatively low consistency observed in the preceding section over developmental time
could arise because USV is highly susceptible to uncontrolled intrinsic or environmental
covariates, present at the time of experimentation, which perturb each individual animal’s
response for the duration of the recording. Alternatively, low consistency could be due
to the inherent noisiness of features of USV. If the latter were the case, we hypothesized
that, even within a recording session, we would find that USV features were inconsistent
across the course of the session. If so, ICC computed across a recording session should
be similar to ICC computed across development. If, however, consistency of USV features
were higher within a recording session compared to across sessions, then we hypothe-
size instead that USV itself is not inherently noisy, but rather reflects perturbation of the
pup’s state at the time of recording by some unmeasured developmental or environmental
variable.
To address this question, we computed the ICC in the PCS and TCS on each postnatal
day within recordings, where repeated measures consisted of 1 minute bins through the
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3 minute recording. In addition to the fixed effects of strain and size modeled previously,
we also controlled for the effect of bin, as the pup’s temperature may change through the
course of the recording, and temperature has been shown to have an effect on aspects
of USV [43, 44]. The estimates of ICC computed across bins by day in the PCS are
shown in Table 2, and for the TCS in Table 3. ICC values are as much as 3-fold higher
when computed across bins than when computed across developmental time, and these
results are summarized in Figure 5 (TCS-Within Session vs. TCS across days Mann
Whitney p = 0.0011, PCS-Within Session vs. PCS across days p=1.6x10−4). ICC values
computed within bins and averaged across days for each study are tabulated in Table 4.
Again, the results are strongly reproducible (Pearson’s R = 0.95 , p = 3.1x10−4) across
studies.
Thus, these data support the hypothesis that most features of USV are not inherently
inconsistent, but instead inconsistencies across development may arise from unknown
variables affecting the animal’s state at the time of recording. Examining results from both
PCS and TCS indicate our estimates of ICC both between and within sessions are robust
to relatively large differences in experimental design, such as the number of time points
considered and sample size.
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Table 2: Values of the ICC and Confidence Intervals Computed in the PCS across minute
bins.
Feature Day Estimate
Lower
95%o
Upper
95%o Feature Day Estimate
Lower
95%o
Upper
95%o
log call rate
5 0.614 0.551 0.668
peak power
5 0.619 0.544 0.688
7 0.673 0.617 0.722 7 0.703 0.646 0.753
9 0.675 0.617 0.724 9 0.700 0.642 0.751
duration
5 0.696 0.632 0.754
variability in
duration
5 0.559 0.476 0.636
7 0.725 0.671 0.771 7 0.501 0.422 0.574
9 0.748 0.697 0.792 9 0.441 0.357 0.519
calls with
pitch jumps
5 0.729 0.671 0.781
variability in
pitch
5 0.649 0.578 0.714
7 0.652 0.588 0.708 7 0.524 0.447 0.594
9 0.687 0.627 0.739 9 0.595 0.524 0.659
median pitch
5 0.690 0.625 0.748
variability in
peak power
5 0.427 0.331 0.517
7 0.712 0.656 0.761 7 0.480 0.399 0.554
9 0.777 0.731 0.816 9 0.610 0.541 0.672
0 95% confidence intervals computed from paramateric bootstrap (N = 1x105) on linear mixed model parameters (see Methods).
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Table 3: Values of the ICC and Confidence Intervals Computed in the TCS across minute
bins.
Features Day Estimate
Lower
95%o
Upper
95%o Features Day Estimate
Lower
95%o
Upper
95%o
log call rate
3 0.571 0.299 0.750
peak power
3 0.862 0.696 0.939
4 0.441 0.150 0.656 4 0.738 0.492 0.874
5 0.563 0.291 0.745 5 0.630 0.311 0.823
6 0.452 0.163 0.666 6 0.439 0.114 0.680
7 0.791 0.605 0.887 7 0.721 0.492 0.851
8 0.497 0.213 0.698 8 0.804 0.623 0.902
9 0.816 0.648 0.902 9 0.817 0.650 0.903
10 0.783 0.594 0.883 10 0.588 0.301 0.774
duration
3 0.860 0.695 0.938
variability in
duration
3 0.585 0.251 0.794
4 0.784 0.570 0.897 4 0.000 0.000 0.313
5 0.851 0.686 0.935 5 0.650 0.343 0.833
6 0.863 0.725 0.934 6 0.651 0.381 0.817
7 0.714 0.482 0.846 7 0.267 0.000 0.530
8 0.905 0.806 0.955 8 0.887 0.772 0.946
9 0.867 0.737 0.931 9 0.161 0.000 0.420
10 0.776 0.574 0.886 10 0.271 0.000 0.545
calls with
pitch jump
3 0.793 0.572 0.906
variability in
pitch
3 0.831 0.639 0.924
4 0.782 0.565 0.897 4 0.339 0.000 0.623
5 0.779 0.552 0.900 5 0.379 0.010 0.667
6 0.773 0.566 0.887 6 0.759 0.545 0.880
7 0.795 0.607 0.893 7 0.102 0.000 0.375
8 0.821 0.651 0.911 8 0.065 0.000 0.355
9 0.790 0.606 0.888 9 0.257 0.000 0.509
10 0.832 0.669 0.917 10 0.265 0.000 0.537
median pitch
3 0.696 0.406 0.857
variability in
peak power
3 0.394 0.023 0.673
4 0.736 0.490 0.873 4 0.433 0.086 0.689
5 0.507 0.152 0.750 5 0.364 0.000 0.655
6 0.731 0.499 0.864 6 0.402 0.077 0.652
7 0.809 0.629 0.901 7 0.511 0.216 0.717
8 0.671 0.412 0.828 8 0.743 0.521 0.870
9 0.800 0.622 0.894 9 0.581 0.307 0.758
10 0.738 0.513 0.864 10 0.652 0.387 0.815
o 95% confidence intervals computed from paramateric bootstrap (N = 1x105) on linear mixed model parameters (see Methods).
58
Table 4: ICC in the PCS and TCS across Minute Bins: Averages and Standard Deviations.
Feature
PCS TCS
Average S.D. Average S.D.
log call rate 0.654 0.035 0.614 0.158
duration 0.723 0.026 0.827 0.063
calls with pitch jumps 0.689 0.039 0.796 0.021
median pitch 0.726 0.045 0.711 0.094
peak power 0.674 0.048 0.700 0.141
variability in duration 0.501 0.059 0.434 0.302
variability in pitch 0.589 0.063 0.510 0.137
variability in peak power 0.506 0.094 0.375 0.281
Consistency of features of USV in adult male-female C57BL/6J dyads
In the preceding sections, we have shown that there is overall low consistency across the
features of USV examined in mouse pups across recording sessions, yet that consistency
is high within a recording session. We next examined whether adult male USV was also
primarily “state” dependent or “trait” dependent. We measured USV from 47 adult male
animals on two test days with a different unfamiliar female on each day, made up entirely
of C57BL/6J animals. This dataset differs in a few fundamental ways: (1) the stimulus
is the presentation of an adult female mouse to the male, rather than isolation of pups
from the dam, (2) the recordings are dyadic. Although historically it has been suggested
that in such a paradigm only the male is vocalizing[45], recently it has been shown that
an appreciable number of vocalizations can be attributed to the female [46]. We make
no strong claims that our data represent something unique to male behavior. Finally, the
number of measurements differs importantly in that for pups each time point represents
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Figure 5: USV features show higher consistency within within sessions than between ses-
sions.
ICCs were recomputed within session on each postnatal day, using 1 minute bins through the recordings (3 for each recording) as the
repeated measure instead of postnatal day, in both the PCS and the TCS. Univariate LMMs were fitted using the model
feature ∼ bin ∗ strain ∗ w where w is day/strain z-score of animal’s weight as previously. Data are shown for (left) ICC values for all
8 USV features computed across postnatal days (see Figures 2 and 3) and (right) computed within session. Overlaid on data points
are box plots. Horizontal line represents the median, and box represents lower and upper quartiles (25% (Q1)and 75% (Q3)), with
whiskers extending to most extreme datapoints not exceeding 1.5 x the interquartile range. Significant differences in ICC were
detected for within session vs between days (Mann Whitney p = 1.6x10−4, TCS p = 0.0011) with the median ICC being 2.8-fold
higher within session than across days for the PCS, and 3.3-fold higher in the TCS. Fold increases in ICC in the PCS and TCS
within session
across days
were largely reproducible: call rate 3.3-fold (PCS), 3.5-fold (TCS), call duration 1.8-fold (PCS), 1.5-fold (TCS), pitch
jumps 2.6-fold (PCS & TCS), median pitch 1.7-fold (PCS), 2.7-fold (TCS), peak power 2.3-fold (PCS), 3.4-fold (TCS) variability in
pitch 4.4-fold (PCS), 4.6-fold (TCS), variability in peak power 2.8-fold (PCS), 2.7-fold (TCS), though variability in duration was less
reproducible (2.8-fold in the PCS, and 5-fold in the TCS). Linear correlation in fold change between PCS and TCS was R=0.68, and
0.83 if variability in duration is omitted. We also did not detect a significant difference in the magnitude of ICC values between PCS
and TCS either within session or across days (ICC across postnatal days, PCS vs. TCS, Mann Whitney p = 0.4418; ICC within
session, averaged across days, PCS vs. TCS Mann Whitney p = 0.96). Thus the ICC and changes to the ICC when computed within
recording session vs. across development appear to be robust calculations for these USV features, despite the fact that the PCS and
TCS differ widely in the number of individual animals, the number of time points.
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potentially a different developmental stage, while for the adults time points are at the
same developmental stage. Linear modeling in either case, however (either modeling
post natal day or adult test day as a fixed effect), allows for the effect of postnatal age or
test session to be regressed before assessing consistency. Consistency itself (the ICC)
is thus still comparable as it resides on the same scale representing the ratio of variance
amongst individuals’ intercepts to the combined variance of random effects and error. For
our adult recordings, as there are only two time points, the ICC values will be expected
to be near the simple pairwise correlation across test days. Pups during development
are changing in a rapidly dynamic fashion, which we do not discount. However, because
the interpretation of the ICC is the same in either case (consistent or inconsistent), we
believed the comparison between the datasets serves to identify which features of USV
may stabilize later in life, and which may remain dynamic.
Dramatically the ICC for adult call rate (Figure 6, Table 5) was much higher than that
observed in pups, and even higher than the value obtained within pup sessions (ICC =
0.87, c.i. [ 0.78, 0.93 ]), which is also reflected in the rank correlation (rs= 0.86). Call
duration showed values of ICC which were similar to that obtained within session for pups
(ICC = 0.77, c.i. [0.60, 0.87], rs = 0.73). However, with the exception of log call rate,
other features of USV, such as the median pitch, peak power, and fraction of calls with
pitch jumps, showed ICC values and rank correlations in the range of those obtained for
pups. This may indicate that features such as call rate and call duration approach trait-
like stability in adult animals, however other features of USV still depend on the state of
the animal and its environment. Descriptive statistics for our adult data are presented in
Supplemental Table 3.
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Figure 6: Stronger consistency in some adult USV features across sessions.
ICC and Spearman correlations computed for adult C57BL/6J M-F dyads across 8 features of USV. ICC and rank correlations were
computed for 47 male-female pairs between 7-11 weeks of age, in which 47 group-housed males were tested two different days with
a unique female each time. LMMs were fitted only using test day as a fixed effect factor: feature ∼ test day + (1|id). (Note: with
only two time points, we expect the correlation coefficients to be very close to the estimates of the ICC). Studentized residuals (z)
between test days are shown for (A) call rate (again, with LMM fitted for log
(
counts+1
minutes
)
, (B) call duration, (C) pitch jumps, (D) peak
power, (E) median pitch, (F) variability in pitch, (G) variability in duration, and (H) variability in peak power. Call rate exhibited a much
higher consistency (ICC = 0.870, [0.778, 0.925], rs =0.86) than observed for any pairwise day comparison in pup data in Figures 2 &
3. Call duration also showed higher consistency (ICC = 0.77, [0.599, 0.875], rs=0.732). However, note other features of USV showed
values of ICC and corresponding correlation coefficients which are in the range of those observed for pups across early postnatal
development. Thus most features of USV appear to remain relatively inconsistent from measurement to measurement, although in
these data, the adult call rate & call duration appear to be stable features and exhibit trait-like behavior. Gray dotted lines show
correlation of 1.0 for comparison.
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Table 5: Spearman’s Correlation and ICC computed for adult C57BL/6J data.
Feature rs ICC Lower 95%o Upper 95%o
log call rate 0.86 0.87 0.78 0.93
duration 0.73 0.77 0.60 0.87
calls with pitch jumps 0.20 0.24 0 0.53
median pitch 0.39 0.24 0 0.52
peak power 0.47 0.47 0.18 0.69
variability in duration 0.34 0.39 0.08 0.64
variability in pitch 0.14 0 0 0.33
variability in peak power 0.42 0.50 0.21 0.71
Discussion
In this investigation, we have examined datasets generated in our laboratory in order to
understand the extent to which features of vocalization show consistent inter- and intra-
individual patterns across measurements. In young pups, we have found, in general, that
across development most features of USV such as the call rate do not show consistent
patterns across an individual’s measurements, though some such as call duration show a
larger degree of consistency. The estimates of consistency in our pup data were largely
reproduced when examined in a replication cohort which increased the number of time
points across development sampled. When looking within a session, pups across devel-
opment show a much higher degree of consistency for most features examined. Thus we
hypothesize that the expression of pup USV, although clearly under the influence of pop-
ulation effects such as strain or age, is highly state dependent. Therefore, we conclude
that while the population average may rise or fall due to strain or age, the relative ranks
of the pups in the distribution must be influenced by other unmeasured aspects of the
animal’s state. It could be that some of this influence derives from the litter to which the
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animal pertains, however we have also estimated ICC at the level of litter and have not
found any increased explanation of remaining variance upon inclusion of this hierarchy
(not shown). As phenotypic expression in an individual’s behavior is a complex integra-
tion of its state, and genetic and environmental factors [47], a lack of consistency is not
entirely surprising. Wild species often display behavioral plasticity in the form of inconsis-
tent individual behavior over time, yet show consistent trends at the group level [48]. The
study of trait consistency over time amongst individuals has also been appreciated in the
domain of human psychology [49] and ecology [50], but rarely in laboratory animals. In
our mice, however, we did observe that there was an increase in intra-animal consistency
near each strain’s respective peak of vocalization behavior at least with respect to rate
of calling. These time points may represent preferable windows to look for effects due
to experimental manipulation as individual animals are performing more predictably from
measurement to measurement. By contrast, in our adult dataset, consistency in call rate
was dramatically higher than for pups, while pitch related features continued to show low
consistency. While adults and pups are in different stages of life and react to their envi-
ronment differently, there appears to be a similarity that pitch features of USV continue
to show dynamic modulation even where other features such as call rate show increased
consistency. However, as described in Methods and Supplemental Figure 3, our adult
data were pooled from a study examining changes to USV in adults after global knockout
of the Celf6 gene, in which we did not detect significant genotype effects. Future cohorts
of animals, with an increased number of test days, should be examined to discern the
reproducibility of any trait stability in call rate or other features. The level of intra-individual
variability and overall reaction to changes in the external environment has been shown
in adult mice to be explainable to some degree by their level of subordinance/dominance
and aggressiveness [51] and more recently, rate of calling in adult males has been directly
correlated to measures of dominance and social hierarchy in tasks such as the tube test,
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and manipulation of the prefrontal cortex is able to alter the hierarchical rank order among
the mice and concomittantly their rates of ultrasonic calling [52]. In our study, males were
socially isolated from their cage hierarchies for 24 hours before test day #1 and up to a
week before test day #2, though this may not be sufficient time to perturb the established
dominance rank order in these males. For features showing poorer consistency (pitch re-
lated features) between test days, our results may be somewhat confounded by not fully
knowing the animal originating the calls (male or female), and the fact that the female’s
estrous state was uncontrolled. It has been claimed that males can pitch modulate their
song due to the presence of an alleged competitor male [53]. It is attractive to hypothe-
size that perhaps the state of the female or her contribution to the dyadic song somehow
influences the pitch characteristics, and may explain why there are poorer correlations for
these features in our study. It will be interesting to observe what other genetic or phar-
macological manipulations are able to change the USV trait consistency of adult mice,
which will reveal the potential neurological correlates of how these features are encoded.
This very fundamental difference in the source of variability between pup USV and adult
USV may explain why so few disease models show a consistent carry-over from pup to
adult USV changes. Reviewing just the literature on call rate in ASD models in particular,
35 of 41 studies have shown alterations in pups behavior which typically manifests as a
decrease in call rate. However, of the models where adult behavior was assayed, only
2 showed carry-over of pup USV phenotype into some kind of adult USV phenotype [54,
55]. Thus, whatever the mechanisms are that mediate the alterations in pup USV, these
largely do not carry over to call rate in male-female song.
In the current study, we have not subcategorized calls into call types based upon
spectral and temporal properties. We have avoided this approach as there is no standard
method for call classification. Some methods, such as a method employed to study mice
with a humanized Foxp2 gene [56], classify by length of call and presence of instanta-
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neous jumps in pitch, while others use jumps exclusively based upon their number and
direction[9, 53]. Another commonly employed method involves manual sorting of calls into
categories based upon spectral shape [57], which integrates information about pitch, the
presence of jumps, harmonics, duration, and slope. Yet another method uses an unbiased
classification scheme [10]. It is not clear the extent to which these different classification
schemes represent biologically relevant categories. It has been well-documented that the
frequency and frequency modulation of the pitch in rat USV is associated with positive
and negative emotionality [58, 59] and rats will even self-administer or exhibit avoidance
of the respective category of calls [60]. While mice emit USV during ostensibly rewarding
circumstances such as mating or juvenile play, it is not clear that individual categories of
calls based on any available scheme are associated with either reward or aversion, al-
though it has been shown that mice can distinguish between calls of different categories
[61]. However, all categorization schemes, either explicitly or implicitly, incorporate some
aspect of the presence of pitch jumps in classification, and we have examined this fea-
ture, which has been shown to exhibit salience in listening animals [40, 62]. In neither
our pup nor adult datasets did we see high degrees of consistency in the fraction of calls
containing pitch jumps. However, it will be interesting to see whether a pup or an adult’s
repertoire, as categorized by one of the above schemes or some other, has the proper-
ties of a stable trait across individuals, or whether it too is highly affected by an animal’s
state. Some categorization schemes may turn out to be more consistent over multiple
measurements than others, and this may be a useful criterion to determine which classi-
fication scheme may be measuring a stable biological feature. To enable these and other
analyses that would benefit from the availability of a standardized dataset for algorithm
testing and optimization, we have provided all of our recordings via the mouseTube portal
(upload pending). We include raw audio files through this platform along with associated
metadata, so that researchers may use this resource to address questions such as the
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stability of categorical assemblies of call types. Future work remains to assess the relative
utility of different categorization schemes and their biological relevance.
Methods
Animals
All protocols involving animals were approved by the Animal Studies Committee of Wash-
ington University in St. Louis. Animals for pooled cohort study (PCS) consisted of 133
C57BL/6J in Cohort 1 (18 litters of median size 8 animals, ranging from 4 to 11 animals
per litter), 105 C57BL/6J in Cohort 2 (15 litters of median size 8 animals, ranging from 2 to
9 animals per litter), and 47 FVB/Ant in Cohort 3 (5 litters of median size 10, ranging from
6 to 12 animals). Animals in Cohorts 1 and 2 were originally planned to determine the
effect of conditional knockout of the Celf6 gene in dopaminergic or GABA-ergic neurons
on USV, and were generated by crossing Celf6flox/flox X Celf6flox/wt; DAT-Cre (Jackson
Laboratory strain B6.SJL-Slc6a3tm1.1(cre)Bkmn/J or Celf6flox/flox X Celf6flox/wt; VGAT-Cre
(Jackson Laboratory strain Slc32a1tm2(cre)Lowl/J). No Celf6 genotype effects were detected
on any USV metric scored (See Supplemental Figures 1 and 2), and these data were
pooled across genotype for the present analysis. Nonetheless, for the follow-up time
course study (TCS) looking at vocalization every day postnatally between days 3 and 14,
we used 13 wild-type C57BL/6J and 13 FVB/Ant (Jackson Laboratory) from two litters
each, of 8 and 5 respectively. Animals were maintained in a barrier facility. Breeding
cages consisted of a single male and a single female, and both parents were present dur-
ing pregnancy, birth, and during the time of assay. Cages were maintained by our facility
on a 12 hr : 12 hr light:dark schedule with food and water supplied ad libidum. Adult mice
were composed of 47 C57BL/6J males and 41 females aged 7-11 weeks. Adult mice were
originally planned to determine the effect of global knockout of the Celf6 gene on adult
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USV in male-female dyadic interactions. No Celf6 genotype effects were detected on any
USV metric scored (Supplemental Figure 3), and data were pooled across genotype for
the present analysis.
USV Recording and Processing
USV recording - Pups
Ultrasonic vocalization for Cohorts 1,2, and 3 (PCS) was recorded on postnatal days 5, 7,
and 9. For follow-up study (TCS), recordings were performed every day postnatally from
days 3 through 14. All recordings were performed in the afternoon between 12:00 and
17:00. On first day of recording, subjects were each marked for identification immediately
after recording by toe clip (PCS) or tattooing (TCS, Aramis Micro Tattoo Kit, Ketchum).
On following days, subjects were recorded in random order and identifying marks were
noted after recording, along with sex and weight. At the time of recording, a litter is sepa-
rated from its parents by placing the parents in a temporary cage. The entire home cage
with litter undisturbed is placed in an incubator and allowed to rest for 10 minutes. The
pups’ external temperature is regularly monitored with an infrared temperature gun digital
thermometer (HDE-B01, HDE) and the incubator is maintained such that external tem-
perature remains between 31-34oC. If the external temperature deviates below 30oC, the
incubator is adjusted until external temperature returns within range, in order to minimize
effects of cooling the pups on USV. For recording a pup, the pup is moved with minimal
handling into an anechoic, sound attenuating chamber (Med Associates Inc.) and audio
is recorded for 3 minutes using a CM16 microphone (Avisoft Bioacoustics), amplified and
digitized using UltraSoundGate USG116H, using a gain of 1.4 dB, 250 kHz sampling rate,
bit depth of 16, using Avisoft RECORDER software.
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USV recording - Adult M-F dyads
Adult male animals were generated from group-housed weaned juveniles and were singly
housed 24 hours before test time. Females were maintained group-housed, between 4-5
animals per cage. The testing chamber consisted of an empty mouse cage (no bedding)
placed inside an anechoic, sound attenuating chamber (the same used for pup testing).
Testing occurred during the beginning of the animals’ dark cycle (between 18:00 - 20:00),
and proceeded as follows: (1) Habituation phase: males were placed in the test environ-
ment for 10 minutes with concurrent recording of USV as in the case of pup recordings. No
USVs were detected for males during the habituation phase. (2) Test phase: A stranger
female was added to the test environment and the dyad was recorded for 10 minutes. Af-
ter testing, males were returned to single housing, and the test environment was cleaned
with 70% ethanol followed by 2% Nolvasan solution (Zoetis Inc) in between each animal.
The number of days between tests was allowed to vary between 1-7 days, and the me-
dian number of intervening days was 4. No significant effect of the number of intervening
days between test days on USV features was detected. Each male was tested on two
days, with a different female each day. Pup and adult audio files were processed using
the same computational pipeline.
White noise filtering in the frequency domain.
An automated method was designed to filter noise and improve automated call detection.
A 10-second chunk is chosen at random from each audio file. The fast Fourier transform
(FFT) is performed using 512 FFT bins corresponding to 5122 + 1 = 257 audio frequencies
ranging from 0 kHz to 125 kHz , and 50% temporal overlap corresponding to a temporal
resolution of 0.5 · 250000512 = 1.024x10−3 seconds. A histogram of log10(FFT magnitude) is
computed for all magnitudes in FFT bins corresponding to frequencies between 20 and
120 kHz. The main bulk of this histogram corresponds to the noise level in the spectrum
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which is assumed to be Gaussian in distribution. The mean of the noise distribution is
estimated to be the peak of this histogram and a threshold is set at µnoise + 2.5σ where
only spectral magnitudes greater than threshold are designated as signal. This reliably
separates the baseline of the FFT magnitudes from signal peaks for pup and adult calls.
Such a threshold is determined for each file individually, however thresholds varied little
across all files indicating a relatively constant background recording environment [not
shown]. The noise distribution was estimated between 20 - 120 kHz since all sound
outside of this range is band-pass filtered.
Spectrogram preparation and band-pass filtering & automated call detection
Spectrogram preparation and automated call detection were performed in MATLAB using
code adapted from [9]. Briefly, after determining a threshold for white noise, the entire
FFT (512 bins, 50% overlap, time resolution 1.024 ms, frequency resolution 488.2 Hz) is
computed for each file, where magnitude< threshold is set to 0 and sound is band-passed
filtered to reside within 20-120 kHz. All sound < 20 kHz and > 120 kHz is also set to
zero. Ultrasound calls are detected using thresholds of 5 msec minimum duration, 0.15
minimum spectral purity, 1.0 maximum spectral discontinuity, with gaps < 30 ms between
adjacent calls merged. In [9], 0.25 spectral purity was suggested as appropriate threshold.
Empirically we have determined that 0.15 is more reliable and results in fewer instances
where spectrally impure parts of longer calls lead to a call artificially scored as two calls.
After automated call detection, random subsets of spectrograms (10 - 20% of all files) are
inspected manually to ensure that automated scores overlap with human-distinguishable
calls observed in the spectrogram.
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Call feature extraction.
After calls are detected, features for each call are extracted as follows. The dominant
frequency (“pitch”) is determined for each 1.024 ms time bin in the spectrogram for each
call by determining the FFT bin with maximum power ( Power ∝magnitude2). The median
pitch is determined, as well as the total duration of each call. The presence of discontinu-
ous jumps in pitch was determined as changes over time greater than ±10 kHz. Calls can
also contain harmonic frequencies; these were not analyzed. . The inverse FFT was com-
puted from each call’s spectrogram to yield the noise- and frequency-filtered waveform. A
smoothed waveform envelope was estimated by computing a windowed RMS amplitude
(512 samples, 50% overlap). The peak RMS amplitude was extracted from this envelope
and power was computed as dB ref 1.0. The CM16 microphone was not calibrated, thus
dB SPL were not computed, but dB are expressed with full-scale reference (max = 0 dB,
dB = 10 · log10
(
full scale amplitude2
)
).
Statistical Analysis
Univariate linear mixed models (LMM) for each feature of USV were computed using the
lme4 package [63] in R [64] fitting a random intercept model grouped by subject id. Models
were fitted using strain, postnatal day, and animal size as fixed effect factors. Postnatal
day and animal size both entered models as continuous variables. Postnatal day was
recentered at day 7 and fitted for both linear and quadratic effects in order to account for
the “inverted U” pattern in development with a rise, peak, and fall in behavior. Animal size
was z-score normalized weight with respect to day and strain as raw weight itself varies
with both. For adults, only test day was used as a fixed effect factor. Significance of main
effects and interactions in the data were computed by likelihood ratio tests (analysis of
deviance) on nested models of increasing complexity using the anova() function in R.
Call rate (calls per minute) was transformed as the natural logarithm before modeling
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(log calls+1
minutes
). Other USV features were not transformed. We also fitted call rate using a
negative binomial generalized linear mixed model (NB-GLMM). Fixed effect coefficients
between the LMM on log-transformed call rate and the NB-GLMM on untransformed count
data were highly similar (Pearson’s R = 0.99). The log-transformed model was used in
order to compare mixed model parameters across all features of USV fitted with the same
algorithm. The intra-class correlation coefficient (ICC) was determined using the fitted
point estimates of random intercept variance (σ2α) and residual error variance (σ2ε ) from
the the LMMs as described in Results.
In order to determine confidence bounds for model parameters, we employed a para-
metric bootstrap procedure. Using the point estimates of σ2α and σ2ε as starting points, the
i th bootstrap sample y∗(i)were computed as:
y∗(i) = X(i) · β + rnorm
(
mean = 0, sd =
√
σ2α
)
+ rnorm
(
mean = 0, sd =
√
σ2ε
)
where X(i) is the i th row of the fixed effects design matrix and β is the vector of fixed effects
coefficients. Thus X(i)β represents the expected value E(y) for the i th observation, which
is then perturbed by drawing a random intercept and error from normal distributions (the
R rnorm() function) with means of 0 and standard deviation as the square-root of the
fitted LMM variance estimates. Each vector y* represents a bootstrap sample dataset.
The LMM was re-fitted using each y* sample dataset for 100,000 iterations. The 95%
confidence bounds for fixed effect coefficients, σ2α, σ2ε , and the ICC were determined as
the lower 2.5% and upper 97.5% quantiles of the bootstrap distribution. This procedure
is preferable to a strict resampling with replacement of the original values of y, as it does
not result in bootstrap sample datasets lacking factor levels and leaves the fixed effect
correlation structure intact.
To compute values of ICC within session, recordings were binned into 3x1-minute bins
and USV aggregate features (e.g. average duration) were recomputed for each bin. LMMs
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were fitted on each postnatal day using strain and bin number as categorical variables,
and z-score normalized weight as previously. ICC values obtained from within session
calculations were compared to ICC values compared from calculations across postnatal
days using a non-parametric Wilcoxon rank-sum test.
In order to explore consistency graphically across all USV features (regardless of
scale, Figures 2,3, & 5), we computed Studentized residuals. Residuals from the full
model take into account both fixed and random effects, and as such are not useful for
looking directly at consistency as any consistent patterns expressed in the random inter-
cepts have been removed. Thus, we computed a first-level residual where a residual ε˜ is
the result of a data point y(i) adjusting for the model’s expected value E(y)(i) (not taking
into account random effects) as:
ε˜(i) = y(i) − E(y)(i)
Such a residual is represented in the middle panel of Figure 1A and 1B and has units
that are the same as the units of y . To normalize for units, a Studentized residual was
computed as:
z(i) = ε˜
(i)
σ˜ (1− h(i)) =
y(i) − E(y)(i)
σ˜ (1− h(i))
where σ˜
(
1− h(i)
)
is the estimate of the standard deviation at ε˜(i). We took σ˜ as the
estimate of the model standard error before partitioning variance:
σ˜ =
√
σ2α + σ2ε
and h(i) is the i th diagonal entry from the hat matrix H:
H = X
(
XTX
)−1
XT
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and h = diag(H). Thus z(i) represents the linear modeling analog to a z-score (e.g. y(i)−x
sd(i)
)
and has units of standard deviation.
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Supplemental Information
Figure S1: Conditional knockout of Celf6 in dopaminergic neurons does not significantly
alter features of USV in Cohort 1 of PCS
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Figure S2: Conditional knockout of Celf6 in GABA-ergic neurons does not alter features of
USV in Cohort 2 of PCS.
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Figure S3: Global knockout of Celf6 does not perturb USV features in adult male-female
dyads.
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Figure S1: Conditional knockout of Celf6 in dopaminergic neurons does not signifi-
cantly alter features of USV in Cohort 1 of PCS. A mouse model was generated possess-
ing a conditional allele of the Celf6 gene, in which the 4th exon was flanked by loxp sites
(Celf6flox, abbreviated \textquotedblf\textquotedbl) in order to allow for Cre recombinase me-
diated excision using the DAT-Cre mouse, which expresses Cre in dopaminergic neurons un-
der control of the dopamine transporter gene Slc6a3. A cross between conditional Celf6flox/+
(\textquotedblf/+\textquotedbl) heterozygotes positive for DAT-Cre and X Celf6flox/flox (\tex-
tquotedblf/f") yielded a cohort of 133 animals constituting Cohort 1 of the PCS: 36 f/+, 23 f/+
Cre+, 42 f/f, 32 f/f Cre+, distributed across 18 litters of median size 8 animals, ranging from
4 to 11 animals per litter. Data are shown by genotype and postnatal day as bee plots for
individual animals and boxplots showing the median (circle) and 25% (Q3) -75% (Q1) quar-
tiles, with whiskers extending to most extreme datapoints not exceeding 1.5 x the interquartile
range, for: (A) Call rate, (B) Call Duration, (C) Pitch Jumps, (D) Peak Power, (E) Median Pitch,
(F) Variability in Pitch, (G) Variability in Duration, (H) Variability in Peak Power. Linear mixed
models and likelihood ratio tests were used to detect main effects of genotype, postnatal day,
or two-way interaction of genotype and postnatal day. Significant main effects of genotype
were not detected for any variable, nor were any significant interactions detected. Collaps-
ing across genotype, significant main effect of postnatal day was detected for: (A) Call rate
(fitted as log( (calls+1)/minutes ), p = 6.5x10−19), which was driven by a significant increase
between days 5 and 7 (log fold change: 0.89, 95% c.i. [0.64, 1.13]) as well as a lesser but
significant increase between days 7 and 9 (log fold change day 9 - 7: 0.31, 95% c.i. [0.05,
0.56]), (B) Call Duration (msec, average over all calls, p = 6.5x10−19), driven by a significant
increase between days 7 and 5 (5.6 msec, 95% c.i [3.4, 7.9]) and a slightly smaller increase
between days 7 and 9 (2.6 msec, 95% c.i. [0.4, 4.9]), (C) Pitch Jumps (fraction of all calls, p
= 1.2x10−9), driven by a significant increase between days 7 and 5 (0.09 (9% increase), 95%
c.i. [0.05, 0.12]) but no significant increase detected between days 7 and 9, (E) Median Pitch
(kHz, p = 1.9x10−13), driven by a small but significant increase between days 7 and 5 (3.1
kHz, 95% c.i. [1.78, 4.42]) and a similar increase between days 9 and 7 (2.6 kHz, 95% c.i.
[1.25, 3.90]), and (H) Variability in Peak Power (coefficient of variation (standard deviation over
all calls/mean, per animal), p = 5.8x10−12), exhibiting a decrease in variability between days
5 and 7 (-0.032, 95% c.i. [-0.043, -0.020]), and smaller amount of decrease between days 7
and 9 (-0.012, 95% c.i. [-0.02, -4.8x10−4]).
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Figure S2: Conditional knockout of Celf6 in GABA-ergic neurons does not alter fea-
tures of USV in Cohort 2 of PCS. As in Supplemental Figure 1, conditional knockout of Celf6
in GABA-ergic neurons was performed by crossing Celf6flox/+ (\textquotedblf/+\textquotedbl)
heterozygotes positive for VGAT-Cre and X Celf6flox/flox , where the VGAT-Cre mouse ex-
presses Cre recombinase under the control of the GABA transporter gene Slc32a1. This
cross yielded a cohort of 105 animals constituting Cohort 2 of the PCS: 34 f/+, 24 f/+ Cre+,
29 f/f, 18 f/f Cre+, distributed across 15 litters of median size 8 animals, ranging from 2 to 9
animals per litter, with 12 of 15 litters possessing 7 to 9 animals. Data are shown by genotype
and postnatal day as bee plots for individual animals and boxplots showing the median (circle)
and 25% (Q3) -75% (Q1) quartiles, with whiskers extending to most extreme datapoints not
exceeding 1.5 x the interquartile range, for: (A) Call rate, (B) Call Duration, (C) Pitch Jumps,
(D) Peak Power, (E) Median Pitch, (F) Variability in Pitch, (G) Variability in Duration, (H) Vari-
ability in Peak Power. Linear mixed models and likelihood ratio tests were used to detect main
effects of genotype, postnatal day, or two-way interaction of genotype and postnatal day. Sig-
nificant main effects of genotype were not detected for any variable, nor were any significant
interactions detected. Collapsing across genotype, significant main effect of postnatal day was
detected for: (A) Call rate (p = 5.54x10−9), showing a significant increase between days 7 and
5 (log fold change in calls/min, 0.75, 95& c.i. [0.47, 1.05]), (B) Call duration (p = 3.03x10−7),
showing a significant increase between days 7 and 5 comparable to Supplemental Figure 2
(4.7 msec, 95% c.i. [2.1,7.3], and a small increase between days 9 and 7 (2.5 msec, 95%
c.i. [0.01, 5.03]), (C) Pitch Jumps (p = 2.67x10−5), as in Supplemental Figure 2 showing an
increase between days 7 -5 in fraction of all calls (0.065, 95% c.i. [0.03, 0.10]) and no signif-
icant increase between days 9 and 7, (D) Peak Power (p = 0.005) showing a small decrease
between days 7 and 5 (-0.55 dB, 95% c.i. [ -1.08, -0.01]) (E) Median Pitch (p = 0.002), ex-
hibiting a small increase between days 7 and 5 similar to Supplemental Figure 2 (2.0 kHz,
95% c.i. [ 0.42, 3.61] but no significant change between days 9 and 7, (F) Variability in Pitch
(p = 0.008), showing a slight decrease in variability between days 7 and 5 (-0.013, 95% c.i
[-0.023, -1.9x10−3]) but no change between 9 and 7, and (H) Variability in Peak Power (p =
4.25x10−7), showing a comparable decrease in peak power variability between days 7 and 5
to Supplemental Figure 2 (-0.030, 95% c.i. [-0.043, -0.016]) but no change between days 7
and 9.
Figure S3: Global knockout of Celf6 does not perturb USV features in adult male-female
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dyads. 24 Celf6 WT and 23 KO adult males (7-11 weeks) were tested on two test days with a
different, stranger female each day as described in Methods. Data are shown by genotype and
test day as bee plots for individual animals and boxplots showing the median (circle) and 25%
(Q3) -75% (Q1) quartiles, with whiskers extending to most extreme datapoints not exceeding
1.5 x the interquartile range, for: (A) Call rate, (B) Call Duration, (C) Pitch Jumps, (D) Peak
Power, (E) Median Pitch, (F) Variability in Pitch, (G) Variability in Duration, (H) Variability in
Peak Power. Linear mixed models and likelihood ratio tests were used to detect main effects of
genotype, postnatal day, or two-way interaction of genotype and postnatal day. No significant
effects of genotype nor interactions between genotype and test day were detected. Collapsing
across genotype, a significant effect of test day was detected in the case of (B) Call Duration
(msec, p = 0.004), in which there was an increase in call duration by 2.1 msec (95% c.i. [0.76,
3.54]) on test day 2. A non-significant trend towards in a increase in (C) Pitch Jumps (fraction
of all calls, p = 0.07) was also observed between test days. USV features do not distinguish
between vocalizations made by either animal in the dyadic assay and represent an aggregate
of both animals, which may effect the precision of some measurements (especially if animals
vocalize at the same time).
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Chapter 4
The Functions of CELF RNA binding
proteins
Abstract
RNA binding proteins (RBPs) are important regulators of RNA molecules
involved throughout their life-cycle from pre-mRNA synthesis and processing,
to mature RNA stability, translation, and localization. RBPs can be defined by
whether they bind their targets in sequence non-specific or a sequence
specific manner, and these RNA-protein interactions are mediated via distinct
families of RNA binding domains (RBDs). A single RBD does not confer
much binding specificity and thus most RBPs possess more than one RBD.
CUGBP and ELAV-like family member 6 (CELF6), which we identified as
associated with behavioral changes in knockout mice and enriched in
monoaminergic neurons, is a member of the CELF family of RBPs which
contain three RBDs of the RNA Recognition Motif (RRM) family. The binding
targets of CELF6 are currently unidentified. Using modern techniques such
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as crosslinking immunoprecipitation (CLIP) followed by next generation
sequencing, we can determine the identity of RNA targets of an RBP and
where on each RNA the RBP is bound. As the CELF family is diverse in its
functions, with other members notably regulating alternative splicing, mRNA
stability, and translation, the knowledge of CELF6’s targets, and its molecular
function, is essential in understanding its biological role in the brain. In this
section, I review the literature related to interactions between RBPs and their
RNA targets, how these interactions can be defined, and the known functions
of other CELF family members.
Introduction
RNA binding proteins (RBPs) are involved in every step of a messenger RNA (mRNA)
molecule’s life cycle: from pre-mRNA formation and splicing into mature mRNA, capping
and polyadenylation, trafficking from the nucleus into the cytoplasm, localization in the
cell, maintenance and degradation, sequestration under stress, and ribosomal machinery
recruitment and translation into polypeptide sequence [1–7]. Because RBPs are involved
throughout the life of an mRNA they have the opportunity to act as key regulators of most
cellular functions.
Neurons are highly polarized cells, and it has long been appreciated that RNA molecules
must be trafficked appropriately in order to generate patterns of localized translation re-
quired for synaptic function [7, 8]. Thus, unsurprisingly, aberrations to a number of RNA
binding proteins are implicated in neurological disorder, such as Fragile X Mental Re-
tardation Protein (FMRP, gene FMR1) which induces ribosomal stalling and is involved
in mRNA localization and translation regulation in neurons [9, 10]. Mutations to FMR1
are associated with ASD and intellectual disability in humans [11, 12]. Members of the
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CUGBP and ELAV-like Factor (CELF) family of RNA binding proteins, which have multiple
functions including alternative splicing and regulation of mRNA decay [3], are known to
be enriched for expression in the central nervous system, and members have been as-
sociated with neurodevelopmental abnormalities such as seizures and ASD [13, 14]. Our
group identified mutations to CELF6 as associated with ASD in humans. Mice with loss of
this protein exhibit reductions to reward-seeking behavior and neonatal ultrasonic vocal-
izations.As described in preceding sections, CELF6 expression is enriched in monoamin-
ergic neurotransmitter populations such as dopaminergic and serotonergic cells, however
single cell type knockouts have thus far been unable to replicate the associated behav-
ioral phenotypes. Thus either either the specific cell type underlying CELF6’s association
with behavioral phenotype has not yet been identified or its effect is mediated by multiple
redundant systems.
In order to better understand how CELF6 may play a role in behavior, its biological
function must be understood. Therefore, in this chapter, I review the foundational con-
cepts and techniques upon which my experiments to understand CELF6 protein function
are based. I review the basic structure and binding properties of RNA binding proteins
such as CELF6. I go on to briefly summarize how target-protein interactions are defined
experimentally and how binding sites may enable us to hypothesize about function. Fi-
nally, I review what has been previously determined for CELF family RBPs with respect to
their regulation of target mRNAs. It is our hope that defining CELF6 and its role in regulat-
ing its targets will enable future experimentation to understand the plausible mechanisms
by which it regulates behavior.
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Interactions with RNA through RNA Binding Domains
RBPs include proteins which bind RNA both specifically and non-specifically with respect
to the RNA sequence. Common RBPs that bind RNA non-specifically include RNA poly-
merase which synthesizes RNA from DNA template and associates with RNA:DNA hy-
brids via positively charged amino acid side chains and the negatively charged phosphate
backbone of the nucleic acid [15]. RBPs that bind RNA in sequence-specific ways do so
through the presence of RNA Binding Domains (RBDs) in the protein’s sequence. RNAs
can be ontologically organized via which families of RBDs they possess. Individual RBDs
typically associate with a small number of nucleotides (as few as two nucleotides), and
thus higher specificity is achieved in RBPs by posession of multiple RBDs separated by
linker sequences [16].
Different RBDs are characteristic of different families of RBPs. Pumilio homology do-
mains (PUM-HDs) have repeated 37 amino acids segments which stack alternating with
the RNA bases, leaving the phosphate backbone exposed to solvent [17]. K Homol-
ogy (KH) domains (found in the RBP NOVA [18], members of the heterogeneous ribonu-
cleoprotein particle proteins (HNRNP) family of proteins [19], and FMRP [20]) contain
70 amino acids with a central (I/L/V)-IGxxGxx-(I/L/V) sequence, and bind at least 4 nu-
cleotides [16]. Among these proteins, NOVA is a nuclearly localized neuronal RBP in-
volved in splicing regulation [21]. HNRNPK exhibits diverse functions including regulating
RNA splicing and stability, both activation and repression of translation, and even tran-
scriptional activation and repression [1]. FMRP is a translation regulator as described
in preceding sections. Thus the specific RBDs that a RBP possesses are not necessar-
ily predictive of the RBPs molecular function. It is likely that the binding location on the
RNA, localization in the cell, and protein-protein interactions confer added specificity to
the functional consequence of a RBP’s binding. CELF proteins contain the RNA recog-
nition motif (RRM) family of RBDs. RRMs are approximately 90 amino acids in size and
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contain 2 conserved stretches: (K/R)-G-(F/Y)-(G/A)-(F/Y)-(V/I/L)-x-(F/Y) and (V/I/L-F/Y-
V/I/L-x-N/L). Each domain has sites which bind 2-4 nucleotides, and thus a full length
CELF protein with 3 RRMs can potentially bind up to 12 nucleotides [16], although recent
work determining RNA binding preferences in vitro have determined binding sites of 7
nucleotides for CELF proteins 3,4, and 6 [22]. The domain structure of human CELF6
is shown below in Figure 1A. CELF6 like other CELF proteins has two N-terminal RRM
domains adjacent to one another and a third C-terminal RRM domain, separated by a
"divergent" domain (DD) less conserved throughout the CELF family with little predicted
secondary structural content. It is believed the DD may function as a flexible linker region
or facilitate protein:protein interactions [5].
I inspected the CELF6 protein sequence and its mammalian homologues across 4
species (H. sapiens, P. troglodytes, M. musculus, R. norvegicus) as well as its homo-
logues in chicken (G. gallus) and zebrafish (D. rerio) and the homologue of the CELF
family in D. melanogaster, the translation regulator Bruno[23]. The amino acid sequences
were subjected to multiple sequence alignment using CLUSTAL Omega [24] and to look
at the rise and fall in sequence variation, I computed the Wu and Kabat variability score
across the multiple alignments [25]. Peaks indicate high variability and valleys indicate
low variability on this scale, and these results are shown in relation to the human do-
main structure in Figure 1B. The N-terminal region and the DD both exhibit the highest
variability across taxa, with RRM1 and RRM3 having low variability and thus increased
conservation across all species considered. Human CELF6 is a 481 amino acid protein,
so for visual ease, rather than presenting the entire multiple sequence alignment, I have
visualized the output of CLUSTAL Omega using a novel amino acid color coded scheme
with black indicating alignment gaps. Higher variability scores for RRM2 are observed, but
upon inspection of the alignment it appears this is driven by the presence of the chicken,
zebrafish, and fruitfly sequences, and the RRM2 shows very similar sequence across all
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Figure 1: The CELF family of RNA binding proteins shows homologous structure with 3
RRMs and two distinct subclasses.
(A) A linear schematic of the structure of human CELF6 showing all 3 RRMs and the DD. (B) CLUSTAL multiple sequence alignment
for CELF6 across 4 mammalian species (H. sapiens, P. troglodytes, M. musculus, R. norvegicus) and its homologues in G. gallus,
D. rerio and D. melanogaster. Multiple sequence alignments are color coded according to the amino acid key given, with gaps in
alignment represented in black. Above the alignment is shown the variability in the amino acid position across species using the Wu
and Kabat variability score. Below the alignment is the structure of human CELF6 according to its position in the alignment. (C)
Multiple sequence alignments as in (B) across human CELF proteins. (D) Clustering dendrogram based on the Hamming distance
between multiple alignments in (C).
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four mammalian species.
The mammalian CELF family consists of 6 proteins, and their multiple sequence align-
ments are shown in Figure 1C as color-coded visualization with variability scores above.
All possess high variabilitity at the N-terminal region of the protein and an increase in
variability near the DD. Inspecting the alignment, it appears that CELF1 and CELF2 are
more highly similar than CELF3-6. Indeed, using the multiple sequence alignment to hier-
archically cluster the CELFs, CELF1 and CELF2 form a distinct cluster, with CELF3-6 in a
second cluster, and CELF5 and CELF6 the most similar. This is shown as a dendrogram
in Figure 1D.
The mammalian CELF family consists of 6 proteins, and the human multiple sequence
alignments are shown in Figure 1C as color-coded visualization with variability scores
above. All possess high variabilitity at the N-terminal region of the protein and an increase
in variability near the DD. Inspecting the alignment, it appears that CELF1 and CELF2 are
more highly similar than CELFs 3-6. Indeed, using the multiple sequence alignment to
hierarchically cluster the CELFs, CELF1 and CELF2 form a distinct cluster, with CELFs3-
6 in a second cluster, and CELF5 and CELF6 the most similar. This is shown as a
dendrogram constructed from in Figure 1D. Thus, all CELF proteins are all highly similar,
particularly in their RRMs. This suggests they may share similar targets as well. Thus it is
necessary to understand the specific RBP-RNA interactions and I review methods to do
so in the following section.
Identifying and defining RBP:RNA interactions
In order to study the function of RBPs, it is desirable to identify its RNA targets and
the location on these targets where the RBP binds. RBP target RNAs are traditionally
identified by some manner of affinity purification: either purification of RNA followed by
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assay of associated proteins, or by purification of a specific RBP and assay of the as-
sociated RNA. In the 1990s it was learned that ultraviolet radiation (e.g. 254 nm) could
be used to covalently crosslink amino acids which were positioned near nucleotides [26].
Methods to purify RNA may make use of this crosslinking technique to purify proteins as-
sociated with, for example, all polyadenylated mRNA using oligo-dT capture and followed
by mass spectrometry to identify proteins [27], or by using anti-sense probes for specific
RNA molecules. Probe mRNAs can be biotinylated and immobilized on a strepatividin-
coated solid support [28], or using other high affinity tagging methods such as the MS2-
and MS2 coat protein protein system [29]. With RNA-protein UV crosslinking, stringent
washes (e.g. high salt concentration, detergent concentrations) can be used to remove
non-specific binding events. In all cases, after purification, the complexes must be eluted,
and digested polypeptides can be analyzed by mass spectrometry to identify which pro-
teins are associated [30–33].
Using the RBP as prey for affinity purification requires the availability of robust anti-
bodies or use of epitope tagging. Purifying a specific RBP and its associated RNA was
originally devised without crosslinking ("RNA Immunoprecipitation", RIP) [34] but includ-
ing UV crosslinking allows for more stringent washing and this is termed Crosslinking
Immunoprecipitation (CLIP) [35]. CLIP’d RNA sequences were originally subcloned and
subjected to Sanger sequencing for identification [36] but modern approaches employ
next-generation sequencing [9, 37–41]. Statistical determination of significant peaks in
sequencing read density over background can be used to identify which RNA molecules
a specific RBP binds, and also where on the body of the RNA this occurs. Once the
location on the RNA where a RBP binds is known, the sequence can be scanned for
evidence of specific binding motifs. These sequence motifs should show enrichment in
bound versus input or unbound fraction of RNAs. Some functionality may be able to be
hypothesized given the location of binding. For example, if CLIP peaks occur at anno-
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tated splice sites on pre-mRNAs or at exon-junctions, it may be that the RBP of interest
regulates splicing at those locations.
In addition to annotated splice sites and exon junctions, binding in the untranslated
regions of mRNA such as the 5’ untranslated region (5’UTR) or 3’ untranslated region
(3’UTR) may indicate regulation of mRNA stability or translation. Certain motifs, such as
the TOP motif (Terminal oligopyrimidine) C[CU]x4−15 [42] exist in the 5’ UTR and are known
to be correlated with the translation of mRNAs in response to growth stimuli [43, 44].
Although primarily known from viruses [45], internal ribosome entry segments (IRES) are
also found endogenously in about 10% of eukaryotic 5’UTRs [46] where they are bound
by IRES Trans activating factors (ITAFs) [47] and promote cap-independent translation,
such as during apoptosis when normal cap-dependent translation is suppressed [48].
In the 3’UTR, the commonest example of a regulatory sequence bound by RBPs is
the polyA tail itself, which is bound by polyA binding proteins, with increased transla-
tional repression and lowered stability of polyA tails under 50 nucleotides in length [49].
Polyadenylation is itself regulated by other interactions between the 3’UTR elements and
RBPs, such as by Cytoplasmic Polyadenylation Elements (CPEBs) which associate with
U-rich sequences 5’-UUUU[A]1−2U-3’ and serve to activate or repress polyadenylation
[50, 51]. AU rich elements (AREs) are bound by several classes of RBPs termed ARE-
binding proteins (AREBPs) including the ELAV family which stabilizes transcripts and
promotes translation, and the TIA family which promotes degradation and translational
repression [52, 53]. Binding in the 3’UTR may also indicate that the RBP facilitates subcel-
lular localization of the mRNA such as that of CaMKIIa [54] or calreticulin [55] in neurons.
Thus taken together, once the targets of a RBP are known, the location and sequence at
which the RBP binds can help to formulate hypotheses about its downstream molecular
function, guiding further experimentation. Additionally, knowledge of the specific targets
of a RBP can help generate hypotheses about its overall biological significance where the
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downstream functions of targets are known.
Regulation of mRNAs by CELF proteins
The preceding sections have briefly surveyed the RNA:RBP binding interactions both
in terms of protein domains and sequence elements, and how experimental techniques
such as CLIP are used to identify and define these interactions. In this section, I would
like to proceed to discuss what is currently known about the CELF family of RBPs setting
the foundation for my work on CELF6. As the CELF family members all possess similar
sequence and domain structure (Figure 1), understanding the prior literature on CELF
proteins may lend insight into CELF6’s possible functions.
In general, RBPs can exhibit a variety of functions uncoupled to their specific RBD
context. For example, in addition to the CELFs, several heterogeneous ribonucleoprotein
particle proteins (HNRNPs), ELAV-like protein human antigen R (HuR), and SRSF1/2 all
contain RRM domains [56], and these proteins exhibit diverse functions. For example,
HNRNPA and HNRNPB are known splicing repressors which can act to suppress splicing
at specific splice acceptors to promote use of more distal sites by blocking exon recogni-
tion [57], and HuR binds AU-rich elements and promotes mRNA stabilization [58] and can
promote dissociation of the RNA-induced silencing complex [59]. All of these proteins use
RRM domains to facilitate association with their target mRNAs, but their specific functions
differ.
For the CELF family of RRM containing proteins, most of the literature on molecular
functions has focused on CELF1, also known as CUG-binding protein 1 (CUGBP1). As
its name suggests, CELF1 was identified via its binding to CUG RNA sequence elements
and is ubiquitously expressed [60]. CUG-containing sequences are present in the 3’ UTR
of myotonin protein kinase gene (DMPK ), expansions of which cause of myotonic muscu-
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lar dystrophy (DM) [61], and CELF1 was primarily studied in the context of this diease. In
DM, muscle cells show upregulation of CELF1 protein expression and this upregulation
is capable of inducing changes to splicing in other genes containing CUG repeats such
as skeletal muscle specific chloride channel 1 (CLC1) and insulin receptor (IR) [62]. DM
skeletal muscle tissue also shows elevated levels of MEF2A transcription factor associ-
ated with delayed myogenesis, and CELF1 is capable of binding MEF2A mRNA and en-
hancing its translation [63]. In addition to changes to splicing and translation, CELF1 can
bind AU-rich elements in TNFα and c-fos, a process which is associated with subsequent
recruitment of polyA-specific ribonuclease leading to poly-deadenylation and degradation
[64]. The Xenopus homologue of CELF1, Embryo Deadenylation Element Binding Pro-
tein (EDEN-BP) also stimulates deadenylation and destabilization of target mRNAs, and
furthermore requires oligomerization of the protein to do so [65, 66]. Thus CELF1 is a
multi-functional protein, originally characterized in skeletal muscle in the context of DM,
and is capable of promoting alternative splicing, enhancing translation, and promoting
mRNA degradation.
CELF2, also referred to as neuroblastoma apoptosis-related RNA binding protein (NA-
POR) and ETR3, is expressed across a variety of tissues including brain, heart, lung, and
skeletal muscle, as well as late embryonic day development central nervous system [67].
CELF2, like CELF1 is also associated with alternative splicing activity in skeletal muscle
using minigene reporter assays [68, 69]. Interestingly, CELF2 has also been associated
with RNA editing - binding to AU rich sequences ahead of edited cytidine and repressing
editing of the apolipoprotein B (apoB) mRNA [70] involved in atherosclerosis and cardio-
vascular disease. Like its relative CELF1, CELF2 is also found to regulate mRNA stability
and translation in the cytoplasm. CELF2 is able to associate to AU rich sequences in
the 3’UTR of cyclooxygenase-2 (COX2), and both stabilizes the COX2 mRNA while also
inhibiting its translation [71].
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CELF3-6 are all enriched for expression in the brain with CELF6 additionally found in
the kidney and testes. There are conflicting reports indicating CELF4 is also expressed
broadly or restricted to the nervous system [3, 72]. Celf4 knockout mice experience con-
vulsive and non-convulsive seizures when electrically stimulated in the cortex (where
CELF4 has highest expression) [73]. Upon identifying CELF4 targets by CLIP, it was
found that CELF4 predominantly associates in the 3’UTR region of mRNAs enriched for
synaptic function, and sequences under CLIP peaks show UGU-containing motifs [74].
There is little literature on the roles of CELF3, CELF5, or CELF6 in the brain. One study
shows an association with a polymorphism in CELF5 and schizophrenia [75]. Aside from
our own group’s work defining the behavior of Celf6−/− mice and describing CELF6’s pat-
tern of expression in the brain [14, 76], there is one report that like CELF2 above, CELF6
is able to activate exon inclusion of a minigene in vitro and the same group also demon-
strated these results for CELFs 3,4, and 5 [77]. However the binding targets of CELF6
have not yet been defined nor has the function this protein has on these targets.
Thus the emerging story of the CELF family of RBPs is that they may all act multifunc-
tionally on different aspects of mRNA regulation, and this is largely supported by a history
of work on CELFs 1 and 2. The CELF4 and CELF6 genes have been linked to neuro-
logical phenotypes in mice. CELF4 is enriched for expression in the cortex [74], whereas
CELF6 shows primary expression in monoaminergic neurotransmitter populations, and
limbic structures [76]. In Chapter 5 of this dissertation, I go on to show that CELF4 and
CELF6 are both able to induce transcript repression in vitro. If it is the case that these
proteins in vivo exhibit redudant functions, then perhaps the cell types in which they are
expressed determine to some extent the phenotypic outcome when these proteins are
absent.
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Summary
In summary, CELF proteins are a versatile family of RBPs, and members exhibit the ability
to regulate mRNA splicing, stability, and translation. Thus, one may hypothesize that
CELF6, the specific object of investigation in this work, may take on any of these functions
in the cell. Using the modern molecular techniques of CLIP followed by next generation
sequencing, I will be able to define the targets of CELF6 and use the knowledge of where
CELF6 CLIP peaks occur to hypothesize how it may act on the mRNA molecules that it
regulates. In the subsequent chapter, I present the current unpublished work regarding
identification of CELF6 targets, as well as the results from a massively parallel reporter
assay I have employed to study the downstream consequence of CELF6 interaction with
target mRNAs.
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Chapter 5
CELF6 preferentially binds 3’UTR
sequences in the brain and is
associated with decreased mRNA
abundance
Abstract
CUGBP and ELAV-like Factor (CELF) proteins have been shown to be in-
volved in the splicing, degradation, and translational regulation of mRNAs. The
CELF protein subfamily, CELF3-6, are enriched for expression in the brain, and
CELF6 in particular is enriched for expression in the diencephalon and the
monoaminergic dopamine, serotonin, and norepinephrine-producing cell pop-
ulations. Recently our laboratory has identified polymorphisms in the CELF6
are associated with ASD in humans, and mice lacking expression of Celf6
show reduced ultrasonic vocalizations and reward-seeking behavior, however
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the molecular function of CELF6 in the brain has not yet been described. We
therefore used cross-linking immunoprecipitation followed by next generation
sequencing (CLIP-Seq) to identify the binding targets of CELF6 in vivo in the
mouse brain. The vast majority (>85%) of all targets showed preference for
binding in the 3’ untranslated region (3’UTR). 3’UTR sequence elements un-
der CLIP-Seq peaks were subjected to analysis for differential enrichment of
RNA binding motifs, and elements showed enriched presence of previously
identified CELF protein UGU-containing binding motifs. In order to determine
the functional consequence of CELF6 interaction with these 3’UTR elements,
we subcloned a library of 436 3’UTR elements under CLIP-Seq peaks as well
as mutations to motifs within these elements into a reporter construct. We
found that when transiently transfected in vitro, reporters in general showed
decreased levels of abundance with CELF6 overexpression which was abol-
ished by mutation, but few showed changes to translation efficiency. Addition-
ally, we tested whether CELF3, CELF4, and CELF5 could exhibit this activity,
and overexpression of all CELFs 3-6 resulted in repression of reporter levels,
with CELF3 and CELF4 exerting the strongest effects, and CELF5 and CELF6
exerting more intermediate effects on reporter levels. We also noted an as-
sociation between strength of motif similarity to consensus motifs, and the
number of motifs present in 3’UTR elements, on the magnitude of repression
of reporter levels. Thus taken together, these data suggest that CELF6 and
other members of its subclass form a group of RNA binding proteins that can
mediate repression of mRNA via the 3’UTR, as has been previously described
for other family members such as CELF1. Future research will help broaden
our understanding of the exact mechanism by which CELF6 down-regulates
its targets and how this may impact neuronal function.
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Introduction
Messenger RNAs (mRNA) are regulated by RNA binding proteins (RBPs) in every aspect
of their life cycle from early steps including transcription, splicing, nuclear export, localiza-
tion, to their maintenance, translation into protein, and finally degradation in the cell [1–6].
CUGBP and ELAV-like Factor (CELF) proteins, originally characterized in relation to the
pathogenesis of myotonic muscular dystrophy [7], are multi-functional RBPs which can
act to regulate splicing in the nucleus, as well as mRNA half-life and translation efficiency
in the cytoplasm [8]. The mammalian family contains 6 proteins (CELF1-6) which can be
divided into two subgroups based on their amino acid compositional similarity: CELF1
and CELF2 which are found ubiquitously, and CELF3-6 which show enriched expression
in the central nervous system [8, 9]. CELF1 binds CUG-repeat containing sequences [10]
and (U)GU-rich motifs [11]. CELF1 has been shown to promote exon skipping [11], as
well as promote degradation via recruitment of deadenylation machinery [12]. CELFs 3-6
however, have not been as well characterized.
Our laboratory recently identified polymorphisms in CELF6 associated with ASD in
humans and reductions to ultrasonic vocalization and exploratory behavior in mice [13].
Upon further study, we found that in the brain, it showed enriched expression in the hy-
pothalamus and in monoaminergic neurotransmitter cell populations (dopamine, sero-
tonin, norepinephrine) [14]. Functionally, CELF6 has been shown in one report to be
capable of regulating splicing in vitro [15], however its targets and function in the brain
have not yet been described. The related RBP CELF4 in the brain shows preference for
binding in the 3’ untranslated region (3’UTR) of its targets affecting mRNA abundance
and translation [16] but has also been shown to regulate alternative splicing in skeletal
muscle [17], thus the function of a CELF RBP may be dependent on the tissue in which it
is expressed.
In order to better understand the function of CELF6 in the brain, we performed cross-
112
linking immunoprecipitation followed by next generation sequencing (CLIP-Seq) on the
brains of mice expressing an epitope-tagged CELF6-YFP/HA transgenic construct which
recapitulates the endogenous pattern of expression [14]. Targets show CELF6 primar-
ily associated with 3’UTRs of mRNAs. These sequences showed increased presence of
UGU-containing motifs, consistent with previous research on other CELFs, and validat-
ing recently described in vitro binding preferences for CELF6 (Ray et al., 2013) in vivo.
To comprehensively define the function of these motifs, we cloned over 400 indepen-
dent sequences found under CLIP-Seq peaks into the 3’UTR of a reporter construct and
measured reporter library mRNA abundance and translation with and without CELF6 ex-
pression, and with or without mutation of binding motif sequences. We found that CELF6
functioned generally as a repressor by decreasing the abundance of mRNAs containing
the wild-type sequences, and this was abolished by mutating the motifs within the ele-
ment. We also found that this behavior was redundant across CELF3-6, with CELF3 and
CELF4 associated with the largest magnitudes of repression, and CELF5 and CELF6
showing intermediate levels of repression. We also assessed the levels of the reporter
library on translating ribosomes using Translating Ribosome Affinity Purification (TRAP)
[18], and found few changes to translation efficiency. The match strength of motifs to a
UGU-containing consensus sequence [19] and the number of such motifs per element
showed some ability to predict the fold repression observed in the reporter after overex-
pression of CELF protein. Thus we infer that CELF6 largely targets 3’UTRs in the brain,
that this is at least in part mediated by UGU-containing sequences, and that this associa-
tion is likely to result in down-regulation of target protein by decreasing mRNA abundance.
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Results
Celf6 primarily associates with 3’UTRs of target mRNAs in vivo.
In order to define the in vivo binding locations of CELF6, we performed CLIP on brains
from BAC transgenic mice expressing an epitope tagged CELF6-YFP/HA (78 kDa) with
the endogenous CELF6 pattern [14]. We harvested tissue on post-natal day 9, near peak
CELF6 expression and at time when Celf6 null mice exhibit a robust behavioral phenotype
(decreased ultrasonic vocalizations) [13, 14]. First, we confirmed CELF6 binds RNA in
vivo. We performed CLIP with anti-EGFP antibodies on CELF6-YFP/HA mice followed
by radiolabeling of nucleic acid (Figure 1A), as compared to immunoprecipitated sample
from wild-type tissue and an uncrosslinked sample, across several RNase concentrations.
As expected, there was a lack of detectable RNA in immunoprecipitated(IP) from WT
tissue and uncrosslinked YFP+ tissue. Next, to capture the targets of CELF6 in vivo, we
chose a region approximately 60-200 nucleotides in size (80-150 kDa region) and purified
this region from PAGE-separated RNase-digested (0.05 U/uL) lysates from 4 pools of
4 CELF6-YFP/HA+ brains. Similar to Vidaki et al.’s [20] study of Mena, we also found
that the stringent lysis and wash conditions of typical CLIP protocols was incompatible
with our CELF6 IP (not shown). Therefore we also collected control samples to be able
to enable quantification and computational adjustments for any remaining background
signal. These included 2% input samples as a measure of starting transcript abundance
in the tissue, as well as IP from 3 pools of 4 WT littermate brains to identify those RNAs
that interact non-specifically with the capture reagents.
To identify CLIP targets by next generation sequencing, we prepared libraries using an
adaptation of the eCLIP/iCLIP workflow [21, 22](Protocol in Appendix 2, Adapter oligonu-
cleotides in Supplemental Table 1). Currently there is no standard statistical approach for
identification of targets from CLIP data. Methods typically include clustering aligned se-
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Figure 1: Celf6 primarily associates with 3’UTRs of target mRNAs in vivo
(A) Crosslinking followed immunoprecipitation and 32P labeling of bound RNA. Brain tissue was dissected and powdered according
to Methods, and tissue from single brains were used for (1) no crosslink, and (2) WT controls, and 1 pool of 3 brains was used for
RNase I digestion. Upper panel shows autoradiogram of radioactively labeled RNA signal, and bottom panel shows immunoblot with
chicken anti-GFP antibodies showing expression of CELF6-HA/YFP. The scissors icon marks a region approximately 80-150 kDa
above the size of CELF6-HA/YFP (78 kDa) which was isolated for RNA in sequencing experiments. Note immunoblot with chicken
anti-GFP detects two bands. The top band is approximately 78 kDa. A second isoform lacking the first RRM of CELF6 is annotated
(ENSMUST00000121266), and because the transgenic animal was generated by using a bacterial artificial chromosome containing
the endogenous structure of the Celf6 gene, both isoforms can be generated and targeted in this animal. ((B) log2 counts-per-million
(CPM) RNA in 4 CELF6-HA/YFP+ replicates and 3 WT replicate samples across nominally significant differentially abundant regions
identified by Piranha peak calling followed by edgeR differential enrichment analysis, showing enrichment in HA/YFP+ immunoprecip-
itate (IP) samples relative to input and WT controls. log2 CPM are normalized to the mean of the YFP input samples for each row.
(C) Summary of differential enrichment analysis in edgeR for genes showing significant (p<0.05) enrichment in HA/YFP+ IP samples
relative to both HA/YFP+ input and WT IP controls, for both the UCSC Gene Annotation method (summing counts for UTR, coding
sequence, and intronic sequence for all annotated genes) as well as the Piranha peak calling method (Calling peaks across the en-
tire genome, and summing reads under peaks for differential analysis). No Piranha peaks were found in intergenic regions. Shown
for each method is the number of identified unique genes at nominal significance level (p<0.05) and Benjamini-Hochberg adjusted
false discovery rate (FDR). (D) Example traces for two identified CLIP target 3’UTRs, showing CPM in YFP IP samples compared to
controls. (E) BiNGO analysis for gene ontology (GO) terms enriched in CLIP target genes determined according to both differential
analysis methods.
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quences in individual CLIP RNA samples or replicate averages, with varying probabilistic
modeling approaches to assessing signal-to-noise in read density [11, 23–32] but rarely
take into account variance across replicates or differential abundance compared to con-
trol samples. It is also worth noting that despite lack of apparent detectable RNA bound
to WT samples by P32 end labeling (Figure 1A), we still found it possible to generate
next generation sequencing libraries readily from WT IP samples, all of which generated
many unique alignable reads even after removing PCR duplicates (Supplemental Table
2). All samples had similar read depth, and on average 94% of all uniquely aligning reads
mapped to exons (%) or introns (%) in genic regions with very few reads mapping to in-
tergenic regions, consistent with RNA expression. Next, to define specific sites of CELF6
binding, we called peaks throughout the genome using Piranha [33] and summed reads
overlapping these peaks. We then performed differential enrichment analysis compar-
ing CLIP to controls using edgeR [34, 35], requiring significant enrichment in both CLIP
vs. input and CLIP vs. WT IP comparisons to define a CLIP target ("Piranha Peak Call-
ing method". We found CLIP peaks called by Piranha to often have very wide bases
(sometimes in excess of 1 kb or greater), or to regularly miss peaks manually observable
in a genome browser display. Because of this, we took two approaches. First, we ana-
lyzed read counts summed narrowly under a 100-bp region below the called Piranha peak
maxima. As an alternate approach, we also summed all reads mapping to genic regions
corresponding to 5’ untranslated (5’UTR), coding sequence (CDS), introns, or 3’ untrans-
lated (3’UTR) of UCSC annotated genes and performed differential enrichment analysis to
define target regions, and then later called peaks based only on the read density in those
regions (“UCSC Gene Annotation method”). Full differential enrichment results from both
of these analysis methods are shown Supplemental Tables 3 & 4.
CELF proteins have previously been identified to function in alternative splicing of mR-
NAs as well as post-transcriptional regulation, thus to gain insight into potential molecular
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functions of CELF6 we first examined where enriched CLIP targets were identified in re-
lation to subgenic regions (5’UTR, 3’UTR, introns, coding sequence). We hypothesized
that Celf6 splicing-related functions would correspond to increased density of reads in
internal coding exons and alternatively spliced introns, while post-transcriptional regula-
tory functions would manifest as an increased density at untranslated regions such as
the 3’UTR known to be involved in mRNA stability and translation regulation. Figure 1B
shows a heatmap of abundance in all samples relative to input samples, for differentially
enriched peaks and the vast majority of differentially enriched peaks are in 3’UTR re-
gions. These results are further summarized in Figure 1C for both Piranha peak calling
and UCSC Gene Annotation method. 37 genes overlap between the two analyses and
these likely represent the highest confidence targets. In all analyses, the strongest signal
came from 3’ UTR regions (>85% of all CELF6 bound regions). The read distribution
in CPM across the 3’UTRs for two high confidence targets, Fgf13 and Vat1l, are shown
across all samples in Figure 1D. The Fgf13 gene is part of the FGF-like family of genes,
and controls localization of voltage-gated Na+ channels in axons [36] and Vat1l (Vesi-
cle Amine Transport 1-Like) is a paralog of the Vat1 gene which regulates monoaminergic
neurotransmitter storage and release [37]. The regulation of such genes may thus directly
impact neuronal cell function. An enrichment for binding in the 3’UTR may indicate that
regulation occurs via altered stability or translation of targets.
In order to examine whether CELF6 CLIP targets represented a specific subclass
of mRNAs we performed gene ontology (GO) analysis using BiNGO [38] (Maere et al.,
2005), on enriched CLIP targets. Although a few terms were found enriched and in com-
mon between both analysis methods, such as synaptic transmission, the gene subsets
driving those terms were not the majority of differentially enriched genes (6.3 - 8.6%) and
the largest subsets were for less specific GO terms such as “protein binding”. Thus we
do not believe that the majority of identified targets represent a specific functional class of
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mRNAs. These results are summarized in Figure 1E.
CELF6-associated 3’ UTRs are enriched for U-rich and UG-, CU- con-
taining motifs
RBPs can bind RNAs via specific sequences, or non-specifically via interaction with the
phosphate backbone. Enriched binding in specific peaks in 3’ UTRs suggests CELF6 has
affinity for specific nucleotide sequences in vivo, as previously reported in biochemical
assays on recombinant protein (RNACompete, [19]). Thus we next desired to define the
sequence specificity of CELF6 binding in these CNS targets. Manual inspection of the
sequence underneath peaks in target 3’UTRs found many contain sequences matching
UGU-rich in vitro binding preferences for CELF6 identified via RNACompete (Figure 2A)
[19, 39]. To systematically identify sequence motifs enriched in CELF6 3’UTR targets we
used the MEME suite tools [40] to identify both de novo motifs [41, 42] and previously
cataloged motifs via Analysis of Motif Enrichment, AME [43], which is based on the Cat-
alog of Inferred Sequence Binding Preferences of RNA binding proteins (CISBP-RNA)
database [19]. The CISBP-RNA database includes binding preferences determined from
RNACompete data as well as experimental data from other sources.For our MEME anal-
ysis, we used a set of sequences 50 nucleotides in length centered on peaks identified in
CELF6 CLIP enriched 3’UTR regions. We analyzed 174 unique UTR in total, from under
491 identified peak maxima, 50 nucleotides in length around the peak center. Most UTRs
possessed between 1-4 peaks. As a control set of sequences, we chose 491 sequences
50 nucleotides in length, sampled randomly from the 3’UTRs of brain expressed genes
which showed a log fold changes ≤ 0 (no change or depletion) in CELF6-YFP/HA IP vs.
input comparisons.
We did not find significantly enriched de novo motifs, but we found 36 enriched mo-
tifs from the CISBP-RNA database at the FDR<0.1 (p<0.001) level compared to control
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Figure 2: CELF6-associated 3’UTRs are enriched for U-rich and UG-, CU- containing motifs
(A) Example 50-nucleotide regions under CLIP target peaks in the 3’UTRs of Fgf13, Vat1l, Syn2, and Tmtc for, all showing evidence for
UG-rich sequence. (B) Clustering of Analysis of Motif Enrichment (AME) tool identified motifs enriched in CELF6 CLIP peak regions
compared to randomly sampled control genes from background samples (HA-YFP input). Color coding shows cluster membership.
(C) Motif logos for the most common clusters found in CLIP target peak regions. Logos represent the average of position weight
matrices (PWMs) for each motif cluster, as well as the individual PWMs making up each cluster’s membership.
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sequences. These included binding motifs for CELF3, CELF4, and CELF6 as previously
defined via RNACompete, as well as the U-rich motifs of the TIA and CPEB families of
RNA binding proteins. RBPs that interact with specific sequence elements exhibit de-
generate preferences and RNA binding domains themselves can associate with as few
as 2 nucleotides and the binding motifs across RBPs are often similar or overlapping
[44, 45]. To generate a more holistic understanding of binding elements enriched in our
CELF6 CLIP targets, we clustered enriched motifs by the Euclidean distance between
their position weight matrices (PWMs). In doing so, we unsurprisingly found that motifs
clustered to some degree by RNA binding protein family (Figure 2B), however matches
to preferences of some very diverse RBPs, such as the HNRNP family, do not necessar-
ily cluster together. Motifs within a cluster are highly similar, such as the CELF motifs
which all show RNAcompete preferences for UGU-containing sequences. To determine
how many sequences in our data were represented by each cluster, we looked for sig-
nificant matches within our sequences using the MEME Suite FIMO tool to the averaged
PWM representing each cluster. With this approach, 473/491 peak sequences showed
significant matches across 172/174 total genes.
The top ranking clusters are depicted in Figure 2C. 105/172 unique genes’ 3UTRs
(61%) showed at least one match to the “CELF”- cluster, the average motif of which
is [U/A]GUGU[G/U][UGA]. In addition to the CELF cluster, 94/172 genes’ 3UTRs (54%)
showed at least one match to the PCBP3 motif which forms its own cluster possesses
a central UUU[C/U]CC sequence. PCBP3 can bind both double stranded and single
stranded nucleic acid and is known primarily as a transcription factor [46] though related
protein PCBP4 has also been shown to regulate mRNA stability [47]. 88/172 (51%) genes
showed at least 1 match to the “U-rich” cluster, whose members all possess a central
stretch of 4-5 Us, and include TIA1 which is involved in stress granule localization [48]
as well as CPEB proteins which are known to be involved in polyadenylation [49], and
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HNRNPC which is involved in both mRNA stability and localization/nuclear trafficking[50,
51]. 59/172 genes (34%) had at least one match to both the CELF cluster & the U-rich
cluster, and 72/172 genes (42%) showed at least one match to both the CELF cluster and
PCBP3. (Matches of these clusters in individual sequences is shown in Supplemental
Table 5)
Massively Parallel Reporter Assay to define the function of CELF6
CLIP enriched motif sequences
Our motif analysis indicates sequence specificity mediates the interactions between CELF6
and RNA in vivo, but the downstream consequence of CELF6 association to elements in
the 3’UTR of mRNAs has not been defined. Because 3’ UTR elements often regulate
mRNA stability or translation efficiency [3, 52–54], we first decided to interrogate the ef-
fect of CLIP-identified UTR sequence elements, and the identified motifs, on transcript
abundance and ribosome occupancy using a recently described massively parallel re-
porter assay: post-transcriptional regulatory element sequencing (PTRE-Seq) [55]. For
PTRE-Seq, we sub-cloned 436 independent CLIP-defined UTR elements, each 120 bp
and centered under CLIP peaks, into the 3’ UTR of a tdtTomato expression plasmid, ex-
cluding elements containing potential sites which would interfere with subcloning (Figure
3A). Each UTR element was included in the library design 6 times, with a unique 9-bp
barcode to provide internal replication and buffer against any barcode effects. In addi-
tion, in order to assess the effect of candidate motifs on expression, we also generated a
mutant version of each element. Mutations were made by swapping highest information
nucleotides in the CISBP-RNA database position weight matrices for motif matches for
their lowest information counterpart. Unmutated sequences we will call "reference" se-
quences, with mutant sequences being their counterparts after undergoing this process.
This procedure was repeated for all significant matches to motifs for each element, al-
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lowing us to disrupt the motif but leave most of the flanking sequence intact. In the final
library, 90% of library UTR elements had <16 nucleotides mutated.
To assay the reporter library in vitro, we used transient transfection in human neurob-
lastoma SH-SY5Y cells. From RNA-Seq data on 8 replicate cultures of these cells, we
assessed the mRNA expression levels of a number of RNA binding protein genes and
found that, with the exception of CELF1, CELFs 2-6 were largely undetectable (Figure
3B). Thus, we were able to use this system to control CELF6 levels by adding human
CELF6 exogenously via co-transfection with an His/Xpress epitope tagged CELF6 con-
struct used in previous research of CELF6 function [15] or empty pcDNA3.1 vector (CTL)
. Additionally, in order to assess abundance of reporter mRNAs on translating ribosomes,
we used co-transfected a construct expressing EGFP-RPL10a and employed Translat-
ing Ribosome Affinity Purification (TRAP) [56]. The Pearson correlation between for re-
covered total reporter RNA from CTL or CELF6 replicates (4 CTL, 4 CELF6 replicates)
ranged between 0.92 and 0.97, and in TRAP samples between 0.93 and 0.95 indicating
good within-group reproducibility. To account for any differences in starting abundance
of elements in the plasmid library, for every counted barcode RNA, log2 CPM were nor-
malized to log2 CPM in the sequenced DNA plasmid pool (henceforth referred to as “log2
expression”). Expression values in TRAP samples were further normalized to input RNA
and this quantity will be referred to as “log2 translation efficiency (T.E.)”. After removing
any barcodes which were absent either in the final plasmid pool or undetectable across
all samples after recovering RNA, the final analyzed library contained 424 UTR element
pairs (reference and mutant) all of which contained between 3-6 surviving barcodes rep-
resented per element, across 172 total genes.
Our analysis strategy comprised using statistical models to identify effects of CELF6
protein presence and how that interacted with motif sequence integrity, which we fitted
independently for RNA expression and T.E. Specifically to determine the relationship be-
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tween CELF6 overexpression and element sequence, we analyzed log2 RNA expression
levels or TE using a 2x2 factorial design linear mixed effects model, fitting fixed effects of
element sequence (“reference” or “mutant”) and overexpression condition (CTL or CELF6
overexpression) and the interaction of condition X sequence, with a random intercept term
for each element, treating individual barcodes as a repeated measure. Individual models
were fitted for each UTR element pair and the summary of effects and estimates of R2 and
main effect and interaction percentages of variance explained for each element is shown
in Supplemental Table 6 (expression) and 7 (T.E.) along with Benjamini-Hochberg FDR
controlled across all elements. At nominal p<0.05, 317/424 (75%) of elements showed
any significant effect at all (main effects of either sequence or condition, or sequence X
condition interaction, 313/424 (74%) at FDR <0.1).
CELF6 CLIP enriched motif sequences represent a set of repressive
elements
We first examined the role of the motifs themselves by comparing the UTR elements with
and without motif mutations. From our mixed model, over 91% of the elements showing
any effect (74%) had a a main effect of sequence. The main effects of sequence indicate
there are effects of sequence mutation even in the absence of any CELF6 expression.
Therefore, we looked at the distribution of average log2 fold changes in expression be-
tween reference and mutant sequence in the CTL condition for the 317 elements showing
any nominally significant effect (Figure 3C). Considering all elements, 83.6% had fold
changes less than 0 indicating a that reference sequences are repressive when com-
pared to their mutated counterparts (median log2 fold change -0.42, 1.3-fold). As UTR
elements with larger numbers of MEME motif matches have higher numbers of mutated
bases, this raises the concern that mutating these motifs may have altered a very large
fraction of the entire element. Thus we also looked at log2 fold changes between ref-
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erence and mutant for elements where the number of mutated bases was smaller (i.e.
Hamming distance (HD) for the mutation of ≤7 and ≤12 nucleotides). These were also
generally repressive, with 71.6% less than zero and 77.8% less than zero for HD≤7 and
HD≤12 respectively. The median log2 fold change for HD≤7 was -0.21 (p=4.2E-6, Mann-
Whitney U test compared to all elements, N=67 HD≤7) and the median log2 fold change
for HD≤12 was -0.30 (p=0.0011 Mann-Whitney U test compared to all elements, N= 189
HD≤12, p=0.022 compared to HD≤7). Both the median estimates (-0.42, -0.30, -0.21)
and the proportion of log2 fold changes less than zero (83.6%, 77.8%, 71.6%) scale with
the maximum number of mutations in each case (≤25, ≤12, ≤ 7 nucleotides) thus indicat-
ing that while there is some effect of the number of mutations on the level of expression,
even just disrupting a relatively small number of bases in the element (7 out of 120) can
abrogate the repressive effects.
CELF6 protein enhances repression in a sequence dependent man-
ner
We next assessed interactions between CELF6 overexpression and sequence. 30 ele-
ments (29 unique genes) showed a nominally significant interaction (p<0.05) between
overexpression condition and sequence with 4 out of these 30 elements possessing
HD≤7 nucleotides, and 17/30 with≤12 nucleotides. Figure 3D plots the average log2
fold change between reference and mutant sequence for both the CTL and CELF6 con-
ditions across each level of HD. In every case, the fold change between reference and
mutant was more steeply negative in the CELF6 condition (All HD CELF6 median log2
fold change reference – mutant -0.71 (~1.6-fold decrease), CTL -0.31, p = 0.001 | HD ≤
7: CELF6 -0.78, CTL -0.22, p = 0.028 | HD ≤ 12 CELF6 -0.78, CTL -0.29 p = 4.8E-4,
Mann Whitney U-tests). This appears to be due in general to a repression of the refer-
ence sequence rather than an elevation of the mutant sequence in the CELF6 condition
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(Median log2 fold change CELF6-CTL reference sequences = -0.38, CELF6-CTL mutant
sequences -0.04, p = 2.1E-4 Mann Whitney U-test).
In addition to impacting mRNA stability, RBPs can also alter protein production by ei-
ther enhancing or repressing recruitment of the mRNA to a ribosome, thus altering its
"translation efficiency" (TE i.e. the TRAP abundance divided by total RNA). However, in
contrast to the consistent direction of effect of Celf6 on abundance, when we looked at
changes to TE, we saw fewer significant effects overall. 78/424 sequences showed any
significant effect on TE at all, with 0/424 showing a significant effect at FDR < 0.1. In
Figure 3E, we plot the log2 fold change in TE between reference and mutant sequence
for sequence elements showing nominally significant interactions of overexpression and
sequence (15/424). We did not detect difference in overexpression condition for log2 fold
changes in TE at any HD considered, and most log2 fold changes were close to 0, thus
the source of interaction was not generalizable across the sequence as for total RNA. We
inspected post hoc multiple comparisons for such elements to determine sources of in-
teraction. 4/15 elements showed detectable changes in the reference sequence between
CELF6 and CTL, with 2 showing an increase (Fnbp1l p=0.0097, log2 fold change 0.43 |
Reep1 p=0.004 log2 fold change = 0.90), and two showing a decrease (Peg10 p = 0.008
log2 fold change -0.37 | Lin7c p=0.006 log2 fold change = -0.54). By contrast, when
looking at total RNA, 23/30 post-hoc comparisons for the change to reference sequence
expression (CELF6 – CTL) were significant and 19/23 of these log2 fold changes were
negative ranging between -1.45 (2.73 fold reduction) to -0.22 (1.16 fold reduction) with a
median of -0.55 (≈1.5 fold reduction). Example element expression is shown in Figure
3F (log2 expression normalized to the CTL/reference condition) and TE in Figure 3G (log2
TE normalized to CTL/reference condition). These findings suggest for elements showing
significant interactions of CELF6 expression and sequence, these interactions are gener-
ally driven by a repression of the reference sequence via a decrease in RNA abundance
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with CELF6 expression. This is abolished after mutation of the sequence. Also, there
are limited effects on TE and where these occur they are not readily generalizable in their
direction of effect.
CELF3-5 show redundancy in ability to enhance repression of Celf6-
CLIP enriched UTR elements
The CELF3, CELF4, and CELF6 binding preferences determined by RNAcompete are
highly similar (Figure 2), and as a group, CELF3-6 are more similar in amino acid identity
than CELF1 or CELF2 [8]. Therefore, we were interested in testing the hypothesis that
the enhanced repression of UTR elements we observed for CELF6 would also be true of
CELF3-5. Thus we transiently transfected our PTRE-Seq library of reference and mutant
UTR elements along with His/Xpress-tagged human CELF3, CELF4, or CELF5 used pre-
viously to study these proteins [15, 57, 58]. We then performed the analysis described in
the preceding section and these results are summarized in Figure 4. Linear mixed effect
models in the preceding section considered only CTL and CELF6 conditions, but in this
section were refitted to include all conditions.
There were 111/424 elements representing 89/172 genes showing nominally signif-
icant sequence by overexpression condition interactions (p<0.05, 91/424 FDR < 0.1) in
total reporter RNA which includes an additional 74 elements compared to the analysis in
the preceding section. Looking at the log2 fold change in reference vs. mutant sequence,
CELF3 and CELF4 showed the largest differences (Figure 4A). The median element with
CELF3 expression shows a -1.15 log2 fold lower expression of the reference sequence
compared to the mutant sequence. CELF4 was comparable with a median -1.01 log2 fold
change (CTL -0.42, vs. CELF3 p = 3.5E-15, vs. CELF4 p=1.5E-12, CELF3 vs. CELF4
p = 0.13, Mann Whitney U tests). CELF6 and CELF5 also showed comparable log2 fold
changes, and these were intermediate between the CTL condition and CELF3/CELF4
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Figure 3: CELF6 CLIP enriched motif sequences represent a set of repressive elements
(A) Schematic of the tdTomato reporter used for PTRE-Seq. All reporter library elements are driven by a CMV promoter expressing
mtdTomato (membrane-localizing tdTomato). The 120 nucleotide regions under CLIP peaks or mutant pairs subcloned after the
tdTomato stop codon followed by a 9 nucleotide barcode sequence, and before a human growth hormone polyadenylation signal. (B)
Fragments per Kilobase of transcript per Million reads (FPKM) levels are shown for several RNA binding proteins in RNA extract from
8 replicate platings of SH-SY5Y cells. (C) Recovered reporter RNA log2fold changes in expression between reference and mutant
elements in the CTL transfection conditions, considering all reference-mutant pairs, as well as only reference-mutant pairs possessing
≤7 nucleotide subsitutions, or ≤12 nucleotide subsitutions. (D) Recovered reporter RNA log2 fold changes in expression between
reference and mutant pairs in CTL and CELF6 overexpression conditions from elements showing significant condition X sequence
interactions. (E) Recovered reporter RNA log2fold changes in translation efficiency (T.E.) between reference and mutant pairs in CTL
and CELF6 conditions for elements showing significant condition X sequence interactions. Data points in (C)-(E) are average estimates
of log2fold change reference vs. mutant per condition, averaged by replicate over barcodes, and then averaged over replicates, with
lines representing medians for each distribution. Comparisons between these point estimates across conditions and total amount of
sequence mutation were assessed by Mann Whitney U tests. (F) Log2expression across 5 example reporter library elements in CTL,
CELF6, reference and mutant conditions. (G) Log2T.E. across example reporters in (F). Data points in (F)-(G) are averaged across
barcodes, with each representing the estimate for each replicate. Horizontal lines represent average estimates for expression or
T.E. (normalized to the CTL/reference sequence condition), and vertical lines represent 95% confidence intervals for these estimates
from the linear mixed effects models. Post hoc pairwise comparisons between conditions shown were computed using the multcomp
package in R with simultaneous multiple comparisons corrections using the multivariate normal distribution ("single step method" in
multcomp). Significance notation: n.s. p>0.1, † p<0.1, *p<0.05, ** p < 0.001, *** p<0.0001, **** p<1E-5
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(CELF5: -0.68, CELF6: -0.59, CELF6 vs. CTL p=0.0024, CELF5 vs. CTL p=0.00034,
CELF5 vs. CELF6 p = 0.26). 12 of these elements had Hamming distances ≤ 7 nu-
cleotides (Figure 4B). For these, CELF3 and CELF4 still showed significantly larger me-
dian log2 fold change compared to control (p=0.007, CTL -0.22, CELF3 -0.93 | p=0.005,
CELF4 = -0.78 | CELF3 vs. CELF4 p = 0.68). With the added 8 elements (compared to
the preceding section), CELF6 no longer showed a significantly larger median log2 fold
change compared to control, and was comparable to CELF5 (CELF6 median log2 fold
change -0.35, CELF5 -0.36, p=0.85). Considering all elements with ≤12 nucleotide dif-
ferences (Figure 4C), the same trends were observed for all CELFs. Namely, CELF6 and
CELF5 showed comparable fold change between reference and mutant sequence which
were of greater magnitude than the CTL condition (CTL: -0.25, CELF6: -0.52, CELF5:
-0.50, CELF6 vs. CTL p = 0.004, CELF5 vs. CTL p = 0.002, CELF6 vs. CELF5 p = 0.56).
CELF3 and CELF4 showed the greatest magnitude changes (CELF3: -0.89 p=1.1E-8,
CELF4: -0.88, p=2.8E-8) compared to CTL. As above, this appeared to be due to a gen-
eral repression of the reference sequence compared to control, and CELF6 and CELF5
showed comparable intermediate effects compared to CELF3 and CELF4 which showed
the strongest effects (Median log2 fold change CELF6-CTL reference -0.16, mutant 0.02,
p=2E-5 | CELF5-CTL reference -0.24, mutant 0.01, p=3.5E-8 | CELF3-CTL reference -
0.86, mutant -0.03, p=4.5E-11 | CELF4-CTL reference -0.62, mutant 0.04, p=2.9E-11).
Thus taken together CELF overexpression in general showed a reduction of the reference
reporter, which was abolished by mutation. Furthermore, CELF3 and CELF4 were asso-
ciated with the strongest effects on reference elements, and CELF5 and CELF6 showed
weaker effects. Thus within the subgroup of CELF proteins, CELFs 5 and 6 and CELFs
3 and 4 appear to form distinct subgroups with respect to their effects on this reporter
library.
When looking at T.E., as in the preceding section, there were fewer significant effects
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Figure 4: CELF3-5 show redundancy in ability to enhance repression of CELF6-CLIP enriched
UTR elements
(A)-(C)Estimates of log2 fold change in expression across CELF conditions considering all reporter elements, or reporter elements
with a difference of ≤7 or ≤12 nucleotides between reference and mutant sequences, for all elements showing significant condition X
sequence interactions. (D)-(F) Estimates of log2 fold change in T.E. across conditions as in (A)-(C). Data points in (A)-(F) represent
estimates averaged by replicate across barcode, and then across replicates, with lines representing medians. Statistical comparisons
in (A)-(F) were assessed by Mann Whitney U tests. (G) Log2expression across 5 example reporter library elements across CELF,
reference and mutant conditions. (H) Log2T.E. across example reporters in (G). Data points in (G)-(H) are averaged across barcodes,
with each representing the estimate for each replicate. As in Figure 3, horizontal lines represent average estimates for expression or
T.E. (normalized to the CTL/reference sequence condition), and vertical lines represent 95% confidence intervals for these estimates
from the linear mixed effects models. Post hoc pairwise comparisons between conditions shown were computed using the multcomp
package in R with simultaneous multiple comparisons corrections using the multivariate normal distribution ("single step method" in
multcomp). Significance notation: n.s. p>0.1, † p<0.1, *p<0.05, ** p < 0.001, *** p<0.0001, **** p<1E-5
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overall. 41 elements showed significant interactions of condition and element sequence
(p<0.05, 6/424 at FDR<0.1). However, when plotted in terms of their fold change between
reference and mutant sequence, we were unable to generalize a direction of effect on
TE across elements. Considering all elements median log2 fold changes in T.E. were
near 0 with no significant differences across conditions (Figure 4D), and this was also
true considering only elements with HD ≤ 7 nucleotides (Figure 4E, 9/41 elements), and
elements with HD≤ 12 nucleotides (Figure 4F, 22/41). In the case of reference sequences
compared to CTL under CELF6 overexpression, 51% of CELF6-CTL log2 fold changes
in T.E were negative, compared to 68% in changes to total RNA. For CELF5, these were
63% negative changes to TE, and 73% negative changes in total RNA. For CELF3 78%
were <0 for total RNA with 51% <0 for TE, and for CELF4 these were 82% <0 for total
RNA and 37% <0 for T.E. Thus the observable trends for decreases to reference reporter
levels were apparent with CELF overexpression for total reporter levels but not for reporter
translation efficiency. Total reporter expression for example reporters from Figure 3 are
shown in Figure 4G with their respective T.E. shown in Figure 4H, with expression or T.E.
normalized to the reference sequence/CTL condition.
In addition to these conditions, we were also curious if CELF proteins when co-expressed
exerted additive or synergistic effects on reporter expression, and thus we transfected
equimolar pairs of CELF6 construct with one of CELF3, CELF4, or CELF5. Among the
111/424 reporter elements (89/172 genes) showing significant sequence by condition in-
teractions, overexpression of CELF3 and CELF6 together resulted in repression of the
reference reporter which was similar in magnitude to overexpression of CELF3 by itself
(Median CELF3/CELF6 log2 fold change compared to CTL: -0.95, CELF3 alone -0.86, p
= 0.38). This was also true of CELF4 (Median CELF4/CELF6 log2 fold change compared
to CTL: -0.85, CELF4 alone -0.62, p=0.14). Thus the effect of CELF4 and CELF3 appears
to be dominant in these cotransfections. When CELF5 and CELF6 were expressed to-
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gether, the median log2 fold change compared to CTL was significantly greater than either
overexpressed singly (Median log2 fold change CELF5/CELF6 vs. CTL: -0.48, CELF5 vs.
CTL -0.24, CELF6 vs. CTL -0.16, p CELF5/CELF6 vs. CELF5 alone = 0.03) indicating a
stronger effect can be observed by overexpressing these two proteins together, however
we did not overexpress CELF6 or CELF5 alone in doubled dosage to determine whether
this effect is simply due to more CELF overexpression or due to the specific combination
of these proteins.
Motif strength and number alone can partially predict CELF6 impact.
Finally, to explore the relationship of enriched motifs in these reporter elements to the
observed effects of CELF proteins on reporter expression, we asked whether the strength
of the match to one of the 14 clusters shown in Figure 2B had any association to the
magnitude of expression change with CELF overexpression compared to control. The
CELF family class of UGU-rich motifs showed significant association with log2 fold change
across all 424 reporters (172 genes) compared to CTL with respect to the match strength
(measured as the –log10 p-value from the MEME suite FIMO tool) and this is shown in
Figure 5A-D for each CELF respectively, although total effect size measured by R2 were
modest. For CELF3 and CELF4 9.9% and 11.8% of variance in reporter repression com-
pared to CTL could be correlated to match strength (CELF3 ANOVA p=3.57E-11, CELF4
p=3.96E-13). CELF5 and CELF6 showed significant but weaker associations (CELF5
7.32% variance explained, p=1.5E-8, CELF6 4.2% variance explained p=2.16E-5). In
all cases, the association was negative: stronger matches tended to be associated with
more negative fold changes. All other clusters showed ≤ 3% variance explained by match
strength, with the exception of CELF5 condition reporter levels and the cluster contain-
ing Mex3c and Sfpq (4% variance explained, p=2.9E-5). This clusters near the CELF
family and also has G/U-rich average motif logo ([G/A/U][G/U][A/G]GU[G/A]U) and this
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is thus likely reflecting the same effect as matches to the CELF cluster. These effects
are weak but nevertheless show some degree of association to previously defined CELF
binding preferences and the effect of CELF overexpression. Among elements showing
significant matches to the CELF motif (139/424 library elements representing 103/172
genes), we also asked whether the number of matches per element showed any relation-
ship to the strength of reporter element repression. These results are shown in Figure
5E-H for each CELF overexpression condition. In all cases, a weak association was ob-
served for match count to log2 fold change in reporter expression, with higher matches
associated with greater repression. For CELF3, CELF4, and CELF5 this accounted for
8.7% (p=4E-4), 9.8% (p=2E-4), and 10% (p=1E-4) of total variance explained, respec-
tively. For CELF6 this association was weaker at 4.25% variance explained by match
count (p=0.015). Thus taken together, there is evidence for some association of CELF
motif element and the number of times it is present in the UTR to reporter levels when
CELF3-6 are overexpressed.
Figure 5: Motif match strength and number of matches can partially predict CELF6 impact.
(A)-(D) Association of match strength to fold change in expression, computed from the output of the Find Individual Motif Occurrences
(FIMO) tool (MEME suite) for the CELF Cluster in Figure 2 across all 424 reporter elements. In all cases "Match Strength" was
computed as the −log10(FIMO p-value) and larger numbers indicate stronger match to the cluster’s PWM. Y-axes are log2 fold
changes between CELF and CTL conditions in the reference sequences only, collapsed by averaging by replicate across barcodes,
and then across replicates. (A) CELF6, p = 2.16E-5, R2=0.042, (B) CELF3 p =3.57E-11, R2=0.099, (C) CELF4 p = 3.96E-13, R2
= 0.118, (D) CELF5 p = 1.5E-8, R2 = 0.0732. (E)-(H) Elements showing at least 1 significant match of the CELF cluster PWM by
FIMO , plotted as log2 fold change for reference sequences in CELF vs. CTL condition as in (A)-(D) by number of observed matches.
(E)CELF6 p = 0.015, R2 = 0.0425,(F) CELF3 p=4E-4, R2 = 0.087, (G) CELF4 p = 2E-4, R2=0.098, (H) p = 1E-4, R2=0.10. Significance
and coefficient of determination computed using lm in R.
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Discussion
In this study, we have identified binding targets of CELF6 in vivo which primarily localize to
3’UTR regions of mRNAs, and this is consistent with what has been observed for CELF4
[16]. 3’UTR elements under CELF6 CLIP peaks are enriched for several motifs identified
previously in a large biochemical study of RBP binding preferences on purified protein
[19], including UGU-containing motifs, which has also been noted as binding CELF1 [11].
Additionally, using PTRE-Seq[55], we show that CELF6 and other CELFs generally down-
regulate these 3’UTR elements in vitro which can be abolished by mutation based on their
motif information content. Although CELF6 has been shown to regulate alternative splic-
ing in skeletal muscle [15], we find very few significant binding events outside of 3’UTR
regions, suggesting that CELF6 in the brain may be largely involved with post-splicing reg-
ulation of mature mRNAs. Additionally, we found few effects to the translation efficiency of
our PTRE-Seq reporter library elements, suggesting that like CELF1, CELF6’s repression
of targets may be primarily mediated by enhancement of mRNA degradation.
Our work here raises a number of questions for future research. When transfected
in vitro, although we are able to generally conclude that where CELF6 exerts an effect
it is associated with lowered mRNA abundance, the majority of our library was not sen-
sitive to CELF6 expression. This suggests that either CELF6 has additional functions
on these transcripts not assessed in our assays (e.g. RNA localization), or that its func-
tional impact on these sequences might depend on the cellular context with regard to
the expression of other genes (e.g. other RBPs or miRNAs). We found that CELF3-6
RNA levels were largely undetectable in SH-SY5Y cells, nevertheless, the complement of
other RBPs is likely to differ in the brain and likely to differ between populations of cells in
which CELF6 is expressed. We did detect levels of MBNL1 in our SH-SY5Y cells, which
has been shown to exist antagonistically with CELF1 [11] leading to mRNA stabilization.
Additionally, it has also been shown that with regard to splicing function, CELF1, CELF2,
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and CELF6 can all antagonize MBNL1 function [59]. If MBNL1 and CELF6 can act an-
tagonistically, then some of the variability we observed in CELF6-responsiveness in cell
culture may be due to competition from this or similar proteins. Antagonistic activity of
RBPs on mRNA translation and stability has also been observed for CELF2 and HUR
[60] and ELAVL1 and ZFP36 [61]. Antagonistic activity of RBPs may be mediated by the
proximity of binding sites in the 3’UTR, with specific knockdown of RBPs freeing access to
other RBP binding sites and resulting in changes to mRNA levels, as has been found for
UTRs containing AU-rich elements [62]. In our analysis of CELF6 CLIP targets, we found
several binding motifs showing enriched abundance in these UTRs for RBPs of different
families. Although the presence of binding sites other than the UGU-rich motifs did not
associate with the observed levels of reporter mRNA, we have not yet determined the ex-
tent of interaction of these binding motifs, nor whether their distance from UGU-containing
motifs associates with expression levels. We did not find significant interactions between
matching multiple motifs (not shown) on expression levels, but their placement with re-
spect to one another is likely to play a role in whether they have a functional consequence
of interaction. Important downstream experimentation includes knockdown of specific
RBPs which may interact with CELF6 either directly or indirectly by competing for the
same UTR, and determining whether this changes expression levels. Such experiments
will lend important insight into the mechanism of CELF6 and other CELFs’ actions at the
3’UTR.
We found that CELF6 expression was associated with down-regulation of library el-
ements. In this study we have inferred that this is not due to changes in translation;
while a subset of elements did show changes in TE in response to CELF proteins, there
was not a general trend in the direction of the effect. In addition, as all reporter ele-
ments contain the same promoter, any alterations are unlikely to be due to changes to
transcriptional activity. To determine whether CELF6 indeed facilitates mRNA decay, our
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experiment should be repeated in the context of pulse ethynyluridine labeling to measure
the decay rates of nascent RNA targets [63]. CELF1 has been shown able to recruit poly
A ribonuclease (PARN) to RNA targets to facilitate mRNA decay, and Moraes and col-
leagues found that CELF1 could associate directly with PARN protein in vitro [12]. Thus
it is intriguing to hypothesize that all the CELFs are able to do this, especially given our
finding that CELFs3-6 can all induce repression of the same reporter elements, as well
as whether knockdown of PARN is sufficient to abolish CELF-dependent down-regulation.
Additionally, the Xenopus homologue of the CELF proteins, Embryo Deadenylation Ele-
ment Binding Protein (EDEN-BP), has been shown to regulate deadenylation of target
mRNA, and that oligomerization of the protein is required for this activity [64]. It is cur-
rently unknown whether any of the mammalian CELF proteins are able to oligomerize and
the extent to which this may affect the functional activity of these proteins. Finally, we do
not yet know the extent to which these findings generalize to CELF6 activity in vivo. Our
reporter library is in a plasmid backbone that facilitates packaging into adeno-associated
virus. Using this tool to transduce brain regions such as monoaminergic neuronal popu-
lations may help determine whether the effects we observe in vitro are also observed in
the context of the brain.
In summary, we have presented the first evidence of CELF6 binding targets in vivo and
our data support the hypothesis that like other CELF family members, CELF6 may function
to regulate mRNA stability in addition to splicing. Future work will help further define the
mechanism behind CELF6’s actions in vivo and the downstream cellular consequences
this may have on neuronal function.
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Methods
Animals
All protocols involving animals were approved by the Animal Studies Committee of Wash-
ington University in St. Louis. Cages were maintained by our facility on a 12 hr : 12 hr
light:dark schedule with food and water supplied ad libidum. Mice used in CLIP experi-
ments comprised 4 pools of 4 CELF6-HA/YFP animals and 3 pools of 4 WT animals (30
animals). Animals were genotyped from toe clip tissue lysed by incubation at 50oC in Tail
Lysis Buffer for 1 hours to overnight ( 0.5 M Tris-HCl pH 8.8, 0.25 M EDTA, 0.5% Tween-20
) containing 4 µL/mL 600 U/mL Proteinase K enzyme (EZ BioResearch), followed by heat
denaturation at 99oC for 10 minutes. Crude lysis buffer was used as template for PCR
with 500 nM HA/YFP genotyping primers: HA-F: 5’ TTAAGCGTAGTCTGGGACGTCG-
TATGGGT 3’, YFP R: 5’ CTACGTCCAGGAGCGCACCATCTTCTT 3’ and Actb control
primers Actb F: 5’AGAGGGAAATCGTGCGTGAC 3’ , Acb R: 5’ CAATAGTGATGACCTG-
GCCGT 3’: using Quickload Taq Mastermix (New England Biolabs) with the following
cycling conditions: 94oC 1 min, (94oC 30 s, 60 oC 30 s, 68oC 30 sec) x 30 cycles, 68oC 5
minutes, 10ohold.
Cell culture
SH-SY5Y neuroblastoma cells (ATCC CRL-2266) were maintained at 5% CO2, 37oC,
95% relative humidity in 1:1 Dulbecco Modified Eagle Medium/Nutrient Mixture F-12
(DMEM/F12 Gibco) supplemented with 10% fetal bovine serum (FBS Sigma). Under
maintenance conditions, cells were also incubated with 1% Penicillin-streptomycin (Thermo),
but antibiotics were not used during transient transfections. Cell passage was performed
with 0.25% Trypsin-EDTA (Thermo).
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CLIP
Our CLIP procedure is modeled after the procedure of Wang et al. [11] and with private
consultation with Eric Wang. Post-natal day 9 mice were euthanized by rapid decapita-
tion, and brains were dissected. Cortices and cerebella were removed, retaining basal
forebrain, striatum, diencephalon, colliculi, and hindbrain regions. Pools of four brains
were flash frozen in liquid nitrogen and then powdered with a mortar and pestle cooled
with liquid nitrogen and kept on dry ice in 10 cm Petri dishes until use. Crosslinking was
performed using 3 rounds of 400 mJ/cm2 dosage of 254 nm ultraviolet radiation, with
petri dishes on dry ice, in a Stratalinker UV crosslinker. After each round of crosslinking,
powder in the dishes was tapped and redistributed to allow for even crosslinking. After
crosslinking, powders were kept on wet ice and incubated with 1mL lysis buffer (50 mM
Tris-HCl pH 7.4, 100 mM NaCl, 1X c0mplete EDTA-free protease inhibitor (Sigma) ,0.04
U/µL recombinant RNasin (Promega) 10 mM activated sodium orthovanadate, 10 mM
NaF. Recombinant RNasin does not inhibit RNase I which was used for RNase digestion
in CLIP and was added to prevent other environmental RNase activity. To obtain both
cytoplasmic and nuclear fractions in the lysate, lysis buffer was supplemented with 1%
NP40 (Sigma CA630) detergent and subjected to mechanical homogenization/lysis in a
teflon homogenizer 10 times, and lysates were allowed to incubate on ice for 5 minutes.
For RNase digestion, RNase If (New England Biolabs) was diluted to final concentra-
tion 0.5, 0.1, or 0.05 U/mL per lysate for radiolabeling. For control radiolabeled sampels
(no crosslink and WT tissue immunoprecipitates), the highest (0.5 U/mL) concentration of
RNase was used. For samples used for sequencing, 0.05 U/mL final concentration was
used. RNase-containing lysates were incubated in a thermomixer set to 1200 RPM at
37oC for 3 minutes and then clarified at 20,000xg for 20 minutes. 2 % input lysate was
saved for input samples for sequencing. Per immunoprecipitation, 120 µL of Dynabeads
M280 streptavidin coated beads (Thermo) were incubated with 17 µL 1 mg/mL biotiny-
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lated Protein L (Thermo), and 36 µg each of mouse anti-EGFP clones 19F7 and 19C8
antibodies (MSKCC) for 1 hour. Beads were prepared in batch for all immunoprecipi-
tations and then washed five times with 0.5% IgG-free bovine serum albumin (Jackson
Immunoresearch) in 1X PBS, followed by three washes in lysis buffer. Clarified lysates
were incubated with coated,washed beads for 2 hours at 4oC with end-over-end rotation
and then washed in 1mL of wash buffer (50 mM Tris-HCl pH 7.4, 350 mM NaCl, 1% NP-
40, 0.04U/µL RNasin) four times, for 5 minutes with end-over-end rotation at 4oC. For
radiolabeling experiments, 60% of washed bead volume was reserved for immunoblotting
and added to 20 µL of 1X Bolt-LDS non-reducing sample buffer (Thermo), and 40% pro-
ceeded to radioactive labeling. Beads for radioactive labeling were subsequently washed
3x200 µL in PNK wash buffer (20 mM Tris-HCl pH 7.4, 10 mM MgCl2, 0.2% Tween-20,
2.5 U/µL RNasin) and then incubated with 10 µL PNK reaction mixture (1X PNK reac-
tion buffer (New England Biolabs), 4 µCi 32P−ATP (Perkin Elmer), 10 U T4 PNK (New
England Biolabs)) for 5 minutes, at 37oC. After labeling, samples were washed in 3x200
µL PNK wash buffer to remove unincorporated label, and then added to 10 µL of 1X Bolt
LDS non-reducing sample buffer. All samples in sample buffer were heated for 10 min-
utes at 70oC and then separated on a 4-12% gradient NuPAGE Bis/Tris gels (Thermo)
and then transferred to PVDF membranes with 10% methanol for 6 hours at constant 150
mA. Samples for immunoblot were blocked for 1 hour in block solution ( 5% nonfat dried
milk in 0.5% Tween-20/1X TBS ), and then overnight with 1:1000 chicken anti-GFP anti-
bodies (AVES) with rocking at 4oC. Blots were washed 3x5minutes in 0.5% Tween20/1X
TBS and then incubated with 1:5000 anti-chicken HRP secondary antibodies (AVES) for 1
hour at room temperature and treated with Biorad Clarity enhanced chemiluminescence
reagents for 5 minutes and chemiluminescent data acquired with a Thermo MyECL in-
strument. Radioactive signal was acquired using an Amersham Typhoon Imaging System
and a BAS Storage Phosphor screen (GE Healthcare Life Sciences).
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CLIP-Seq Sequencing Library Preparation
For CLIP-Seq, EGFP immunoprecipitated WT and HA-YFP+ tissue and 2% input samples
were purified from PVDF membranes as follows. Membrane slices were cut with a clean
razor according to the diagram in Figure 1A, from unlabeled samples as has been per-
formed in eCLIP [21]. In order to minimize sample processing, slices were incubated in
1.7 mL microcentrifuge tubes with 200 µL Proteinase K buffer ( 100 mM Tris-HCl pH 7.4,
50 mM NaCl, 10 mM EDTA, 1% Triton-X 100 ) containing 40 µL of 800 U/mL Proteinase K
(NEB) and incubated in a horizontal shaker at 250 RPM, 37oC for 1 hour. Horizontal shak-
ing reduces the need to cut the membrane into small pieces per sample which is seen in
many protocols, and 1% Triton-X 100 in the Proteinase K buffer facilitates increased yield
from the membrane. 200 µL of fresh 7M Urea/Proteinase K buffer is then added to slices
and tubes are incubated an additional 20 minutes with horizontal shaking at 250 RPM,
37oC. RNA is purified by addition of 400 µL of acid phenol/chloroform/isoamyl alcohol
and shaken vigorously for 15 s and allowed to incubate 5 minutes on the bench. RNA
samples are centrifuged at 20,000xg for 10 minutes. Aqueous layers are purified using
a Zymo-5 RNA Clean & Concentrator column. Output from CLIP’d RNA samples was
estimated for total concentration using an Agilent Bioanalyzer and approximately 0.5 ng
of RNA was used to prepare next generation sequencing libraries. The full protocol for
sequencing library preparation is given in Appendix 2. This is a unified protocol based
on eCLIP but which we also use for general RNA-Seq library preparation.
CLIP-Seq Sequencing Data Processing
CLIP-Seq samples were sequenced paired-end 2x40 on an Illumina Next-Seq. Unique
Molecular Identifier (UMI) sequences were extracted from Illumina Read 2, and reads
were trimmed from quality using Trimmomatic [65]. Reads aligning to ribosomal RNA
were depleted and remaining RNA reads were aligned to the mm10 mouse reference
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genome using STAR [66] and assembled into BAM formatted alignment files. BAM files
were annotated with UMI information using the FGBio Java package (https:/ /github.com/
fulcrumgenomics/fgbio). PCR duplicates assessed by their UMIs were removed from the
BAM files using picard-tools (https:// broadinstitute.github.io/picard/). For Piranha peak
calling analysis, the genome was windowed into 100 bp contiguous windows with 50%
overlap. A merged BAM file pooling reads from all YFP-HA+ immunoprecipitated CLIP
samples was used to count reads per window. Zero count windows were truncated,
and Piranha [33] was used to call peaks on the remaining read density throughout the
genome. Piranha p-values for significant peaks were adjusted for multiple testing using
Benjamini Hochberg, and all peaks called with False Discovery Rate < 0.1 were kept for
further analysis and stored as a Gene Transfer Format (GTF) file. For the UCSC anno-
tated gene based analysis, UCSC table browser was used to generate GTF files contain-
ing all annotated: 3’UTR, coding sequence (CDS), 5’UTR, and intron regions. In order
to ensure mapping of reads to splice sites, the table of intron annotations was allowed
to overlap the surrounding exons by 10 bases. All GTFs (Piranha peaks, 3’UTR, CDS,
5’UTR, introns) were subsequently as feature sets for read counting with Subread[67,
68], summing reads for each annotated subgenic region. Samples were imported in R
using the edgeR package [35] and normalized for both total library size per sample and
feature length as Fragments per Kilobase per Million reads (FPKM). To identify a mini-
mum detection level for subsequent analysis, the relationship between standard deviation
across CLIP samples and mean log2 FPKM was computed and fitted to a spline. Vari-
ability across replicates increases dramatically at poor detection level, and the minimum
FPKM required for a feature was set to where the standard deviation decayed to half
maximal as a threshold (here determined at 2.5 FPKM). We required that all YFP-HA+
CLIP samples have FPKM > threshold across all YFP-HA+ CLIP samples to be included
in analysis. Differential testing was then performed in edgeR against read counts deriving
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from WT samples or YFP-HA+ input samples. We defined CLIP targets as having positive
fold change enrichment in YFP-HA+ CLIP samples compared to both WT CLIP and input
samples, with nominal edgeR p-values <0.05. We have proceeded throughout our analy-
sis and PTRE-Seq library generation using targets defined this way in order to maximize
exploration of the data. However, we also computed Benjamini-Hochberg adjusted False
Discovery Rate for each feature/gene and these are summarized in Supplemental Tables
3 and 4.
CLIP Motif Enrichment Analysis
Because the Piranha peak-based analysis initially yielded often very broad peaks when
called genome-wide, we repeated peak finding considering only read density across
3’UTRs of CLIP targets. It is likely that estimating the background across all transcripts
even after removing zeros across the genome underestimated the background level for
many genes. 50 bp regions under the maxima of peaks in CLIP target 3’UTRs were used
in MEME Suite and compared to 50 bp regions sampled randomly from the 3’UTRs of
"non-targets" - genes which exhibited 0 or negative fold enrichment in YFP-HA+ CLIP
samples compared to input or WT controls. These sample sets were then submitted to
both DREME web tool for de novo motif finding, and AME web tool for searching against
the CISBP-RNA database (http://meme-suite.org/).
PTRE-Seq Reporter Library Preparation
All cloning oligos are as shown in Supplemental Table 8. We generated the pmrPTRE-
AAV backbone from an existing mtdTomato construct by PCR amplification and sub-
cloning of the following elements: CMV promoter and a T7 promoter, PCR amplified and
subcloned into the MluI restriction site of a AAV-GFAP-mtdTomato construct and ampli-
fied from pcDNA3.1. Then, in order to add a NheI-KpnI restriction enzyme cassette into
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the 3’UTR, the entire pmrPTRE-AAV plasmid was amplified and recircularized using In-
fusion HD (Clontech). The correct backbone sequence of pmrPTRE-AAV was confirmed
by Sanger sequencing.
Originally 473 120 bp sequences under CLIP Peaks were considered for cloning into
the library across significant genes. Mutations to motifs found by AME were made as
follows. Significant matches to motifs were determined using FIMO (p<0.005). Next, for
each matched motif, the position weight matrix (PWM) representing this motif in CISBP-
RNA was used to determine the choice of mutation at each base. Only bases showing a
probability of 0.8 or greater were mutated at any position. Bases showing PWM probability
>0.8 were mutated to the base showing the minimum value of PWM at that position. If
all other three bases showed equal probability, a base was randomly selected from the
three. The procedure was repeated at each position for each motif match, before moving
to the next matching motif, ranked by FIMO p-value. Where motifs overlapped, lower
ranking motifs (based on match strength) did not override mutations already made based
on higher ranking motifs. After completion this generated a set of 473 mutant elements
which ranged between 1 - 25 mutated nucleotides depending on the number of motif
matches and number of highly conserved positions in each motif. These sequences were
scanned for poly A signals and restriction enzyme sites likely to interfere with cloning,
which were removed. A final set of 436 120 bp sequences, attached to 6 unique 9 base
pair barcodes, as well as priming sites for amplification and cloning (final length 210 bp),
and a paired set of 436 mutant sequences were synthesized by Agilent Technologies.
Obtained synthesized sequences were amplified with 4 cycles of PCR using Phusion
polymerase (Thermo) using primers GFP-F and GFP-R, which are standard PCR primers
in our laboratory that result in robust amplification. The library was PAGE purified and
concentration of recovered library was estimated by Agilent TapeStation. The library was
digested with NheI and KpnI enzymes and ligated into pmrPTRE-AAV with T4 Ligase
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(Enzymatics). In order to ensure high likelihood of obtaining all library elements, we
prepared our plasmid pool from approximately 40,000 colonies. .
PTRE-Seq Reporter Library Transfection
His/Xpress-tagged CELF3,4,5,&6 were obtained from the laboratory of Tom Cooper [58].
For four plasmid experiments, 2500 ng containing equimolar: 2xHis/Xpress-CELF con-
structs, 1 EGFP-RPL10a, and CELF6 PTRE-Seq library were prepared with Lipofec-
tamine 2000 in Optimem-I (Gibco). For plasmids with 3 plasmids, remaining mass was
made up with empty pcDNA3.1-His. SH-SY5Y cells trypsinized and incubated in with
Lipofectamine/DNA complexes overnight in DMEM/F12 supplemented with 10% FBS. The
following day media was replaced with fresh DMEM/F12 supplemented with 10%FBS and
cells were pelleted for TRAP and RNA extraction 40 hours post-transfection. TRAP and
total RNA extraction were performed according to the protocol in Appendix 3 with total
RNA quality assessed by Agilent TapeStation and all samples had RINe values > 8. 5
replicates per condition were generated in batches balanced for all conditions. In each
case, replicates were transfected from newly thawed aliquots of cells to control for cell
passage. Read counts from 1 batch were found to cluster separately from all others after
sequencing and data from this batch were excluded. The final data were analyzed from 4
replicates per condition.
PTRE-Seq Sequencing Library Preparation
PTRESeq sequencing libraries were prepared by cDNA synthesis using pmrPTRE-AAV
antisense oligo (Supplemental Table 8) for library specific priming, and Superscript III Re-
verse Transcriptase (Thermo) according to the protocol shown in Appendix 4. After cDNA
synthesis, cDNA libraries were enriched with PCR using Phusion polymerase (Thermo),
and pmrPTRE-AAV antisense and sense oligos using 18 cycles. In parallel, plasmid pool
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DNA was also amplified for sequencing the original plasmid pool. Purified PCR prod-
ucts were digested with NheI and KpnI enzymes and ligated to 4 equimolar staggered
adapters to provide sequence diversity for sequencing on the NextSeq. Ligated products
were amplified with Illumina primers as in CLIP-Seq library preparation (Appendix 2) and
subjected to 2x40 paired end next generation sequencing on an Illumina sequencer.
PTRE-Seq Sequencing Library Data Processing
Barcode counts from sequencing read FASTQ files for each element were determined
using a Python script. Read counts were imported into R using edgeR and converted to
counts-per-million (CPM) to normalize for differences in library size. Elements showing
no counts in the DNA plasmid pool sequencing were removed. Expression was then
computed as:
log2expression = log2
CPMRNA
CPMDNA
Translation efficiency was computed as:
log2TE = log2expressionTRAP − log2expressionTotalRNA
The mean and standard deviation relationship within condition groups were deter-
mined for log2expression across elements as in processing for CLIP-Seq in order to filter
out poorly detected elements. A minimum log2expression value of -4.29 was determined
as a lower bound cutoff which corresponded to approximately 10 counts. We required that
all 4 replicates in at least 1 condition had expression levels above this threshold. Finally,
after filtering on expression, we required that all elements have at minimum 3 out of the
original 6 barcodes present, and present for both reference and mutant alleles.
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PTRE-Seq Sequencing Library Statistical Analysis
The final set of elements ammenable to testing after filtering on expression and numbers
of barcodes was 424 across 172 unique gene UTRs. Individual linear mixed models were
performed using lme4 [69] fitting the following:
expression ( or TE ) ∼ condition ∗ sequence+ (1|sample)
where barcodes were used as repeated measures for each sample, per element. Fixed
effect terms of condition referred to either: (a) CTL or CELF6 expression for analyses
in Figure 3, or (b) CTL, CELF6, CELF3, CELF4, CELF5, CELF3/6, CELF4/6, CELF5/6
for analyses related to Figure 4. Fixed effect term of sequence was either (a) reference
or (b) mutated sequence. Omnibus tests for significant effects of fixed effect terms were
computed using likelihood ratio tests in R compared to models lacking a term of inter-
est (Analysis of Deviance). Estimates of R2 and percentage variance explained by fixed
effects were determined according to the procedure of Nakagawa and Schielzeth [70].
Omnibus p-values for fixed effects are also reported in Supplemental Tables 6 & 7 for
models containing all 8 conditions alongside Benjamini Hochberg adjusted False Discov-
ery Rates. For generalized analysis of trends across all elements in Figures 3 and 4
we have considered all elements showing main effects or interaction effects with nominal
p<0.05.
Figures 3 and 4 show analysis of these trends across all models and for subsets
of elements with less than or equal to 7 or 12 mutations to discern whether radically
mutating elements has exerted a strong effect. Because these subsets are nested and
pooling independently fitted models, we have assessed significance between them using
non-parametric Mann Whitney U tests for differences between medians. Post hoc multi-
ple comparisons significance and confidence intervals reported for individual elements in
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Figure 3 and 4, in order to identify the sources of interaction, were computed using the
multcomp R package [71].
Data Accessibility
Raw and processed sequencing data from CLIP-Seq and PTRE-Seq studies will be sub-
mitted to NCBI’s Gene Expression Omnibus as part of publication of this manuscript.
Supplemental Information
Table S1: Oligos for CLIPSeq Library Preparation
name sequence (5´-3´)
A01m /5Phos/rArGrArUrCrGrGrArArGrArGrCrGrUrCrGrUrGrUrArG/3SpC3/
AR17 primer ACACGACGCTCTTCCGA
Rand103tr3 /5Phos/NNNNNNNNNNAGATCGGAAGAGCACACGTCTG/3SpC3/
Table S2: CLIP-Seq Aligned Read Summary
total pairs duplication unique aligners % aligning to subgenic features
Sample Genotype Fraction (millions) % (millions) 3UTR CDS 5UTR introns
yfp-1-ip yfp ip 9.9 6.59 5.9 19.2 25.53 4.5 50.77
wt-1-ip wt ip 15.6 4.64 9.7 15.53 27.98 4.91 51.57
yfp-1-input yfp input 4.6 6.15 2.7 12.4 20.47 12.58 54.55
wt-1-input wt input 4.9 6.96 2.7 13.5 19.15 11.38 55.97
yfp-2-ip yfp ip 6.9 4.48 4.1 14.7 27 10.2 48.1
wt-2-ip wt ip 3.2 5.14 1.6 10.86 27.8 10.28 51.06
yfp-2-input yfp input 29.3 19.48 21.2 11.61 16.12 4.2 68.06
wt-2-input wt input 5.1 3.49 3.9 11.54 16.44 4.49 67.53
yfp-3-ip yfp ip 5.8 35.53 3.2 15.12 26.36 7.16 51.36
yfp-3-input yfp input 10.7 9.11 7.8 15.11 18.69 4.14 62.06
yfp-4-ip yfp ip 6.7 26.52 3.3 21.48 26.19 9.01 43.31
wt-3-ip wt ip 14.4 49.98 3.7 15.15 31.49 7.21 46.15
yfp-4-input yfp input 2.2 56.86 0.8 13.43 17.16 8.36 61.06
wt-3-input wt input 9.8 20.42 6.7 16.46 21.24 4.15 58.14
146
Table S3: CLIP Targets Defined from Piranha Peaks
chr start end strand gene geneFeature logFCIP/input PValue FDR logFCIP/WTIP
chrX 59062650 59062749 - Fgf13 utr3 4.239 1.83E-5 0.0109 5.397
chrX 134305100 134305199 + Tmem35a utr3 3.249 3.04E-5 0.0109 2.103
chr13 54381300 54381399 + Cplx2 utr3 2.856 2e-04 0.0328 3.227
chr15 38489550 38489649 - Azin1 utr3 3.027 2e-04 0.0352 3.71
chrX 105123550 105123649 + Magee1 utr3 2.897 0.001 0.0922 4.86
chr7 62417850 62417949 - Gm32061,Mkrn3 utr3 2.228 0.0013 0.0922 3.591
chr2 165112550 165112649 - Cdh22 cds|utr3 2.5 0.0013 0.0922 0.279
chr4 47469950 47470049 - Alg2 utr3 2.643 0.0015 0.0922 4.436
chr12 72795000 72795099 + Ppm1a utr3 2.233 0.0017 0.0922 3.021
chr11 116359800 116359899 - Rnf157 cds 2.408 0.0017 0.0922 0.313
chr15 98169950 98170049 + Ccdc184 utr3 2.457 0.0023 0.1167 2.886
chr18 12991250 12991349 + Impact utr3 2.407 0.0027 0.1238 4.225
chr7 100273200 100273299 + Pgm2l1 utr3 2.558 0.0028 0.1238 2.193
chr2 28230250 28230349 + Olfm1 utr3 2.309 0.0034 0.1329 2.751
chr2 164501050 164501149 + Pigt cds|utr3 2.161 0.0035 0.1329 0.671
chr2 134595150 134595249 - Tmx4 utr3 2.247 0.0054 0.1329 2.892
chr7 131566150 131566249 + Bub3 cds|utr3 1.949 0.0057 0.1329 2.505
chr5 144556150 144556249 + Nptx2 cds 2.563 0.0058 0.1329 0.963
chr4 59221850 59221949 + Ugcg utr3 2.097 0.0059 0.1329 2.159
chr11 75496400 75496499 + Prpf8 cds 1.831 0.0059 0.1329 0.865
chr13 91881950 91882049 - Rasgrf2 utr3 2.07 0.0059 0.1329 3.467
chr5 105486400 105486499 + Lrrc8b utr3 1.905 0.0061 0.1329 1.945
chr6 118602050 118602149 - Cacna1c cds 2.118 0.0061 0.1329 2.988
chr17 64281900 64281999 - Pja2 utr3 2.316 0.0062 0.1329 3.536
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CLIP Targets Defined from Piranha Peaks Cont’d
chr start end strand gene geneFeature logFCIP/input PValue FDR logFCIP/WTIP
chrX 153171600 153171699 + Rragb utr3 2.182 0.0063 0.1329 3.684
chr2 127226000 127226099 + Snrnp200 cds 1.816 0.0069 0.1329 0.751
chr10 117814850 117814949 - Rap1b utr3 2.122 0.0073 0.1329 1.384
chr13 110055800 110055899 - Rab3c utr3 2.068 0.0074 0.1329 3.075
chr10 108499000 108499099 - Syt1 utr3 2.116 0.0075 0.1329 2.778
chr17 80396600 80396699 - Sos1 utr3 1.978 0.0078 0.1329 2.826
chrX 56588450 56588549 - Mmgt1 utr3 2.023 0.0078 0.1329 3.04
chrX 100816550 100816649 + Dlg3 utr3 1.925 0.0081 0.1329 1.673
chrX 152610300 152610399 - Shroom2 utr3 2.166 0.0083 0.1329 2.445
chr5 21795750 21795849 + Psmc2 cds 1.949 0.0083 0.1329 1.236
chr7 62349525 62349624 + Ndn utr3 2.082 0.0088 0.1329 3.153
chr1 118300500 118300599 - Tsn utr3 1.958 0.0088 0.1329 3.318
chr3 51251250 51251349 + Noct utr3 1.977 0.0089 0.1329 1.595
chr4 135412450 135412549 - Rcan3 cds|utr3 1.88 0.0094 0.1376 1.988
chr9 71479050 71479149 - Polr2m utr3 2.281 0.0099 0.1376 3.733
chr13 95954850 95954949 - Sv2c utr3 2.022 0.0106 0.1376 3.358
chr4 33945150 33945249 + Cnr1 utr3 1.802 0.0107 0.1376 3.775
chr7 59310600 59310699 + Ube3a utr3 1.947 0.0108 0.1376 2.046
chr18 24580550 24580649 - Slc39a6 utr3 2.032 0.011 0.1376 3.12
chr16 44087100 44087199 - Atp6v1a utr3 2.077 0.0111 0.1376 2.83
chrX 147195850 147195949 + Htr2c utr3 1.999 0.0124 0.1503 2.964
chr2 181549550 181549649 + Dnajc5 utr3 2.052 0.0138 0.1647 1.768
chr8 114371950 114372049 + Vat1l utr3 1.965 0.0145 0.169 1.719
chr1 180144850 180144949 + Cdc42bpa cds 1.938 0.0148 0.169 1.002
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CLIP Targets Defined from Piranha Peaks Cont’d
chr start end strand gene geneFeature logFCIP/input PValue FDR logFCIP/WTIP
chr9 26755900 26755999 + B3gat1 cds 1.682 0.0153 0.1713 0.52
chr11 77504600 77504699 + Git1 cds 1.822 0.0158 0.1726 0.373
chr17 34612600 34612699 + Agpat1 utr3 1.818 0.0166 0.1754 0.669
chr1 23845900 23845999 - Smap1 utr3 1.839 0.0166 0.1754 1.374
chr6 71810400 71810499 + Reep1 utr3 1.95 0.0169 0.1757 1.891
chr1 33798550 33798649 - Zfp451 utr3 1.771 0.0173 0.1759 3.289
chrX 8894600 8894699 + B630019K06Rik utr3 1.992 0.0174 0.1759 3.328
chr11 106058850 106058949 + Dcaf7 utr3 1.947 0.018 0.1768 2.347
chr1 63314350 63314449 + Zdbf2 utr3 1.909 0.0182 0.1768 2.11
chr4 118235900 118235999 - Ptprf cds 1.619 0.0192 0.1768 0.617
chrX 133587350 133587449 - Pcdh19 utr3 1.837 0.0193 0.1768 2.483
chr11 84984975 84985074 - Usp32 utr3 1.739 0.0193 0.1768 0.901
chr3 10418700 10418799 - Snx16 utr3 1.855 0.0194 0.1768 3.879
chr4 65615600 65615699 + Trim32 utr3 2.007 0.0201 0.1768 3.071
chr1 82290450 82290549 - Irs1 utr5|cds 1.67 0.0202 0.1768 2.591
chr8 34827800 34827899 - Tnks utr3 1.811 0.0202 0.1768 2.548
chrX 36198900 36198999 + Zcchc12 utr3 1.892 0.0215 0.1854 3.072
chr9 62792400 62792499 - Fem1b utr3 1.737 0.0226 0.1864 2.53
chr7 6964500 6964599 + Usp29 utr3 1.835 0.0227 0.1864 4.552
chr15 4575200 4575299 + Plcxd3 utr3 1.896 0.0228 0.1864 5.418
chr1 169741750 169741849 - Rgs4 utr3 1.766 0.0233 0.1864 1.675
chr2 70601800 70601899 + Gad1 utr3 1.91 0.0235 0.1864 2.717
chr11 100347450 100347549 - Hap1 utr3 1.754 0.0236 0.1864 2.944
chr5 129984100 129984199 + Vkorc1l1 utr3 1.731 0.0237 0.1864 2.222
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CLIP Targets Defined from Piranha Peaks Cont’d
chr start end strand gene geneFeature logFCIP/input PValue FDR logFCIP/WTIP
chr4 101642350 101642449 + Dnajc6 utr3 1.68 0.0254 0.1958 3.198
chr6 113168150 113168249 - Lhfpl4 utr3 1.651 0.0258 0.1969 1.921
chr4 105036050 105036149 - Prkaa2 cds|utr3 1.643 0.0275 0.2058 2.536
chr11 20225100 20225199 + Rab1a utr3 1.888 0.0276 0.2058 3.239
chr10 52338250 52338349 - Gopc utr3 1.668 0.0281 0.2058 3.138
chr12 29923000 29923099 + Myt1l utr3 1.599 0.0291 0.2107 2.642
chr13 25252900 25252999 - Nrsn1 utr3 1.855 0.0303 0.2114 3.102
chr3 157315150 157315249 + Negr1 utr3 1.659 0.0303 0.2114 1.599
chr3 124322500 124322599 + Tram1l1 utr3 1.617 0.0319 0.2193 4.022
chr4 40733350 40733449 + Dnaja1 utr3 1.742 0.0321 0.2193 2.401
chr2 26921000 26921099 - Surf4 utr3 1.445 0.0325 0.2195 0.764
chr6 57737850 57737949 + Lancl2 utr3 1.628 0.0329 0.2205 1.496
chr18 37186700 37186799 + Pcdha1-12 utr3 1.74 0.0333 0.2206 3.928
chr8 83435450 83435549 - Scoc utr3 1.735 0.0335 0.2206 2.528
chr10 112925600 112925699 - Atxn7l3b utr3 1.734 0.0344 0.2213 1.291
chr11 100459650 100459749 - Acly intron 1.563 0.0346 0.2213 1.804
chr17 13016450 13016549 + Sod2 utr3 1.607 0.0378 0.2249 3.007
chr14 122480100 122480199 + Zic2 utr3 1.608 0.0379 0.2249 4.444
chr2 121194900 121194999 - Trp53bp1 utr3 1.57 0.0383 0.2249 2.8
chr7 122080500 122080599 + Ubfd1 utr3 1.49 0.0385 0.2249 2.195
chr2 164999300 164999399 + Slc12a5 cds|utr3 1.735 0.0386 0.2249 2.14
chr14 19874950 19875049 - Gng2 utr3 1.868 0.039 0.2249 3.824
chr13 102732600 102732699 - Mast4 utr3 1.531 0.0395 0.2249 2.395
chr17 24685650 24685749 - Syngr3 utr3 1.768 0.0401 0.2249 2.449
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CLIP Targets Defined from Piranha Peaks Cont’d
chr start end strand gene geneFeature logFCIP/input PValue FDR logFCIP/WTIP
chr3 9427250 9427349 - Zfp704 utr3 1.409 0.0403 0.2249 2.453
chr5 125787250 125787349 + Tmem132b cds 1.398 0.0404 0.2249 0.282
chr9 27010400 27010499 - Vps26b cds 1.395 0.0404 0.2249 0.346
chr17 27426750 27426849 - Grm4 cds|utr3 1.543 0.0405 0.2249 0.618
chr18 76941400 76941499 + Ier3ip1,Hdhd2 utr3 1.532 0.0425 0.2296 2.278
chr13 97251300 97251399 + Enc1 utr3 1.76 0.0426 0.2296 2.727
chr10 24188100 24188199 + Stx7 utr3 1.673 0.044 0.2329 3.171
chr1 131177050 131177149 - Rassf5 utr3 1.481 0.0442 0.2329 2.781
chrX 143791700 143791799 + Pak3 utr3 1.788 0.0448 0.2332 3.025
chr11 97509750 97509849 - Srcin1 utr3 1.686 0.0458 0.2332 3.346
chr8 79675050 79675149 + Otud4 utr3 1.545 0.0465 0.2332 3.731
chr7 15945300 15945399 - Nop53 cds 1.353 0.0466 0.2332 1.587
chr2 148697200 148697299 - Napb utr3 1.723 0.0468 0.2332 2.628
chr12 86694850 86694949 + Vash1 utr3 1.362 0.0472 0.2332 1.359
chr6 30446600 30446699 + Klhdc10 cds 1.464 0.0488 0.2353 0.293
Table S4: CLIP Targets Defined From Annotated Subgenic Regions
*FDR was computed within feature for pairwise tests in 5’UTR,3’UTR, CDS, or intron data.
gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Fgf13 utr3 3.093 1.12E-8 2.3E-5 2.995
Magee1 utr3 2.779 1.21E-7 1e-04 2.806
Pgr15l utr3 2.497 3.47E-6 0.0018 2.157
Syn2 utr3 1.815 5.74E-6 0.002 1.973
Olfm1 utr3 1.784 1.2E-5 0.0035 1.427
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CLIP Targets Defined From Annotated Subgenic Regions (Cont’d)
gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Snca utr3 2.041 1.73E-5 0.0044 1.78
Arxes1 utr3 1.963 2.57E-5 0.0059 1.877
Gad1 utr3 2.006 3.06E-5 0.0063 2.02
Slc39a6 utr3 2.427 3.39E-5 0.0063 1.88
Ndn utr3 1.911 7.39E-5 0.0117 1.674
Atp6ap2 utr3 1.891 1e-04 0.0151 2.605
Impact utr3 1.491 1e-04 0.0175 1.561
Klhdc2 utr3 1.849 2e-04 0.0206 2.033
Morf4l2 utr3 1.931 2e-04 0.0206 2.359
Cd200 utr3 1.558 2e-04 0.023 2.062
Enc1 utr3 1.597 2e-04 0.0235 1.314
Syt1 utr3 1.336 3e-04 0.0237 1.376
Rps6ka6 utr3 2.137 3e-04 0.0252 1.249
Zcchc12 utr3 1.787 3e-04 0.0273 2.176
Mkrn3 utr3 2.163 4e-04 0.0278 2.848
Rragb utr3 1.764 4e-04 0.0313 2.024
Ubfd1 utr3 1.351 4e-04 0.0313 1.032
Commd3 utr3 2.64 5e-04 0.0313 0.803
AW551984 utr3 1.731 5e-04 0.0313 1.835
Nrsn1 utr3 1.758 5e-04 0.0313 1.448
Nap1l5 utr3 1.428 6e-04 0.0356 1.967
Cnr1 utr3 1.517 6e-04 0.0366 1.54
Epm2aip1 utr3 1.511 6e-04 0.0366 1.63
Ccrn4l utr3 1.869 8e-04 0.0408 1.466
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CLIP Targets Defined From Annotated Subgenic Regions (Cont’d)
gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Htr7 utr3 1.631 9e-04 0.0419 0.475
Trim32 utr3 1.79 9e-04 0.0419 2.408
B3galnt1 utr3 1.756 9e-04 0.0419 0.878
Plcxd3 utr3 2.375 9e-04 0.0419 3.014
Pfn2 utr3 1.298 0.001 0.043 0.933
Zcchc18 utr3 1.718 0.001 0.0449 1.512
Shroom2 utr3 1.248 0.0011 0.0449 1.375
Gpm6a utr3 1.471 0.0012 0.0464 1.849
Ube2e3 utr3 1.879 0.0013 0.0469 0.891
Synpr utr3 1.662 0.0013 0.0469 1.968
Rab18 utr3 1.288 0.0014 0.0469 1.516
Penk utr3 1.647 0.0014 0.0469 2.103
Gpr101 utr3 1.595 0.0014 0.0469 1.168
Snap25 utr3 1.302 0.0014 0.0472 1.756
Htr2c utr3 1.255 0.0015 0.0474 2.108
Mpped1 utr3 1.68 0.0015 0.0476 0.741
Pja2 utr3 1.502 0.0016 0.0479 1.076
Zdbf2 utr3 1.654 0.0016 0.0479 2.055
Hmgn1 utr3 1.56 0.0016 0.0481 0.747
Rae1 utr3 3.251 0.0017 0.0497 0.478
Dcaf12l1 utr3 1.749 0.0017 0.0497 1.913
Tmem35 utr3 1.503 0.0019 0.0526 1.514
Scg2 utr3 1.467 0.002 0.0526 1.288
Hsp90aa1 utr3 1.736 0.002 0.0534 1.702
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gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Uhrf2 utr3 1.614 0.0021 0.0537 0.515
Vav2 utr3 2.145 0.0022 0.0556 0.336
Isca1 utr3 1.638 0.0023 0.0566 0.938
Spsb4 utr3 1.672 0.0023 0.0566 0.597
Dek utr3 1.487 0.0024 0.0566 2.017
Zic4 utr3 1.315 0.0026 0.0566 0.781
Rgmb utr3 1.406 0.0026 0.0566 1.259
Irs4 utr3 1.611 0.0027 0.0566 1.948
Gabrq utr3 1.593 0.0027 0.0566 1.791
Azin1 utr3 1.271 0.0028 0.057 1.223
Rnf14 utr3 1.104 0.0029 0.0597 0.976
Srp9 utr3 1.567 0.003 0.0599 1.008
Wif1 utr3 3.005 0.003 0.0599 5.663
Phox2b utr3 2.121 0.003 0.0599 1.284
Ran utr3 1.381 0.0031 0.0601 0.448
Inpp4b utr3 2.563 0.0032 0.0609 2.786
Atmin utr3 1.349 0.0033 0.0631 0.742
Tmtc4 utr3 2.144 0.0034 0.0639 1.62
Ttc3 utr3 1.489 0.0035 0.0651 1.281
Arxes2 utr3 1.565 0.0036 0.0654 2.156
Rraga utr3 1.31 0.0036 0.0655 2.268
Qdpr utr3 1.694 0.0037 0.0668 1.266
Ube2b utr3 1.514 0.0042 0.0735 1.123
Gprasp2 utr3 1.828 0.0044 0.0751 2.206
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gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Dnm3 utr3 1.164 0.0048 0.0811 1.073
Gpr149 utr3 2.436 0.0049 0.0821 1.711
Tnks2 utr3 1.53 0.0049 0.0822 1.734
Rab3c utr3 0.959 0.0051 0.0834 1.195
Cdk5rap2 utr3 3.507 0.0051 0.0834 3.845
Kif2a utr3 1.229 0.0052 0.0834 1.153
Fnbp1l utr3 1.29 0.0052 0.0834 2.051
Atl1 utr3 1.613 0.0052 0.0834 2.061
Cadps utr3 1.46 0.0056 0.0867 1.195
Rnf11 utr3 1.338 0.0058 0.0887 1.349
Atp8a1 utr3 1.145 0.0058 0.0891 1.165
Lrrc47 utr3 1.431 0.0059 0.0891 2.41
Ddc utr3 2.352 0.006 0.0893 2.685
Ubqln2 utr3 1.28 0.006 0.0893 1.906
Slc25a1 utr3 1.235 0.0063 0.0921 1.277
Plcb1 utr3 1.36 0.0063 0.0921 1.224
Myh10 utr3 1.064 0.0064 0.0924 0.824
Wdr82 utr3 0.992 0.0064 0.0925 0.681
Plxnc1 utr3 1.322 0.0066 0.0933 1.34
Nap1l2 utr3 1.438 0.0069 0.0961 2.311
Nsf utr3 1.144 0.007 0.0961 0.787
Peg3 utr3 1.161 0.007 0.0961 1.719
Cltc utr3 1.204 0.007 0.0961 1.257
Nap1l3 utr3 1.694 0.0071 0.0961 3.077
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gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Atp6v1a utr3 1.219 0.0072 0.0971 1.108
Pgap1 utr3 1.06 0.0073 0.0971 1.205
Scoc utr3 1.227 0.0073 0.0971 1.587
Itfg1 utr3 1.229 0.0074 0.0974 1.331
Lpin2 utr3 1.038 0.0075 0.0978 0.825
Susd2 utr3 1.4 0.0076 0.0987 1.034
Plagl1 utr3 1.339 0.0077 0.0995 1.729
Syt4 utr3 1.277 0.0078 0.0995 2.004
Dnajc6 utr3 1.281 0.0079 0.1004 1.286
Lingo3 utr3 1.286 0.0081 0.1004 0.366
Mecp2 utr3 1.022 0.0083 0.1004 0.789
Dner utr3 1.188 0.0083 0.1004 2.069
Nxph1 utr3 1.411 0.0084 0.1004 1.075
Fos utr3 2.405 0.0084 0.1004 1.352
Rit2 utr3 1.375 0.0086 0.1015 2.105
Slc39a11 utr3 1.351 0.0087 0.1015 0.561
Glrb utr3 1.22 0.009 0.1016 2.03
Snx16 utr3 1.37 0.009 0.1016 2.319
Map2k1 utr3 1.365 0.0091 0.1016 1.865
Ppa2 utr3 2.533 0.0091 0.1016 1.56
Frmpd4 utr3 1.225 0.0091 0.1016 0.48
Tceal1 utr3 1.766 0.0092 0.1022 2.302
Tmem30a utr3 1.146 0.0095 0.1037 0.848
Stx7 utr3 1.169 0.0095 0.1039 1.777
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gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Ahi1 utr3 1.165 0.0097 0.1045 1.064
C1d utr3 1.807 0.0101 0.1069 1.596
Hap1 utr3 0.941 0.0106 0.1111 0.966
Cdk17 utr3 1.333 0.0107 0.1113 0.996
Alkbh7 utr3 2.092 0.0108 0.1117 1.351
Mir3473d utr3 5.437 0.011 0.113 5.319
Pcdh18 utr3 1.314 0.011 0.113 2.144
Slc9a6 utr3 0.908 0.0111 0.1136 1.571
Pip5kl1 utr3 2.177 0.0114 0.1154 1.623
Zfp385b utr3 1.593 0.0116 0.1163 2.17
Lin7c utr3 1.046 0.0119 0.1176 1.695
Gstm4 utr3 1.907 0.012 0.1182 0.749
Slc45a1 utr3 3.654 0.0121 0.1184 0.812
Hipk1 utr3 1.132 0.0121 0.1184 1.035
Nptn utr3 1.09 0.0123 0.119 1.517
Nbea utr3 0.975 0.0126 0.1212 1.213
Lrp12 utr3 1.549 0.0127 0.1212 0.932
Peg10 utr3 1.047 0.0128 0.1212 0.891
Pih1d1 utr3 3.504 0.0129 0.1217 1.427
Grem1 utr3 2.572 0.0129 0.1217 2.032
Dcaf7 utr3 0.993 0.0131 0.1223 0.415
Cnrip1 utr3 1.457 0.0134 0.1246 1.193
App utr3 0.918 0.0138 0.1261 1.437
Tle4 utr3 1.245 0.014 0.1261 1.909
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gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Arf1 utr3 0.899 0.014 0.1261 0.717
Por utr3 1.626 0.0141 0.1261 0.619
Nrep utr3 0.912 0.0142 0.1261 1.108
Fgd4 utr3 1.734 0.0142 0.1261 2.047
Fem1b utr3 0.916 0.0144 0.1275 1.048
Atp2c1 utr3 1.121 0.0145 0.1275 1.888
Pgs1 utr3 1.346 0.0146 0.1275 0.264
Kcnd2 utr3 1.101 0.015 0.1298 0.76
Mapk9 utr3 0.923 0.0153 0.132 0.584
Sybu utr3 1.362 0.0158 0.1338 1.892
Ube2i utr3 1.302 0.0158 0.1338 1.058
Ptcd3 utr3 2.495 0.0158 0.1338 1.726
Hcrtr2 utr3 1.777 0.0159 0.1338 1.392
Fam160b1 utr3 1.05 0.0161 0.135 0.618
Cul4b utr3 1.127 0.0167 0.1383 0.91
Lysmd4 utr3 1.427 0.0174 0.1417 1.034
Lancl2 utr3 1.422 0.0174 0.1417 0.802
Cdc42se2 utr3 1.298 0.0177 0.1431 0.973
Klhl13 utr3 1.116 0.0178 0.1431 1.371
Pum1 utr3 0.954 0.0178 0.1431 1.235
Slc19a1 utr3 1.608 0.0185 0.1472 0.673
Zbtb5 utr3 1.155 0.0185 0.1472 0.408
Hoxa5 utr3 1.657 0.0187 0.1473 2.196
Blcap utr3 0.828 0.0188 0.1473 0.841
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gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Pspc1 utr3 1.233 0.0189 0.1473 1.47
Usp14 utr3 1.365 0.0195 0.1512 1.931
Fem1c utr3 1.484 0.0197 0.1513 1.591
Crocc utr3 1.415 0.0197 0.1513 0.717
Serinc1 utr3 0.939 0.02 0.1521 1.398
Trim37 utr3 0.922 0.0201 0.1525 1.137
Fsd1 utr3 1.982 0.0202 0.1527 1.923
Gnai1 utr3 0.967 0.0203 0.1527 1.362
Pnma2 utr3 1.009 0.0204 0.1528 0.646
Eid3 utr3 5.333 0.0205 0.1528 5.215
Tspan7 utr3 0.921 0.0207 0.1528 1.229
Pcdh17 utr3 0.982 0.0208 0.1531 1.314
Hnmt utr3 1.478 0.0212 0.1548 1.356
Grm7 utr3 1.239 0.0212 0.1548 1.149
Tomm20 utr3 1.059 0.0212 0.1548 0.716
Ccdc74a utr3 2.935 0.0213 0.1548 1.229
Dnaja1 utr3 1.006 0.0216 0.1565 1.097
Zdhhc13 utr3 1.393 0.0219 0.1575 0.699
8430427H17Rik utr3 0.852 0.0221 0.1575 0.271
Ube2d2a utr3 1.081 0.0221 0.1575 1.147
Rab11a utr3 1.083 0.0222 0.1575 1.175
Psd3 utr3 0.848 0.0222 0.1575 0.763
Srsf3 utr3 1.239 0.0223 0.1575 1.073
Kif26b utr3 1.101 0.0223 0.1575 0.621
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gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Reln utr3 1.257 0.0224 0.1575 1.672
Pbx3 utr3 1.017 0.0234 0.1618 0.787
Mir7226 utr3 4.795 0.0234 0.1618 3.003
Ppp1r12a utr3 1.189 0.0235 0.1625 1.001
Dmxl2 utr3 1.144 0.0241 0.1651 0.499
Gucy1b3 utr3 1.026 0.0247 0.1676 1.053
Srp72 utr3 1.113 0.025 0.169 0.992
Ambra1 utr3 1.096 0.0252 0.1697 0.291
Znfx1 utr3 1.37 0.0253 0.1697 0.363
Ranbp6 utr3 1.143 0.0254 0.1705 1.124
Myo5a utr3 0.791 0.0256 0.1708 0.377
Tmeff1 utr3 1.038 0.0258 0.1708 1.984
Pkia utr3 0.946 0.0258 0.1708 0.836
Pcdh11x utr3 1.071 0.0258 0.1708 1.499
Slc6a5 utr3 1.837 0.0263 0.1736 0.437
Hivep2 utr3 1.1 0.0267 0.1748 1.056
Ywhaq utr3 1.22 0.0268 0.1748 0.46
Cav2 utr3 1.092 0.0268 0.1748 1.97
Klf10 utr3 1.479 0.0269 0.1754 1.56
Sv2c utr3 0.949 0.0273 0.1765 0.818
Spryd7 utr3 1.234 0.0273 0.1765 1.107
Atp1b1 utr3 0.878 0.0274 0.1765 1.354
Cox14 utr3 1.319 0.0278 0.1779 0.408
Dnajb4 utr3 1.117 0.0282 0.1798 1.729
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gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Nova1 utr3 0.967 0.0288 0.18 1.719
Hcfc1 utr3 0.95 0.0288 0.18 1.065
Plch1 utr3 0.955 0.0288 0.18 0.661
Dnajb6 utr3 1.428 0.0292 0.18 2.583
Lmo3 utr3 0.928 0.0292 0.18 0.627
Jazf1 utr3 1.084 0.0293 0.18 1.141
Arl8b utr3 1.172 0.0294 0.18 0.877
Canx utr3 0.892 0.0294 0.18 0.828
Lztfl1 utr3 1.001 0.0303 0.1823 1.046
Desi2 utr3 1.023 0.0307 0.1833 0.412
Eif4g2 utr3 0.943 0.0307 0.1833 0.716
Syt13 utr3 0.899 0.0308 0.1833 0.347
Reep1 utr3 0.762 0.0309 0.1833 0.462
Arl6ip1 utr3 0.879 0.031 0.1837 0.869
Fam134b utr3 0.986 0.0313 0.1839 1.38
Cdk20 utr3 1.586 0.0316 0.1842 1.103
Agbl5 intron 1.185 1.23E-5 9e-04 0.498
Syn2 intron 0.994 1.24E-5 9e-04 0.937
Gm3086 intron 2.086 1.82E-5 0.0012 1.781
Apba3 intron 2.224 1.87E-5 0.0012 1.431
Cxadr intron 0.847 4.46E-5 0.0024 0.914
Etfb intron 1.349 1e-04 0.0044 0.746
Dohh intron 2.048 2e-04 0.0068 0.48
Nxt2 intron 2.367 3e-04 0.0075 1.367
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gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Dnajb1 intron 2.234 3e-04 0.008 1.005
Pisd-ps2 intron 1.368 3e-04 0.008 1.492
Nudt11 intron 2.043 4e-04 0.0084 1.692
Rac3 intron 1.146 5e-04 0.0104 0.547
Araf intron 1.084 7e-04 0.0116 0.989
Pcdha4-g intron 0.927 7e-04 0.0118 0.621
Mrps6 intron 1.144 7e-04 0.0118 0.579
Siva1 intron 1.866 8e-04 0.0123 0.642
Ufm1 intron 1.117 0.001 0.0152 0.372
Unc5b intron 0.907 0.0015 0.0195 0.422
Pomgnt2 intron 1.016 0.0018 0.0219 0.267
Rps27l cds 2.888 2.44E-6 0.0019 0.318
Rpl29 cds 1.472 1e-04 0.0307 0.693
Peli3 cds 1.378 3e-04 0.0521 1.17
Gtf3a cds 1.579 4e-04 0.0521 0.851
Rnf144a cds 1.437 4e-04 0.0521 0.454
Urm1 cds 1.514 8e-04 0.0765 0.73
Sfrp2 cds 1.829 8e-04 0.0765 1.631
Bckdha cds 1.041 0.001 0.0765 0.356
Rnf122 cds 1.451 0.0018 0.0991 0.36
Cbfa2t2 cds 1.054 0.0021 0.1005 0.599
Hist1h2bb cds 1.633 0.0022 0.1005 0.448
Hist1h2af cds 2.169 0.0027 0.113 1.092
Plod1 cds 1.088 0.0033 0.113 0.587
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gene feature logFCIP/input pIP/input FDR logFCIP/WTIP
Anapc16 cds 1.202 0.0035 0.113 0.336
Zc2hc1a utr5 3.118 6e-04 0.0298 1.533
Rrs1 utr5 3.327 0.0012 0.041 1.569
Table S5: Top Ranking Motif Cluster Matches Across UTR peaks
Gene.UTR_Peak: Gene name, alternate annotated UTR, identified peaks (if >1)
Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Pgap1_p6 + + - chr1 54479487 54479536 -
Zdbf2_p1 - + + chr1 63312283 63312332 +
Zdbf2_p2 + + + chr1 63314408 63314457 +
Dnm3 + + + chr1 161987589 161987638 -
Dnm3.1_p3 - + - chr1 161990860 161990909 -
Dnm3.1_p4 - + - chr1 161991885 161991934 -
Srp9_p1 - + - chr1 182132193 182132242 +
Plagl1_p2 + + + chr10 13131042 13131091 +
Cdk17_p1 + + - chr10 93240363 93240412 +
Plxnc1_p2 - + - chr10 94792253 94792302 -
Plxnc1_p3 - + - chr10 94792353 94792402 -
C1d - + + chr11 17266833 17266882 +
C1d_p1 - + + chr11 17267008 17267057 +
Mapk9 - + - chr11 49883571 49883620 +
Mapk9.1 - + - chr11 49883577 49883626 +
Mapk9.1_p1 - + - chr11 49883727 49883776 +
Mapk9_p1 - + - chr11 49883746 49883795 +
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Ube2b - + + chr11 51985958 51986007 -
Ube2b_p1 + + + chr11 51986433 51986482 -
Arf1 - + - chr11 59211649 59211698 -
Arf1_p1 - + - chr11 59212399 59212448 -
Myh10_p1 - + - chr11 68816284 68816333 +
Cltc + + + chr11 86694840 86694889 -
Cltc_p1 - + + chr11 86695315 86695364 -
Hap1.1 + + - chr11 100347464 100347513 -
Nsf_p1 - + - chr11 103822995 103823044 -
Dcaf7 - + - chr11 106055168 106055217 +
Dcaf7_p1 + + - chr11 106055418 106055467 +
Dcaf7_p3 + + - chr11 106058818 106058867 +
Dcaf7_p4 + + - chr11 106058993 106059042 +
Slc39a11 - + - chr11 113245117 113245166 -
Slc39a11_p1 - + - chr11 113245217 113245266 -
Pgs1.1 - + - chr11 118023467 118023516 +
Nrsn1_p1 + + + chr13 25252926 25252975 -
Dek_p1 - + - chr13 47085554 47085603 -
Ankra2.1 - + - chr13 98273796 98273845 +
Ankra2_p1 - + - chr13 98273797 98273846 +
Kif2a - + - chr13 106961697 106961746 -
Rab3c_p1 - + - chr13 110055774 110055823 -
Rab3c_p2 - + + chr13 110056049 110056098 -
Rab3c_p6 - + + chr13 110057674 110057723 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Synpr - + + chr14 13614319 13614368 +
Pcdh17 + + + chr14 84534745 84534794 +
Pcdh17_p2 - + - chr14 84535070 84535119 +
Pcdh17_p5 + + + chr14 84536395 84536444 +
Tmtc4_p2 - + - chr14 122919237 122919286 -
Tmtc4_p3 - + - chr14 122919912 122919961 -
Azin1 + + - chr15 38489117 38489166 -
Lrp12_p1 - + + chr15 39870990 39871039 -
Mpped1 + + - chr15 83856404 83856453 +
Slc25a1_p2 + + - chr16 17925673 17925722 -
Cd200 + + + chr16 45382422 45382471 -
App - + - chr16 84954948 84954997 -
Ttc3_p2 + + - chr16 94468988 94469037 +
Rgmb_p1 - + - chr17 15806865 15806914 -
Alkbh7 + + - chr17 56999080 56999129 +
Lpin2 - + - chr17 71247584 71247633 +
Lpin2_p2 - + - chr17 71249159 71249208 +
Socs5 - + + chr17 87135882 87135931 +
Rab18_p2 - + + chr18 6788868 6788917 +
Rab18_p3 + + + chr18 6788993 6789042 +
Rab18_p5 - + - chr18 6789468 6789517 +
Rab18_p6 - + + chr18 6789543 6789592 +
Slc39a6_p1 - + - chr18 24580368 24580417 -
Syt4 + + - chr18 31437845 31437894 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Syt4_p2 - + + chr18 31438645 31438694 -
Nrep + + + chr18 33437231 33437280 -
Nrep_p1 - + + chr18 33437956 33438005 -
Rnf14_p2 - + + chr18 38317600 38317649 +
Tle4 - + - chr19 14448284 14448333 -
Ranbp6 - + - chr19 29808495 29808544 -
Ranbp6_p2 - + - chr19 29809370 29809419 -
Htr7_p1 - + - chr19 35959491 35959540 -
Tnks2 - + - chr19 36891291 36891340 +
Tnks2_p1 - + - chr19 36892616 36892665 +
Tnks2_p2 - + - chr19 36892691 36892740 +
Tnks2_p3 + + - chr19 36892816 36892865 +
Fam160b1_p3 - + - chr19 57387414 57387463 +
Fam160b1_p5 - + - chr19 57387889 57387938 +
Zfp385b_p2 - + - chr2 77411839 77411888 -
Ube2e3 + + - chr2 78920493 78920542 +
Lin7c + + + chr2 109899289 109899338 +
Lin7c_p1 + + - chr2 109899764 109899813 +
Plcb1.1_p3 - + + chr2 135474540 135474589 +
Plcb1.2_p4 - + - chr2 135474543 135474592 +
8430427H17Rik - + + chr2 153407623 153407672 -
8430427H17Rik_p2 + + - chr2 153408823 153408872 -
Nbea_p1 + + + chr3 55625835 55625884 -
Gpr149 - + - chr3 62529950 62529999 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
B3galnt1_p1 - + + chr3 69574306 69574355 -
B3galnt1_p2 - + - chr3 69574831 69574880 -
Serpini1 - + - chr3 75640914 75640963 +
Serpini1_p2 - + - chr3 75642189 75642238 +
Glrb_p2 - + - chr3 80844736 80844785 -
Hipk1 + + + chr3 103740077 103740126 -
Hipk1_p1 + + + chr3 103741202 103741251 -
Fnbp1l - + - chr3 122539456 122539505 -
Fnbp1l_p1 + + - chr3 122540306 122540355 -
Cnr1_p3 - + - chr4 33946148 33946197 +
Cnr1_p5 - + - chr4 33948523 33948572 +
Dnaja1_p1 - + - chr4 40733359 40733408 +
Zbtb5_p1 - + + chr4 44992605 44992654 -
Zbtb5_p2 - + - chr4 44992680 44992729 -
Alg2 + + - chr4 47469995 47470044 -
Trim32 - + - chr4 65615563 65615612 +
Dnajc6 - + + chr4 101642286 101642335 +
Rnf11 - + - chr4 109452894 109452943 -
Rnf11_p2 - + - chr4 109453994 109454043 -
2510039O18Rik_p1 + + + chr4 147947006 147947055 +
Lrrc47 - + - chr4 154020139 154020188 +
Lrrc47_p1 - + - chr4 154020264 154020313 +
Lrrc47_p2 + + - chr4 154020364 154020413 +
Qdpr + + - chr5 45434394 45434443 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Atp8a1_p3 - + - chr5 67621426 67621475 -
Atp8a1_p4 - + - chr5 67621526 67621575 -
Ran - + - chr5 129022831 129022880 +
Ran_p1 - + - chr5 129024231 129024280 +
Peg10_p5 - + + chr6 4758564 4758613 +
Kcnd2_p3 - + + chr6 21729580 21729629 +
Reep1_p2 - + + chr6 71808239 71808288 +
Reep1_p3 + + + chr6 71809964 71810013 +
Grm7_p2 + + + chr6 111566505 111566554 +
Syn2 - + - chr6 115275162 115275211 +
Peg3 + + - chr7 6706522 6706571 -
Peg3_p1 - + - chr7 6706822 6706871 -
Ndn - + - chr7 62349523 62349572 +
Mkrn3 - + - chr7 62417905 62417954 -
Ubfd1_p2 + + - chr7 122079898 122079947 +
Vat1l + + - chr8 114371933 114371982 +
Atmin - + + chr8 116958247 116958296 +
Fem1b - + - chr9 62791917 62791966 -
Fem1b_p4 + + - chr9 62793592 62793641 -
Map2k1 - + + chr9 64185955 64186004 -
Myo5a_p4 - + + chr9 75220606 75220655 +
Tmem30a_p2 + + + chr9 79769953 79770002 -
Zic4_p1 + + - chr9 91388498 91388547 +
Spsb4 - + - chr9 96943719 96943768 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Wdr82_p1 - + - chr9 106189688 106189737 +
Atp6ap2 - + - chrX 12616486 12616535 +
Zcchc12 - + - chrX 36198878 36198927 +
Cul4b_p1 + + - chrX 38532083 38532132 -
Dcaf12l1_p1 - + - chrX 44787929 44787978 -
Slc9a6 - + - chrX 56663461 56663510 +
Slc9a6_p1 + + + chrX 56663661 56663710 +
Gpr101_p3 - + - chrX 57498055 57498104 -
Fgf13 + + - chrX 59062658 59062707 -
Gabrq.1_p1 - + - chrX 72841253 72841302 +
Mecp2_p1 + + + chrX 74028261 74028310 -
Mecp2_p2 + + - chrX 74028336 74028385 -
Mecp2_p9 + + + chrX 74035211 74035260 -
Magee1 - + - chrX 105123605 105123654 +
Tmem35 - + - chrX 134305178 134305227 +
Gprasp2 - + - chrX 135844487 135844536 +
Arxes2_p1 - + + chrX 135995039 135995088 +
Arxes1_p1 - + - chrX 136034461 136034510 +
Tceal1 - + + chrX 136709445 136709494 +
Morf4l2 + + - chrX 136733135 136733184 -
Pgap1 + - + chr1 54473087 54473136 -
Pgap1_p1 - - - chr1 54475187 54475236 -
Pgap1_p2 - - - chr1 54476087 54476136 -
Pgap1_p3 - - - chr1 54478587 54478636 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Pgap1_p4 + - - chr1 54479262 54479311 -
Pgap1_p5 - - - chr1 54479337 54479386 -
Pgap1_p7 - - - chr1 54480487 54480536 -
Zdbf2 - - + chr1 63311458 63311507 +
Scg2 + - - chr1 79435031 79435080 -
Dner + - + chr1 84370251 84370300 -
Dnm3_p1 - - + chr1 161988989 161989038 -
Dnm3_p2 + - - chr1 161989739 161989788 -
Dnm3.1 - - + chr1 161990560 161990609 -
Dnm3.1_p1 - - - chr1 161990660 161990709 -
Dnm3.1_p2 - - - chr1 161990785 161990834 -
Dnm3.1_p5 - - - chr1 161991960 161992009 -
Srp9 + - + chr1 182131793 182131842 +
Plagl1 + - + chr10 13130592 13130641 +
Plagl1_p1 + - - chr10 13130767 13130816 +
Ahi1 + - + chr10 21079899 21079948 +
Stx7 - - - chr10 24188133 24188182 +
Stx7_p1 - - + chr10 24188208 24188257 +
Stx7_p2 - - + chr10 24188708 24188757 +
Susd2_p1 - - - chr10 75637056 75637105 -
Susd2_p2 - - - chr10 75637156 75637205 -
Slc19a1_p1 - - - chr10 77049944 77049993 +
Lingo3 + - - chr10 80833713 80833762 -
Cdk17 - - + chr10 93240188 93240237 +
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Cdk17_p2 - - - chr10 93240438 93240487 +
Plxnc1 + - - chr10 94791778 94791827 -
Plxnc1_p1 + - - chr10 94791903 94791952 -
Syt1 - - + chr10 108497687 108497736 -
Syt1_p1 - - - chr10 108497787 108497836 -
Syt1_p2 - - - chr10 108498987 108499036 -
Syt1_p3 - - + chr10 108500312 108500361 -
Ddc - - - chr11 11814188 11814237 -
Mapk9.1_p2 - - - chr11 49884002 49884051 +
Mapk9_p2 + - + chr11 49884046 49884095 +
Mapk9.1_p3 - - - chr11 49884102 49884151 +
Ube2b_p2 - - - chr11 51986558 51986607 -
Arf1_p2 + - - chr11 59212449 59212498 -
Myh10 - - - chr11 68815509 68815558 +
Nsf + - - chr11 103821945 103821994 -
Dcaf7_p2 + - + chr11 106058043 106058092 +
Slc39a11_p3 - - - chr11 113246042 113246091 -
Slc39a11_p4 + - - chr11 113246117 113246166 -
Klhdc2 - - - chr12 69310639 69310688 +
Atl1 - - - chr12 69963651 69963700 +
Hsp90aa1 - - - chr12 110691373 110691422 -
Nrsn1 - - - chr13 25252151 25252200 -
Dek_p2 - - + chr13 47085829 47085878 -
Isca1 - - - chr13 59755702 59755751 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Isca1_p1 - - - chr13 59755902 59755951 -
Enc1.1_p1 - - - chr13 97251374 97251423 +
Enc1.1_p2 + - - chr13 97251999 97252048 +
Enc1.1_p3 - - - chr13 97252374 97252423 +
Ankra2 - - - chr13 98273397 98273446 +
Rab3c - - - chr13 110054974 110055023 -
Rab3c_p3 - - - chr13 110056199 110056248 -
Rab3c_p4 - - - chr13 110056474 110056523 -
Rab3c_p5 + - - chr13 110056974 110057023 -
Cadps - - + chr14 12372700 12372749 -
Cadps_p1 + - + chr14 12372875 12372924 -
Cadps_p2 - - - chr14 12372925 12372974 -
Synpr_p1 + - - chr14 13614469 13614518 +
Synpr_p2 - - + chr14 13614819 13614868 +
Synpr_p3 - - - chr14 13615319 13615368 +
Pspc1 - - - chr14 56722636 56722685 -
Pspc1_p1 + - - chr14 56722736 56722785 -
Pcdh17_p1 - - - chr14 84534920 84534969 +
Pcdh17_p3 - - + chr14 84535195 84535244 +
Pcdh17_p4 + - + chr14 84535270 84535319 +
Tmtc4 - - + chr14 122918987 122919036 -
Tmtc4_p1 - - - chr14 122919162 122919211 -
Plcxd3 + - - chr15 4575215 4575264 +
Azin1_p1 - - - chr15 38489567 38489616 -
172
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Lrp12 - - - chr15 39870890 39870939 -
Lrp12_p2 - - - chr15 39871265 39871314 -
Sybu - - - chr15 44672243 44672292 -
Mpped1_p2 - - + chr15 83858304 83858353 +
Cox14 - - - chr15 99727814 99727863 +
Atp6v1a - - - chr16 44087166 44087215 -
Cd200_p1 + - - chr16 45382597 45382646 -
Cd200_p2 + - - chr16 45382797 45382846 -
Ttc3 + - + chr16 94468488 94468537 +
Ttc3_p1 - - - chr16 94468738 94468787 +
Hmgn1 - - + chr16 96122000 96122049 -
Hmgn1_p1 - - - chr16 96122325 96122374 -
Rgmb - - - chr17 15806765 15806814 -
Syngr3 - - - chr17 24685679 24685728 -
Pja2_p1 - - - chr17 64281793 64281842 -
Pja2_p2 + - + chr17 64281943 64281992 -
Pja2_p3 - - - chr17 64283368 64283417 -
Lpin2_p1 - - - chr17 71248884 71248933 +
Socs5_p1 + - - chr17 87136357 87136406 +
Calm2 + - + chr17 87433813 87433862 -
Rab18 - - - chr18 6788643 6788692 +
Rab18_p1 - - + chr18 6788818 6788867 +
Rab18_p4 - - - chr18 6789168 6789217 +
Rab18_p7 - - - chr18 6789643 6789692 +
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Rab18_p8 - - - chr18 6789818 6789867 +
Impact + - - chr18 12991246 12991295 +
Slc39a6 - - - chr18 24580293 24580342 -
Slc39a6_p2 - - - chr18 24580543 24580592 -
Slc39a6_p3 - - - chr18 24580618 24580667 -
Rit2 + - + chr18 30975151 30975200 -
Syt4_p3 + - + chr18 31439245 31439294 -
Rnf14 - - - chr18 38316900 38316949 +
Rnf14_p1 + - - chr18 38317525 38317574 +
Fem1c + - + chr18 46504668 46504717 -
Tle4_p1 - - - chr19 14448459 14448508 -
Ranbp6_p1 - - - chr19 29809245 29809294 -
Uhrf2 + - + chr19 30093102 30093151 +
Uhrf2_p1 - - - chr19 30093177 30093226 +
Htr7 - - - chr19 35959116 35959165 -
Fam160b1 + - - chr19 57386564 57386613 +
Fam160b1_p1 - - + chr19 57387214 57387263 +
Fam160b1_p2 - - + chr19 57387289 57387338 +
Fam160b1_p6 - - - chr19 57388364 57388413 +
Fam160b1_p7 + - + chr19 57388464 57388513 +
Fam160b1_p8 - - - chr19 57388564 57388613 +
Fam160b1_p9 + - + chr19 57388814 57388863 +
Commd3 - - - chr2 18675914 18675963 +
Hnmt + - + chr2 24003125 24003174 -
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Top Ranking Motif Cluster Matches Across UTR peaks cont’d
Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Vav2 + - - chr2 27263747 27263796 -
Vav2_p1 - - - chr2 27264122 27264171 -
Olfm1 - - + chr2 28214094 28214143 +
Olfm1.1 + - - chr2 28230316 28230365 +
Gad1 - - - chr2 70601059 70601108 +
Gad1_p1 - - + chr2 70601809 70601858 +
Zfp385b + - + chr2 77411264 77411313 -
Zfp385b_p1 + - - chr2 77411339 77411388 -
Lin7c_p2 - - - chr2 109899964 109900013 +
Lin7c_p3 + - - chr2 109900089 109900138 +
Lin7c_p4 + - + chr2 109900239 109900288 +
Lin7c_p5 - - - chr2 109900364 109900413 +
Plcb1.1 - - - chr2 135472765 135472814 +
Plcb1.2 - - - chr2 135472768 135472817 +
Plcb1.1_p1 - - - chr2 135473190 135473239 +
Plcb1.2_p1 - - - chr2 135473193 135473242 +
Plcb1.2_p2 - - - chr2 135473343 135473392 +
Plcb1.1_p2 - - - chr2 135473390 135473439 +
Plcb1.2_p3 - - - chr2 135473393 135473442 +
Plcb1.1_p4 + - + chr2 135474740 135474789 +
Plcb1.2_p5 + - - chr2 135474743 135474792 +
Snap25 - - + chr2 136781456 136781505 +
Snap25_p1 - - - chr2 136782131 136782180 +
8430427H17Rik_p1 - - - chr2 153408373 153408422 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
8430427H17Rik_p3 + - - chr2 153409498 153409547 -
8430427H17Rik_p5 + - + chr2 153410823 153410872 -
Blcap - - - chr2 157556774 157556823 -
Blcap_p1 + - + chr2 157557474 157557523 -
Snx16 - - - chr3 10418729 10418778 -
Pcdh18 - - - chr3 49743383 49743432 -
Pcdh18_p1 - - + chr3 49743533 49743582 -
Ccrn4l + - + chr3 51251245 51251294 +
Nbea + - + chr3 55625760 55625809 -
Nbea_p2 - - - chr3 55626310 55626359 -
Pfn2 - - - chr3 57843007 57843056 -
Gpr149_p1 - - - chr3 62530125 62530174 -
B3galnt1 - - - chr3 69574206 69574255 -
Serpini1_p1 - - - chr3 75641864 75641913 +
Glrb - - - chr3 80844411 80844460 -
Glrb_p1 + - - chr3 80844536 80844585 -
Hipk1_p2 - - - chr3 103741877 103741926 -
Hipk1_p3 + - + chr3 103742202 103742251 -
Hipk1_p4 - - - chr3 103742377 103742426 -
Fnbp1l_p2 - - - chr3 122540431 122540480 -
Prkacb - - - chr3 146729941 146729990 -
Prkacb_p1 - - - chr3 146730891 146730940 -
Prkacb_p2 + - - chr3 146731141 146731190 -
Prkacb_p3 + - + chr3 146732291 146732340 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Penk - - - chr4 4133698 4133747 -
Cnr1 - - - chr4 33945148 33945197 +
Cnr1_p1 - - - chr4 33945648 33945697 +
Cnr1_p2 + - - chr4 33945973 33946022 +
Cnr1_p4 - - - chr4 33948048 33948097 +
Cnr1_p6 - - + chr4 33948598 33948647 +
Dnaja1 - - - chr4 40732934 40732983 +
Dnaja1_p2 - - - chr4 40733709 40733758 +
Zbtb5 - - - chr4 44992130 44992179 -
Zbtb5_p3 - - - chr4 44993330 44993379 -
Trim32_p1 - - - chr4 65615663 65615712 +
Rraga + - - chr4 86576973 86577022 +
Rnf11_p1 - - - chr4 109453219 109453268 -
Rnf11_p3 - - + chr4 109454069 109454118 -
Pum1 + - - chr4 130779916 130779965 +
Pum1_p1 - - - chr4 130781241 130781290 +
Crocc - - - chr4 141016974 141017023 -
2510039O18Rik + - + chr4 147946806 147946855 +
2510039O18Rik_p2 - - - chr4 147947056 147947105 +
Atp8a1 + - + chr5 67620376 67620425 -
Atp8a1_p1 + - + chr5 67620426 67620475 -
Atp8a1_p2 + - - chr5 67621326 67621375 -
Atp8a1_p5 + - + chr5 67621776 67621825 -
Atp8a1_p6 - - - chr5 67622026 67622075 -
177
Top Ranking Motif Cluster Matches Across UTR peaks cont’d
Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Por - - - chr5 135734970 135735019 +
Peg10_p2 - - - chr6 4756439 4756488 +
Peg10.1 - - - chr6 4757478 4757527 +
Peg10_p3 - - - chr6 4757489 4757538 +
Peg10.1_p1 - - + chr6 4757628 4757677 +
Peg10_p4 - - + chr6 4757639 4757688 +
Peg10.1_p2 - - + chr6 4758628 4758677 +
Peg10_p6 + - + chr6 4758689 4758738 +
Nxph1 - - - chr6 9248009 9248058 +
Kcnd2 - - - chr6 21727330 21727379 +
Kcnd2_p1 + - + chr6 21728280 21728329 +
Kcnd2_p2 - - + chr6 21728380 21728429 +
Nap1l5 - - - chr6 58905570 58905619 -
Reep1 - - - chr6 71807789 71807838 +
Reep1_p1 - - - chr6 71808039 71808088 +
Reep1_p4 + - - chr6 71810389 71810438 +
Grm7 - - - chr6 111566230 111566279 +
Grm7_p1 - - + chr6 111566330 111566379 +
Grm7_p3 - - + chr6 111566905 111566954 +
Syn2_p1 + - + chr6 115276137 115276186 +
Syn2_p2 - - + chr6 115276437 115276486 +
Syn2.1 + - - chr6 115281711 115281760 +
Zdhhc13 - - + chr7 48826995 48827044 +
Mkrn3_p1 + - + chr7 62418305 62418354 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Ubfd1_p1 + - + chr7 122079673 122079722 +
Ubfd1_p3 + - - chr7 122080048 122080097 +
Ubfd1_p4 + - - chr7 122080573 122080622 +
Ubfd1_p5 - - + chr7 122081048 122081097 +
Carkd - - + chr8 11513158 11513207 +
Tmem66 - - - chr8 34170659 34170708 +
Gpm6a + - + chr8 55060492 55060541 +
Psd3 - - - chr8 67689569 67689618 -
Psd3_p1 - - - chr8 67691819 67691868 -
Psd3_p2 - - - chr8 67692969 67693018 -
Psd3_p3 + - - chr8 67693044 67693093 -
Psd3_p4 + - + chr8 67693144 67693193 -
Psd3_p5 + - + chr8 67693819 67693868 -
Psd3_p6 + - - chr8 67694369 67694418 -
Psd3_p7 + - + chr8 67695094 67695143 -
Psd3_p8 - - - chr8 67695294 67695343 -
Psd3_p9 - - - chr8 67695969 67696018 -
Psd3_p10 - - - chr8 67696569 67696618 -
Scoc - - - chr8 83435479 83435528 -
Itfg1 - - - chr8 85718519 85718568 -
Atmin_p2 + - - chr8 116960297 116960346 +
AW551984 - - - chr9 39588383 39588432 -
AW551984_p1 + - - chr9 39588608 39588657 -
AW551984_p2 - - - chr9 39588783 39588832 -
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Gene.UTR_Peak Pcbp3 Celf U-rich chr start stop strand
Nptn.1 + - - chr9 58652071 58652120 +
Nptn.1_p1 - - - chr9 58652346 58652395 +
Fem1b_p1 - - - chr9 62791967 62792016 -
Fem1b_p2 + - + chr9 62792217 62792266 -
Fem1b_p3 - - - chr9 62792467 62792516 -
Fem1b_p5 - - - chr9 62793967 62794016 -
Map2k1_p1 + - - chr9 64186130 64186179 -
Myo5a - - - chr9 75217981 75218030 +
Myo5a_p1 - - - chr9 75218731 75218780 +
Myo5a_p2 + - - chr9 75220156 75220205 +
Myo5a_p3 + - - chr9 75220506 75220555 +
Myo5a_p5 + - - chr9 75220731 75220780 +
Myo5a_p6 - - - chr9 75220881 75220930 +
Myo5a_p7 + - - chr9 75221506 75221555 +
Myo5a_p8 - - + chr9 75222331 75222380 +
Myo5a_p9 - - - chr9 75222781 75222830 +
Tmem30a - - - chr9 79769703 79769752 -
Tmem30a_p1 + - - chr9 79769828 79769877 -
Tmem30a_p3 - - + chr9 79770203 79770252 -
Tmem30a_p4 - - - chr9 79770653 79770702 -
Zic4 - - - chr9 91387348 91387397 +
Zic4_p2 - - - chr9 91388873 91388922 +
Spsb4_p1 + - - chr9 96944019 96944068 -
Spsb4_p2 + - - chr9 96944144 96944193 -
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Spsb4_p3 - - - chr9 96944494 96944543 -
Atp2c1 - - + chr9 105411624 105411673 -
Wdr82 + - - chr9 106189538 106189587 +
Wdr82_p2 + - - chr9 106190213 106190262 +
Epm2aip1 + - - chr9 111276194 111276243 +
Epm2aip1_p1 - - + chr9 111276444 111276493 +
Epm2aip1_p2 + - - chr9 111276594 111276643 +
Epm2aip1_p3 + - + chr9 111276969 111277018 +
Epm2aip1_p4 + - + chr9 111278944 111278993 +
Zcchc12_p1 - - - chrX 36198953 36199002 +
Cul4b + - - chrX 38532008 38532057 -
Cul4b_p3 - - - chrX 38532708 38532757 -
Dcaf12l1 + - + chrX 44787579 44787628 -
Gpr101 - - + chrX 57497705 57497754 -
Gpr101_p1 + - - chrX 57497805 57497854 -
Gpr101_p2 - - + chrX 57497955 57498004 -
Gpr101_p4 - - + chrX 57498255 57498304 -
Gpr101_p5 - - - chrX 57498605 57498654 -
Gpr101_p6 + - + chrX 57499330 57499379 -
Gpr101_p7 + - - chrX 57500105 57500154 -
Gabrq.1 - - - chrX 72839928 72839977 +
Gabrq.1_p2 + - - chrX 72841503 72841552 +
Mecp2 + - + chrX 74028086 74028135 -
Mecp2_p3 + - - chrX 74032061 74032110 -
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Mecp2_p4 - - - chrX 74032736 74032785 -
Mecp2_p6 - - - chrX 74033186 74033235 -
Mecp2_p7 - - + chrX 74033986 74034035 -
Pgr15l - - + chrX 97079888 97079937 +
Pgr15l_p1 + - - chrX 97080038 97080087 +
Pgr15l_p2 + - + chrX 97080263 97080312 +
Pgr15l_p3 - - - chrX 97081088 97081137 +
Pgr15l_p4 - - - chrX 97081663 97081712 +
Nap1l2 - - - chrX 103184646 103184695 -
Nap1l3 - - - chrX 122395023 122395072 -
Arxes2 - - + chrX 135994989 135995038 +
Arxes1 - - + chrX 136034036 136034085 +
Zcchc18 + - - chrX 136996132 136996181 +
Irs4 - - - chrX 141711060 141711109 -
Irs4_p1 - - - chrX 141711635 141711684 -
Irs4_p2 - - - chrX 141711985 141712034 -
Htr2c - - - chrX 147195133 147195182 +
Htr2c_p1 - - - chrX 147195283 147195332 +
Htr2c_p2 + - - chrX 147195883 147195932 +
Shroom2 - - - chrX 152610321 152610370 -
Shroom2_p1 + - + chrX 152610946 152610995 -
Rragb - - + chrX 153171651 153171700 +
Ubqln2 - - + chrX 153500908 153500957 +
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Table S6: PTRE-Seq - Effects on Expression
Terms shown: Main effect of sequence (reference or mutant), Main effect of condition (CELF overexpression or CTL),Interaction between sequence and condition.
FDR is shown for sequence x condition interactions
p % variance explained
Gene.UTR_Peak sequence condition interaction R2 sequence condition interaction within samples unexplained FDR
Fgf13 1.41E-62 5.51E-38 2e-04 66.48% 23.33% 40.76% 2.34% 4.1% 29.47% 1.03E-61
Magee1 6.06E-188 1.42E-20 1.92E-16 75.36% 51.67% 18.27% 5.37% 3.42% 21.27% 2.14E-186
Plcxd3 3.13E-38 6.22E-11 0.8759 38.45% 26.48% 11.46% 0.49% 0.85% 60.72% 1.26E-37
Ddc 1.65E-177 3.97E-8 0.6832 69.18% 64.94% 3.84% 0.39% <0.01% 30.84% 4.37E-176
Mkrn3 1.06E-100 3.02E-6 2.6E-6 57.47% 41.81% 12.11% 3.53% 7.24% 35.32% 1.21E-99
Mkrn3_p1 3.77E-48 0.1221 0.5946 36.94% 33.06% 3.02% 0.86% 3.49% 59.57% 1.86E-47
Carkd 5.55E-19 0.0435 0.8034 23.41% 19.02% 3.47% 0.91% 0% 76.6% 1.41E-18
Nap1l3 0.4012 1.32E-10 0.092 25.26% 0.15% 22.42% 2.69% 4.88% 69.86% 0.4264
Pgr15l 0.1286 0.412 0.8656 3.2% 0.58% 1.81% 0.81% 0% 96.8% 0.1435
Pgr15l_p1 1.64E-180 1.86E-5 0.3659 65.27% 51.19% 13.57% 0.48% 10.83% 23.93% 4.95E-179
Pgr15l_p2 5.79E-10 0.0133 0.9723 14.15% 9.39% 4.33% 0.43% <0.01% 85.85% 1.07E-9
Pgr15l_p3 7.62E-8 0.7091 0.4398 10.34% 7.31% 1.28% 1.74% 0.82% 88.84% 1.25E-7
Slc39a6 4.66E-25 3.59E-24 4.2E-5 45.29% 16.28% 24.12% 4.86% 1.23% 53.5% 1.37E-24
Slc39a6_p1 1.78E-59 6.12E-7 0.2513 47.78% 37.68% 8.8% 1.28% 2.2% 50.03% 1.15E-58
Slc39a6_p2 7.57E-43 2.18E-7 0.0351 39.76% 29.02% 8.4% 2.32% 1.19% 59.07% 3.34E-42
Slc39a6_p3 ~0 2.11E-23 1.62E-35 85.34% 71.06% 7.01% 7.24% 0.54% 14.15% ~0
Trim32 8.03E-181 4e-04 1.75E-11 71.88% 61.56% 5.47% 4.83% 4.23% 23.9% 2.62E-179
Trim32_p1 6.62E-77 1.64E-21 1e-04 58.13% 41.09% 13.54% 3.47% <0.01% 41.9% 5.84E-76
Gpr149 2.35E-17 8.41E-9 1.98E-10 32.87% 12.44% 10.14% 10.28% 0.8% 66.34% 5.64E-17
Gpr149_p1 5.77E-11 0.0558 0.8073 17.39% 12.35% 3.96% 1.08% 0% 82.62% 1.1E-10
Tceal1 3.26E-79 0.0134 0.1449 56.79% 51.92% 3.27% 1.58% 1.24% 41.98% 2.94E-78
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Gprasp2 3.59E-56 3.12E-10 0.001 48.62% 36.49% 8.54% 3.57% 0% 51.39% 2.15E-55
Gad1 0.6579 0.009 0.9142 13.56% 0.04% 12.92% 0.6% 14.8% 71.64% 0.6821
Gad1_p1 5.52E-34 0.0212 0.0479 35.86% 29.7% 3.31% 2.85% <0.01% 64.14% 1.98E-33
Zcchc12 7.04E-26 1.32E-11 0.4131 34.28% 20.71% 12.22% 1.34% 0% 65.73% 2.1E-25
Zcchc12_p1 1.59E-22 0.0374 0.045 28.28% 20.38% 4.83% 3.07% 3.52% 68.2% 4.41E-22
Klhdc2 3e-04 0.0491 0.4923 8.86% 3.02% 4.36% 1.48% 2.47% 88.66% 4e-04
Lrrc47 4.76E-33 0.0023 0.0153 36.91% 25.72% 8.07% 3.11% 5.88% 57.23% 1.64E-32
Lrrc47_p1 0.0193 2.34E-5 0.6748 15.2% 1.57% 12.23% 1.4% 2.58% 82.22% 0.0233
Lrrc47_p2 7.7E-38 1.67E-9 4.69E-5 41.77% 27.43% 9.08% 5.25% 0% 58.25% 3.02E-37
Alg2 ~0 4.41E-58 3.41E-44 86.05% 62.51% 15.83% 7.66% 0.66% 13.34% ~0
Arxes1_p1 8.53E-59 2.25E-6 0.1049 47.05% 39.42% 5.83% 1.79% 0% 52.96% 5.32E-58
Snca 5.15E-10 0.1305 0.5689 13.67% 9.5% 2.75% 1.41% <0.01% 86.34% 9.54E-10
Syn2 5.87E-69 1.83E-19 6e-04 53.3% 37.55% 12.64% 3.09% 0% 46.72% 4.79E-68
Syn2_p2 1.18E-13 1.53E-14 0.9021 28.61% 11.14% 16.89% 0.57% 0.3% 71.1% 2.53E-13
Syn2.1 0.0143 0.0017 0.0392 11.08% 1.52% 5.82% 3.74% 0% 88.93% 0.0173
Rragb 1.2E-43 0.0046 0.5271 40.65% 35.7% 3.81% 1.14% 0% 59.35% 5.42E-43
Nap1l2 1.8E-116 4.96E-14 4.88E-11 68.15% 44.35% 18.49% 5.25% 4.95% 26.95% 2.38E-115
Tmtc4 3.55E-146 0.0361 0.3886 65.47% 62.72% 2.04% 0.7% 1.32% 33.22% 6.28E-145
Tmtc4_p1 7.95E-34 0.5793 0.8662 28.6% 26.65% 1.37% 0.58% 1.96% 69.44% 2.81E-33
Tmtc4_p2 2.17E-105 0.0633 2.42E-17 57.23% 44.31% 4.21% 8.7% 7.08% 35.7% 2.56E-104
Tmtc4_p3 3.02E-11 2.05E-9 0.8204 25.94% 10.02% 15.08% 0.83% 1.62% 72.45% 5.84E-11
Zfp385b 7.58E-14 4e-04 0.3586 24.03% 12.52% 9.78% 1.73% 4.53% 71.45% 1.63E-13
Zfp385b_p1 2.49E-19 2e-04 0.0017 34.15% 20.87% 7.34% 5.93% 0% 65.86% 6.36E-19
Zfp385b_p2 6.51E-138 7.5E-6 0.5434 65.51% 61.39% 3.52% 0.59% <0.01% 34.5% 1.1E-136
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Zdbf2 3.13E-55 6.03E-6 0.0156 45.98% 37.71% 5.6% 2.66% 0% 54.03% 1.82E-54
Zdbf2_p1 6.55E-31 0.5821 0.9957 32.82% 31.28% 1.32% 0.22% 0% 67.18% 2.12E-30
Zdbf2_p2 1.39E-47 1.11E-24 8e-04 50.88% 29.37% 18.02% 3.46% 0% 49.15% 6.8E-47
Arxes2 1.24E-7 0.4597 0.045 13.53% 7.22% 2.6% 3.71% 4.14% 82.34% 2E-7
Arxes2_p1 5.39E-59 0.5829 0.9109 45.66% 44.14% 1.06% 0.45% 0.67% 53.68% 3.41E-58
Penk 2.1E-11 3.25E-10 3e-04 25.43% 8.74% 11.36% 5.33% 0% 74.58% 4.12E-11
Atl1 9.92E-27 4.19E-6 0.0476 32.98% 21.27% 9.06% 2.64% 1.84% 65.2% 3E-26
Snx16 0.0382 0.1214 0.813 5.92% 1.01% 4.04% 0.87% 3.76% 90.32% 0.0451
Dcaf12l1 7.44E-30 0.2444 0.5463 27.31% 24.45% 1.73% 1.13% 0% 72.69% 2.32E-29
Dcaf12l1_p1 0.0284 0.0098 0.2053 10.33% 1.5% 5.79% 3.03% <0.01% 89.67% 0.0338
Synpr 5.25E-54 0.8101 0.0026 41.57% 36.51% 1.71% 3.35% 9.79% 48.64% 2.93E-53
Synpr_p1 1.67E-33 0.0198 0.8463 32.1% 27.5% 3.95% 0.64% 1.55% 66.36% 5.87E-33
Synpr_p2 0.0039 2e-04 3.71E-8 18.1% 1.78% 6.07% 10.24% 0% 81.9% 0.005
Cd200 7.48E-14 0.004 0.9559 19.81% 14.06% 5.23% 0.52% 0% 80.19% 1.62E-13
Cd200_p1 0.0069 1.07E-5 0.5173 14.49% 2.18% 10.46% 1.84% <0.01% 85.52% 0.0086
Cd200_p2 2.38E-151 2.06E-5 0.429 67.45% 63.68% 3.11% 0.65% 0% 32.56% 4.59E-150
Ndn 6.28E-39 2.1E-8 3.63E-7 43.41% 22.75% 14.93% 5.71% 5.43% 51.18% 2.63E-38
AW551984 3.67E-44 0.0017 0.6153 43.61% 36.27% 6.32% 1% 2.8% 53.61% 1.69E-43
AW551984_p1 6.17E-7 0.233 0.8339 9.69% 6.4% 2.39% 0.9% 0% 90.31% 9.79E-7
Ankra2 0.1558 0.0696 0.9395 12.04% 0.35% 11.29% 0.4% 22% 65.96% 0.1707
Ankra2_p1 0.0058 0.0325 0.015 13.21% 2.22% 5.91% 5.08% 3.02% 83.78% 0.0073
Ankra2.1 4.05E-8 0.7013 0.2419 12.14% 7.93% 1.8% 2.41% 3.94% 83.93% 6.71E-8
Rraga 3.99E-38 5e-04 1.54E-7 45.29% 31.77% 4.99% 8.52% <0.01% 54.72% 1.6E-37
Irs4 5.67E-109 0.4301 9e-04 60.4% 56.11% 1.5% 2.79% 3.2% 36.4% 7.28E-108
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Irs4_p1 3.94E-43 0.1778 0.9734 34.47% 32.43% 1.74% 0.3% 0% 65.53% 1.76E-42
Irs4_p2 0.0079 0.0191 0.5271 7.85% 1.85% 4.4% 1.6% 0% 92.15% 0.0098
Dek 5.33E-12 0.1305 0.2045 18.03% 11.75% 3.87% 2.4% 3.15% 78.82% 1.08E-11
Dek_p1 1.34E-9 0.0045 0.2018 19.25% 7.57% 9.66% 2.01% 8.42% 72.33% 2.42E-9
Dek_p2 5.37E-108 0.1844 0.0015 56.05% 51.41% 2.18% 2.46% 3.55% 40.41% 6.7E-107
Rit2 8.59E-46 3.97E-6 0.4564 40.8% 28.4% 11.44% 0.95% 5.28% 53.94% 4.05E-45
Pcdh18 ~0 0.3564 8.55E-8 82.73% 79.87% 0.92% 1.94% 2.44% 14.84% ~0
Pcdh18_p1 1.39E-9 0.0247 0.1786 15.47% 7.65% 5.7% 2.12% 4.7% 79.83% 2.5E-9
Hsp90aa1 0.0706 0.8391 0.9818 2.79% 1.11% 1.17% 0.51% 0% 97.21% 0.0805
C1d 1.3E-17 0.7183 0.0454 19.26% 15.19% 1.09% 2.98% 1.03% 79.71% 3.17E-17
C1d_p1 1.05E-7 0.0212 0.3052 13.13% 7% 4.07% 2.06% 0% 86.87% 1.71E-7
Alkbh7 2.88E-6 0.4154 0.1414 11.25% 6% 2.26% 2.99% 1.39% 87.36% 4.43E-6
Gabrq.1 3.15E-20 6.09E-6 0.0383 26.7% 16.06% 7.83% 2.8% 0.83% 72.48% 8.14E-20
Gabrq.1_p1 5.75E-37 0.1359 0.002 33.38% 26.65% 2.99% 3.74% 3.36% 63.26% 2.12E-36
Nap1l5 0.001 0.1613 0.5184 8.73% 3.41% 3.34% 1.97% <0.01% 91.27% 0.0014
Htr2c_p1 2.38E-7 6.76E-5 0.8587 16% 7.03% 8.11% 0.86% 0% 84% 3.82E-7
Htr2c_p2 1.8E-65 2.2E-26 6.84E-12 58.54% 34.48% 16.16% 7.87% 0% 41.49% 1.38E-64
Commd3 0.0055 0.4373 0.0611 8.3% 2.17% 2.33% 3.8% 1.72% 89.98% 0.007
Fnbp1l 3.64E-24 0.0034 0.0039 33.57% 23.8% 4.92% 4.84% <0.01% 66.44% 1.04E-23
Fnbp1l_p1 3.21E-16 0.3059 0.4381 18.92% 15.4% 1.92% 1.6% <0.01% 81.08% 7.4E-16
Fnbp1l_p2 3.25E-24 5.73E-8 0.0044 33.67% 16.76% 13.54% 3.35% 4.02% 62.32% 9.31E-24
Ccrn4l 0.0124 2.64E-7 0.0019 15.93% 1.37% 9.56% 5% 0% 84.07% 0.0152
Dner 6.45E-8 3.45E-11 0.5483 23.69% 6.98% 15.29% 1.41% 0.1% 76.21% 1.06E-7
Syt4 6.34E-10 0.0024 7e-04 19.56% 8.76% 5.06% 5.74% 0% 80.44% 1.16E-9
186
PTRE-Seq - Effects on Expression Cont’d
Gene.UTR_Peak sequence condition interaction R2 sequence condition interaction within samples unexplained FDR
Syt4_p3 1.66E-8 2.69E-6 0.991 16.89% 7.54% 9.06% 0.28% 0% 83.11% 2.85E-8
Sybu 4.45E-53 8.69E-12 0.6853 44.42% 34.12% 9.6% 0.69% 0% 55.59% 2.42E-52
Tnks2 4.76E-60 0.0196 1.26E-13 47.67% 34.16% 3.89% 9.61% 3.36% 48.98% 3.15E-59
Tnks2_p1 4.79E-56 0.021 2.23E-11 45.98% 34.18% 2.99% 8.8% 1.4% 52.62% 2.82E-55
Tnks2_p2 1.73E-126 6.64E-5 0.9511 65.37% 61.45% 3.67% 0.23% 0.38% 34.27% 2.44E-125
Zcchc18 0.0071 0.0584 0.8686 6.54% 1.92% 3.78% 0.84% 0.4% 93.05% 0.0088
Map2k1 6e-04 1.48E-19 0.1715 26.45% 2.47% 21.83% 2.16% <0.01% 73.55% 8e-04
Map2k1_p1 3.83E-11 0.614 0.0622 15.12% 10.57% 1.3% 3.25% <0.01% 84.88% 7.35E-11
Glrb_p2 0.1669 0.2188 0.7591 4.66% 0.57% 2.84% 1.25% <0.01% 95.34% 0.1819
Olfm1.1 6.48E-18 2.76E-46 7.61E-8 55.08% 11.63% 36.18% 7.24% 0% 44.95% 1.61E-17
Nrsn1 8.09E-9 1.04E-6 0.5903 29.72% 5.4% 23.41% 0.9% 13.3% 56.99% 1.42E-8
Nrsn1_p1 4.97E-47 3.01E-8 3.31E-9 50.46% 29.3% 13.62% 7.51% 4.48% 45.08% 2.39E-46
Epm2aip1 0.1202 0.137 0.9518 3.91% 0.61% 2.77% 0.54% 0% 96.09% 0.1348
Epm2aip1_p1 1.97E-148 0.0037 0.6417 64.62% 62.19% 1.94% 0.47% <0.01% 35.39% 3.63E-147
Epm2aip1_p2 1.01E-15 3.07E-9 0.6988 33.36% 10.82% 21.73% 0.79% 7.62% 59.03% 2.28E-15
Epm2aip1_p3 5.52E-15 0.4225 0.9785 21.47% 18.8% 2.17% 0.49% 0% 78.53% 1.23E-14
Epm2aip1_p4 1.42E-193 7.06E-26 3.15E-11 76.07% 40.78% 32.29% 2.93% 6.19% 17.81% 6.02E-192
Tle4 1.41E-37 2.13E-5 0.2779 37.02% 29.45% 6.01% 1.55% 0% 62.99% 5.5E-37
Tle4_p1 7.53E-22 0.0066 3.94E-5 27.7% 16.88% 4.96% 5.86% 2.26% 70.05% 2.03E-21
Snap25 6.59E-7 0.4014 0.0605 11.3% 5.28% 3.14% 2.88% 6.99% 81.71% 1.04E-6
Snap25_p1 0.0049 1.06E-11 0.1573 27.46% 1.37% 24.26% 1.83% 6.25% 66.29% 0.0062
Cnr1 0.0614 0.0219 0.2675 8.25% 1.01% 4.71% 2.53% <0.01% 91.75% 0.0706
Cnr1_p4 0.1544 1e-04 0.8457 8.3% 0.49% 7% 0.81% 0% 91.7% 0.17
Cnr1_p5 2.15E-169 1.38E-11 1.02E-13 70.05% 53.26% 11.53% 5.23% 3.44% 26.54% 5.36E-168
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Cnr1_p6 0.974 1.12E-6 0.3756 14.58% <0.01% 12.6% 1.98% 1.6% 83.83% 0.9763
Plagl1 2e-04 1.11E-5 0.0372 14.3% 3.12% 7.84% 3.34% 0% 85.71% 3e-04
Plagl1_p1 2.55E-9 0.0557 0.2314 15.51% 9.4% 3.64% 2.46% <0.01% 84.49% 4.54E-9
Plagl1_p2 1.12E-99 5.24E-7 2e-04 57.55% 49.78% 4.65% 3.11% 0% 42.47% 1.24E-98
Impact 8.83E-22 1.83E-11 0.2155 39.02% 14.25% 23.28% 1.48% 6.56% 54.44% 2.37E-21
Tmem35 7.54E-165 1.61E-6 6.52E-15 72.27% 59.82% 5.92% 6.51% 2.25% 25.51% 1.78E-163
Atp2c1 2.11E-6 4.72E-10 0.3188 35.84% 2.98% 31.78% 1.08% 13.4% 50.76% 3.25E-6
Fem1c 5.66E-96 7.3E-6 0.3183 57.57% 52.23% 4.34% 0.99% 0% 42.44% 6E-95
Qdpr 4.02E-7 0.053 0.0107 15.36% 6.82% 3.69% 4.85% <0.01% 84.64% 6.44E-7
Stx7 4.56E-62 8.86E-10 0.4698 46.96% 38.27% 7.77% 0.92% 0% 53.05% 3.22E-61
Stx7_p1 2.3E-268 5.07E-26 2.27E-32 79.96% 62.74% 8.73% 8.46% 0.43% 19.65% 1.63E-266
Stx7_p2 1.02E-5 0.0284 0.8128 11.92% 5.98% 4.8% 1.14% 0% 88.08% 1.55E-5
Enc1.1 5.04E-21 1.93E-7 0.3437 29.24% 17.61% 10.06% 1.57% 0.91% 69.85% 1.33E-20
Enc1.1_p1 0.0023 0.1353 0.6598 8.13% 2.58% 4.16% 1.39% 3.1% 88.77% 0.0031
Enc1.1_p2 1.01E-80 2e-04 0.1638 58.22% 52.48% 4.21% 1.51% 0.18% 41.62% 9.29E-80
Enc1.1_p3 9.01E-11 1.66E-29 0.7954 47.35% 5.79% 41.01% 0.53% 4.22% 48.45% 1.7E-10
Peg3_p1 3.37E-84 2.57E-10 1.91E-10 60.92% 45.84% 7.85% 7.2% 0.39% 38.71% 3.33E-83
Scoc 5.71E-22 7.38E-12 2.24E-15 40.93% 15.62% 11.2% 14.1% 0% 59.08% 1.55E-21
Rab18_p1 3.69E-53 1.14E-5 0.0607 44.72% 37.09% 5.5% 2.12% 0% 55.29% 2.03E-52
Rab18_p2 0.4696 0.0282 0.1328 7.89% 0.15% 4.53% 3.21% 0% 92.11% 0.4929
Rab18_p3 8.65E-58 0.0382 0.265 46.27% 41.36% 3.48% 1.42% 2.35% 51.39% 5.32E-57
Rab18_p4 2.22E-11 0.1212 0.9392 18.67% 14.28% 3.64% 0.74% <0.01% 81.34% 4.32E-11
Rab18_p5 3.95E-208 4.04E-32 1.63E-41 79.08% 55.85% 10.92% 12.27% 0.24% 20.72% 1.86E-206
Rab18_p6 2.95E-16 0.7679 0.9043 17.36% 15.74% 0.97% 0.65% <0.01% 82.64% 6.83E-16
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Rab18_p7 0.8295 0.0841 0.9956 4.5% 0.02% 4.17% 0.32% 0% 95.5% 0.8475
Rab18_p8 3.16E-11 0.0331 0.5144 17.04% 11.46% 3.96% 1.62% <0.01% 82.96% 6.09E-11
Ube2e3 2.64E-13 0.137 0.3587 20.1% 14.88% 3.07% 2.15% <0.01% 79.9% 5.57E-13
Ttc3 3.03E-35 1.97E-8 0.5604 40.19% 24.01% 15.25% 0.91% 4.88% 54.96% 1.1E-34
Ttc3_p2 1.62E-5 9.19E-21 0.3329 42.78% 2.42% 39.31% 1.04% 7.24% 49.98% 2.44E-5
Lin7c 0.0206 1.49E-10 0.6379 18.7% 1.22% 16.3% 1.18% 1.4% 79.91% 0.0247
Lin7c_p3 3.85E-8 0.0028 0.0636 17% 7.86% 5.66% 3.48% 0% 83% 6.42E-8
Lin7c_p4 2.53E-74 0.2992 0.9766 51.79% 50.27% 1.27% 0.25% 0% 48.21% 2.1E-73
Lin7c_p5 1.54E-6 0.4142 0.9026 9.39% 6.56% 2.03% 0.8% <0.01% 90.61% 2.4E-6
Gpr101_p1 0.9667 0.0174 0.5901 8.92% <0.01% 7.42% 1.5% 5.35% 85.74% 0.9713
Gpr101_p2 6.77E-15 1.54E-17 0.0011 44.36% 10.88% 29.13% 4.33% 4.12% 51.55% 1.5E-14
Gpr101_p3 7.7E-87 5.84E-14 7.83E-7 60.12% 41.57% 14.14% 4.37% 2.47% 37.45% 7.96E-86
Gpr101_p4 1.53E-13 0.5174 0.151 15.78% 10.74% 2.92% 2.11% 8.78% 75.44% 3.25E-13
Gpr101_p5 1.67E-11 0.0039 0.9563 20.71% 11.83% 8.34% 0.54% 4.37% 74.93% 3.3E-11
Gpr101_p6 0.0016 0.2409 0.9412 6.29% 2.92% 2.69% 0.68% 0% 93.71% 0.0021
Gpr101_p7 2.24E-5 8e-04 0.7383 10.99% 4.18% 5.81% 1.01% 0% 89.01% 3.33E-5
Hnmt 3.54E-65 0.1518 0.8069 45.33% 41.87% 2.92% 0.54% 4.11% 50.57% 2.68E-64
Syt1 0.0069 0.0113 0.1897 9.17% 1.89% 4.7% 2.58% <0.01% 90.84% 0.0087
Syt1_p1 2.75E-31 1.17E-6 0.4486 32.79% 23.39% 8.21% 1.18% 1.01% 66.21% 9.05E-31
Syt1_p3 0.0075 0.2326 0.7969 5.47% 1.93% 2.5% 1.04% 0% 94.53% 0.0093
Pspc1 8.96E-47 9.13E-5 0.8123 38.89% 31.91% 6.39% 0.57% 1.85% 59.28% 4.27E-46
Pspc1_p1 0.0479 1.66E-10 0.5146 19.59% 1.1% 16.75% 1.74% 0% 80.41% 0.0556
Rnf11 9.97E-130 0.2523 0.0065 60.62% 57.25% 1.45% 1.91% 2.04% 37.34% 1.57E-128
Rnf11_p1 7.8E-18 0.4534 0.0955 22.56% 17.97% 1.64% 2.95% <0.01% 77.44% 1.92E-17
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Rnf11_p2 2.16E-8 0.002 0.7659 16.84% 9.08% 6.56% 1.19% 0% 83.17% 3.69E-8
Plxnc1 0.1293 2.34E-5 0.7028 20.57% 0.44% 19.24% 0.89% 12.35% 67.08% 0.1439
Plxnc1_p1 4.66E-13 0.3894 0.6023 15.67% 12.58% 1.78% 1.31% 0% 84.33% 9.69E-13
Plxnc1_p2 2.8E-38 0.0271 0.0164 43.55% 35.27% 4.66% 3.61% 2.71% 53.75% 1.14E-37
Plxnc1_p3 3.72E-36 3.46E-7 2.96E-7 38.9% 25.15% 6.84% 6.9% 0% 61.11% 1.36E-35
Rgmb 6.78E-52 0.5061 0.001 40.24% 34.21% 2.41% 3.61% 7.49% 52.27% 3.55E-51
Rgmb_p1 1.07E-49 6e-04 0.0012 45.65% 35.01% 6.83% 3.79% 3.49% 50.87% 5.55E-49
Cadps 2.26E-18 0.4513 0.1141 21.27% 17.15% 1.52% 2.6% <0.01% 78.73% 5.71E-18
Cadps_p1 1.08E-40 1.87E-6 5.04E-12 50.08% 29.62% 9.27% 11.17% 2.27% 47.67% 4.61E-40
Cadps_p2 0.9781 0.0501 0.7899 4.87% <0.01% 3.81% 1.06% 0% 95.13% 0.9781
Ube2b 2.47E-60 0.001 3.09E-6 46.33% 37.62% 3.39% 5.31% 0% 53.68% 1.66E-59
Ube2b_p1 4.53E-53 2e-04 0.0067 46.95% 34.61% 9.44% 2.87% 6.08% 46.99% 2.43E-52
Shroom2_p1 3.13E-22 0.012 0.7034 23.87% 18.04% 4.94% 0.89% 2.64% 73.49% 8.56E-22
Nptn.1 4.02E-8 0.001 0.4376 13.8% 6.78% 5.46% 1.56% 0% 86.2% 6.68E-8
B3galnt1 0.0014 0.0397 0.9907 6.93% 2.7% 3.9% 0.32% 0% 93.07% 0.0019
B3galnt1_p1 7.2E-33 0.768 0.0961 28.77% 25.51% 1.08% 2.17% 2.71% 68.53% 2.46E-32
B3galnt1_p2 2.9E-18 6.95E-5 0.8009 23.32% 14.85% 7.71% 0.75% 1.77% 74.92% 7.23E-18
Calm2 1.06E-159 0.0431 0.166 64.48% 59.36% 4.26% 0.85% 6.78% 28.75% 2.25E-158
Dnajc6 1.5E-81 8.75E-39 2e-04 69.57% 27.38% 40.01% 2.13% 4.13% 26.36% 1.42E-80
Plcb1.1 3.48E-31 0.0169 0.0189 30.67% 23.96% 3.73% 2.98% 1.3% 68.03% 1.13E-30
Plcb1.1_p1 9.02E-17 3.62E-5 0.8722 24.69% 16.33% 7.62% 0.74% 0% 75.32% 2.14E-16
Plcb1.1_p2 4.55E-277 3.04E-7 8e-04 80.69% 76.57% 2.61% 1.5% <0.01% 19.32% 3.86E-275
Plcb1.1_p3 2.51E-20 9.77E-10 0.0516 28.84% 15.85% 10.39% 2.6% 0% 71.17% 6.52E-20
Plcb1.2 6.18E-131 1.22E-12 0.3387 66.38% 44.72% 21.01% 0.6% 7.13% 26.55% 1.01E-129
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Plcb1.2_p1 8.43E-25 0.2079 0.1815 24.66% 20.49% 2.21% 1.96% 1.13% 74.21% 2.46E-24
Plcb1.2_p2 7e-04 0.1351 0.6028 8.22% 2.91% 3.93% 1.38% 3.27% 88.52% 9e-04
Plcb1.2_p3 6.03E-69 7.2E-5 0.1668 57.78% 50.98% 5.06% 1.72% 0% 42.24% 4.83E-68
Plcb1.2_p4 2.14E-11 2.04E-12 0.0181 29.66% 8.74% 17.62% 3.29% 1.89% 68.46% 4.19E-11
Plcb1.2_p5 0.0768 0.0091 0.7275 7.62% 0.91% 5.43% 1.29% 0% 92.38% 0.0871
Srp9 1.53E-59 0.0081 6e-04 44.69% 38.24% 2.75% 3.7% 0% 55.31% 9.98E-59
Srp9_p1 3.61E-8 0.185 0.0366 15.04% 7.89% 3.26% 3.88% 2.06% 82.91% 6.08E-8
Pja2 5.9E-38 0.4074 0.9183 33.36% 31.49% 1.37% 0.5% 0% 66.64% 2.34E-37
Pja2_p1 2.89E-13 1.17E-6 0.8086 20.69% 10.95% 8.96% 0.77% 0.56% 78.76% 6.07E-13
Pja2_p2 1.69E-9 0.1975 0.1769 13.84% 8.91% 2.42% 2.51% 0% 86.17% 3.03E-9
Pja2_p3 8.27E-7 0.2718 0.8618 11.22% 7.51% 2.7% 1% <0.01% 88.78% 1.3E-6
Isca1 0.4501 0.3835 0.9469 3.82% 0.17% 3.01% 0.64% 3.63% 92.55% 0.4748
Isca1_p1 0.2462 0.387 0.9557 2.99% 0.37% 2.05% 0.57% <0.01% 97.01% 0.2656
Isca1_p2 0.0489 0.4219 0.8781 4.2% 1.04% 2.34% 0.82% 2.03% 93.77% 0.0567
Azin1 9.5E-10 3e-04 0.7717 19.35% 10.51% 7.69% 1.14% 0% 80.65% 1.74E-9
Lrp12 1e-04 0.0185 0.9939 9.31% 4.23% 4.79% 0.3% 0% 90.69% 2e-04
Lrp12_p1 6.44E-34 2e-04 0.0993 37.12% 29.05% 5.69% 2.37% 0% 62.89% 2.29E-33
Lrp12_p2 0.0012 0.0198 0.1116 9.95% 2.68% 4.27% 3% <0.01% 90.05% 0.0017
Nxph1 0.593 0.401 0.3967 4.46% 0.09% 2.18% 2.19% 0% 95.54% 0.6178
Nxph1_p1 0.0231 0.0069 0.4785 9.79% 1.62% 6.11% 2.05% <0.01% 90.21% 0.0275
Slc25a1_p1 0.4628 7.44E-42 0.6957 45.58% 0.08% 44.8% 0.7% 2.03% 52.39% 0.4869
Slc25a1_p2 7.39E-44 1.88E-33 1.79E-7 62.35% 16.32% 42.24% 3.75% 5.2% 32.48% 3.37E-43
Slc9a6 4.22E-5 0.6986 0.8326 6.64% 4.46% 1.25% 0.94% 0% 93.36% 6.11E-5
Slc9a6_p1 1.57E-75 2.86E-6 1.55E-7 54.53% 41.66% 7.36% 5.5% 2.23% 43.25% 1.33E-74
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Cltc 1.13E-128 1.25E-61 9.65E-28 72.88% 41.23% 21.46% 10.14% <0.01% 27.17% 1.71E-127
Vav2 0.0388 4.25E-7 0.1202 13.19% 0.97% 9.62% 2.59% 0% 86.81% 0.0458
Vav2_p1 0.0866 2e-04 0.2078 11.46% 0.81% 7.96% 2.68% 0% 88.54% 0.098
Kif2a 3.26E-27 1e-04 0.4757 28.49% 21.8% 5.47% 1.22% 0% 71.51% 9.93E-27
Susd2_p1 0.203 0.0723 0.5508 5.08% 0.4% 3.22% 1.46% 0% 94.92% 0.2207
Susd2_p2 0.0039 0.0025 0.9948 8.21% 2.18% 5.77% 0.26% 0% 91.79% 0.005
Grm7 1.61E-6 2e-04 0.7029 14.2% 5.58% 7.49% 1.13% 0.74% 85.06% 2.5E-6
Grm7_p1 0.383 4e-04 0.7955 11.71% 0.16% 10.72% 0.83% 6.03% 82.26% 0.408
Ubfd1 3.28E-5 0.1578 0.7465 7.74% 4.15% 2.55% 1.03% 0% 92.26% 4.77E-5
Ubfd1_p1 7e-04 0.9952 0.563 4.55% 2.86% 0.24% 1.45% 0% 95.45% 0.001
Ubfd1_p2 0.8695 0.0177 4.44E-6 12.38% 0.01% 3.88% 8.49% 0% 87.62% 0.8863
Ubfd1_p4 0.0028 0.1452 0.1208 7.54% 2.16% 2.62% 2.76% 0% 92.46% 0.0036
Ubfd1_p5 6e-04 0.0015 0.4795 9.8% 2.76% 5.5% 1.54% 0% 90.2% 8e-04
Mpped1 7.66E-15 0.1725 0.6959 16.76% 12.67% 3.09% 0.99% 2.9% 80.35% 1.68E-14
Mpped1_p1 1.68E-5 0.4921 0.9816 8.44% 5.91% 2.05% 0.48% 0% 91.56% 2.51E-5
Mpped1_p2 2.48E-5 0.0702 0.0717 11.24% 3.95% 4.4% 2.89% 3.63% 85.13% 3.65E-5
App 4.44E-14 3.54E-5 0.563 28.25% 15.5% 11.16% 1.58% 2.34% 69.42% 9.66E-14
Syngr3 0.0479 1.13E-8 0.2425 14.33% 0.87% 11.41% 2.04% 0.08% 85.59% 0.0556
Cdk17 3.96E-12 0.0367 0.4355 16.65% 11.42% 3.59% 1.64% 0.09% 83.26% 8.03E-12
Cdk17_p1 0.0136 8.15E-6 0.3393 16.1% 1.75% 12.08% 2.27% 1.64% 82.27% 0.0166
Cdk17_p2 6.93E-30 1.04E-12 0.4034 35.08% 21.85% 11.99% 1.23% 0% 64.93% 2.18E-29
Pcdh17 1.53E-62 0.0468 0.2543 46.23% 42.67% 2.18% 1.37% 0% 53.77% 1.1E-61
Pcdh17_p1 0.7976 0.0084 0.0616 10.63% 0.02% 6.97% 3.64% 3.13% 86.24% 0.8188
Pcdh17_p3 2.32E-85 1.75E-6 0.0057 60.53% 51.3% 6.54% 2.67% 1.06% 38.43% 2.34E-84
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Pcdh17_p4 2.24E-37 0.7396 0.5829 33.04% 31.14% 0.83% 1.07% <0.01% 66.96% 8.55E-37
Pcdh17_p5 1.44E-5 0.4801 0.5572 7.53% 4.54% 1.57% 1.41% 0% 92.47% 2.17E-5
Atp8a1 0.9436 0.0354 0.7259 5.31% <0.01% 4.11% 1.2% 0.12% 94.57% 0.9549
Atp8a1_p1 0.0143 0.0272 0.8797 8.96% 1.31% 6.97% 0.67% 7.11% 83.94% 0.0173
Atp8a1_p2 0.0416 0.6018 0.9938 3.24% 1.26% 1.66% 0.32% 0% 96.76% 0.0489
Atp8a1_p3 3.06E-10 5.1E-9 0.891 23.5% 7.57% 15.36% 0.56% 3.27% 73.23% 5.69E-10
Atp8a1_p4 1.7E-21 8.31E-48 0.6356 62.28% 7.87% 53.94% 0.45% 4.45% 33.29% 4.52E-21
Atp8a1_p5 8.4E-24 1.95E-6 0.7958 31.11% 21.85% 8.42% 0.83% 0% 68.9% 2.37E-23
Atp8a1_p6 9.27E-63 5.63E-18 1.94E-6 61% 24.62% 32.9% 3.43% 8.07% 30.98% 6.9E-62
Socs5 0.1048 2e-04 0.1596 9.79% 0.62% 6.68% 2.48% <0.01% 90.21% 0.1179
Socs5_p1 4.89E-16 5.17E-44 1.59E-7 61.14% 5.89% 51.24% 3.99% 4.56% 34.32% 1.11E-15
Hmgn1 2.11E-67 2.57E-6 6.75E-9 54.98% 34.68% 14.32% 5.95% 8.24% 36.81% 1.66E-66
Hmgn1_p1 0.3511 0.0136 0.6076 10.86% 0.2% 9.44% 1.23% 9.84% 79.3% 0.376
Pgap1 3.04E-41 4.69E-7 4e-04 50.04% 33.25% 11.84% 4.92% 3.09% 46.9% 1.31E-40
Pgap1_p1 1e-04 0.0136 0.56 12.79% 4.34% 6.74% 1.71% 2.78% 84.43% 2e-04
Pgap1_p3 7.43E-11 3e-04 0.5903 19.11% 10.75% 6.94% 1.41% 0% 80.89% 1.41E-10
Pgap1_p4 0.1552 0.0776 0.4956 6.26% 0.48% 4.27% 1.51% 3.12% 90.62% 0.1704
Pgap1_p5 1.41E-20 0.0093 0.8669 22.05% 17.6% 3.79% 0.65% 0% 77.95% 3.68E-20
Ranbp6 1.98E-8 0.6931 0.2018 12.61% 8.63% 1.3% 2.68% 0% 87.39% 3.39E-8
Ranbp6_p2 2.49E-30 0.005 0.6049 30.87% 25.8% 3.99% 1.07% 0% 69.14% 8.01E-30
Ahi1 2.19E-5 0.2968 0.2266 8.55% 4.3% 2.01% 2.24% 0% 91.45% 3.25E-5
Dnm3 1.51E-48 2.73E-9 0.0938 42.68% 31.65% 9.21% 1.8% 0.77% 56.57% 7.55E-48
Dnm3_p1 1.2E-60 8.97E-26 0.0739 58.68% 29.29% 27.94% 1.4% 3.19% 38.17% 8.22E-60
Dnm3_p2 2.07E-24 0.0799 0.6813 24.75% 17.47% 6.47% 0.81% 10.9% 64.36% 6E-24
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Dnm3.1_p3 5.38E-5 0.0284 0.6581 9.53% 4.2% 4.04% 1.29% <0.01% 90.47% 7.76E-5
Dnm3.1_p5 3.16E-9 0.0198 0.2398 15.7% 8.12% 5.46% 2.12% 3.08% 81.22% 5.6E-9
Slc19a1 2.43E-8 4e-04 0.8781 16.44% 7.13% 8.6% 0.7% 3.12% 80.45% 4.15E-8
Slc19a1_p1 1.06E-10 0.6271 0.8161 11.74% 9.39% 1.52% 0.83% 2.03% 86.23% 1.99E-10
Spsb4 0.0069 0.6346 0.5186 5.53% 2.16% 1.54% 1.83% <0.01% 94.47% 0.0087
Spsb4_p1 7.29E-17 8.89E-7 0.9357 31.1% 13.43% 17.19% 0.46% 7.29% 61.62% 1.74E-16
Spsb4_p2 0.0458 0.0173 0.5033 16.21% 0.71% 14.38% 1.12% 21.27% 62.52% 0.0535
Spsb4_p3 0.0229 0.1821 0.215 6.09% 1.27% 2.48% 2.34% 0% 93.91% 0.0274
Pum1 0.2316 0.5587 0.2283 4.52% 0.39% 1.59% 2.54% 0% 95.48% 0.2511
Pum1_p1 3.91E-33 0.0698 0.0927 32.52% 27.65% 2.52% 2.35% <0.01% 67.48% 1.36E-32
Por 0.8231 0.496 0.951 2.8% 0.01% 2.26% 0.53% 3.5% 93.7% 0.843
Nbea 0.7873 7.91E-13 0.0578 18.17% 0.02% 15.24% 2.91% 0% 81.83% 0.8122
Nbea_p1 4.75E-13 0.5399 0.9613 13.6% 11.8% 1.35% 0.45% 0% 86.4% 9.82E-13
Nbea_p2 3.53E-9 0.2983 0.9383 16.98% 12.98% 3.13% 0.87% <0.01% 83.02% 6.23E-9
Wsb2 0.9515 0.6873 0.6682 3.27% <0.01% 1.61% 1.66% 0% 96.73% 0.9605
Rab3c 0.1634 0.1011 0.156 6.15% 0.47% 3.09% 2.59% 0.43% 93.42% 0.1785
Rab3c_p1 6.11E-83 0.2047 0.7578 52.07% 49.96% 1.55% 0.56% 0.82% 47.11% 5.89E-82
Rab3c_p2 7.75E-20 0.1101 0.0023 26.85% 17.24% 4.99% 4.61% 6.98% 66.17% 1.99E-19
Rab3c_p3 1.38E-25 8.39E-10 0.3395 33.34% 18.34% 13.66% 1.33% 2.4% 64.28% 4.1E-25
Rab3c_p4 9.57E-18 1.2E-41 0.3791 46.06% 10.18% 34.82% 1.04% 0.89% 53.06% 2.35E-17
Rab3c_p5 0.0026 0.3318 0.7269 5.77% 2.43% 2.15% 1.19% 0% 94.23% 0.0035
Rab3c_p6 6.65E-32 0.0853 0.038 32.05% 26.75% 2.42% 2.87% 0% 67.96% 2.24E-31
Hipk1 2.91E-5 7.19E-7 0.4762 20.72% 3.32% 16.14% 1.25% 6.41% 72.87% 4.23E-5
Hipk1_p2 4.22E-37 0.7322 0.0487 33.96% 30.47% 0.83% 2.66% <0.01% 66.04% 1.57E-36
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Hipk1_p3 0.0674 0.0054 0.7579 9.47% 0.74% 7.8% 0.93% 5.3% 85.23% 0.0772
Hipk1_p4 7.47E-39 0.0642 0.4912 33.09% 29.37% 2.61% 1.11% 0.73% 66.18% 3.11E-38
Prkacb_p1 3.57E-61 1.14E-16 5.06E-5 53.18% 31.28% 18.26% 3.61% 2.8% 44.05% 2.48E-60
Prkacb_p2 3.03E-37 9.35E-6 0.6625 36.64% 29.35% 6.39% 0.9% <0.01% 63.37% 1.15E-36
Prkacb_p3 3.12E-163 0.0026 0.2398 66.59% 63.51% 2.29% 0.79% 0.59% 32.82% 6.97E-162
Dnaja1 0.007 0.021 0.167 10.64% 2.27% 5.14% 3.24% 0% 89.36% 0.0087
Dnaja1_p1 2.59E-8 1.61E-8 1.16E-6 27.75% 6.17% 13.58% 8% 2.35% 69.9% 4.39E-8
Dnaja1_p2 1.44E-11 4e-04 0.6387 18.09% 10.64% 6.23% 1.21% 0% 81.92% 2.87E-11
Atmin 4.24E-7 0.5125 0.7231 9.62% 6.37% 2.13% 1.12% 2.93% 87.45% 6.75E-7
Atmin_p1 0.001 5.8E-6 0.9035 12.48% 2.68% 9.1% 0.7% 0% 87.52% 0.0014
Atmin_p2 2.58E-30 6.99E-14 0.0389 40.85% 21.33% 17.09% 2.41% 1.93% 57.24% 8.24E-30
Htr7 0.9255 3e-04 0.0459 10.64% <0.01% 6.99% 3.64% <0.01% 89.36% 0.9388
Htr7_p1 0.0028 0.7285 0.8876 4.87% 2.66% 1.32% 0.89% <0.01% 95.13% 0.0036
Uhrf2 0.0013 0.3105 0.3158 7.11% 2.75% 2.19% 2.17% <0.01% 92.89% 0.0017
Uhrf2_p1 0.0942 4.26E-5 0.9181 8.88% 0.67% 7.59% 0.62% 0% 91.12% 0.1063
Rnf14 0.005 7e-04 0.5141 12.07% 2.41% 7.75% 1.91% 0% 87.93% 0.0064
Zic4 0.9575 0.0022 0.9797 6.44% <0.01% 6.06% 0.38% 0.9% 92.66% 0.9643
Zic4_p1 1.07E-41 0.0026 0.8205 39.54% 34.68% 4.16% 0.69% <0.01% 60.47% 4.67E-41
Zic4_p2 6.48E-5 0.3764 0.0614 8.92% 3.76% 1.99% 3.17% 0.93% 90.15% 9.24E-5
Crocc 0.5337 0.7102 0.6495 2.77% 0.1% 1.41% 1.27% 1.87% 95.36% 0.5574
Nrep 4.51E-15 2.98E-10 0.0187 27.31% 11.52% 12.63% 3.15% 0.91% 71.79% 1.01E-14
Cul4b 0.7493 0.1914 0.8638 3.35% 0.03% 2.51% 0.81% <0.01% 96.65% 0.7749
Cul4b_p1 1.23E-236 0.7077 0.3866 75.06% 74.11% 0.44% 0.51% 0.83% 24.11% 6.52E-235
Cul4b_p2 0.1371 3.13E-7 0.8434 12.2% 0.55% 10.79% 0.86% 0% 87.8% 0.1522
195
PTRE-Seq - Effects on Expression Cont’d
Gene.UTR_Peak sequence condition interaction R2 sequence condition interaction within samples unexplained FDR
Cul4b_p3 1.96E-105 3.07E-6 0.0024 57.59% 42.35% 13.24% 1.97% 8.3% 34.15% 2.37E-104
Tmem30a_p1 0.0504 0.0414 0.2058 7.42% 1.01% 3.85% 2.56% 0% 92.58% 0.0583
Tmem30a_p2 4.27E-30 0.2566 9e-04 31.78% 25.25% 1.74% 4.79% <0.01% 68.22% 1.35E-29
Tmem30a_p3 1.69E-23 7.9E-9 0.8568 32.62% 21.07% 10.84% 0.69% 0% 67.4% 4.71E-23
Tmem30a_p4 5.83E-159 1.51E-9 2e-04 67.76% 60.74% 4.62% 2.39% <0.01% 32.25% 1.18E-157
Fem1b 0.0015 0.0089 0.0342 10.41% 2.36% 4.52% 3.53% 0.23% 89.36% 0.002
Fem1b_p1 2.5E-10 0.0305 0.7899 15.7% 10.58% 4.09% 1.03% 0% 84.3% 4.67E-10
Fem1b_p2 1.22E-23 9e-04 0.5505 27.16% 20.84% 5.09% 1.23% 0% 72.85% 3.43E-23
Fem1b_p3 0.7916 0.8798 0.9138 1.78% 0.02% 0.94% 0.82% <0.01% 98.22% 0.8147
Fem1b_p5 2.18E-31 0.0849 0.6544 30.41% 26.92% 2.48% 1% 0.02% 69.58% 7.23E-31
Zdhhc13 1.41E-12 0.001 0.6949 18.39% 11.66% 5.63% 1.1% <0.01% 81.61% 2.9E-12
Peg10 1.49E-8 0.0166 0.2657 13.15% 7.27% 3.88% 2% 0% 86.85% 2.59E-8
Peg10_p2 0.0038 0.002 0.9816 11.32% 2.53% 8.33% 0.46% 2.17% 86.51% 0.0049
Peg10_p3 0.1228 3e-04 0.1402 10.45% 0.61% 7.04% 2.8% 0% 89.55% 0.1374
Peg10_p4 0.6056 0.1264 0.8284 8.05% 0.05% 7.27% 0.72% 14.06% 77.89% 0.6293
Peg10_p5 2E-323 1.83E-12 2.12E-11 81.5% 71.86% 6.5% 3.12% 1.43% 17.09% 2.1E-321
Peg10_p6 0.0023 6.06E-7 0.5259 18.29% 2.98% 13.35% 1.96% 0% 81.71% 0.003
Peg10.1 0.0182 0.0128 0.2832 10.03% 1.75% 5.59% 2.69% 0% 89.97% 0.022
Peg10.1_p1 0.2897 0.0718 0.996 4.11% 0.31% 3.55% 0.25% 0% 95.89% 0.3118
Peg10.1_p2 3.83E-16 0.4709 0.0786 19.33% 13.38% 3.37% 2.57% 9.85% 70.82% 8.78E-16
Nsf 3e-04 4.85E-39 0.8142 53% 1.56% 50.98% 0.45% 4.38% 42.63% 5e-04
Hap1 2.15E-178 7.87E-31 7.53E-34 79.25% 43.5% 26.44% 9.24% 3.63% 17.19% 6.07E-177
Tmem66 0.0044 0.0012 0.9312 8.94% 2.11% 6.2% 0.63% <0.01% 91.06% 0.0056
Serpini1 3.59E-13 8.21E-7 0.0379 25.41% 12.36% 9.58% 3.47% <0.01% 74.6% 7.5E-13
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Serpini1_p1 0.2433 0.1656 0.6025 5.3% 0.36% 3.5% 1.44% 2.33% 92.37% 0.2632
Serpini1_p2 1.12E-16 0.0111 0.9091 22.27% 11.78% 10.01% 0.47% 12.08% 65.66% 2.64E-16
Myh10 0.3453 2.71E-13 0.6543 21.58% 0.19% 20.29% 1.1% 1.83% 76.59% 0.3707
Myh10_p1 2e-04 0.0661 0.6705 8.27% 3.25% 3.86% 1.15% 1.8% 89.93% 3e-04
Slc39a11 3.77E-8 0.9076 0.6158 9.11% 7.18% 0.65% 1.27% 0% 90.89% 6.32E-8
Slc39a11_p1 0.1471 6.89E-8 0.9477 15.93% 0.49% 14.93% 0.51% 2.85% 81.22% 0.1624
Slc39a11_p3 4.92E-15 0.0063 0.7417 20.44% 11.63% 7.99% 0.82% 6.89% 72.68% 1.1E-14
Slc39a11_p4 5.83E-5 0.1653 0.3222 10.54% 4.35% 4.01% 2.18% 3.67% 85.79% 8.38E-5
Kcnd2 9.86E-8 0.0079 0.9683 17.92% 8.58% 8.79% 0.55% 5.05% 77.04% 1.61E-7
Kcnd2_p1 1.78E-56 2.69E-16 0.446 53.59% 29.99% 22.75% 0.82% 4.4% 42.04% 1.08E-55
Kcnd2_p2 2.77E-18 0.091 0.6829 23.31% 15.95% 6.35% 1.01% 9.77% 66.93% 6.94E-18
Kcnd2_p3 2.08E-241 1.71E-38 1.57E-38 81.08% 58% 12.81% 10.23% 0.42% 18.54% 1.26E-239
Lpin2 0.0043 0.0221 0.3901 10.78% 2.47% 6.07% 2.24% 2.17% 87.06% 0.0056
Lpin2_p1 2.3E-16 0.3159 0.921 18.47% 13.76% 4.19% 0.53% 9.79% 71.74% 5.36E-16
Lpin2_p2 1.5E-37 1.21E-17 0.007 44.6% 25.74% 15.79% 3.04% 0.31% 55.12% 5.8E-37
Mecp2 7.88E-21 0.3226 0.0501 22.28% 17.78% 1.65% 2.85% 0% 77.72% 2.08E-20
Mecp2_p1 9.71E-33 0.0019 0.5073 32.48% 21.8% 9.7% 0.96% 8.71% 58.82% 3.29E-32
Mecp2_p3 0.421 0.0026 0.8738 6.29% 0.16% 5.37% 0.76% 0% 93.71% 0.4463
Mecp2_p4 2.32E-5 0.8829 0.8871 6.63% 4.25% 1.67% 0.71% 10.07% 83.3% 3.43E-5
Mecp2_p6 1.85E-39 1.05E-9 0.3026 42.57% 26.51% 14.76% 1.28% 3.55% 53.9% 7.85E-39
Mecp2_p7 1.48E-17 0.0061 0.8508 20.02% 15.19% 4.13% 0.7% 0% 79.99% 3.59E-17
Mecp2_p8 1.13E-5 2.71E-6 0.7896 13.83% 4.34% 8.61% 0.88% 0% 86.18% 1.72E-5
Mecp2_p9 1.88E-9 0.0347 0.9604 13.16% 8.93% 3.73% 0.49% 0% 86.84% 3.36E-9
Ran 1.29E-11 0.61 0.1619 14.95% 10.89% 1.56% 2.5% 1.61% 83.44% 2.58E-11
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Ran_p1 1.42E-29 0.5233 0.5218 30.48% 27.8% 1.34% 1.34% <0.01% 69.53% 4.38E-29
Cox14 2.76E-5 0.4229 0.9857 6.36% 4.3% 1.73% 0.34% <0.01% 93.64% 4.04E-5
Blcap 2.54E-5 3.72E-8 0.8983 17.37% 3.73% 13.04% 0.6% 1.96% 80.67% 3.73E-5
Blcap_p1 0.0231 0.0053 0.1747 16.59% 0.9% 13.89% 1.79% 16.46% 66.95% 0.0275
Wdr82 1.5E-48 8e-04 0.4212 39.13% 34.07% 3.93% 1.12% 0% 60.88% 7.55E-48
Wdr82_p1 3.11E-14 0.8397 0.5788 15.05% 11.72% 2.18% 1.15% 13.6% 71.35% 6.8E-14
Wdr82_p2 1.77E-10 0.039 0.2872 14.32% 9.11% 3.31% 1.91% 0% 85.68% 3.32E-10
Fam160b1 0.0037 0.1987 0.1962 13.3% 1.26% 10.57% 1.47% 29.56% 57.14% 0.0047
Fam160b1_p1 0.0687 0.3232 0.5956 5.58% 1.09% 2.67% 1.82% 0% 94.42% 0.0785
Fam160b1_p2 0.0014 0.5748 0.0514 7.85% 2.68% 1.5% 3.67% <0.01% 92.15% 0.0019
Fam160b1_p3 1.55E-11 1.74E-11 0.0549 30.55% 7.68% 20.54% 2.33% 4.74% 64.71% 3.07E-11
Fam160b1_p5 2.06E-6 2e-04 0.1157 15.2% 5.45% 6.96% 2.79% 0% 84.8% 3.18E-6
Fam160b1_p6 0.4286 0.1062 0.4071 6.24% 0.16% 4.22% 1.86% 3.14% 90.62% 0.4532
Fam160b1_p7 3.87E-12 0.0229 0.9601 16.14% 9.96% 5.76% 0.41% 4.72% 79.14% 7.9E-12
Fam160b1_p8 1.15E-11 9.18E-15 0.9528 26.88% 9.59% 16.84% 0.44% 0% 73.13% 2.3E-11
Fam160b1_p9 1.8E-52 0.1284 0.153 39.9% 36.46% 1.76% 1.67% 0% 60.1% 9.52E-52
Arf1 0.0381 0.058 0.892 5.17% 1.07% 3.38% 0.72% 0% 94.83% 0.0451
Arf1_p2 2.31E-17 0.2817 1.4E-6 25.46% 15.05% 2.08% 8.32% 1.02% 73.52% 5.57E-17
Psd3_p1 0.0012 3e-04 0.6897 11.74% 2.88% 7.54% 1.32% 0% 88.26% 0.0017
Psd3_p3 0.0565 0.0052 0.7025 7.51% 0.96% 5.32% 1.23% <0.01% 92.49% 0.0651
Psd3_p4 8.77E-6 2.9E-9 0.5007 23.17% 4.1% 17.75% 1.32% 3.95% 72.88% 1.34E-5
Psd3_p5 1e-04 2e-04 0.4158 15.5% 3.74% 9.92% 1.82% 2.87% 81.64% 2e-04
Psd3_p7 0.0141 0.2733 0.2161 6.59% 1.59% 2.48% 2.52% 0.62% 92.79% 0.0172
Psd3_p8 1.33E-16 0.4491 0.5355 17.5% 14.74% 1.47% 1.3% 0% 82.5% 3.11E-16
198
PTRE-Seq - Effects on Expression Cont’d
Gene.UTR_Peak sequence condition interaction R2 sequence condition interaction within samples unexplained FDR
Psd3_p9 1.27E-6 0.0052 0.9908 11.33% 5.93% 5.09% 0.3% 0% 88.67% 1.98E-6
Psd3_p10 5.2E-13 0.0375 0.8371 19.72% 14.58% 4.16% 0.97% <0.01% 80.29% 1.07E-12
Pgs1.1 1.04E-9 0.0015 0.3734 18.17% 9.39% 6.87% 1.9% 1.39% 80.45% 1.89E-9
2510039O18Rik 5.61E-9 0.0162 0.0352 15.87% 8.14% 4.12% 3.61% 0% 84.13% 9.86E-9
2510039O18Rik_p1 1.43E-5 0.2626 0.3288 9.24% 4.87% 2.29% 2.08% 0% 90.76% 2.16E-5
2510039O18Rik_p2 0.9048 0.0072 0.5442 6.2% <0.01% 4.73% 1.46% 0% 93.8% 0.92
Lingo3 1e-04 0.004 0.6001 12.6% 3.47% 7.83% 1.3% 4.45% 82.95% 2e-04
Zbtb5_p1 1.5E-75 1.15E-71 6.43E-11 66.63% 29.33% 31.9% 5.36% 0.14% 33.27% 1.3E-74
Zbtb5_p2 1.73E-27 2.45E-8 5.15E-7 40.38% 18.28% 15.58% 6.5% 5.24% 54.4% 5.32E-27
Zbtb5_p3 0.3608 6.85E-5 0.4975 9.13% 0.2% 7.42% 1.51% 0.14% 90.74% 0.3854
Mapk9 1.54E-45 2.29E-9 9.47E-8 46.12% 30.79% 8.29% 7.03% <0.01% 53.89% 7.16E-45
Mapk9_p1 2.02E-38 1.51E-6 0.2334 40.24% 26.05% 12.73% 1.44% 5.32% 54.47% 8.31E-38
Mapk9_p2 0.0076 0.0185 0.445 8.07% 1.86% 4.41% 1.79% <0.01% 91.93% 0.0094
Mapk9.1 4.73E-128 5.49E-29 2.6E-20 72.77% 33.12% 33.44% 6.16% 5.32% 21.96% 6.92E-127
Mapk9.1_p1 3.88E-37 3.25E-6 0.1034 37.68% 28.73% 6.83% 2.11% 0.11% 62.22% 1.46E-36
Mapk9.1_p2 4.59E-49 0.0469 0.063 38.57% 32.9% 3.63% 2.03% 3.3% 58.14% 2.34E-48
Mapk9.1_p3 1.32E-7 0.0017 0.4655 17.47% 5.35% 10.84% 1.28% 8.93% 73.6% 2.14E-7
Dcaf7 3.56E-8 5.91E-7 9e-04 21.6% 6.78% 9.32% 5.49% 0% 78.41% 6.01E-8
Dcaf7_p1 0.0712 0.0946 0.416 6.04% 0.87% 3.26% 1.91% 0% 93.96% 0.0809
Dcaf7_p2 1.29E-31 1.93E-10 0.8523 36.26% 24.85% 10.79% 0.61% 0% 63.76% 4.29E-31
Dcaf7_p3 6.06E-5 0.0032 0.7009 10.09% 3.76% 5.24% 1.09% 0.35% 89.56% 8.68E-5
Dcaf7_p4 1.37E-54 1.15E-5 0.0316 44% 33.02% 8.87% 2.09% 3.76% 52.26% 7.73E-54
Vat1l 5.69E-189 0.0018 1.84E-27 72.38% 60.28% 2.15% 9.95% 0.77% 26.86% 2.19E-187
Reep1 1.64E-8 0.117 0.7496 11.07% 7.4% 2.68% 0.99% 0% 88.93% 2.84E-8
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Reep1_p1 1.45E-26 7.34E-6 0.3629 29.58% 20.66% 7.52% 1.39% 0.88% 69.54% 4.35E-26
Reep1_p2 6.46E-126 1.09E-7 7e-04 62.38% 52.78% 7.25% 2.32% 2.14% 35.51% 8.83E-125
Reep1_p3 7.03E-55 0.5456 0.0396 42.54% 39% 1.18% 2.36% 1.23% 56.23% 4.03E-54
Reep1_p4 4.39E-8 1.66E-15 0.2027 26.16% 5.7% 18.6% 1.86% 0.95% 72.9% 7.24E-8
Myo5a 0.5135 9e-04 0.6632 9.46% 0.13% 7.75% 1.57% <0.01% 90.54% 0.5376
Myo5a_p1 0.0115 4e-04 0.0597 11.69% 1.61% 6.67% 3.41% 0% 88.31% 0.0141
Myo5a_p2 9.45E-9 0.6505 0.8371 10.22% 6.89% 2.6% 0.73% 9.66% 80.13% 1.65E-8
Myo5a_p3 1.02E-97 3.15E-15 0.0054 59.47% 44.66% 12.74% 2.03% 1.66% 38.91% 1.11E-96
Myo5a_p4 7.04E-7 0.2699 0.1955 10.15% 5.77% 2.06% 2.32% <0.01% 89.85% 1.11E-6
Myo5a_p5 2.42E-24 0.4207 0.9684 21.4% 14.9% 6.23% 0.26% 23.53% 55.07% 6.98E-24
Myo5a_p6 1.44E-13 0.7722 0.5453 15.56% 13.15% 0.98% 1.43% <0.01% 84.44% 3.07E-13
Myo5a_p7 1.97E-5 0.0715 0.5023 8.93% 4.33% 3.1% 1.5% 0% 91.07% 2.94E-5
Myo5a_p8 9e-04 0.0902 0.0306 9.97% 2.85% 3.16% 3.96% 0% 90.03% 0.0012
Myo5a_p9 2.38E-22 1.39E-5 0.6711 28.44% 18.83% 8.62% 0.98% 1.62% 69.94% 6.56E-22
8430427H17Rik 0.002 0.1281 0.1013 7.89% 2.3% 2.71% 2.88% 0% 92.11% 0.0026
8430427H17Rik_p2 5.22E-16 0.9948 0.788 13.71% 12.13% 0.86% 0.72% 21.5% 64.78% 1.18E-15
8430427H17Rik_p3 5e-04 0.0051 0.6375 8.88% 2.84% 4.81% 1.23% 0% 91.12% 8e-04
8430427H17Rik_p5 0.1428 0.1049 0.6061 6.99% 0.48% 5.28% 1.22% 7.04% 85.98% 0.1581
8430427H17Rik_p6 0.0421 0.5847 0.451 4.5% 1.12% 1.53% 1.85% 0% 95.5% 0.0493
Table S7: PTRE-Seq - Effects on Translation Efficiency
Terms shown: Main effect of sequence (reference or mutant), Main effect of condition (CELF overexpression or CTL),Interaction between sequence and condition.
FDR is shown for sequence x condition interactions
p % variance explained
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Fgf13 0.1654 0.1631 0.6852 7.8% 0.44% 6.27% 1.1% 11.77% 80.43% 0.9457
Magee1 0.0024 0.4062 0.8532 6.6% 2.25% 3.54% 0.81% 7.85% 85.55% 0.9907
Plcxd3 0.3675 0.4976 0.3561 3.75% 0.2% 1.6% 1.94% <0.01% 96.25% 0.8712
Ddc 3.01E-5 0.025 0.6919 9.06% 4.13% 3.8% 1.12% 0% 90.94% 0.9457
Mkrn3 0.011 0.3065 0.0847 7.21% 1.51% 2.77% 2.93% 3.18% 89.61% 0.6101
Mkrn3_p1 0.0554 0.9581 0.8372 2.47% 0.9% 0.71% 0.86% 3.37% 94.15% 0.9888
Carkd 0.6736 0.0395 0.3666 6.6% 0.05% 4.32% 2.23% <0.01% 93.4% 0.8712
Nap1l3 0.9285 0.3001 0.3714 5.83% <0.01% 3.71% 2.11% 5.23% 88.95% 0.8712
Pgr15l 0.0058 0.9929 0.2946 4.23% 1.77% 0.48% 1.97% 6.4% 89.37% 0.8427
Pgr15l_p1 3.5E-7 0.1308 0.4861 10.77% 5.87% 3.43% 1.46% 2.56% 86.67% 0.8917
Pgr15l_p2 0.4423 0.4867 0.4235 3.86% 0.16% 1.77% 1.93% 0% 96.14% 0.8712
Pgr15l_p3 0.2851 0.7304 0.6429 3.2% 0.31% 1.51% 1.38% 2.32% 94.47% 0.9457
Slc39a6 0.4539 0.7327 0.046 6.2% 0.13% 2.76% 3.31% 12.6% 81.2% 0.5072
Slc39a6_p1 0.6159 0.8096 0.1754 4.43% 0.06% 1.79% 2.58% 7.24% 88.33% 0.7619
Slc39a6_p2 0.5351 0.3386 0.432 3.84% 0.1% 1.99% 1.75% <0.01% 96.16% 0.8719
Slc39a6_p3 4.58E-6 0.6608 0.1528 9.8% 4.97% 2.3% 2.53% 7.15% 83.06% 0.7361
Trim32 0.3037 0.2695 0.834 5.49% 0.29% 4.23% 0.97% 6.58% 87.93% 0.9877
Trim32_p1 0.2457 0.1575 0.0246 8.17% 0.34% 3.78% 4.05% 3.35% 88.48% 0.4019
Gpr149 0.7417 0.3131 0.6917 3.55% 0.03% 2.34% 1.18% 1.16% 95.29% 0.9457
Gpr149_p1 0.9955 0.4117 0.0242 8.52% <0.01% 3.82% 4.7% 7.68% 83.8% 0.4019
Tceal1 0.1215 0.0566 0.0755 9.5% 0.75% 4.74% 4.01% 1.1% 89.41% 0.5766
Gprasp2 0.6685 0.7363 0.8271 2.31% 0.05% 1.27% 0.99% 0.41% 97.28% 0.9877
Gad1 0.6795 0.1318 0.7071 5.54% 0.05% 4.16% 1.33% 2.72% 91.75% 0.9457
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Gad1_p1 0.1012 0.2444 0.646 5.04% 0.8% 2.71% 1.52% 0% 94.96% 0.9457
Zcchc12 0.1121 0.0227 0.5946 6.48% 0.67% 4.34% 1.48% 0% 93.52% 0.9445
Zcchc12_p1 0.5519 0.8838 0.9252 1.98% 0.11% 1.12% 0.76% 2.27% 95.75% 0.9962
Klhdc2 0.8542 0.4877 0.4288 3.4% 0.01% 1.63% 1.77% <0.01% 96.6% 0.8712
Lrrc47 0.0132 0.0406 0.0048 13.52% 1.53% 6.92% 5.07% 7.11% 79.37% 0.1852
Lrrc47_p1 1.09E-6 0.0742 0.4098 14.96% 6.4% 6.63% 1.93% 7.78% 77.26% 0.8712
Lrrc47_p2 0.0015 0.5216 0.2111 6.92% 2.65% 1.74% 2.53% 0.59% 92.48% 0.7651
Alg2 2.51E-7 0.0545 6e-04 17% 5.05% 7.07% 4.87% 10.28% 72.73% 0.0511
Arxes1_p1 0.8096 0.0062 0.7659 6.38% 0.02% 5.26% 1.1% 0% 93.62% 0.9788
Snca 0.5326 0.6871 0.5878 2.97% 0.11% 1.32% 1.55% <0.01% 97.03% 0.9441
Syn2 0.5604 0.1124 0.6819 4.21% 0.08% 2.92% 1.21% 0% 95.79% 0.9457
Syn2_p2 0.2671 0.0486 0.7497 5.9% 0.32% 4.45% 1.12% 1.64% 92.46% 0.9721
Syn2.1 0.895 0.2166 0.0805 5.95% <0.01% 2.55% 3.4% 0% 94.05% 0.5985
Rragb 5.26E-7 0.449 0.5571 10.6% 7.05% 1.91% 1.64% 0% 89.4% 0.9226
Nap1l2 0.0069 0.4243 0.3484 8.33% 1.8% 4.59% 1.93% 12.93% 78.75% 0.8712
Tmtc4 0.4688 0.0837 0.8161 4.73% 0.14% 3.6% 0.99% 0.53% 94.73% 0.9877
Tmtc4_p1 0.1508 0.1533 0.6019 5.3% 0.5% 3.49% 1.31% 2.78% 91.92% 0.9445
Tmtc4_p2 0.4345 0.0362 0.1092 7.64% 0.14% 4.74% 2.75% 2.63% 89.73% 0.6273
Tmtc4_p3 0.9114 0.1083 0.1583 6.55% <0.01% 3.45% 3.1% <0.01% 93.45% 0.7457
Zfp385b 0.853 0.3157 0.2242 5.48% 0.01% 2.72% 2.75% 1.26% 93.26% 0.7744
Zfp385b_p1 0.0828 0.0517 0.0532 10.8% 1.05% 4.89% 4.86% <0.01% 89.2% 0.513
Zfp385b_p2 0.1108 0.0016 0.0553 10.12% 0.65% 5.95% 3.53% 0% 89.88% 0.5211
Zdbf2 0.0605 0.812 0.7355 3.2% 0.97% 1.02% 1.21% <0.01% 96.8% 0.9609
Zdbf2_p1 0.0609 0.0693 0.4825 7.46% 1.13% 4.23% 2.1% 0% 92.54% 0.8917
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Zdbf2_p2 0.1148 0.6064 0.285 5.02% 0.64% 2.16% 2.21% 4.47% 90.52% 0.8333
Arxes2 0.3582 0.6449 0.6015 3.69% 0.25% 1.82% 1.62% 1.88% 94.43% 0.9445
Arxes2_p1 0.0097 0.8694 0.9604 3.58% 2.02% 0.96% 0.6% <0.01% 96.42% 0.9962
Penk 0.0799 0.6176 0.053 7.62% 0.58% 4.44% 2.61% 20.49% 71.88% 0.513
Atl1 0.7935 0.158 0.208 5.7% 0.02% 3.11% 2.57% 0.88% 93.42% 0.7651
Snx16 0.6086 0.043 0.6767 5.05% 0.06% 3.78% 1.2% 0.45% 94.5% 0.9457
Dcaf12l1 3e-04 0.1631 6e-04 11.48% 3.05% 2.55% 5.88% 0.42% 88.1% 0.0511
Dcaf12l1_p1 0.0645 0.1423 0.2403 7.57% 1.1% 3.52% 2.95% <0.01% 92.43% 0.8022
Synpr 0.9653 0.1933 0.3999 6.3% <0.01% 4.28% 2.03% 4.87% 88.82% 0.8712
Synpr_p1 0.9991 0.0194 0.6035 5.94% <0.01% 4.48% 1.46% 0% 94.06% 0.9445
Synpr_p2 0.7208 0.7343 0.0502 4.62% 0.03% 1.09% 3.5% <0.01% 95.38% 0.5072
Cd200 0.0229 0.1476 0.7109 10.07% 1.21% 7.8% 1.07% 15.61% 74.31% 0.9457
Cd200_p1 0.9199 0.3454 0.2453 5.58% <0.01% 2.58% 2.99% 0% 94.42% 0.8105
Cd200_p2 0.0289 0.2727 0.0155 8.07% 1.25% 2.29% 4.54% 0% 91.93% 0.3399
Ndn 0.0581 0.9288 0.0025 6.88% 0.78% 1.31% 4.79% 9.97% 83.16% 0.1426
AW551984 0.7713 0.426 0.5918 4.81% 0.03% 3% 1.78% 3.43% 91.76% 0.9445
AW551984_p1 0.5957 0.6231 0.8898 2.37% 0.08% 1.47% 0.82% 0% 97.63% 0.9959
Ankra2 3.64E-5 0.0221 0.5226 10.57% 3.84% 5.35% 1.38% 3.25% 86.19% 0.8955
Ankra2_p1 0.6155 0.5104 0.2016 5.37% 0.08% 2.06% 3.22% 0% 94.63% 0.7639
Ankra2.1 0.8554 0.8529 0.1971 4% 0.01% 1.04% 2.95% 0.36% 95.64% 0.7639
Rraga 0.0824 0.1558 0.3618 6.91% 0.98% 3.45% 2.49% 0% 93.09% 0.8712
Irs4 0.5861 0.5536 0.2535 4.94% 0.09% 2.26% 2.59% 3.08% 91.98% 0.8105
Irs4_p1 0.1477 0.4416 0.831 3.16% 0.53% 1.74% 0.89% 0% 96.84% 0.9877
Irs4_p2 0.5425 0.0228 0.3549 6.54% 0.1% 4.37% 2.06% 0.09% 93.37% 0.8712
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Dek 0.5373 0.4453 0.0496 6.26% 0.11% 2.01% 4.14% <0.01% 93.74% 0.5072
Dek_p1 0.0265 0.384 0.4163 5.68% 1.29% 2.53% 1.86% 2.47% 91.85% 0.8712
Dek_p2 3e-04 0.2351 0.2793 8.34% 2.93% 3.44% 1.96% 4.63% 87.03% 0.8333
Rit2 0.7804 0.0404 0.0306 10.12% 0.02% 6.8% 3.3% 7.97% 81.91% 0.4415
Pcdh18 0.0475 0.4806 0.2247 5.92% 1.01% 2.49% 2.41% 4.02% 90.06% 0.7744
Pcdh18_p1 0.3161 0.3336 0.1854 4.74% 0.25% 1.99% 2.5% 0% 95.26% 0.7619
Hsp90aa1 0.7101 0.6272 0.9994 2.03% 0.05% 1.81% 0.17% 0.05% 97.92% 0.9997
C1d 0.281 0.7413 0.7317 2.52% 0.3% 1.1% 1.12% 0% 97.48% 0.9609
C1d_p1 0.6457 0.8531 0.939 1.65% 0.06% 0.93% 0.65% 0% 98.35% 0.9962
Alkbh7 0.1137 0.832 0.4634 3.83% 0.75% 1.06% 2.01% 0% 96.17% 0.8886
Gabrq.1 0.5011 0.0623 0.5738 5.29% 0.11% 3.79% 1.39% 1.2% 93.51% 0.9424
Gabrq.1_p1 0.1423 0.3405 0.0996 5.45% 0.53% 1.95% 2.97% <0.01% 94.55% 0.6101
Nap1l5 0.1522 0.7045 0.4879 4.82% 0.65% 2.13% 2.04% 4.63% 90.56% 0.8917
Htr2c_p1 2e-04 0.2936 0.0955 9.65% 3.81% 2.4% 3.44% 0% 90.35% 0.6101
Htr2c_p2 0.4903 0.0801 0.1566 6.34% 0.13% 3.39% 2.83% 0% 93.66% 0.7457
Commd3 0.1521 0.4742 0.1646 5.64% 0.61% 1.95% 3.09% <0.01% 94.36% 0.7619
Fnbp1l 0.0713 0.3674 0.4533 5.79% 1.07% 2.5% 2.22% 0% 94.21% 0.8796
Fnbp1l_p1 0.3274 0.019 0.0346 8.55% 0.25% 4.37% 3.94% <0.01% 91.45% 0.4509
Fnbp1l_p2 0.5452 0.5877 0.4193 5.84% 0.07% 4.37% 1.4% 18.6% 75.56% 0.8712
Ccrn4l 0.6856 0.5658 0.9132 2.2% 0.04% 1.48% 0.68% <0.01% 97.8% 0.9962
Dner 0.022 0.0779 0.0668 8.92% 1.5% 3.65% 3.77% <0.01% 91.08% 0.5744
Syt4 0.8734 0.1662 0.9867 3.25% 0.01% 2.87% 0.38% <0.01% 96.75% 0.9997
Syt4_p3 1e-04 0.735 0.909 6% 4% 1.27% 0.72% 0.8% 93.2% 0.9962
Sybu 0.2192 0.0074 0.5445 6.52% 0.37% 4.7% 1.45% <0.01% 93.48% 0.9126
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Tnks2 0.7385 0.3702 0.1142 4.88% 0.03% 1.99% 2.87% 0.47% 94.64% 0.6372
Tnks2_p1 0.0609 0.6622 0.3116 4.77% 0.82% 2.01% 1.93% 5.37% 89.87% 0.8427
Tnks2_p2 0.1367 0.07 0.1022 7.87% 0.64% 3.78% 3.45% 0% 92.13% 0.6101
Zcchc18 0.845 0.0779 0.818 4.48% 0.01% 3.48% 1% <0.01% 95.52% 0.9877
Map2k1 0.6406 0.805 0.8268 2.45% 0.06% 1.43% 0.96% 3.56% 94% 0.9877
Map2k1_p1 0.3144 0.4505 0.0484 5.89% 0.27% 1.82% 3.8% <0.01% 94.11% 0.5072
Glrb_p2 0.2946 0.0203 0.552 6.88% 0.32% 4.84% 1.72% <0.01% 93.12% 0.9215
Olfm1.1 0.0885 0.142 0.6081 7.2% 0.9% 4.61% 1.69% 3.55% 89.25% 0.9445
Nrsn1 0.6589 0.8472 0.9827 2.52% 0.05% 2.11% 0.36% 12.12% 85.36% 0.9997
Nrsn1_p1 0.259 0.0722 0.7942 7.59% 0.34% 6.21% 1.04% 6.67% 85.74% 0.9875
Epm2aip1 0.4896 0.0034 0.6733 7.13% 0.11% 5.84% 1.17% 1.14% 91.73% 0.9457
Epm2aip1_p1 0.8947 0.594 0.0702 4.64% <0.01% 1.38% 3.26% 0% 95.36% 0.5766
Epm2aip1_p2 0.9445 0.08 0.2619 6.98% <0.01% 4.72% 2.26% 3.75% 89.28% 0.8105
Epm2aip1_p3 0.0647 0.8404 0.7892 4.06% 1.28% 1.3% 1.47% 0% 95.94% 0.9842
Epm2aip1_p4 6e-04 0.2632 0.1843 9% 2.53% 4.3% 2.17% 8.63% 82.37% 0.7619
Tle4 0.5659 0.8261 0.6778 2.59% 0.09% 1.18% 1.32% 1.84% 95.57% 0.9457
Tle4_p1 0.3776 0.1224 0.1002 7.66% 0.17% 4.79% 2.7% 6.24% 86.1% 0.6101
Snap25 0.9964 0.718 0.6202 2.92% <0.01% 1.62% 1.3% 3.65% 93.43% 0.9457
Snap25_p1 0.6404 0.7483 0.6696 3.46% 0.05% 2.29% 1.11% 9.93% 86.61% 0.9457
Cnr1 0.1081 0.4565 0.8324 3.87% 0.78% 2.03% 1.06% <0.01% 96.13% 0.9877
Cnr1_p4 0.6004 0.2607 0.6471 3.59% 0.07% 2.24% 1.28% <0.01% 96.41% 0.9457
Cnr1_p5 0.0017 0.0041 0.0928 10.07% 2.31% 4.89% 2.87% <0.01% 89.93% 0.6101
Cnr1_p6 0.4981 0.3502 0.4539 4.65% 0.14% 2.51% 2% 0.81% 94.53% 0.8796
Plagl1 0.2929 0.307 0.1368 5.07% 0.27% 2.06% 2.74% 0% 94.93% 0.7076
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Plagl1_p1 0.794 0.7469 0.4026 3.54% 0.02% 1.33% 2.19% 0.31% 96.15% 0.8712
Plagl1_p2 3e-04 0.8854 0.9288 4.7% 3.33% 0.75% 0.62% <0.01% 95.3% 0.9962
Impact 0.2997 0.5767 0.207 4.48% 0.29% 1.55% 2.64% 0% 95.52% 0.7651
Tmem35 0.1239 0.0184 0.6581 7.48% 0.68% 5.36% 1.44% 1.01% 91.51% 0.9457
Atp2c1 0.6931 0.9134 0.7388 2.74% 0.03% 1.76% 0.94% 14.1% 83.16% 0.9609
Fem1c 0.0302 0.7743 0.0448 6.28% 1.23% 1.29% 3.77% 1.79% 91.92% 0.5072
Qdpr 0.9618 0.0474 0.0031 10.08% <0.01% 4.01% 6.07% 0% 89.92% 0.144
Stx7 0.2115 0.4116 0.6971 3.39% 0.39% 1.81% 1.18% 0% 96.61% 0.9457
Stx7_p1 0.0524 0.4357 0.4676 5.46% 0.86% 3.08% 1.52% 6.88% 87.66% 0.8886
Stx7_p2 0.5915 0.3225 0.8817 4.6% 0.09% 3.54% 0.97% 3.72% 91.67% 0.9959
Enc1.1 0.0538 0.9095 0.8572 2.7% 1.03% 0.75% 0.91% 0% 97.3% 0.9907
Enc1.1_p1 0.2905 0.3021 0.7674 5.92% 0.3% 4.52% 1.1% 8.72% 85.36% 0.9788
Enc1.1_p2 0.4434 0.7487 0.8243 3.19% 0.19% 1.83% 1.17% 3.29% 93.52% 0.9877
Enc1.1_p3 0.5375 0.3051 0.1441 7.34% 0.09% 4.7% 2.54% 10.57% 82.1% 0.7252
Peg3_p1 0.3487 0.2373 0.184 5.95% 0.26% 2.72% 2.97% 0% 94.05% 0.7619
Scoc 0.0481 0.066 0.0145 9.27% 1% 3.8% 4.47% 0.99% 89.74% 0.3399
Rab18_p1 0.0624 0.0943 0.7747 5.32% 0.94% 3.29% 1.09% <0.01% 94.68% 0.9788
Rab18_p2 0.061 0.8027 0.2347 4.94% 1.05% 1.13% 2.76% <0.01% 95.06% 0.796
Rab18_p3 0.1163 0.5161 0.0341 7.24% 0.7% 2.26% 4.28% 2.61% 90.15% 0.4509
Rab18_p4 0.5959 0.4064 0.78 4.31% 0.11% 2.71% 1.5% <0.01% 95.69% 0.9788
Rab18_p5 0.0322 0.7587 0.4356 4.72% 1.18% 1.77% 1.78% 5.35% 89.92% 0.8719
Rab18_p6 0.1799 0.869 0.6796 2.72% 0.5% 0.88% 1.34% <0.01% 97.28% 0.9457
Rab18_p7 0.4666 0.9461 0.8926 1.94% 0.18% 0.76% 1% 0% 98.06% 0.9959
Rab18_p8 0.2002 0.4079 0.8911 3.56% 0.5% 2.18% 0.89% 0% 96.44% 0.9959
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Ube2e3 0.0509 0.256 0.5111 6.21% 1.25% 2.93% 2.04% 0% 93.79% 0.893
Ttc3 0.1204 0.2113 0.8541 6.45% 0.58% 5.07% 0.8% 9.17% 84.38% 0.9907
Ttc3_p2 0.0988 0.3589 0.4107 5.94% 0.61% 3.73% 1.61% 8.28% 85.77% 0.8712
Lin7c 0.1473 0.4796 0.5086 4.07% 0.57% 1.78% 1.71% 0% 95.93% 0.893
Lin7c_p3 0.7888 0.0162 0.0124 9.93% 0.02% 4.86% 5.06% 0% 90.07% 0.3086
Lin7c_p4 0.0817 0.0204 0.5387 7.43% 0.88% 4.81% 1.74% <0.01% 92.57% 0.9063
Lin7c_p5 0.0109 0.0137 0.6299 8.43% 1.86% 5.07% 1.51% 0% 91.57% 0.9457
Gpr101_p1 0.0027 0.0512 0.029 11.34% 2.46% 4.64% 4.24% 1.9% 86.76% 0.4396
Gpr101_p2 0.1456 0.1875 0.0944 10.09% 0.58% 6.15% 3.36% 10.77% 79.13% 0.6101
Gpr101_p3 0.0051 3.02E-5 1.16E-5 17.7% 1.84% 7.67% 8.19% 0% 82.3% 0.0049
Gpr101_p4 0.0963 0.649 0.5238 4.39% 0.64% 2.33% 1.42% 7.26% 88.35% 0.8955
Gpr101_p5 0.04 0.9848 0.8443 3.11% 1.37% 0.63% 1.11% 3.75% 93.14% 0.9907
Gpr101_p6 0.0941 0.4993 0.6208 4.44% 0.83% 2.02% 1.58% 0.66% 94.9% 0.9457
Gpr101_p7 0.0254 0.0021 0.2241 8.79% 1.19% 5.36% 2.24% 0% 91.21% 0.7744
Hnmt 0.8362 0.0026 0.7825 6.89% 0.01% 5.82% 1.05% 0% 93.11% 0.9788
Syt1 0.5351 0.8899 0.4543 3.03% 0.1% 1.13% 1.79% 3.82% 93.15% 0.8796
Syt1_p1 0.2291 0.1834 0.6724 5.28% 0.34% 3.79% 1.15% 4.46% 90.26% 0.9457
Syt1_p3 0.358 0.1425 0.3422 5.3% 0.23% 2.94% 2.13% 0% 94.7% 0.8712
Pspc1 0.0158 0.3046 0.2745 5.73% 1.43% 2.18% 2.13% 0.54% 93.73% 0.8313
Pspc1_p1 0.9132 0.0139 0.4295 7.9% <0.01% 5.65% 2.24% 0% 92.1% 0.8712
Rnf11 0.3719 0.3903 0.685 3.28% 0.2% 1.86% 1.21% <0.01% 96.72% 0.9457
Rnf11_p1 0.3738 0.1946 0.252 5.81% 0.23% 2.92% 2.66% <0.01% 94.19% 0.8105
Rnf11_p2 0.1378 0.1066 0.9371 5.4% 0.73% 3.9% 0.78% 0% 94.6% 0.9962
Plxnc1 0.1244 0.2678 0.3548 6.06% 0.6% 3.48% 1.98% 4.48% 89.46% 0.8712
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Plxnc1_p1 0.0322 0.4876 0.4686 4.79% 1.24% 1.75% 1.8% 0% 95.21% 0.8886
Plxnc1_p2 0.1538 0.6781 0.8241 4.16% 0.75% 2.08% 1.33% 1.95% 93.89% 0.9877
Plxnc1_p3 0.2833 0.9444 0.9423 1.46% 0.3% 0.58% 0.59% 0% 98.54% 0.9962
Rgmb 0.0753 0.1973 0.0456 7.57% 0.82% 3.05% 3.71% 1.62% 90.81% 0.5072
Rgmb_p1 0.5595 0.645 0.5118 3.54% 0.1% 1.55% 1.89% 0% 96.46% 0.893
Cadps 0.1233 0.1075 0.2212 6.31% 0.63% 3.15% 2.53% <0.01% 93.69% 0.7744
Cadps_p1 0.4468 0.2296 0.1291 6.86% 0.19% 3.03% 3.64% 0% 93.14% 0.6843
Cadps_p2 0.3335 0.6435 0.8127 3.04% 0.25% 1.79% 1% 2.51% 94.45% 0.9877
Ube2b 0.4301 0.0328 0.0923 6.85% 0.15% 3.71% 2.98% 0% 93.15% 0.6101
Ube2b_p1 0.6005 0.5539 0.8974 3.6% 0.08% 2.71% 0.81% 5.62% 90.78% 0.9961
Shroom2_p1 0.2131 0.4297 0.019 6.99% 0.35% 2.8% 3.83% 5.49% 87.53% 0.3834
Nptn.1 0.1259 0.06 0.7101 5.07% 0.58% 3.36% 1.14% 0% 94.93% 0.9457
B3galnt1 0.6395 0.7892 0.9256 1.86% 0.06% 1.1% 0.7% <0.01% 98.14% 0.9962
B3galnt1_p1 0.5119 0.1698 0.3891 4.53% 0.11% 2.58% 1.84% <0.01% 95.47% 0.8712
B3galnt1_p2 0.0278 0.1013 0.9235 5.55% 1.16% 3.78% 0.61% 2.39% 92.06% 0.9962
Calm2 0.7258 0.5677 0.1256 5.24% 0.03% 2.3% 2.91% 4.53% 90.23% 0.6742
Dnajc6 6.34E-5 0.0092 5e-04 19.17% 3.11% 10.98% 5.07% 12.53% 68.3% 0.0511
Plcb1.1 0.0061 0.543 0.3031 5.53% 1.83% 1.66% 2.04% 1.08% 93.4% 0.8427
Plcb1.1_p1 0.0012 0.0559 0.7102 8.28% 3.01% 3.95% 1.32% 0% 91.72% 0.9457
Plcb1.1_p2 0.4311 0.7482 0.6586 3.85% 0.17% 2.31% 1.38% 8.46% 87.69% 0.9457
Plcb1.1_p3 0.7066 0.7139 0.4786 3.31% 0.03% 1.7% 1.58% 4.21% 92.47% 0.8901
Plcb1.2 2e-04 0.0089 0.5357 13.21% 3.13% 8.72% 1.36% 7.63% 79.15% 0.905
Plcb1.2_p1 0.1193 0.7309 0.5876 3.24% 0.61% 1.23% 1.4% 0.92% 95.85% 0.9441
Plcb1.2_p2 0.9232 0.7616 0.3487 3.35% <0.01% 1.21% 2.14% 0.53% 96.12% 0.8712
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Plcb1.2_p3 0.2463 0.0188 0.9763 9.48% 0.45% 8.48% 0.55% 5.47% 85.04% 0.9997
Plcb1.2_p4 0.442 0.0064 0.0747 8.63% 0.15% 5.12% 3.36% <0.01% 91.37% 0.5766
Plcb1.2_p5 0.1246 0.6224 0.5179 4.16% 0.71% 1.59% 1.86% 0% 95.84% 0.8955
Srp9 0.0058 0.0288 0.202 7.94% 1.83% 3.76% 2.35% <0.01% 92.06% 0.7639
Srp9_p1 0.1528 0.0814 0.7356 5.64% 0.6% 3.74% 1.29% <0.01% 94.36% 0.9609
Pja2 0.7249 0.7964 0.9837 1.53% 0.03% 1.08% 0.41% <0.01% 98.47% 0.9997
Pja2_p1 0.0136 0.0302 0.4848 6.83% 1.48% 3.77% 1.58% <0.01% 93.17% 0.8917
Pja2_p2 0.2752 0.266 0.9973 2.99% 0.33% 2.44% 0.22% <0.01% 97.01% 0.9997
Pja2_p3 0.3545 0.1078 0.4951 6.22% 0.28% 3.85% 2.09% 0% 93.78% 0.893
Isca1 0.1339 0.0371 0.0212 10.62% 0.61% 5.58% 4.44% 3.32% 86.06% 0.4019
Isca1_p1 0.9522 0.2373 0.417 4.51% <0.01% 2.58% 1.93% 0.28% 95.21% 0.8712
Isca1_p2 0.2066 0.1432 0.2569 7% 0.4% 4.35% 2.25% 4.72% 88.28% 0.8105
Azin1 0.5168 0.7746 0.8 2.81% 0.14% 1.37% 1.29% 0% 97.19% 0.9877
Lrp12 4e-04 0.3855 0.3814 7.95% 3.65% 2.14% 2.16% 0% 92.05% 0.8712
Lrp12_p1 0.0101 0.025 0.6941 7.9% 1.91% 4.62% 1.36% 0% 92.1% 0.9457
Lrp12_p2 0.3463 0.3006 0.3457 4.65% 0.24% 2.28% 2.13% 0% 95.35% 0.8712
Nxph1 0.3667 0.0736 0.965 4.68% 0.24% 3.87% 0.57% 0% 95.32% 0.9962
Nxph1_p1 0.1833 0.8857 0.5225 3.86% 0.57% 1.31% 1.98% 3.7% 92.44% 0.8955
Slc25a1_p1 0.9723 0.2735 0.7753 6.04% <0.01% 5.09% 0.95% 11.09% 82.86% 0.9788
Slc25a1_p2 0.0036 0.2292 0.4033 9.23% 1.69% 6.09% 1.44% 14.46% 76.32% 0.8712
Slc9a6 0.4667 0.8334 0.7282 2.36% 0.15% 0.98% 1.23% <0.01% 97.64% 0.9609
Slc9a6_p1 0.0342 0.4426 0.7385 4.71% 1.19% 2.37% 1.15% 2.59% 92.7% 0.9609
Cltc 2e-04 0.0752 0.5056 9.48% 3.11% 4.96% 1.4% 5.19% 85.33% 0.893
Vav2 0.077 0.7348 0.5261 3.44% 0.79% 1.1% 1.54% 0% 96.56% 0.8959
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Vav2_p1 0.2318 0.1752 0.4028 5.6% 0.42% 3.03% 2.15% <0.01% 94.4% 0.8712
Kif2a 0.0519 0.319 0.1779 5.46% 0.93% 2.01% 2.52% 0% 94.54% 0.7619
Susd2_p1 0.3467 0.4455 0.4928 3.56% 0.22% 1.72% 1.61% 0% 96.44% 0.893
Susd2_p2 0.4741 0.0277 0.3045 6.54% 0.14% 4.19% 2.22% <0.01% 93.46% 0.8427
Grm7 0.0437 0.1216 0.066 7.57% 1.07% 3.01% 3.49% 0% 92.43% 0.5744
Grm7_p1 0.2865 0.0247 0.517 5.95% 0.28% 4.16% 1.51% 0.48% 93.57% 0.8955
Ubfd1 0.8776 0.3107 0.5081 3.66% 0.01% 2.08% 1.58% 0% 96.34% 0.893
Ubfd1_p1 0.006 0.7334 0.1473 5.61% 1.86% 1.08% 2.66% 0% 94.39% 0.7261
Ubfd1_p2 2.54E-7 0.1178 0.5806 10.25% 6.23% 2.7% 1.32% <0.01% 89.75% 0.9432
Ubfd1_p4 0.0257 0.1241 0.5757 5.44% 1.23% 2.8% 1.41% <0.01% 94.56% 0.9424
Ubfd1_p5 0.0912 0.6345 0.6866 3.24% 0.72% 1.32% 1.21% 0% 96.76% 0.9457
Mpped1 0.0204 0.4659 0.102 6.57% 1.24% 2.57% 2.76% 4.93% 88.49% 0.6101
Mpped1_p1 0.6774 0.2398 0.3526 5.63% 0.06% 3.02% 2.56% 0% 94.37% 0.8712
Mpped1_p2 0.0024 0.2101 0.1917 7.21% 2.21% 2.61% 2.38% 1.01% 91.78% 0.7639
App 0.0105 0.0511 0.371 9.94% 2.32% 4.95% 2.68% 0% 90.06% 0.8712
Syngr3 0.9149 0.3487 0.6154 3.33% <0.01% 1.97% 1.35% <0.01% 96.67% 0.9457
Cdk17 0.7858 0.0464 0.0395 9.45% 0.02% 5.86% 3.58% 5.35% 85.2% 0.4927
Cdk17_p1 0.033 0.2496 0.1011 8.18% 1.45% 2.89% 3.83% <0.01% 91.82% 0.6101
Cdk17_p2 0.0238 0.4576 0.8051 4.72% 1.21% 2.63% 0.89% 4.93% 90.34% 0.9877
Pcdh17 0.5732 0.0248 0.4497 6.19% 0.08% 4.29% 1.82% 0% 93.81% 0.8796
Pcdh17_p1 1.47E-8 0.047 0.3284 14.57% 8.59% 3.81% 2.15% 0% 85.44% 0.8712
Pcdh17_p3 0.9176 0.7498 0.4079 3.84% <0.01% 1.43% 2.41% <0.01% 96.16% 0.8712
Pcdh17_p4 0.995 0.1384 0.0762 6.36% <0.01% 2.94% 3.42% <0.01% 93.64% 0.5766
Pcdh17_p5 0.4082 0.0126 0.0245 8.29% 0.16% 4.28% 3.85% 0% 91.71% 0.4019
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Atp8a1 0.0965 0.8743 0.1109 5.05% 0.7% 1.39% 2.96% 6.17% 88.78% 0.6273
Atp8a1_p1 0.0036 0.9422 0.9958 3.06% 2.09% 0.74% 0.23% 2.44% 94.51% 0.9997
Atp8a1_p2 0.0576 0.8312 0.8666 3.14% 1.09% 1.07% 0.97% 0% 96.86% 0.9938
Atp8a1_p3 0.5322 0.158 0.4185 6.41% 0.09% 4.72% 1.6% 7.02% 86.56% 0.8712
Atp8a1_p4 0.516 0.8016 0.904 3.43% 0.09% 2.76% 0.58% 16.43% 80.14% 0.9962
Atp8a1_p5 0.6154 0.249 0.6161 4.39% 0.08% 2.71% 1.61% 0% 95.61% 0.9457
Atp8a1_p6 0.1102 0.7728 0.5788 4.89% 0.57% 3.06% 1.26% 16.98% 78.12% 0.9432
Socs5 0.5832 0.9467 0.3699 2.57% 0.08% 0.56% 1.93% <0.01% 97.43% 0.8712
Socs5_p1 0.0761 0.0987 0.314 9.95% 0.62% 7.69% 1.63% 14.03% 76.02% 0.8427
Hmgn1 0.0013 3.1E-7 0.0027 19.11% 2.62% 10.95% 5.54% 0% 80.89% 0.1426
Hmgn1_p1 0.0246 0.1382 0.1014 10.27% 1.12% 6.48% 2.66% 11.69% 78.04% 0.6101
Pgap1 0.7216 0.2296 0.4934 6.42% 0.05% 4.09% 2.28% 2.59% 90.99% 0.893
Pgap1_p1 0.3568 0.9044 0.2016 4.64% 0.27% 1.28% 3.09% 4.58% 90.78% 0.7639
Pgap1_p3 0.1073 0.2416 0.2391 6.16% 0.76% 2.69% 2.7% 0% 93.84% 0.8022
Pgap1_p4 0.7189 0.5008 0.0742 4.82% 0.03% 1.58% 3.21% <0.01% 95.18% 0.5766
Pgap1_p5 3e-04 0.9201 0.9615 4.47% 3.33% 0.65% 0.49% 0% 95.53% 0.9962
Ranbp6 0.5973 0.4734 0.1343 5.33% 0.08% 1.95% 3.29% 0% 94.67% 0.703
Ranbp6_p2 0.6069 0.3829 0.643 3.56% 0.07% 2.08% 1.41% 0.15% 96.28% 0.9457
Ahi1 0.6689 0.7743 0.2736 3.27% 0.05% 1.02% 2.2% 0% 96.73% 0.8313
Dnm3 0.0848 0.9497 0.256 3.94% 0.64% 1.35% 1.94% 12.91% 83.15% 0.8105
Dnm3_p1 0.7136 0.0012 0.3852 12.21% 0.03% 10.46% 1.72% 6.65% 81.14% 0.8712
Dnm3_p2 0.3259 0.2046 0.6053 6.04% 0.22% 4.6% 1.22% 7.92% 86.04% 0.9445
Dnm3.1_p3 0.109 0.0051 0.4098 7.87% 0.67% 5.31% 1.89% <0.01% 92.13% 0.8712
Dnm3.1_p5 0.7425 0.7085 0.1207 4.4% 0.03% 1.25% 3.11% <0.01% 95.6% 0.656
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Slc19a1 0.3533 0.563 0.7803 4.01% 0.22% 2.78% 1.01% 7.22% 88.77% 0.9788
Slc19a1_p1 0.1077 0.5897 0.8793 2.88% 0.65% 1.45% 0.77% 0.21% 96.91% 0.9959
Spsb4 0.3143 0.2449 0.6007 4.78% 0.3% 2.85% 1.63% 0.5% 94.72% 0.9445
Spsb4_p1 0.0264 0.0325 0.8987 7.22% 1.41% 4.98% 0.82% 1.25% 91.54% 0.9961
Spsb4_p2 0.5633 0.1465 0.4289 6.44% 0.08% 4.61% 1.75% 5.58% 87.98% 0.8712
Spsb4_p3 0.3235 0.2058 0.008 7.2% 0.24% 2.35% 4.61% 0% 92.8% 0.2437
Pum1 0.732 0.7011 0.0047 6.7% 0.03% 1.24% 5.43% 0% 93.3% 0.1852
Pum1_p1 0.3058 0.052 0.649 5.41% 0.28% 3.76% 1.37% <0.01% 94.59% 0.9457
Por 0.8519 0.6179 0.928 2.32% 0.01% 1.69% 0.62% 2.13% 95.55% 0.9962
Nbea 0.2321 0.0511 0.1869 6.23% 0.35% 3.43% 2.46% 0% 93.77% 0.7619
Nbea_p1 0.0538 0.6131 0.8804 3.08% 0.94% 1.36% 0.77% <0.01% 96.92% 0.9959
Nbea_p2 0.7394 0.1553 0.4487 7.37% 0.05% 4.5% 2.82% 0.3% 92.33% 0.8796
Wsb2 0.9121 0.785 0.9192 2.24% <0.01% 1.35% 0.89% 0% 97.76% 0.9962
Rab3c 0.5903 0.3861 0.016 6.11% 0.07% 1.82% 4.22% 0% 93.89% 0.3399
Rab3c_p1 0.3588 0.1859 0.556 4.63% 0.23% 2.82% 1.59% 0.31% 95.06% 0.9226
Rab3c_p2 0.0055 0.4626 0.4742 6.16% 2.26% 1.97% 1.93% 0% 93.84% 0.8886
Rab3c_p3 0.2649 0.2551 0.4732 6.23% 0.28% 4.5% 1.46% 8.94% 84.83% 0.8886
Rab3c_p4 0.2417 0.1028 0.7631 4.36% 0.34% 2.98% 1.03% <0.01% 95.64% 0.9788
Rab3c_p5 0.0121 0.8862 0.2036 5.14% 1.7% 0.81% 2.63% 0% 94.86% 0.7639
Rab3c_p6 0.033 0.8229 0.4027 4.21% 1.24% 0.99% 1.98% <0.01% 95.79% 0.8712
Hipk1 0.506 0.8396 0.6768 2.85% 0.1% 1.61% 1.14% 7.39% 89.76% 0.9457
Hipk1_p2 0.6762 0.0071 0.0119 10.21% 0.04% 5.62% 4.55% 1.21% 88.57% 0.3086
Hipk1_p3 0.4493 0.884 0.9833 1.57% 0.14% 1.07% 0.36% 3.39% 95.04% 0.9997
Hipk1_p4 0.5746 0.2862 0.6357 3.54% 0.08% 2.15% 1.31% <0.01% 96.46% 0.9457
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Prkacb_p1 0.8851 0.6 0.3956 5.19% <0.01% 3.65% 1.54% 14.52% 80.29% 0.8712
Prkacb_p2 0.2123 0.4879 0.9997 2.34% 0.43% 1.8% 0.12% <0.01% 97.66% 0.9997
Prkacb_p3 0.5627 0.8378 0.0965 4.08% 0.08% 1% 3% 1.28% 94.64% 0.6101
Dnaja1 0.006 0.0835 0.0117 11.74% 2.32% 3.86% 5.55% 0% 88.26% 0.3086
Dnaja1_p1 0.8911 0.5804 0.4512 4.14% <0.01% 2.38% 1.75% 5.21% 90.65% 0.8796
Dnaja1_p2 0.4797 0.1678 0.1751 5.68% 0.13% 2.79% 2.75% 0% 94.32% 0.7619
Atmin 0.6364 0.9283 0.9991 0.97% 0.06% 0.75% 0.16% 0.69% 98.34% 0.9997
Atmin_p1 0.0692 0.5216 0.8998 4.14% 0.85% 2.55% 0.73% 4.95% 90.91% 0.9961
Atmin_p2 0.1166 0.5215 0.4757 4.25% 0.67% 1.8% 1.78% 0.69% 95.07% 0.8886
Htr7 0.5165 0.0636 0.1514 6.53% 0.11% 3.56% 2.85% 0% 93.47% 0.7361
Htr7_p1 0.1139 0.0145 0.693 7.19% 0.73% 5.09% 1.38% 0% 92.81% 0.9457
Uhrf2 0.962 0.5299 0.8632 2.72% <0.01% 1.83% 0.89% 0.82% 96.47% 0.9938
Uhrf2_p1 0.0175 0.1714 0.8501 4.8% 1.4% 2.56% 0.83% 0% 95.2% 0.9907
Rnf14 0.9305 0.0738 0.2506 7.11% <0.01% 4.19% 2.92% 0% 92.89% 0.8105
Zic4 0.3792 0.3562 0.9429 4.75% 0.17% 4.06% 0.51% 9.62% 85.63% 0.9962
Zic4_p1 0.6155 0.297 0.3009 5.07% 0.08% 2.51% 2.49% 0% 94.93% 0.8427
Zic4_p2 0.2842 0.6931 0.1741 4.11% 0.29% 1.27% 2.55% 0.67% 95.22% 0.7619
Crocc 0.3484 0.1654 0.4573 4.5% 0.22% 2.6% 1.68% <0.01% 95.5% 0.8814
Nrep 0.4004 0.5309 0.2031 5.06% 0.16% 2.64% 2.25% 6.52% 88.42% 0.7639
Cul4b 0.079 0.9198 0.508 3.03% 0.78% 0.66% 1.59% 0% 96.97% 0.893
Cul4b_p1 0.5651 0.6337 0.3479 3.89% 0.09% 1.7% 2.1% 1.8% 94.31% 0.8712
Cul4b_p2 0.97 0.337 0.8321 3.17% <0.01% 2.19% 0.97% 0% 96.83% 0.9877
Cul4b_p3 0.0804 0.5834 0.111 5.16% 0.75% 1.54% 2.87% 0.87% 93.97% 0.6273
Tmem30a_p1 0.7061 0.4268 0.8726 2.86% 0.04% 1.95% 0.87% 0.04% 97.1% 0.9959
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Tmem30a_p2 0.1292 0.7606 0.0062 7.06% 0.6% 1.36% 5.1% 2.2% 90.74% 0.22
Tmem30a_p3 0.6741 0.0377 0.7723 5.65% 0.05% 4.4% 1.2% 0% 94.35% 0.9788
Tmem30a_p4 0.0628 0.4597 0.3747 4.51% 0.86% 1.78% 1.87% 0.57% 94.92% 0.8712
Fem1b 2.68E-9 0.5939 0.6265 10.8% 8.18% 1.41% 1.22% 0.74% 88.46% 0.9457
Fem1b_p1 0.3682 0.9916 0.8922 1.51% 0.25% 0.36% 0.9% 0% 98.49% 0.9959
Fem1b_p2 0.0031 0.1327 0.658 6.63% 2.33% 2.96% 1.33% <0.01% 93.38% 0.9457
Fem1b_p3 0.1279 0.993 0.2606 3.72% 0.7% 0.33% 2.68% 0% 96.28% 0.8105
Fem1b_p5 0.5986 0.4938 0.3323 4.01% 0.08% 1.75% 2.19% <0.01% 95.99% 0.8712
Zdhhc13 0.0038 0.4974 0.0747 7.3% 2.22% 1.68% 3.41% <0.01% 92.7% 0.5766
Peg10 0.1793 0.4435 0.6391 3.49% 0.45% 1.73% 1.3% 0% 96.51% 0.9457
Peg10_p2 0.0811 0.0011 0.7115 9.95% 0.95% 7.56% 1.44% 0% 90.06% 0.9457
Peg10_p3 0.0077 0.0847 0.3112 7.35% 1.87% 3.3% 2.18% 0% 92.65% 0.8427
Peg10_p4 0.1364 0.0965 0.3126 7.95% 0.49% 5.65% 1.81% 7.87% 84.18% 0.8427
Peg10_p5 1e-04 0.3267 0.2099 9.02% 3.79% 2.82% 2.41% 3.17% 87.81% 0.7651
Peg10_p6 0.4436 0.9187 0.2908 4.85% 0.19% 1.94% 2.72% 13.48% 81.67% 0.8427
Peg10.1 0.1064 0.8676 0.9853 2.45% 0.89% 1.08% 0.48% 0% 97.55% 0.9997
Peg10.1_p1 0.7797 0.106 0.7108 6.1% 0.02% 4.92% 1.16% 5.19% 88.72% 0.9457
Peg10.1_p2 0.4913 0.0718 0.3008 5.86% 0.13% 3.49% 2.25% <0.01% 94.14% 0.8427
Nsf 0.4592 0.525 0.9724 4.95% 0.12% 4.43% 0.39% 15.89% 79.16% 0.9997
Hap1 2.74E-5 0.3825 0.0013 14.8% 3.49% 6.62% 4.69% 21.98% 63.22% 0.0915
Tmem66 0.1918 0.923 0.8867 2.02% 0.48% 0.71% 0.83% 0% 97.98% 0.9959
Serpini1 0.9715 0.0812 0.1038 8.37% <0.01% 5.11% 3.26% 4.14% 87.49% 0.6112
Serpini1_p1 0.966 0.0976 0.2239 7.18% <0.01% 4.81% 2.36% 4.69% 88.13% 0.7744
Serpini1_p2 0.6695 0.1626 0.2592 5.87% 0.04% 3.73% 2.1% 3.82% 90.31% 0.8105
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Myh10 0.189 0.6342 0.2994 4.53% 0.45% 1.86% 2.21% 2.99% 92.48% 0.8427
Myh10_p1 0.5524 0.3412 0.4455 3.87% 0.09% 2.07% 1.71% 0.4% 95.73% 0.8796
Slc39a11 0.0049 0.9812 0.9939 2.68% 1.99% 0.43% 0.27% 0.89% 96.43% 0.9997
Slc39a11_p1 0.0036 0.2468 0.4359 6.52% 2.25% 2.42% 1.85% 0% 93.48% 0.8719
Slc39a11_p3 0.0315 0.0977 0.0677 8.92% 1.03% 4.97% 2.93% 6.03% 85.04% 0.5744
Slc39a11_p4 2e-04 0.9401 0.7713 6.15% 3.86% 1.19% 1.1% 7.7% 86.15% 0.9788
Kcnd2 0.0028 0.4407 0.9215 6.77% 3.26% 2.57% 0.94% 0.28% 92.95% 0.9962
Kcnd2_p1 0.1966 0.9763 0.1811 3.85% 0.4% 1.01% 2.44% 11.73% 84.42% 0.7619
Kcnd2_p2 0.3368 0.1383 0.9572 4.2% 0.28% 3.31% 0.61% 0% 95.8% 0.9962
Kcnd2_p3 0.0022 0.0198 3e-04 13.27% 2.33% 4.11% 6.83% 0% 86.73% 0.0511
Lpin2 8e-04 0.6968 0.0351 10.36% 2.85% 3.69% 3.82% 16.96% 72.68% 0.4509
Lpin2_p1 0.3347 0.3943 0.6604 4.96% 0.23% 3.47% 1.25% 7.09% 87.96% 0.9457
Lpin2_p2 0.0308 0.3211 0.0482 7.16% 1.23% 2.18% 3.74% 0.14% 92.71% 0.5072
Mecp2 0.0948 0.8247 0.3113 3.68% 0.7% 0.9% 2.07% <0.01% 96.32% 0.8427
Mecp2_p1 0.3585 0.1163 0.6381 4.39% 0.21% 2.88% 1.29% 0% 95.61% 0.9457
Mecp2_p3 0.9 0.611 0.6075 2.89% <0.01% 1.52% 1.36% 0.99% 96.12% 0.9445
Mecp2_p4 0.132 0.2321 0.1201 6.15% 0.61% 2.49% 3.06% <0.01% 93.85% 0.656
Mecp2_p6 0.0207 0.0128 0.9485 6.74% 1.42% 4.73% 0.58% <0.01% 93.26% 0.9962
Mecp2_p7 0.0035 0.9234 0.7547 3.94% 2.07% 0.85% 1.03% 2.82% 93.23% 0.9755
Mecp2_p8 0.2527 0.266 0.3837 4.39% 0.33% 2.2% 1.86% <0.01% 95.61% 0.8712
Mecp2_p9 0.9841 0.7242 0.4001 3.24% <0.01% 1.23% 2.01% <0.01% 96.76% 0.8712
Ran 0.293 0.0029 0.0668 9.99% 0.28% 6.37% 3.34% 1.3% 88.71% 0.5744
Ran_p1 0.2252 0.4682 0.9602 3.07% 0.45% 2.02% 0.61% <0.01% 96.93% 0.9962
Cox14 0.3651 0.9106 0.9338 1.53% 0.21% 0.7% 0.62% <0.01% 98.47% 0.9962
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Blcap 0.1165 0.0026 0.9473 7.89% 0.58% 6.79% 0.52% 2.39% 89.73% 0.9962
Blcap_p1 0.3152 0.0116 0.0235 20.56% 0.14% 18.25% 2.18% 27.9% 51.53% 0.4019
Wdr82 0.5984 0.8801 0.1807 3.74% 0.07% 1.29% 2.39% 5.91% 90.35% 0.7619
Wdr82_p1 0.4712 0.4746 0.7819 3.44% 0.14% 2.23% 1.07% 2.25% 94.32% 0.9788
Wdr82_p2 0.5805 0.2268 0.2939 4.52% 0.08% 2.34% 2.11% <0.01% 95.48% 0.8427
Fam160b1 0.4801 0.2157 0.5357 7.62% 0.1% 6.29% 1.23% 14.55% 77.83% 0.905
Fam160b1_p1 0.9734 0.8169 0.8419 2.42% <0.01% 1.25% 1.17% <0.01% 97.58% 0.9907
Fam160b1_p2 0.0056 0.2788 0.1406 7.22% 2.03% 2.29% 2.9% <0.01% 92.78% 0.7182
Fam160b1_p3 0.216 0.1888 0.2663 6.01% 0.36% 3.57% 2.07% 3.91% 90.09% 0.8181
Fam160b1_p5 0.3947 0.1314 0.3627 5.28% 0.2% 3.01% 2.07% 0% 94.72% 0.8712
Fam160b1_p6 0.7972 0.1586 0.1726 5.63% 0.02% 2.84% 2.77% 0% 94.37% 0.7619
Fam160b1_p7 0.947 0.3531 0.5733 5.1% <0.01% 3.81% 1.29% 8.45% 86.44% 0.9424
Fam160b1_p8 0.1517 0.2354 0.6536 5.99% 0.51% 4.22% 1.26% 6.62% 87.39% 0.9457
Fam160b1_p9 0.0949 0.5299 0.6869 3.44% 0.7% 1.53% 1.2% 0% 96.56% 0.9457
Arf1 0.0015 0.3383 0.8556 7.02% 2.19% 4.11% 0.72% 9.6% 83.38% 0.9907
Arf1_p2 0.0222 0.5029 0.343 5.37% 1.4% 1.87% 2.1% 0.94% 93.69% 0.8712
Psd3_p1 0.5512 0.418 0.2767 5.44% 0.1% 2.87% 2.47% 3.82% 90.74% 0.8321
Psd3_p3 0.0629 0.8639 0.957 2.43% 0.96% 0.9% 0.57% 0% 97.57% 0.9962
Psd3_p4 0.8392 0.3364 0.0892 6.84% 0.01% 3.81% 3.02% 7.48% 85.68% 0.6101
Psd3_p5 0.9168 0.2492 0.3828 4.92% <0.01% 2.7% 2.22% <0.01% 95.08% 0.8712
Psd3_p7 0.3795 0.2382 0.0885 6.08% 0.21% 2.58% 3.3% 0.43% 93.49% 0.6101
Psd3_p8 0.8037 0.6519 0.8052 2.27% 0.02% 1.29% 0.96% 0% 97.73% 0.9877
Psd3_p9 0.4385 0.1516 0.9134 3.83% 0.16% 2.94% 0.73% 0% 96.17% 0.9962
Psd3_p10 0.1235 0.0426 0.6481 7.19% 0.77% 4.78% 1.64% 0.2% 92.61% 0.9457
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Pgs1.1 0.2334 0.0203 0.475 7.7% 0.4% 5.42% 1.87% 1.33% 90.98% 0.8886
2510039O18Rik 0.9649 0.2783 0.2842 4.68% <0.01% 2.35% 2.33% 0% 95.32% 0.8333
2510039O18Rik_p1 0.0018 0.3082 0.3707 6.79% 2.58% 2.2% 2.01% 0% 93.21% 0.8712
2510039O18Rik_p2 0.2287 0.8179 0.9657 1.79% 0.37% 0.94% 0.48% 0% 98.21% 0.9962
Lingo3 0.7884 0.4077 0.912 2.76% 0.02% 2% 0.75% 0% 97.24% 0.9962
Zbtb5_p1 0.6298 0.7104 0.8576 2.18% 0.06% 1.29% 0.83% 0.88% 96.95% 0.9907
Zbtb5_p2 0.581 0.6364 0.8241 3.19% 0.08% 2.16% 0.94% 4.95% 91.87% 0.9877
Zbtb5_p3 0.7297 0.7934 0.6424 2.65% 0.03% 1.36% 1.26% 3.34% 94.01% 0.9457
Mapk9 0.5889 0.9307 0.2293 3.38% 0.08% 0.77% 2.53% 1.39% 95.23% 0.784
Mapk9_p1 0.0041 0.0616 0.7093 7.97% 2.08% 4.73% 1.16% 3.12% 88.91% 0.9457
Mapk9_p2 0.1368 0.3219 0.4294 4.95% 0.59% 2.49% 1.87% 1.26% 93.79% 0.8712
Mapk9.1 0.0015 0.5044 0.1921 8.2% 2.03% 4.17% 2% 14.67% 77.13% 0.7639
Mapk9.1_p1 0.3381 0.0376 0.1694 7.59% 0.24% 4.68% 2.67% 1.8% 90.61% 0.7619
Mapk9.1_p2 0.0595 0.4747 0.029 6.29% 0.87% 1.61% 3.82% 0% 93.71% 0.4396
Mapk9.1_p3 0.4623 0.0482 0.3804 5.48% 0.13% 3.5% 1.85% <0.01% 94.52% 0.8712
Dcaf7 5e-04 0.0377 0.0596 10.59% 3.11% 4.06% 3.43% 0.63% 88.78% 0.5492
Dcaf7_p1 0.6107 0.1285 0.2841 5.41% 0.07% 3.03% 2.31% 0% 94.59% 0.8333
Dcaf7_p2 0.2326 0.7672 0.83 2.52% 0.4% 1.14% 0.99% 0% 97.48% 0.9877
Dcaf7_p3 0.7722 0.6439 0.5856 2.75% 0.02% 1.3% 1.43% 0% 97.25% 0.9441
Dcaf7_p4 0.1959 0.8031 0.3704 3.3% 0.42% 0.96% 1.92% <0.01% 96.7% 0.8712
Vat1l 0.0657 0.1438 0.626 5.02% 0.83% 2.88% 1.3% 0.58% 94.41% 0.9457
Reep1 0.0872 0.069 0.2158 6.27% 0.72% 3.21% 2.34% 0% 93.73% 0.7744
Reep1_p1 0.5347 0.4383 0.4279 3.6% 0.1% 1.74% 1.76% 0% 96.4% 0.8712
Reep1_p2 0.0036 0.1655 0.0312 8.67% 1.97% 3.11% 3.59% 2.09% 89.23% 0.4415
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PTRE-Seq - Effects on Translation Efficiency Cont’d
Gene.UTR_Peak sequence condition interaction R2 sequence condition interaction within samples unexplained FDR
Reep1_p3 0.7378 0.8131 0.9319 1.9% 0.03% 1.2% 0.67% 1.56% 96.54% 0.9962
Reep1_p4 0.0269 0.8156 0.1454 4.95% 1.19% 1.12% 2.64% 1.93% 93.13% 0.7252
Myo5a 0.4281 0.9587 0.8853 1.93% 0.21% 0.69% 1.02% <0.01% 98.07% 0.9959
Myo5a_p1 0.0281 0.2048 0.2481 6.3% 1.29% 2.6% 2.42% <0.01% 93.7% 0.8105
Myo5a_p2 0.0195 0.007 0.1967 8.31% 1.31% 4.64% 2.36% 0% 91.69% 0.7639
Myo5a_p3 0.6171 0.1128 0.008 9.17% 0.06% 4.93% 4.19% 6.46% 84.36% 0.2437
Myo5a_p4 0.1569 0.0635 0.4069 5.62% 0.49% 3.36% 1.77% 0.16% 94.22% 0.8712
Myo5a_p5 0.6729 0.1462 0.8315 7.34% 0.04% 6.56% 0.74% 12.67% 79.99% 0.9877
Myo5a_p6 0.9636 0.9273 0.8672 1.63% <0.01% 0.74% 0.89% 0.55% 97.82% 0.9938
Myo5a_p7 0.4751 0.341 0.3838 4.15% 0.13% 2.17% 1.85% 0.86% 95% 0.8712
Myo5a_p8 0.2185 0.1607 0.046 6.98% 0.4% 2.79% 3.79% <0.01% 93.02% 0.5072
Myo5a_p9 0.8096 0.741 0.3461 3.64% 0.02% 1.53% 2.09% 2.8% 93.56% 0.8712
8430427H17Rik 0.2992 0.1714 0.507 4.41% 0.27% 2.57% 1.57% 0% 95.59% 0.893
8430427H17Rik_p2 0.3032 0.9238 0.1717 3.81% 0.29% 0.7% 2.83% 0% 96.19% 0.7619
8430427H17Rik_p3 0.3465 0.2641 0.7167 3.59% 0.22% 2.23% 1.14% <0.01% 96.41% 0.9497
8430427H17Rik_p5 0.1553 0.2367 0.9626 3.33% 0.51% 2.33% 0.49% <0.01% 96.67% 0.9962
8430427H17Rik_p6 0.3231 0.4226 0.5014 3.93% 0.27% 1.93% 1.73% 0% 96.07% 0.893
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Table S8: Oligos for PTRESeq Library Generation
name sequence (5´-3´)
pCMV_T7-F tgacacgcgtGTTGACATTGATTATTGACTAGTTA
pCMV_T7-R tgacggatccTCCCTATAGTGAGTCGTATTAATTT
pmrPTRE_AAV_Full_F taagctagcctggtaccGGCATCCCTGTGACCCCTC
pmrPTRE_AAV_Full_R ggtaccaggctagcttaCTTGTACAGCTCGTCCATGCCGTAC
GFP-F CCTACGGCGTGCAGTGCTTCAGC
GFP-R CGGCGAGCTGCACGCTGCGTCCTC
pmrPTRE antisense GGCACTGGAGTGGCAACT
pmrPTRE sense gcatggacgagctgtacaag
KpnI_overhang_1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCATgta*c
KpnI_overhang_2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGGTgta*c
KpnI_overhang_3 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTTCCTgta*c
KpnI_overhang_4 ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCAGCTgta*c
KpnI_complement_1 /5phos/A*TGAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-3
KpnI_complement_2 /5phos/A*CCTGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-3
KpnI_complement_3 /5phos/A*GGAACAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-3
KpnI_complement_4 /5phos/A*GCTGCTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-3
NheI_overhang /5phos/c*tagAGATCGGAAGAGCACACGTCTG
NheI_complement CAGACGTGTGCTCTTCCGATC*T
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Conclusions and Future Directions
Summary
In this dissertation I have presented data along two parallel lines of inquiry regarding
the function of the CELF6 RNA binding protein. First, I have presented additional data
to our original 2013 study of this protein’s association to behavior by characterizing the
spectral and temporal features of the vocalization of Celf6−/− mice. These data have
not been published previously, but were presented at the International Meeting for Autism
Research in 2013. At that time, I proposed that we use a conditional knockout strategy to
narrow the phenotype of Celf6−/− mice. Initially, before Susan Maloney in our group went
on to fully describe where in the brain CELF6 is expressed, we hypothesized that the loss
of CELF6 to the serotonergic cells would be sufficient to recapitulate the phenotype of the
global null. This was not the case, and was also not the case when we expanded our
search to include dopaminergic neurons.
In parallel, I was interested in understanding the biology of CELF6 which may con-
tribute to the USV phenotype. When I uncovered that CELF6 primarily associated with
3’UTRs in vivo my immediate hypothesis was that it may, like CELF1, affect transcript
stability or translation. PTRE-Seq enabled me to ask this question across hundreds of in
vivo-identified regulatory elements. In vitro, CELF6 overexpression was not associated
with changes to all of them. This is actually expected: some targets may be false posi-
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tives or of low binding affinity, furthermore, in vitro the molecular context in which CELF6
is embedded is different from its in vivo context(s). Nevertheless, wherever CELF6 did
correlate to changes in reporter abundance, these were overwhelmingly to reduce the
levels of the reporter. These reductions were ablated by mutating in silico defined se-
quence motifs, many of which were UGU-containing elements. Translation efficiency of
reporter library elements was altered in some cases, but some reporters went up and
some went down and there were no generalizable trends. Thus on a case-by-case basis
it seems that CELF6 can exert effects on translation, but that largely its effects are on
mRNA abundance.
Future Directions
Does CELF6 enhance mRNA decay?
So far, I have been conservative in my language regarding the mechanism of CELF6’s
action on elements of the PTRE-Seq library, and thus on its 3’UTR targets. Nevertheless,
the lack of generalizable effects on translation, and the apparent trends in reporter level
reduction lead me to hypothesize that CELF6’s actions are on destabilizing mRNA. This
is supported by previous research on CELF1 which can associate and recruit the PARN
de-adenylase which enhances mRNA degradation.
To replicate the findings of the reporter assay, I have subcloned example reporters
shown in Chapter 5, Figures 3 and 4, as individual plasmids. This replication work is cur-
rently on-going. Additionally, using ethynyl uridine incorporation into nascent transcripts
will allow us to calculate decay constants for each element in the library. Repeating the
PTRE-Seq assay at multiple time points using this pulse labeling procedure can allow
us to determine whether CELF6 condition interacts with the slope of mRNA decay, the
hypothesis being that it quickens mRNA decay rates.
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CELF1 association has been shown to enhance de-adenylase enzymatic activity as
described in Chapter 4. Using co-immunoprecipitation, we can determine whether CELF6
can directly associate with PARN or another de-adenylase enzyme, and whether mu-
tations of key domains in the CELF6 protein ablate this association and prevent target
degradation.
Does CELF6 result in target repression in vivo?
It is clear from the literature that CELF proteins, like other RNA binding proteins, are
versatile in their function. Thus the cell type and molecular context in which CELF6 is
embedded likely determines the outcome on target molecules. It remains to be shown
whether or not I can generalize my findings in vitro to the brain.
Our PTRE-Seq library was prepared in a construct which can be used to generate
adeno-associated virus (AAV) for in vivo targeting. Currently, work is on-going in our group
to validate and maximize recovery from massively parallel assays injected as virus in vivo.
The CELF6 PTRE-Seq library can be introduced into regions exhibiting enriched CELF6
expression in wild-type and knockout animals. This can enable us to determine whether
(a) CELF6 represses reporter elements in vivo as it does in vitro, and (b) whether these
effects are cell type specific or whether they are true across all regions where CELF6 is
expressed.
Does loss of CELF6 impact neuronal function in vivo?
A number of target mRNAs I identified in CLIP are regulators of synaptic function. One of
most enriched species was the gene coding for the fibroblast growth factor 13 (FGF13).
FGF13 is expressed in the noradrenergic neurons of the locus coeruleus (LC). However,
unlike canonical FGFs, FGF13 is not a growth factor, but rather regulates localization
of voltage-gated sodium channels. Mutations in the FGF13 gene are associated with
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cognitive impairment and an epilepsy-like seizure disorder, and seizures present in mice
with disruption of Fgf13 (Puranam et al., Journal of Neuroscience 2015).
The cited Maloney et al. 2016 study analyzing patterns of CELF6 expression in the
brain found that the LC had the strongest levels of expression across all populations.
Based on its phenotype in vitro, I would hypothesize that FGF13 protein levels would be
reduced in the LC when CELF6 is present and that we would observe elevated levels
in the knockout. These findings can be demonstrated by microscopy study with anti-
FGF13 antibodies. Additionally, we can determine whether the localization of sodium
channels has changed and whether firing patterns of LC neurons are altered in Celf6−/−
knockout mice. The monoaminergic neurotransmitter populations send projections widely
throughout the brain affecting many systems. It is intriguing to hypothesize that changes
to neuronal function in the LC underlie the USV or other behavioral phenotypes observed
in these animals.
What are the molecular and circuit contributions to variability in be-
havior?
Tangential to the CELF6 story was the observation that USV production in neonates was
highly variable from animal to animal, and that animals displayed inconsistent patterns of
behavior from day to day. This is unlike other milestones from this time period such as
righting reflex and weight gain. One cannot predict that measuring the loudest animal on
day X, or the animal of highest pitch, or the animal of largest amount of response on that
day will be likely to exhibit the same position in the population’s distribution on a subse-
quent day. Although numerous environmental signals converge to affect USV, all of which
cannot always be controlled, I still find it remarkable that across hundreds of animals that
are otherwise genetically identical and reared in otherwise identical circumstances, that
such variability can be observed.
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As adults, although some measures of vocalization appeared to stabilize, a number of
features primarily in the frequency domain remained unpredictable from test day to test
day. These findings have two implications: (a) large sample sizes are often necessary to
detect effects on neonatal USV, and (b) there are unknown or unmeasured factors which
contribute to individual variability. Some of these factors may be genes and molecules,
some environmental, and some may be stochasticity in circuit activity. The way this in-
formation is integrated to produce USV is not well understood. Because neonatal mouse
USV is a robust milestone of development, is relatively easy to acquire, and can be an-
alyzed in an automated fashion, a forward genetic screen in mice could be performed to
identify genetic contributions to variability in USV. Work by groups such as Cori Bargmann
and Benjamin de Bivort have begun to uncover genes and circuits that control variability
in C. elegans and D. melanogaster respectively, but to my knowledge no such work has
been performed in mice. Disorders of the nervous system, such as ASD, often present
with highly idiosyncratic features from case to case, so a better understanding of the cel-
lular and molecular factors contributing to idiosyncracy may help us better understand the
etiology of these disorders.
Broader Impact and Significance
In my graduate work, I have been able to gain insight into the functions of an impor-
tant regulatory molecule affecting numerous targets in the mouse brain. The targets of
CELF6 have not been previously defined, so it is my hope that this is of great benefit to
researchers of CELF proteins. Additionally, I have uncovered a hierarchy of activity across
CELF3-6. This adds to the growing literature of functional cooperativity, competition, and
antagonism exhibited by other families of RNA binding proteins.
In addition to my studies on CELF6 protein, my pipeline of analysis of vocalization
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has been used to study the effects of a number of proteins on behavior, including the
forkhead box transcription factors FOXP1 & FOXP2. This dissertation also provides the
accompanying software documentation for this MATLAB package.
A dense web of molecules in cells regulates cellular function. It is my hope that the
data I have presented help to spur more research in how RNA binding proteins regulate
neuronal function. Ultimately, these important molecules contribute to the overall architec-
ture of the nervous system, allowing animals to integrate sensory information and respond
to stimuli through a complex repertoire of behavior.
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Appendix 1
Using the MATLAB
VocalizationFunctions Package
Installation & upgrades
Important note: It is very important that your default path in MATLAB does not con-
tain any references to previous instances of the VocalizationFunctions package. Your
package should be installed to your default MATLAB directory locally (usually “Docu-
ments/MATLAB”). We will not add these to the path (this will be done using the library()
function). If there are any old entries from previous iterations make sure to remove these
entries and save your path. To inspect your path (in R2013,R2014), click “Set Path”:
If MATLAB complains (usually this happens on Windows) that you cannot save your
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path after making changes, restart MATLAB using Administrative privileges.
Installing for the first time
Downloading the Archives
The archives containing the package functions are stored on the genstorage server at the
following address:
“//genstorage.wustl.edu/jdlab/Behavior/Behavior Assay Procedures and Proto-
cols/Maternal Isolation Pup USV Recording”
There are two files you will need to copy:
• Rlike
• VocalizationFunctions-mm-dd-yyyy
Both are provided as either .zip or .tar.gz archives depending on your environment. Do
not extract these on the server! Download them to your
Documents/MATLAB/
directory and then extract them there. Do this on your computer, not on an external disk,
not anywhere else. To your Documents/MATLAB directory and nowhere else.
Installing the Rlike library
Unzip Rlike.tar.gz or Rlike.zip in the Documents/MATLAB directory. A number of files will
appear:
• asvector.m
This function vectorizes a matrix. Useful for nested function calls.
• between.m
This function performs a logical test for values between a and b. Useful for readabil-
ity.
• betwout.m
This function performs a logical test for values outside of a and b. Useful for read-
ability.
• head.m
This function displays the first 10 rows of a dataset or other matrix-like object.
head(X, n) displays the first n rows.
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• tail.m
This function displays the last 10 rows of a dataset or other matrix-like object.
tail(X,n) displays the last n rows.
• nrow.m
This function returns the number of rows. It is a call to size(X,1).
• ncol.m
This function returns the number of columns. It is a call to size(X,2).
• library.m
This function is executed as library(’LibraryName’). LibraryName is the name of a
folder under Documents/MATLAB. library() temporarily adds this folder and its sub-
folders to the MATLAB path during a session. This method avoids clashes between
functions of the same name, and simplifies the path update procedure.
Because these are unzipped in the Documents/MATLAB directory they will always be
available in your MATLAB path for use in any MATLAB session. If you unzip them else-
where, this will not occur.
Installing the VocalizationFunctions library package
Unzip the VocalizationFunctions-mm-dd-yyy.zip or VocalizationFunctions-mm-dd-yyyy.tar.gz
in the Documents/MATLAB directory. If you are using a graphical archive utility (e.g.,
WinZip, WinRAR, Mac Archive Manager), right-click and use an option for “Extract Here”.
This will produce a top level VocalizationFunctions folder (which is also its library name),
and three subfolders:
• VocalizationFunctions
– Clean
This folder contains the functions for running a console-only version of the
pipeline. The console-only version is recommended as it robustly checks files
and data for inconsistencies and prevents crashes.
– GUI
This folder contains functions for running the GUI frontend. The GUI version
will no longer be updated after this version.
– Misc
This folder contains many other functions that need to be catalogued, including
Tim Holy’s legacy functions from Holy & Guo 2005.
This is it for installation. Before running any function it will be necessary to execute:
>> library(’VocalizationFunctions’)
from the MATLAB command prompt.
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Upgrading to the newest version
Recent versions can contain fixes to bugs or cosmetic changes or both, and it is always a
good idea to upgrade. To do so, download the most recent version of VocalizationFunctions-
mm-dd-yyyy.tar.gz or .zip and unzip as in the previous section. It should overwrite existing
functions in previous folders.
Running the GUI
Preparing your data
Create a destination folder for your project. In this example, I have created MyProject.
Inside the MyProject folder I have created a folder calls WAVs.
Copy over the WAV files from their source to the WAVs folder:
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Preparing a CSV for upload
If you would like the output dataset to contain metadata (weight, sex, other variables),
prepare a CSV file. The top line of your CSV should contain header names for each
of the metadata variables you’d like to add. These names should not contain special
characters: ~!@#$%^&*()-+= and no spaces.
Under the header row you should make sure that the number of rows equals the num-
ber of files you want to process. It is very important that the data in each row corre-
sponds to the files in the order in which they appear in your WAVs folder. Usually
this is how the files are acquired in the first place. If you don’t make sure this is the case,
potentially the wrong files will be paired with the wrong data. (This error is avoided in
the console-only version.) Make sure the CSV doesn’t have empy cells. For Matlab use
“NaN” as the “Not-A-Number” code for missing data where data are numeric. NaN, Inf,
-Inf are the only non-numeric characters MATLAB will allow in a column otherwise filled
with numbers.
Below shows an example CSV:
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Save this CSV to your project folder:
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NOTE: If you make a CSV in Windows, but do processing in Mac/Linux, or vice
versa, errors can occur. This is because “under the hood” Windows and Unix use
different “end-of-line” characters in text files. Make sure to save your CSV in the
operating system environment you plan to do your processing in. This is as easy as
opening up the Excel spreadsheet and saving to CSV.
Checking files for consistency
It is important that your files are of similar length. During processing a small chunk will
be used for background calculations. If some of your files are abnormally short (such as
an aborted recording) they will not have a chunk of adequate length and the processing
pipeline will crash. You will note that VGAT_p7_007.WAV is 6.2 MB while most of the files
are around ≈90 MB. This indicates you should remove this file (and its correspondingly
line in the metadata CSV) before beginning:
241
Starting the GUI
From the MATLAB command line, execute the following:
>> library(’VocalizationFunctions’)
>> vocalizationRun
After typing each line, hit Enter. The first line loads the VocalizationFunctions package
into the path.
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Setting options for processing
From the GUI, under Project Folder, Browse to choose the project folder location.
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Project details
Under Project details, type a name for your project. If this is a new project, leave Process
All Files checked. If you have a CSV, click “Upload metadata from CSV...” and navigate
and choose its location. The last three checkboxes are:
• Skip spectrogram spot check : If checked, you will not check the automatic scores of
call start/end points in the spectrogram. If this is a new project, leave this unchecked.
I like to verify about 10 % of files. Later it will ask how many files you want to check.
• Generate Quality Control Plots: Leave checked to generate QC variable histograms.
• Generate output report: Leave checked to generate output CSV with processed
data.
Audio File Parameters
• Sampling Rate: Enter the sampling rate in kHz (default is 250000).
• Bits: Enter the bit depth. (default is 16 bits).
• Gain: Set the gain level. Default is 0. The default gain will return amplitude values
in dB re 1.0. dB are a relative unit, where 1dB = 10 · log10
(
amplitude2
referencevalue2
)
. Each dB is
10 log10 units relative to some reference power unit. “dB re 1.0” means the reference
is the detector maximum. Since 1.0 is the detector max (read: “100%”), values are
fraction, and dB are negative. “-20 dB re 1.0” , or -20 dB in common parlance means
20 dB units below the maximum, where the maximum is 0 dB.
If you choose the gain setting, voltage data will be reported in actual Volt units
based upon estimated conversion factors from the manufacturer and dB data will
be reported as dB SPL re 2 µPa, or dB SPL for short. Amplitude in Volts is con-
verted to Pressure data in Pascals based upon manufacturer estimated microphone
sensitivity for the Avisoft Bioacoustics CM16 microphone. These data are not true
measurements of sound pressure because over time the microphone’s plate is dif-
ferently sensitivity than initially. To know the true sound pressure, the microphone
must be calibrated (using, surprise, surprise, a calibrated microphone! which in turn
must be calibrated with another calibrated microphone...).
Unless you have strong feelings about what units to report, report the default (leave
Gain set to 0) and no conversion will be performed.
White Noise Filtering
• Leave “Use manual thresholding?” unchecked. If checked, white noise levels must
be approximated by eye. The pipeline will present a graph for each file of a (de-
fault) 15 second chunk of audio (frequencies on the x axis and log10 unscaled FFT
magnitude on the y-axis. A magic red line will be drawn based upon an automated
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algorithm and the user can enter and select to change the position of this line. such
that it approximates the noise floor level.
• sigma: The sensitivity of the automated noise threshold (default = 2.5). You can turn
this nob up and down. The min value is 1. Larger numbers are more sensitive. If
you feel that spectrograms are not being correctly scored, increase or decrease as
desired.
• length: Default is 15 seconds. Processing the entire file for noise will be very labori-
ous, so only a small chunk is chosen.
FFT Settings
• Window length: The fast Fourier transform is computed in 50% overlapping win-
dows. The % overlap is not tweakable at this time. Changing the window length
changes the temporal and spectral resolution which is shown in real time in the box
at right. Big windows make for better spectral resolution, but poorer temporal reso-
lution, and vice versa. 512 is the default. Each time point in the spectrogram will be
1.024 msec with a bin size of 512 samples.
• Band-pass filter: From (25000 Hz default) To (120000 Hz default). The high fre-
quency spectrum is saved for mice, with non-white noise, but low frequency audio
filtered out.
Automated Call Scoring
These are the parameters used to improve the automated scoring of USV call start and
stop times.
• Power calc: Linear vs. Log. If your signal is very weak, log-scale scoring might
improve signal detection accuracy. Linear is default.
• Smooth size: 0.01 seconds default. Frequency data is smoothed over 10 millisec-
onds. Helps smooth out “empty” spots where signal may drop below detection.
• Min. duration: 0.005 seconds default. The minimum duration for a USV call (for the
so-called “whistle” calls).
• Min. purity: 0.25 default (in practice I think 0.15 works better). This says at
any moment in time, within a call, some % (the “spectral purity”) must be concen-
trated in the frequency where the maximum occurs. This means you have a nice
tall peak somewhere in the spectrum, and the rest of the audio can be alternatively
distributed. Small numbers are “dirtier” more peaky spectra, and bigger number are
“clean” spectra. A purity of 1.0 would be the Dirac delta function in the spectrum
(100% of the power at the max, 0 elsewhere). I find pup calls are sometimes a lil
dirty, so I use 0.15.
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• Min mean pitch: Wherever the frequency of maximum power (“pitch”) is , it should
be at least 35 kHz or greater (default).
• Max spec. discontinuity: Consecutive time bins within a call should have their peaks
in mostly the same place. Values range from 0 (identical spectra from t to t+1)
to 2 (spectra with peaks in opposite place from t to t+1). A value of 1 indicates
consecutive spectra have a shape that is 50% the same. Gradual evolution over
time suggest spectral discontinuity is on the range of 0:1. Discontinuities between
1:2 are very abrupt changes in the spectra. By the way, these occur whenever a
pitch jump occurs, but this is taken care of by the next paramter.
• Min gap: 0.03 seconds default. Any areas between two calls where the signal is : (a)
too dirty, (b) too discontinuous, (c) below detection, or would otherwise be scored
as “not a call”, if these areas are 30 milliseconds are less, the two disjointed calls
are merged and scored as a single call. This also allows the discontinuities evident
in calls with pitch jumps to be scored as a single call despite violating the spectral
discontinuity threshold.
If you don’t know what you’re doing, I would change the spectral purity to 0.15 and leave
the rest alone.
This is my filled out GUI:
246
Spectrogram Spot-Check
In the spectrogram view, the upper plot is the gray-scale spectrogram, and the lower
plot shows the locations of calls as scored automatically from start time to stop time. The
spectrogram can be navigated by selecting and using the arrow keys or arrow buttons
in the lower “slider window”. Your goal is to make sure the automated scores overlap
with calls you would score manually. If they don’t you may have restart and tweak some
settings.
On subsequent runs if you think that the utilized settings do a good job, then you can
check the box in the main GUI to skip this step.
When everything is complete, you should return the following at the MATLAB console:
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Inspecting output reports
The first report that you will want to inspect is the <project name>_qcgraphs.pdf file.
These are histograms which give you a sense of how different USV features are dis-
tributed.
• Noise Mean & Threshold: These are actually a bit redundant, but they both are the
estimates of the background white noise level in the spectrum, in the original FFT
units and then rescaled to the units which the spectrograms are stored in (Voltage in
the case that Gain>0 is used, or full scale where Gain=0). The threshold represents
the magnitude level in the spectrum. FFT magnitudes below this value are set to 0
in the spectrum. The noise level is set on a per-file basis. You should be concerned
however if the distribution appears bimodal - i.e., that some files appear to have a
different noise level than other files. This is likely due to changes in the recording
environment (such as switching boxes or rooms), or changes to the gain level on
the the microphone’s pre-amplifier. This may make results non-comparable as a
change in the noise level or the sensitivity of the recording equipment will likely alter
the number of calls detected.
• Fraction of calls peaking: The x-axis is file number, and the y-axis is the number
of calls exceeding the maximum of the detector limit somewhere within the call.
Peaking may not effect call counts, but will likely skew the computation of other
features of USV such as features based on the pitch or amplitude envelope of the
call.
• Other features of USV: Unlike the preceding two distributions, the other distributions
are mostly informational. They inform you what each of these USV features looks
like:
– Call number: # of calls in each recording.
– Call duration: Pooled duration times (milliseconds) over all calls.
– Call duration averages: Average duration for each recording.
– Pauses (<0.5 sec): Inter-call pause times. Pauses > 0.5 seconds are consid-
ered “silence” in the recording and not a pause before the next call.
– Average Pause times per file.
– Bout #: Number of bouts per recording, where a bout is a sequences of calls
separated by pauses < 0.5 sec.
– Fraction of bouts with only one call: # of bouts of length = 1.
– Correlation between duration & subsequent pause length. This is usually around
0 but may be slightly negative.
– Correlation between adjacent duration times: This is usually positive.
– Correlation between adjacent pause times: This is also usually positive.
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– Mean Pitch: The average pitch of each call, pooling all calls.
– Mean Pitch average: The average Mean Pitch for each file.
– Pitch Range: Pitch range observed pooled over all calls.
– Pitch Range file averages.
– Pitch slope: Hz/millisecond slopes in calls, usually center on 0 (flat calls).
– Pitch slope file averages.
– Spectral purity: “Noisiness” of the calls, with a minimum as defined by the
processing parameters (e.g., 0.15).
– Spectral purity file averages.
– dB: Peak amplitude level pooled across all calls.
– dB file averages.
– Fraction with jumps (>10 kHz).
Adding new data to an existing project
This capability exists but is currently untested so use at your own risk. It should work.
As of this issue, the GUI is deprecated, so I will not be supporting future updates to this
feature.
From the GUI main page:
• Uncheck the box that says New Project. The GUI will check for the presence of
a Vars subfolder containing initialization parameters and a “data.mat” file. If these
don’t exist, it will tell you that it does not think there is actually an existing project.
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• Uncheck Process All Files and change the Start at File to be the number of the next
file to run, in numerical order from their listing in the WAVs folder, or in row order
from your metadata CSV.
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Appendix 2
Generalized RNA-Sequencing Library
Preparation with Unique Molecular
Identifiers
This protocol is written presuming a strip tube format. Make sure to have a Permagen
Labware strip tube magnet, a 1.7 mL tube magnet as well to prepare beads, strip tube
mini-centrifuge, and 10 µL 8-channel multichannel pipettor, and 300 µL 8-channel multi-
channel pipettor.
For samples deriving from CLIP or other pre-fragmented techniques, proceed to sec-
tion "Dephosphorylation Reaction".
This protocol is modified from the protocol in:
Van Nostrand, Eric L., et al. "Robust transcriptome-wide discovery of RNA-
binding protein binding sites with enhanced CLIP (eCLIP)." Nature methods
13.6 (2016): 508.
Specific modification include rRNA depletion & fragmentation for application to total RNA-
Seq, as well as generalization of the RNA adapters to use a single adapter across sam-
ples for increased cost-effectiveness, using Illumina Index (Read #3) sequences for sam-
ple multiplexing.
rRNA Probe Annealing
Materials: NEBNext rRNA depletion kit (E6310)
RNA should be 10ng-1µg in a 12µL volume
The NEBNext rRNA depletion kit functions by hybridizing a proprietary mix of
DNA probes complementary to rRNA. RNase H then degrades RNA:DNA hy-
brids, leaving unhybridized RNA intact. Afterwards, DNA probes are degraded
by DNase I treatment. (Because the RNA is DNase treated at this stage, I
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do not bother performing additional DNase I treatment & cleanup after RNA
isolation.)
1. Per reaction assemble:
1 µL NEBNext rRNA depletion solution
2 µL Probe hybridization buffer
12 µL RNA Sample
2. Vortex and spin down.
3. Thermal cycling program (with lid at 105°C) is as follows:
95°C 2 min
95-22°C 0.1°C/sec
22°C 5 min hold
* On our Biorad Thermal Cyclers, we have to set the following for second stage:
731 total cycles, 1 sec
95C start, -0.1deg/cycle
4. Spin and place on ice.
RNase H Digestion
1. Make a master mix. Per reaction add:
2 µL NEBNext RNase H
2 µL RNase H Reaction Buffer
1 µL H2O
2. Add 5 µL to 15 µL rRNA annealing reaction (20 µL final volume)
3. Vortex, spin, and heat to 37°C for 30 minutes with lid at 40°C
DNase I Digestion
1. Make a master mix. Per reaction add:
5 µL DNase I Reaction Buffer
2.5 µL DNase I (RNase-free)
22.5 µL H2O
2. Add 30 µL to 20 µL reaction (50 µL final volume)
3. Vortex, spin, and heat to 37°C for 30 minutes with lid at 40°C
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Clean up with MyONE Silane Beads
Materials: MyONE Silane Beads (Thermo Scientific 37002D)
Buffer RLT (Qiagen, any RNA kit or Product # 79216)
5M NaCl,100% EtOH,75% EtOH,80% EtOH (later steps in this protocol)
Strip tube magnet (Permagen Labware 0.2 mL PCR Strip Magnetic Separator)
1.7 mL tube magnet
MyONE Silane and Agencourt RNAClean are not the same technology. MyONE
Silane can purify small fragments given the right proportion of EtOH, Agencourt RNA-
Clean bottoms out at 100 nt.
1. Separate 20 µL of MyONE Silane beads per sample on magnet and remove storage
buffer. (For 10 samples, separate 200 µL, etc. Use 1.7 mL tube for batch prepara-
tion.)
2. Wash beads in batch with 900 µL of Qiagen Buffer RLT.
3. Resuspend beads in 150 µL/sample of Qiagen Buffer RLT (3 starting sample vol-
umes) and 5 µL per sample 5M NaCl. (For large numbers of samples, you may
need to use a 15 mL conical. For 10 samples of 50 µL each, resuspend beads in
1500 µL Buffer RLT + 50 µL 5M NaCl.)
4. Split rRNA depletion reaction to two sets of strip tubes (50 µL  25 & 25). This is
to ensure strips can accommodate total volume (you can also use 1.7 mL tubes, but
the strip tube magnet is more convenient).
5. To each sample add. 77.5 µL Beads, RLT, NaCl with multichannel. Mix by pipetting
up and down 10 times.
6. Add 154 µL 100% EtOH (1.5 mix volumes) to each strip tube with multichannel.
7. Mix by pipetting up and down and rotate samples at room temp for 15 minutes.
8. Separate on magnet for 30 seconds and remove supernatant.
9. Wash beads with 0.2 mL 75% EtOH. Pipette to fully resuspend and move to new
strip. At this step, combine strips that were split in step (4).
10. Separate on magnet for 30 seconds. Remove wash with multichannel.
11. Wash 2 more times with 75% EtOH. Add wash buffer and let sit for 30 seconds on
magnet and remove with multichannel. No need to resuspend.
12. Dry 5 minutes on magnet. Remove excess EtOH with vacuum or by pipette which
may collect at bottom.
13. Resuspend in 10 µL of H2O and let sit for 5 minutes off magnet. Then to clean up
put back on magnet, separate, and move eluates to new strip tubes.
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Optional: Resuspend 10 μL and assess a small amount by Agilent TapeStation
or Agilent Bioanalyzer to confirm loss of small (18S) and large (28S) rRNA
peaks.
Note: Contamination with MyONE Silane beads does not appear to inhibit any
downstream steps, so don’t worry about a small amount of magnetic beads
coming along.At the very end of library preparation, however, you do want to
ensure libraries are bead-free before pooling for sequencer.
Fragmentation
If doing CLIP or another prep where RNA samples are already fragmented, use mix com-
ponents in step (1) and skip to dephosphorylation reaction.
1. Per reaction assemble:
2.5 μL 10X PNK Buffer (Enzymatics Y9040)
19.0 μL rRNA-depleted sample RNA
2. Thermal cycler 94°C (lid at 105°C) for 5-15 minutes
3. Move to ice.
Dephosphorylation Reaction
RNase I digestion in CLIP, and heat based fragmentation for total RNA-Seq
both leave 3’ phosphates and 5’ -hydroxyl. 3’ phosphates must be removed
before adapter ligation. Triton-X 100 is added to 1% based upon personal
communication with NEB Tech Support that this improves dephosphorylase
activity of T4 PNK to 90%.
1. Make a master mix. Per reaction add:
2.5 µL 10% Triton-X 100
0.5 µL T4 PNK
0.5 µL rRNasin
2. Add 3.5 µL master mix to each sample (final volume 25 µL).
3. Vortex briefly and spin down.
4. Heat to 37°C for 30 minutes with lid at 40°C
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Clean up with MyONE Silane Beads (Abbreviated, see above
for full protocol)
1. 20 µL of MyONE Silane beads per sample.
2. Wash beads in batch with 900 µL RLT.
3. Resuspend beads in 75 µL/sample of Qiagen Buffer RLT (3 volumes, last step is 25
µL) and 2.5 µL/sample 5M NaCl.
4. Add 77.5µL NaCl/RLT/beads to samples.
5. Add 154 µL EtOH (1.5 mix volumes) and mix.
6. Mix and rotate samples at room temp for 15 minutes.
7. Separate on magnet for 30 seconds and remove supernatant.
8. Wash with 0.2 mL 75% EtOH and move to new strip.
9. Wash 2 more times with 0.2 mL 75% EtOH.
10. Dry 5 minutes on magnet.
11. Remove residual EtOH.
12. Resuspend in 10.5 µL of H2O and let sit off magnet for 5 minutes.
13. Separate on magnet and move 10 µL eluate to strip tubes containing A01m adapter.
(See next section).
Optional: Resuspend in larger volume and assess a small amount by Agilent TapeStation
to confirm size shift as a result of fragmentation. Elution volume is slightly larger than 10
µL to ensure you can move volume safely to next set of tubes.
A01m Ligation
A01m Adapter:
/5Phos/rArGrArUrCrGrGrArArGrArGrCrGrUrCrGrUrGrUrArG/3SpC3/
(IDT: Purify at 250 nmol RNA Oligo scale using RNase-Free HPLC Purification, store at
200 µM in H2O, aliquoted, at -80° C. SpC3 is a molecule which is a carbon chain that
can be added to oligos. It blocks any ligation at its own end, since there is no 3’ OH
group, thus adapter chains are not possible. Heat fragmentation (or digestion with RNase
I) leaves 5’ OH groups, thus chains of RNA fragments are also not possible.)
RNA Ligase High Concentration (NEB M0437)
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1. Strip tube should contain 10.5 µL total: 10 µL dephosphorylated RNA fragments &
0.5 µL 40 μM A01m.
2. Heat to 65°C for 2 minutes with lid at 105°C to melt any secondary structure.
3. Place immediately on ice for 1 minute.
4. Make a master mix. Per reaction add:
1.5 µL DMSO (100%)
2.0 µL RNA Ligase Buffer (10x (Enzymatics buffer contains ATP))
0.5 µL Promega rRNasin (40 U / mL)
5. Add 4.0 µL mix to each sample.
6. Vortex briefly and spin down.
7. Per reaction add 4 µL PEG8K (50%). (Cut pipette tip for easier pipetting.)
8. Vortex briefly and spin down.
9. Add 1.5 µL T4 RNA Ligase (Enzymatics L6050, 20 U/ µL).
10. Vortex briefly and spin down.
11. Tape down horizontally into a container and place on a shaker at 250 rpm for 2 hours
at room temp.
Clean up with MyONE Silane Beads (Abbreviated, see above
for full protocol)
NaCl is not added as there is NaCl in the RNA Ligase buffer. According to Eric
Van Nostrand, the EtOH percentage is changed to favor larger fragments and
not unligated adapter.My own experiments with MyONE Silane are somewhat
inconclusive as to whether that matters.
1. Separate 10 µL of MyONE Silane beads per sample.
2. Wash beads in batch with 900 µL of Qiagen Buffer RLT.
3. Resuspend beads in 60 µL/sample of Qiagen Buffer RLT.
4. Add 60 µL beads/RLT to each sample and mix.
5. Add 52.5 µL EtOH (0.75 mix volumes) and mix.
6. Rotate samples at room temp for 15 minutes.
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7. Separate on magnet for 30 seconds and remove supernatant.
8. Wash with 0.2 mL 75% EtOH. Resuspend and move to new tube.
9. Separate on magnet for 30 seconds. Wash 2 more times with 75% EtOH with re-
suspending (30 seconds on magnet).
10. Dry 5 minutes on magnet.
11. Remove residual EtOH.
12. Resuspend in 7.5 µL of H2O and let sit for 5 minutes. Separate on magnet and
move 7 µL to a new set of strip tubes containing 1.5 µL of 20 μM AR17 primer.
Reverse Transcription
AR17 primer: ACACGACGCTCTTCCGA
Order as standard primer. Store in H2O at 200 μM at -20°C.
Working dilution is 20 μM.
Thermo Superscript RT III First Strand Synthesis system (Thermo 18080051)
1. Strip tubes should contain 1.5 µL AR17 (20 µM) and 7 µL A01m-ligated RNA
2. Heat to 65°C for 2 minutes with lid at 105°C
3. Place on ice for 1 minute.
4. Make a master mix. Per reaction add (total 11.5 µL mix):
2.0 µL SSRTIII 10x Buffer
2.0 µL dNTPs (10 mM)
4.0 µL MgCl2 (25 mM)
2.0 µL DTT (100 mM)
0.6 µL RnaseOUT
0.9 µL SSRTIII Enzyme
(Old kits fail!)
5. Add 11.5 µL master mix to each 8.5 µL sample (f.v. 20 µL).
6. Vortex briefly and spin down.
7. Heat to 50°C for 45 minutes.
ExoSAP-It degrades primers and dNTPs, and thus only true RNA:cDNA hybrids
remain intact.
8. Per reaction add 3.5 µL ExoSAP-It.
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9. Vortex briefly and spin down.
10. Heat to 37°C for 15 minutes.
11. Per reaction add 1 µL EDTA (0.5M). Vortex briefly and spin down.
12. Per reaction add 3 µL 1M NaOH. Vortex briefly and spin down.
13. Heat to 70°C for 12 minutes in thermal cycler to degrade RNA.
14. Per reaction add 3 µL 1M HCl to neutralize pH. (Final volume is 30.5 µL.)
Clean up with MyONE Silane Beads (Abbreviated, see above
for full protocol)
1. Separate 10 µL of MyONE Silane beads per sample.
2. Wash beads in batch with 900 µL of Qiagen Buffer RLT.
3. Resuspend beads in 91.5 µL/sample of Qiagen Buffer RLT (3 starting sample vol-
umes).
4. Add 91.5 µL Beads in Buffer RLT to each sample and mix.
5. 111 µL EtOH (0.91 mix volumes) and mix.
6. Rotate samples at room temp for 15 minutes.
7. Separate on magnet for 30 seconds and remove supernatant.
8. Wash with 0.2 mL 80% EtOH. Resuspend and move to new tube.
9. Separate on magnet for 30 seconds. Wash 2 more times with 80% EtOH with re-
suspending (30 seconds on magnet).
10. Dry 5 minutes on magnet.
11. Remove residual EtOH.
12. Resuspend in 11 µL of H2O and let sit for 5 minutes. Separate on magnet and move
10.5 µL to a new set of strip tubes containing 0.5 µL of 80 μM Rand103tr3 adapter.
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Rand103tr3 Ligation
NEB has two protocols using T4 RNA Ligase High Concentration. The ligation protocol
for a ssRNA oligo to an RNA molecule has a 2 hour incubation, but the protocol for ligating
to DNA says to proceed overnight. T4 RNA Ligase may be less efficient with ssDNA than
it is with RNA.
Rand103tr3 Adapter:
/5Phos/NNNNNNNNNNAGATCGGAAGAGCACACGTCTG/3SpC3/
Purify at 100 nmol scale using PAGE Purification, and when asked for random Ns, I
used “Machine Mixing” option (there are two options, hand mixing and machine mixing).
Hand mixing might be better to ensure equimolar probabilities of random incorporation.
Store in H2O at 200 μM in -200C. Working dilution is 80 μM.
1. Strip tubes should contain 0.5 µL Rand103tr3 (80 µM) and 10.5 µL cDNA
2. Heat to 65°C for 2 minutes with lid at 105°C.
3. Place on ice for 1 minute
4. Per reaction add (total 5.5 µL mix):
1.5 µL DMSO (100%)
2.0 µL RNA Ligase Buffer (10x)
5. Add 3.5 µL mix to each sample.
6. Vortex briefly and spin down.
7. Per reaction add 4 µL PEG8K (50%). (Cut pipette tip for easier pipetting.)
8. Vortex briefly and spin down.
9. Add 1.5 µL T4 RNA Ligase High Conc (20 U/ µL).
10. Vortex briefly and spin down.
11. Tape down horizontally into a container and place on a shaker at 250 rpm overnight.
Note: Because MyONE Silane allows for purification of small things, some cDNA gen-
erated from free A01m adapter can make it through to this step, thus A01m:Rand103tr3
dimers are possible. The final PCR product of this adapter is 139 nt. This can be removed
by size selection after PCR, and you can run a negative control (no starting RNA) through
the protocol to verify the adapter. If you start with a high concentration of RNA in the
protocol, it seems that very little of this gets made, but if the amount of RNA is limiting, it
becomes more prevalent.
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Clean up with MyONE Silane Beads
Unclear to me why the eCLIP protocol switches back to washes in 75% EtOH.
1. Separate 10 µL of MyONE Silane beads per sample.
2. Wash beads in batch with 900 µL of Qiagen Buffer RLT.
3. Resuspend beads in 60 µL/sample of Qiagen Buffer RLT (3 starting sample vol-
umes).
4. Add 60 µL Beads in Buffer RLT to each sample and mix.
5. Add 60 µL EtOH (0.75 mix volumes) and mix.
6. Rotate samples at room temp for 15 minutes.
7. Separate on magnet for 30 seconds and remove supernatant.
8. Wash with 0.2 mL 75% EtOH. Resuspend and move to new tube.
9. Separate on magnet for 30 seconds. Wash 2 more times with 75% EtOH with re-
suspending (30 seconds on magnet).
10. Dry 5 minutes on magnet.
11. Remove residual EtOH.
12. Resuspend in 10 µL of H2O and let sit for 5 minutes.
Trial Library PCR
NEBNext Q5 Ultra II Q5 Master Mix (NEB M0544)
Universal Primer
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC*T
(The * is a phosphorothioate bond, which helps preserve the primer and prevent degra-
dation. Make up at 100 µM and use 10 µM in reaction.)
Index Primers
Can be anything containing the Illumina Read2 priming site with an index that is also
compatible with the adapter ligated template. Here is an SIC index primer (index in lower
case)
CAAGCAGAAGACGGCATACGAGATtccgtattaGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
1. Make a master mix. Per sample:
10 µL Q5 Ultra Master Mix
1 µL 10 µM NEBNext Universal primer
7 µL H2O
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2. In individual tubes, combine:
1 µL 10 µM Index primer
1 µL adapter ligated cDNA
3. Add 18 µL master mix to index primer/cDNA.
4. Run using Q5 Ultra PCR program
98°C 30 sec
(98°C 10 sec
55°C 15 sec
65°C 60 sec ) Repeat for N cycles and pull samples at desired cycle numbers and
keep on ice. 65°C 5 min
12°C Hold
Run 2.5% agarose gel/1X TBE. Determine cycle showing robust amplification of library
and not high MW overamplification bands.
You don’t want to run out of sample. Potentially use a test sample for this and you
should be able to guess a couple different cycle numbers between 10 - 20. You can fine
tune from there. Or another way to make a test sample is pull 1 μL from all your libraries,
and pool them together. Or, pull a small amount and dilute it in H2O, then back-calculate
using the base-2 logarithm of the dilution factor how many cycles to use for preparative
PCR.
For 1 μg of input RNA for total RNA-Seq, I found 10 cycles to be sufficient.
Preparative Library PCR
Cycle number to use should reflect proportional amount of cDNA input. Suppose I used
1 µL in a test reaction in the previous step. If I use 8 µL here, that is 8 fold more starting
material, which is 3 base-2 logarithm units. If I determined 15 cycles in the previous step,
then use 15-3 = 12 cycles in the preparative PCR.
1. Make a master mix. Per sample:
25 µL Q5 Ultra Master Mix
2.5 µL 10 µM NEBNext Universal primer
12 µL H2O
2. In individual tubes, combine:
2.5 µL 10 µM Index primer
8 µL adapter ligated cDNA
3. Add 39.5 µL master mix to each sample.
4. Run using Q5 Ultra PCR program
98°C 30 sec
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(98°C 10 sec
55°C 15 sec
65°C 60 sec ) x desired cycles
65°C 5 min
12°C Hold
SPRI Purification
Purification is a size selection step using altered polyethylene glycol concen-
tration with Beckman Coulter AMPure XP beads (Beckman Coulter Product #
A63881). This selects for things between 200 - 400 bp (I have empirically opti-
mized this using a DNA ladder.) You add the beads directly from a well mixed
container without washing them first. It works using the PEG in the bead stor-
age buffer. This is preferable to gel purification because gel purification results
in heavy loss of yield compared to magnetic bead based purification. It is also
preferable to electroelution after gel purification because electroelution does
not scale well to large numbers of samples.
Size selection is important because, especially for small amounts of starting
material, the A01m:Rand103tr3 adapter dimer is a prevalent species, and will
soak up a lot of reads.
1. Bring volume to 100 µL with 50 µL H2O.
2. Add 80 µL of AMPure XP. Mix 10 times by pipetting and incubate 5 minutes.
3. Separate on magnet.
4. Move supernatant to new tube.
5. Add 40 µL of AMPure XP. Mix 10 times by pipetting and incubate 5 minutes.
6. Separate on magnet 2-3 minutes.
7. Wash 2x30s 80% EtOH. It is really important with SPRI beads not to disturb them
on the magnet. Just add and let sit for thirty seconds. Remove with multichannel.
8. Dry 5 min.
9. Remove any residual ethanol which collects.
10. Elute in 10 µL of 10 mM Tris pH 7.8.
11. Assay by TapeStation or Bioanalyzer.
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Appendix 3
Translating Ribosome Affinity
Purification - Optimized
This protocol is based on previous TRAP protocols as cited elsewhere in this manuscript.
See:
1. Doyle, Joseph P., Joseph D. Dougherty, Myriam Heiman, Eric F. Schmidt, Tanya
R. Stevens, Guojun Ma, Sujata Bupp et al. "Application of a translational profiling
approach for the comparative analysis of CNS cell types." Cell 135, no. 4 (2008):
749-762.
2. Heiman, Myriam, Anne Schaefer, Shiaoching Gong, Jayms D. Peterson, Michelle
Day, Keri E. Ramsey, Mayte Suárez-Fariñas et al. "A translational profiling approach
for the molecular characterization of CNS cell types." Cell 135, no. 4 (2008): 738-
748.
3. Dougherty, Joseph D., Susan E. Maloney, David F. Wozniak, Michael A. Rieger,
Lisa Sonnenblick, Giovanni Coppola, Nathaniel G. Mahieu et al. "The disruption of
Celf6, a gene identified by translational profiling of serotonergic neurons, results in
autism-related behaviors." Journal of Neuroscience 33, no. 7 (2013): 2732-2753.
Protocol
Bead Prep
1. Add 60 µL x N IPs of Streptavidin MyOne T1 or 120 µL x N IPs of Strepatividn
M-280 beads to a tube. Put the tube on the magnet stand and give it a minute to
separate. Remove storage buffer (0.1%BSA/1XPBS)
2. Prepare a binding mixture containing:
17 µL of 1 µg
µL
Protein L (17 µg ) x N IPs
20 µL of 1.78 µg
µL
anti-EGFP clone 19F7 (36 µg) x N IPs
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36 µL of 1 µg
µL
anti-EGFP clone 19F7 (36 µg) x N IPs
127 µL of 1X PBS (f.v. 200 µL) x N IPs
3. Resuspend beads in the antibody/Protein L mixture by pipetting.
4. Incubate beads and antibody/Protein L mixture at room temperature for at least 1
hour with end-over-end rotation (or up to overnight at 4C with end-over-end rotation).
5. Put beads on magnet stand and give it a minute to separate.
6. Discard supernatant.
7. Resuspend beads in 1 mL 1XPBS/0.1% BSA. Give it a minute in suspension and a
minute on the stand to wash.
8. Repeat step 7 4 times (total of 5 washes).
9. Resuspend beads in 1 mL of Wash Buffer. Give it a minute in suspension and a
minute on the stand to wash.
10. Repeat step 9 2 times (total of 3 washes).
11. After last wash, resuspend in 1.05xN IPsx100µL Wash Buffer (5% more than the
number of IPs.)
This step allows you to distribute 100 µL equally to all your IP tubes from the batch of beads. 5% extra volume ensures that
you can do this equally. You will find if you resuspend your beads in 500 µL of lysis buffer and try to put 100 µL in each of 5
tubes, you will be unable to do so as the detergent in lysis buffer makes this difficult. You can also plan for N+1 IPs, but this
works just as well.
12. Distribute 100 µL to N tubes equal to the number of actual IPs.
13. Keep on ice until you are ready to use them. Remove the Wash buffer you used to
aliquot the beads before use.
Homogenization and Lysis
I use the (1mL) proportions for <half a brain, and the 2 mL proportions for a whole brain.
1. Dissect tissue or pellet cells.
2. Keep glass mortar(s) on ice and fill each with (1 mL | 2 mL) of lysis buffer (I use 1 mL
for smaller dissections of brain or a pellet of cells from 6cm - 10cm dishes, and use 2 mL for a whole brain, or see the Big
Protocol/Background document for recommendations about lysis buffer to mg tissue recommendations).
3. Plop tissue into mortar.
4. Take drill fitted with teflon pestle and homogenize up and down 6 times at medium/high
power (see demo).
5. After homogenization, pour off homogenate into a 1.7 mL tube (if homogenizing in
1 mL) or some larger size of tube that will accommodate your volume (2 mL tubes
are nice).
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6. Spin 2000 xg, 10 min, 40C.
7. Remove (800 µL | 1.6 mL) of homogenate from Step 6 and move to a new tube and
add:
(0.1 mL | 0.2 mL) 10% NP40 (final concentration 1%)
(0.1 mL | 0.2 mL) 300 mM DHPC (final concentration 30 mM)
8. Invert to mix and incubate on ice for 10 minutes.
9. Spin at 20,000xg, 15 minutes, 4C.
10. Measure total lysate. Take 0.1 volumes as Input sample and bring total volume to
250 µL with Wash Buffer. Add 750 µL Trizol LS and store at -80C until you are ready
to extract RNA.
11. Take the remaining 0.9 volumes and resuspend your beads in it.
12. IP for 2 hours at 4C (or up to overnight).
13. After IP put the samples on the stand and let sit for a minute. Remove the super-
natant and discard (you can also take this supernatant to compare to input if you like, in which case repeat step 10
above).
14. Resuspend in 1 mL of High Salt Wash Buffer. Let sit for a minute in suspension,
then a minute on the stand.
15. Repeat step 14 3 more times (total of 4 washes).
16. Resuspend beads in 250 uL Wash Buffer. Add 750 µL of Trizol LS and store at -80C
until you are ready to extract RNA.
RNA Extraction
1. Bring samples to room temperature if they have been stored at -80C and incubate
at room temperature for 5 minutes. If you haven’t done so already, take out the
Glycoblue (stored at -20) and bring to room temperature.
2. Add 0.2 mL chloroform.
3. Shake vigorously by hand for 15 seconds.
4. Incubate for 7 minutes on bench.
At this point, you can use Phase Lock Gel Heavy tubes to help you separate phases later. Pellet Phase Lock Gel 12,000 xg,
30 seconds. Add your sample to the pelleted Phase Lock Gel. Mix well but do not vortex.
5. Centrifuge at 12,000xg, 15minutes, 4C.
6. Vortex the crap out of the Glycoblue and spin briefly. (The dye is not always perfectly
distributed).
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7. Add 1 µL of Glycoblue to new tubes equal to the number of samples you have.
8. Remove the aqueous phase to a new tube (the upper layer) from step (5) to the
tubes with glycoblue and mix well.
9. Add 0.7 volumes of 100% isopropanol.
10. Incubate on the bench for 10 minutes.
11. Centrifuge at 4C, max speed (≥12,000xg), for 15 minutes.
12. Pour off the supernatant. Do not pipette off the supernatant.
13. Add 1 mL of 80% EtOH. I like to dislodge the pellet and invert several times to wash.
14. Repeat the centrifugation in step 11.
15. Pour off the supernatant. Do no pipette off the supernatant.
16. Spin again to collect the EtOH you couldn’t pour off.
17. Remove remaining supernatant using the pipette tip method (see demo).
18. Leave tubes open on your tube rack while you prepare the DNase treatment mix
(3-5 minutes. Do not overdry!). DNase Treatment Mix:
10 µL 10X Qiagen RDD Buffer x n+1 samples
87 µL H2O x n+1 samples
3 µL Qiagen DNase I x n+1 samples
Final volume is 100 µL per sample (planning for 1 extra).
19. Resuspend the pellet in 100 µL of DNase Treatment Mix.
20. Incubate at 37 C for 15 minutes.
21. Add 350 µL of Qiagen Buffer RLT to each sample(RNeasy Minelute kit). Mix by
pipetting 5 times.
22. Add 250 µL of 100% EtOH to each sample (RNeasy Minelute kit). Mix by pipetting
5 times.
23. Pass volume (700 µL ) over a Qiagen RNeasy Minelute kit by centrifugation at
≥10,000xg for 15 seconds at room temp.
In subsequent steps after centrifugation you should dump out the flow-through, but it can help to have multiple collection tubes
you can just move the column to in order to speed things up.
24. Add 500 µL of Buffer RPE to each column and centrifuge at ≥10,000xg for 15
seconds at room temp.
25. Add 500 µL of 80% EtOH to each column and centrifuge at ≥10,000xg for 2 minutes
at room temp.
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26. After you discard the last flow through dry the column by spinning for 1 minute at
max speed at room temp.
27. Take a 1.7 mL tube and cut off the cap (or I just rip them off). This will collect your
sample.
28. Put column into tubes from step 27. Add 15 µL of RNase-free H2O to the middle of
each column (make sure you see the liquid getting onto the silica matrix).
29. Incubate on bench 1 minute.
30. Spin for 1 minute at max speed at room temp.
31. Congratulations you now have RNA. Assess quality and quantity of RNA by some
method and wait till I distribute the next protocol.
Buffers and Reagents
Products Numbers
1% BSA/1XPBS
Add IgG-Free Bovine Serum Albumen (100 mg per 10 mL) to 1X PBS and allow to rock
gently for >10 minutes to go into solution.
0.1% BSA/1XPBS
Dilute 1% BSA/1XPBS 10-fold.
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10% NP40
Carefully make up 10% v/v NP40 (IGEPAL CA-630, Sigma) by pipetting 100% NP4O into
H2O and let rock for >10 minutes to fully dilute.
300 mM DHPC
Resuspend 100 mg 07:0 PC (DHPC, Avanti polar lipids) in 692 µL of H2O. To avoid
foaminess, add H2O and let it rock for a few minutes and then transfer to Eppendorf
tubes.
100 mg/mL cycloheximide
Dissolve cycloheximide in 100% methanol at 100 mg/mL.
10X Roche cOmplete EDTA-free protease inhibitor
Crush tablet in a small volume (~300-500 µL) of water. Pipette up and down to start to
dissolve. Bring volume to 1 mL and mix until fully dissolved.
Wash Buffer
units start final df 1 10 25 mL
hepes ph 7.4 mM 1000 10 100 0.01 0.100 0.25
kcl mM 2000 150 13.3333333333 0.075 0.750 1.875
mgcl2 mM 1000 5 200 0.005 0.050 0.125
dtt mM 1000 0.5 2000 0.0005 0.005 0.0125
rnasin %v/v 100 0.1 1000 0.001 0.010 0.025
superase-in %v/v 100 0.1 1000 0.001 0.010 0.025
roche protease inh X 25 1 25 0.040 0.400 0.625
cyclohex mg/mL 100 0.1 1000 0.001 0.010 0.025
np40 %v/v 10 1 10 0.1 1.000 2.5
water 0.8815 8.815 22.0375
Add DTT, RNasin, Superase-In, protease inhibitor, and cycloheximide just prior to use.
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Homogenization Buffer
units start final df 1 5 10 mL
hepes ph 7.4 mM 1000 10 100 0.010 0.050 0.100
kcl mM 2000 150 13.3333333333 0.075 0.375 0.750
mgcl2 mM 1000 5 200 0.005 0.025 0.050
dtt mM 1000 0.5 2000 0.0005 0.0025 0.005
rnasin %v/v 100 0.1 1000 0.001 0.005 0.010
superase-in %v/v 100 0.1 1000 0.001 0.005 0.010
roche protease inh X 25 1 25 0.040 0.200 0.400
cyclohex mg/mL 100 0.1 1000 0.001 0.005 0.010
water 0.8665 4.3325 8.665
Add DTT, RNasin, Superase-In, protease inhibitor, and cycloheximide just prior to use.
High Salt Wash Buffer
units start final df 1 10 25 mL
hepes ph 7.4 mM 1000 10 100 0.010 0.100 0.250
kcl mM 2000 350 5.7142857143 0.175 1.75 4.375
mgcl2 mM 1000 5 200 0.005 0.05 0.125
dtt mM 1000 0.5 2000 0.0005 0.005 0.0125
rnasin %v/v 100 0.1 1000 0.001 0.010 0.025
superase-in %v/v 100 0.1 1000 0.001 0.010 0.025
roche protease inh X 25 1 25 0.040 0.400 1.000
cyclohex mg/mL 100 0.1 1000 0.001 0.010 0.025
np40 %v/v 10 1 10 0.100 1.000 2.500
water 0.6665 6.665 16.6625
Add DTT, RNasin, Superase-In, protease inhibitor, and cycloheximide just prior to use.
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Appendix 4
PTRE-Seq Sequencing Library
Preparation Protocol
cDNA Synthesis
1. Add 2.5 µL of 12 µM pmrPTRE_Antisense1 to each of tube.
2. Add 8.0 µL of RNA/water (f.v. 10.5) to each tube containing 10 ng of total RNA or
TRAP RNA.
3. Heat to 65◦C for 2 minutes with lid at 105◦C. Place immediately on ice for 1 minute.
4. Make mastermix, see spreadsheet for full calculations using strip tubes.:
single(µL)
5x buffer 4
10 mM dntps 2
100 mM dtt 2
Promega rRNasin 0.6
ssrt iii 0.9
5. Split master mix into a strip tubes..
6. Add 9.5 µL of mastermix to each sample.
7. Incubate all at 50C for 45 minutes.
8. Add 3.5 µL of ExoSAP-It
9. Vortex & spin
10. Heat to 37C for 15 minutes. (f.v. 23.5)
11. Add 1 µL 0.5 M EDTA per reaction. Vortex & spin. (f.v. 24.5)
12. Add 3 µL 1 M NaOH. Vortex and Spin. (f.v. 27.5)
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13. Heat to 70C for 12 minutes.
14. Add 3 µL 1M HCl. Vortex and Spin. (f.v. 30.5)
15. Clean up with MyONE Silane:
(a) Wash N*10 µL beads for N samples with 900 µL RLT
(b) Resuspend in 91.5 µL/sample buffer RLT.
(c) Add 91.5 µL to each sample and mix (f.v. 122)
(d) Add 111 µL 100% EtOH. Incubate 15 minutes. (f.v. 233)
(e) Wash MyONE silane style 3x80% Etoh (1 resus, 2 on mag)
(f) Dry 5. Remove EtOH. Elute in 12 µL 50 mM Tris pH 7.8 and incubate 5 minutes
before clarifying.
ds cDNA amplification and plasmid DNA amplification
1. Dilute Plasmid DNA based on Nanodrop readings to ~5 ng/µL
2. Seed 20 µL PCR reactions with 8 µL of cDNA samples or 8 µL of 5 ng/µL DNA
samples. Master mix:
10.0 µL 2X Phusion HF Master Mix
1.0 µL 10 µM PTRE UTR antisense 1
1.0 µL 10 µM PTRE UTR sense 1
8.0 µL cDNA
3. Add 12 µL of master mix to each.
4. Run following program:
98oC 30s
98oC 10s, 60oC 10s, 72oC 15s | 12 cycles (DNA) or 18 cycles (cDNA)
72oC 10 min
4oC∞
AMPure 80/40 selection
1. Bring AMPure XP beads to room temperature ≥ 30 min.
2. Bring volume to 100 µL with H2O (add 80 µL).
3. Vortex beads and pipette 80 µL and add to PCR products. Mix by pipetting up and
down 10x.
4. Incubate on bench 5 minutes.
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5. Put on strip tube magnet for 3 minutes.
6. Re-vortex beads and pipette 40 µL to a clean strip tube.
7. Harvest supernatant (~160 µL recoverable) and add to new tube with 40 µL beads
in it. Mix by pipetting up and down 10x.
8. Incubate on bench 5 minutes.
9. Put on strip tube magnet 3 minutes.
10. Wash beads on magnet with 200 µL 80% EtOH for 30 seconds. Do not disturb
pellet. Add wash, let sit, then remove.
11. Repeat for total of two washes.
12. Dry beads for 5 minutes and remove any excess EtOH with vacuum or by pipette.
13. Resuspend beads in 10.5 µL Buffer EB (so that it will be possible to recover 10 µL)
and incubate on bench 5 minutes.
14. Add to magnet for 1 minute and harvest 10 µL.
NheI/KpnI Digest
1. Remove 10 µL of 80/40 purified PCR product and add to:
2 µL 10X CutSmart Buffer
1 µL NheI HF
1 µL KpnI HF
6 µL H2O
2. Mix well, spin, and incubate in thermal cycler for 1 hour at 37oC with lid set to 40oC.
AMPure 100/50 selection
1. Bring volume to 100 µL with H2O (80 µL).
2. Vortex beads and pipette 100 µL and add to digested products. Mix by pipetting up
and down 10x.
3. Incubate on bench 5 minutes.
4. Put on strip tube magnet for 3 minutes.
5. Re-vortex beads and pipette 50 µL to a clean strip tube.
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6. Harvest supernatant and add to new tube with 50 µL beads in it. Mix by pipetting
up and down 10x.
7. Incubate on bench 5 minutes.
8. Put on strip tube magnet 3 minutes.
9. For QC, save the first bead pellet. This is the first round of selection. Mostly selects
out high MW stuff, but may select out a bit of desired product too.
10. Wash beads on magnet with 200 µL 80% EtOH for 30 seconds. Do not disturb
pellet. Add wash, let sit, then remove.
11. Repeat for total of two washes.
12. Dry beads for 5 minutes and remove any excess EtOH with vacuum or by pipette.
13. Resuspend beads in 10.5 µL Buffer EB (so that it will be possible to recover 10 µL)
and incubate on bench 5 minutes.
14. Add to magnet for 1 minute and harvest 10 µL.
Adapter Ligation
1. Combine 10 µL purified/digested PCR product in the follow reaction
6 µL H2O
2 µL Enzymatics T4 DNA Ligase buffer 10X
0.5 µL 1 µM NheI/P2 adapter
0.5 µL 1 µM mix of KpnI/P1 adapters 1-4
1 µL of Enzymatics T4 DNA Ligase
2. Incubate at 16 C for 1 hour
3. Purify products with Ampure 80/40 and elute in 10.5 µL EB, and harvest 10 µL.
Preparative PCR
1. Master mix:
25 µL NEB Q5 Ultra II pcr master mix
2.5 µL 10 µM universal primer
12 µL H2O
2. Aliquot 39.5 to each tube.
3. Add 2.5 µL of index primer.
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4. Run with Q5 program for 9 cycles:
98oC 30 s
(98oC 10 s | 55oC 15 s | 65oC 1 min) X 9
65oC 5 min
12oC hold
5. Purify with 80/40 ampure XP (see above).
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